Current Phase,Phase III Date,Phase III Event Date,Phase II Date,Phase II Event Date,Phase I Date,Molecule,Route of Administration,Lead Company Name,Ticker,Drug Name,Generic Name/API,Disease Group,Sub Disease Group,Indication Name,Target,Partner,Other Names,Lead Indication,Event Phase,Likelihood of Approval,Est. US Approval Date,Est. EU Approval Date,Est. Japan Approval Date,Actual US Approval Date,Actual EU Approval Date,Actual Japan Approval Date,Future PDUFA Date,Future NDA/BLA Date,NDA/BLA Date,Phase I Event Date,IND Date,Drug Classification,Designations,,Imaging Agent,Approved Strengths,State,Country,Continent,Lead Company Revenue % (US),Drug ID,Drug Indication ID,Lead Company ID,Indication ID,QLS POA,Market Cap,Top Weighted Feature,Feature Application
Preclinical,,,,,,Peptide,,Titan Pharmaceuticals Inc.,TTNP,JT-09,,Allergy,General,Pruritus,Opioid receptors,,"JT09, JT 09",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,43610,61499,380,3196,N/A,$22.86M ,,
Preclinical,,,,,,Peptide,,"Bioniz Therapeutics, Inc.",,BNZ-3,,Autoimmune/immunology,General,Autoimmune Disorders,"IL-21 (Interleukin-21),IL-4 (Interleukin-4),IL-9 (Interleukin-9)",,"BNZ 3, BNZ3, BNZ-132-3",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,36021,50091,7115,180,N/A, ,,
Suspended,,,,,,Peptide,,Takeda Pharmaceutical Co. Ltd.,TAK,F-1324,,Autoimmune/immunology,General,Autoimmune Disorders,Bcl6/B-cell lymphoma 6,,"F1324, F 1324, Ac-LWYTDIRMSWRVP-OH, BCL6 Inhibitor (Takeda)",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Japan,Asia,,35683,49604,826,180,N/A,$46.05B ,,
Preclinical,,,,,,Peptide,,"ReAlta Life Sciences, Inc.",,PIC1-03,,Autoimmune/immunology,Other,Complement Deficiencies / Abnormalities,"Complement Component 1q (C1q),Complement Pathway",,"PIC103, PIC1 03",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Virginia,United States,North America,,41341,58020,9429,738,N/A, ,,
Suspended,,,,,,Peptide,,"OncoImmune, Inc.",,Echinomycin,echinomycin,Autoimmune/immunology,Transplant Rejection,Graft vs. Host Disease (GVHD) - Treatment,DNA,,,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,Maryland,United States,North America,,36608,50983,6512,250,N/A, ,,
Preclinical,,,,,,Peptide,,Galmed Pharmaceuticals Ltd.,GLMD,Amilo-5MER,,Autoimmune/immunology,Inflammatory Bowel Disease,Inflammatory Bowel Disease (IBD),"Apolipoprotein - B100 (Apo-B100),Transthyretin (TTR)",,"Amilo5MER, Amilo 5MER",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Israel,Asia,,43065,60707,4606,464,N/A,$72.25M ,,
Preclinical,,,,,,Peptide,,Find Therapeutics,,GPCR Allosteric Modulator Program (Find),,Autoimmune/immunology,General,Inflammatory Disorders,,,,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Quebec,Canada,North America,,42669,60060,25074,422,N/A, ,,
I,,,,,10/19/2017,Peptide,,Amyndas Pharmaceuticals,,AMY-101,,Autoimmune/immunology,Paroxysmal Nocturnal Hemoglobinuria,Paroxysmal Nocturnal Hemoglobinuria (PNH),Complement Pathway,,"AMY101, AMY 101, Compstatin",N,I,14% (Same As Avg.), - , - , - ,,,,,,,10/19/2017,,Biologic,"Orphan,Rare Disease",,No,,Pennsylvania,United States,North America,,24691,34312,4858,394,N/A, ,,
Preclinical,,,,,,Peptide,,WntResearch AB,WNT.ST,Box-5,,Autoimmune/immunology,Psoriasis,Psoriasis,WNT Signaling Pathway,,"Box 5, Box5",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Sweden,Europe,,31126,54535,6117,155,N/A, ,,
Preclinical,,,,,,Peptide,,CEL-SCI Corporation,CVM,CEL-4000,,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),"Immune System,T lymphocytes",,"CEL4000, CEL 4000, DerG-PG70, DerGPG70",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Vaccine,,,No,,Virginia,United States,North America,,32216,44496,519,154,N/A,$536.71M ,,
Suspended,,,,,,Peptide,,Genovax S.r.l.,,GX 101,,Autoimmune/immunology,Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus (SLE),T lymphocytes,,GX101,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Italy,Europe,,22373,30332,4261,282,N/A, ,,
Preclinical,,,,,,Peptide,,Arrevus Inc. ,,ARV-1502,,Autoimmune/immunology,General,Wound Healing,"DnaK,Protein synthesis",,"ARV 1502, ARV1502, Chex-Arg20, Chex Arg20, Chex-Arg 20",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,North Carolina,United States,North America,,37737,59908,8302,1578,N/A, ,,
Suspended,,,,,,Peptide,,LEO Pharma A/S,,Peptide Derived Program (Leo/Morphosys),,Dermatology,General,Dermatology,,MorphoSys AG,,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Denmark,Europe,,39087,54659,589,151,N/A, ,,
II,,,,06/09/2016,,Peptide,,Strongbridge Biopharma plc,SBBP,COR-005,somatoprim,Endocrine,Other,Acromegaly,Somatostatin Receptors,Evotec SE,"DG3173, Somatoprim, COR 005, COR005, DG-3173, DG 3173, PTR-3173, Veldoreotide, somatostatin analogue, Peptor, Biomeas",Y,II,24% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,Pennsylvania,United States,North America,,22479,30510,5262,680,N/A,$188.28M ,,
Suspended,,,,,,Peptide,,Amryt Pharma plc,AMYT,AP102,,Endocrine,Other,Acromegaly,Somatostatin Receptors,,"AP 102, AP-102, G-02113, G02113, somatostatin analogue",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,United Kingdom,Europe,,32115,44360,4435,680,N/A,$461.79M ,,
Suspended,,,,,,Peptide,,Amryt Pharma plc,AMYT,AP102,,Endocrine,Other,Cushing's Syndrome,Somatostatin Receptors,,"AP 102, AP-102, G-02113, G02113, somatostatin analogue",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,United Kingdom,Europe,,32115,44361,4435,637,N/A,$461.79M ,,
Preclinical,,,,,,Peptide,,Follicum AB,,Diabetes Peptide Program (Follicum),,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",,,"FOL-014, FOL 014, FOL014",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Sweden,Europe,,40116,56105,8698,157,N/A, ,,
Suspended,,,,,,Peptide,,Novartis AG,NVS,Biosimilar Insulin Aspart (Sandoz),,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,Insulin Aspart (Sandoz),N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biosimilar,,,No,,,Switzerland,Europe,,39820,55688,289,157,N/A,$183.31B ,,
Suspended,,,,,,Peptide,,Novartis AG,NVS,Biosimilar Insulin Glargine (Sandoz),,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,Insulin Glargine (Sandoz),N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biosimilar,,,No,,,Switzerland,Europe,,39819,55687,289,157,N/A,$183.31B ,,
Suspended,,,,,,Peptide,,Novartis AG,NVS,Biosimilar Insulin Lispro (Sandoz),,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"Biosimilar Humalog (Sandoz), Insulin Lispro (Sandoz)",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biosimilar,,,No,,,Switzerland,Europe,,39808,55671,289,157,N/A,$183.31B ,,
Suspended,,,,,,Peptide,,Sanofi,SNY,Pancreate,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Human proIslet Peptide (HIP) Receptor,"Boston Therapeutics, Inc.","Human proIslet Peptide (HIP), proisletide acetate, SAR-288233, CDM-1101",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,France,Europe,,16597,21435,51,157,N/A,$107.55B ,,
Suspended,,,,,,Peptide,,Viatris Inc.,VTRS,Biosimilar Humalog (Mylan/Biocon),,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,"Biocon, Ltd.","Biosimilar Lispro (Biocon/Mylan), Insulin lispro (Biocon/Mylan)",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biosimilar,,,No,,Pennsylvania,United States,North America,,39116,54711,266,157,N/A, ,,
Preclinical,,,,,,Peptide,,Carmot Therapeutics Inc.,,CT-388,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GIP Receptor (GIPR)/Glucose-Dependent Insulinotropic Polypeptide Receptor,GLP-1 Receptor",,"CT 388, CT388",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,43399,61192,7821,137,N/A, ,,
Preclinical,,,,,,Peptide,,Thermalin Diabetes LLC,,Fluorolog,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Ohio,United States,North America,,31716,43791,6587,137,N/A, ,,
Preclinical,,,,,,Peptide,,"Zucara Therapeutics, Inc.",,ZT-01,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Somatostatin Receptors,,"PRL 2903, PRL2903, PRL-2903, ZT01, ZT 01",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,British Columbia,Canada,North America,,31788,61569,6608,137,N/A, ,,
Suspended,,,,,,Peptide,,Nordic Bioscience A/S,,UGP302,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Amylin Receptor,"Unigene Laboratories, Inc.",UGP302,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,20852,27913,2459,137,N/A, ,,
Suspended,,,,,01/31/2012,Peptide,,Bristol Myers Squibb Company,BMY,AC165198,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Unknown,AstraZeneca PLC,AC165198,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,01/31/2012,01/09/2012,New Molecular Entity (NME),,,No,,New York,United States,North America,,17834,23284,73,137,N/A,$140.92B ,,
Suspended,,,,,,Peptide,,"CohBar, Inc.",CWBR,CB4209,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Mitochondria,,"CB 4209, CB-4209, CB-211, CB211, CB 211",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,34915,48369,7466,137,N/A,$84.34M ,,
Suspended,,,,,,Peptide,,"Eloxx Pharmaceuticals, Inc.",ELOX,SVN-003,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,SVN003,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Massachusetts,United States,North America,,26361,36783,7414,137,N/A,$164.63M ,,
Suspended,,,,06/08/2017,,Peptide,,Eli Lilly and Company,LLY,DACRA-042,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","Amylin Receptor,Calcitonin Receptor",Nordic Bioscience A/S,"KBP042, KBP 042, KBP-042",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/19/2015,,New Molecular Entity (NME),,,No,,Indiana,United States,North America,,35200,48825,136,137,N/A,$158.63B ,,
Suspended,,,,,,Peptide,,MorphoSys AG,MOR,PanCyte,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",,,"Lanthionine-Stabilized Angiotensin-(1-7), Long-Acting Angiotensin (1-7)",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Germany,Europe,,41626,58435,264,137,N/A,$3.88B ,,
Suspended,,,,,,Peptide,,Novartis AG,NVS,Biosimilar Insulin Aspart (Sandoz),,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,Insulin Aspart (Sandoz),N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biosimilar,,,No,,,Switzerland,Europe,,39820,55689,289,137,N/A,$183.31B ,,
Suspended,,,,,,Peptide,,Novartis AG,NVS,Biosimilar Insulin Glargine (Sandoz),,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,Insulin Glargine (Sandoz),N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biosimilar,,,No,,,Switzerland,Europe,,39819,55690,289,137,N/A,$183.31B ,,
Suspended,,,,,,Peptide,,Novartis AG,NVS,Biosimilar Insulin Lispro (Sandoz),,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"Biosimilar Humalog (Sandoz), Insulin Lispro (Sandoz)",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biosimilar,,,No,,,Switzerland,Europe,,39808,55691,289,137,N/A,$183.31B ,,
Suspended,,,,,,Peptide,,Roche Holding AG,RHHBY,RG7089,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Neuropeptide Y (NPY)/Peptide YY (PYY) Receptors,,RG7089,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/23/2009,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,15591,19857,149,137,N/A,$227.10B ,,
Suspended,,,,,,Peptide,,Sanofi,SNY,Pancreate,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Human proIslet Peptide (HIP) Receptor,"Boston Therapeutics, Inc.","Human proIslet Peptide (HIP), proisletide acetate, SAR-288233, CDM-1101",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,France,Europe,,16597,21434,51,137,N/A,$107.55B ,,
Suspended,,,,,,Peptide,,Viatris Inc.,VTRS,Biosimilar Humalog (Mylan/Biocon),,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,"Biocon, Ltd.","Biosimilar Lispro (Biocon/Mylan), Insulin lispro (Biocon/Mylan)",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biosimilar,,,No,,Pennsylvania,United States,North America,,39116,54703,266,137,N/A, ,,
Suspended,,,,,,Peptide,,"Assertio Therapeutics, Inc.",ASRT,Synthetic ACTH Depot,cosyntropin,Endocrine,General,Endocrine Disorder,Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),Slán Medicinal Holdings Limited,"injectable formulation of cosyntropin (synthetic adrenocorticotropic hormone, or ACTH) depot",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,12/20/2018,,,Non-NME,505b2,,No,,Illinois,United States,North America,,36555,55682,120,182,N/A,$76.07M ,,
I,,,,,09/29/2020,Peptide,,"Zucara Therapeutics, Inc.",,ZT-01,,Endocrine,Other,Hyperinsulinemia/Hypoglycemia,Somatostatin Receptors,,"PRL 2903, PRL2903, PRL-2903, ZT01, ZT 01",N,I,14% (Same As Avg.), - , - , - ,,,,,,,09/29/2020,,New Molecular Entity (NME),,,No,,British Columbia,Canada,North America,,31788,43926,6608,3358,N/A, ,,
Preclinical,,,,,,Peptide,,AmideBio LLC,,AB-G023,,Endocrine,Other,Hyperinsulinemia/Hypoglycemia,Glucagon Receptor,,"ABG023, ABG 023, Soluble Glucagon Analog",Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,Orphan,,No,,Colorado,United States,North America,,42299,59491,20064,3358,N/A, ,,
Suspended,,,,,,Peptide,,"DiObex, Inc.",,DIO-901,,Endocrine,Other,Hyperinsulinemia/Hypoglycemia,Glucagon Receptor,Camurus AB,"very low dose glucagon (VLD Glucagon), VLDG",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,06/22/2007,,Non-NME,Fast Track,,No,,California,United States,North America,,10058,12571,1274,3358,N/A, ,,
I,,,,,12/14/2020,Peptide,,Amolyt Pharma,,AZP-3601,,Endocrine,Other,Hypoparathyroidism,Parathyroid Hormone (PTH),,"AZP3601, AZP 3601",N,I,14% (Same As Avg.), - , - , - ,,,,,,,12/14/2020,,Biologic,Orphan,,No,,,France,Europe,,40285,56376,9118,2557,N/A, ,,
Suspended,,,,,,Peptide,,"CohBar, Inc.",CWBR,CB4209,,Endocrine,Other,Non-Alcoholic Steatohepatitis (NASH),Mitochondria,,"CB 4209, CB-4209, CB-211, CB211, CB 211",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,34915,48368,7466,683,N/A,$84.34M ,,
Suspended,,,,,,Peptide,,Biosidus S.A.,,Osteofortil,Teriparatide,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Parathyroid Hormone Receptor (PTHR),,Biosimilar Teriparatide (Biosidus),N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biosimilar,,,No,,,Argentina,South America,,21913,29620,4119,242,N/A, ,,
Suspended,,,,,,Peptide,,"Hanmi Pharmaceutical Co., Ltd.",128940,HM15910,,Gastroenterology (Non Inflammatory Bowel Disease),Other,Short Bowel Syndrome (SBS),GLP-2 Receptor,,"HM-15910, HM 15910, LAPS-GLP-2 Analog",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Korea (South),Asia,,37080,51698,3379,581,N/A,$4.34B ,,
Preclinical,,,,,,Peptide,,"ReAlta Life Sciences, Inc.",,PIC1-02,,Hematology,Marrow Or Peripheral Blood Stimulator,Autoimmune Hemolytic Anemia (AIHA),"Complement Component 1q (C1q),Complement Pathway",,"PIC102, PIC1 02",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Virginia,United States,North America,,41340,58018,9429,3647,N/A, ,,
Preclinical,,,,,,Peptide,,Apitope Technology (Bristol) Ltd,,ATX-F8,,Hematology,Factor Augmentation,Factor VIII Intolerance,Unknown,,"ATX-F8-117, ATXF8117, ATX FVIII, ATX-F8-17, ATXF817, ATX F8 17",Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Orphan,,No,,,Belgium,Europe,,23121,31613,1403,3372,N/A, ,,
Suspended,,,,,,Peptide,,Chemokine Therapeutics Corp.,,CTCE-0214,,Hematology,Marrow Or Peripheral Blood Stimulator,Neutropenia / Leukopenia,Chemokine (C-X-C motif) Receptor 4 (CXCR4),,CTCE-0214,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,10/19/2004,,New Molecular Entity (NME),,,No,,British Columbia,Canada,North America,,6588,6792,1257,91,N/A, ,,
Preclinical,,,,,,Peptide,,NovaBiotics Ltd,,Novarifyn,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Antibacterial - General,Cell Membrane,,NP432,Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,26886,37580,5540,3121,N/A, ,,
Preclinical,,,,,,Peptide,,"Soligenix, Inc.",SNGX,SGX943,dusquetide,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Antibacterial - General,Immune System,,"SGX101, SGX94 technology, susquetide, dusquetide",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Fast Track,,No,,New Jersey,United States,North America,,23763,32727,143,3121,N/A,$42.68M ,,
Suspended,,,,,,Peptide,,Arrevus Inc. ,,ARV-1501,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Antibacterial - General,"DnaK,Protein synthesis",,"ARV 1501, ARV1501, A3-APO",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,North Carolina,United States,North America,,37738,52625,8302,3121,N/A, ,,
Suspended,,,,,,Peptide,,Arrevus Inc. ,,ARV-1503x,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Antibacterial - General,"DnaK,Protein synthesis",,"ARV 1503x, ARV1503x",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,North Carolina,United States,North America,,37739,52626,8302,3121,N/A, ,,
Suspended,,,,,,Peptide,,Arrevus Inc. ,,ARV-1601,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Antibacterial - General,"DnaK,Gram-Negative Bacteria,Protein synthesis",,"ARV 1601, ARV1601",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,North Carolina,United States,North America,,37740,52627,8302,3121,N/A, ,,
Suspended,,,,,,Peptide,,EligoChem Ltd.,,Helical Antimicrobial Peptide Program,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Antibacterial - General,Gram-Negative Bacteria,,,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,36582,50946,7970,3121,N/A, ,,
Suspended,,,,,,Peptide,,Promore Pharma AB,PROMO,Pergamum-Cadila compound,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Antibacterial - General,Unknown,Cadila Pharmaceuticals Ltd.,"Pergamum-Cadila compound, Pergamum Cadila compound",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Sweden,Europe,,21858,29527,3854,3121,N/A,$13.68M ,,
Preclinical,,,,,,Peptide,,Vaxil Bio Ltd.,,CorVax,,Infectious Disease,Antiviral,COVID-19 Prevention,"Immune System,SARS-CoV-2",,,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Vaccine,,,No,,,Israel,Asia,,41890,58837,24750,3665,N/A, ,,
I,,,,,12/17/2020,Peptide,,"Vasomune Therapeutics, Inc.",,AV-001,,Infectious Disease,Antiviral,COVID-19 Treatment,Angiopoietin Receptors (TIE-1 and TIE-2),"AnGes, Inc.","Peptide-based Tie2 Receptor Agonist Program, ARDS Program (Vasomune/AnGes), Peptide-based Tie2 Receptor Agonist Program (Vasomune/AnGes), AV001, AV 001",N,I,19% (Same As Avg.), - , - , - ,,,,,,,12/17/2020,11/12/2020,New Molecular Entity (NME),,,No,,,Canada,North America,,38682,53999,8580,3651,N/A, ,,
IND,,,,,,Peptide,,Amyndas Pharmaceuticals,,AMY-101,,Infectious Disease,Antiviral,COVID-19 Treatment,Complement Pathway,,"AMY101, AMY 101, Compstatin",N,IND,0% (Same As Avg.), - , - , - ,,,,,,,,05/30/2020,Biologic,,,No,,Pennsylvania,United States,North America,,24691,59907,4858,3651,N/A, ,,
IND,,,,,,Peptide,,"ReAlta Life Sciences, Inc.",,RLS-0071,,Infectious Disease,Antiviral,COVID-19 Treatment,"Complement Component 1q (C1q),Complement Pathway",,"PIC1 01, PIC101, PIC1-01, RLS0071, RLS 0071, PIC1-dPEG24, PIC1dPEG24, PIC1 dPEG24",N,IND,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Virginia,United States,North America,,41339,60584,9429,3651,N/A, ,,
Preclinical,,,,,,Peptide,,"Ligandal, Inc",,Ligandal COVID-19 Vaccine,,Infectious Disease,Antiviral,COVID-19 Treatment,,,,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Vaccine,,,No,,California,United States,North America,,42196,59350,24868,3651,N/A, ,,
Suspended,,,05/04/2015,05/04/2015,,Peptide,,Fortress Biotech Inc.,FBIO,PepVax,,Infectious Disease,Antiviral,Cytomegalovirus (CMV) Infection (Antiviral),Human Cytomegalovirus (HCMV),City of Hope National Medical Center,"PepVax, Tetanus-CMV",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,04/02/2015,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,25768,35871,3307,411,N/A,$325.15M ,,
Suspended,,,,,,Peptide,,"Enzo Biochem, Inc.",ENZ,EHC18,,Infectious Disease,Antiviral,Hepatitis C (HCV) (Antiviral),Unknown,,EHC-18,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/15/2001,,Biologic,,,No,,New York,United States,North America,,1176,1715,650,176,N/A,$128.84M ,,
Suspended,,,,,,Peptide,,"Spero Therapeutics, Inc.",SPRO,Gram-negative Program (Spero/Cantab),,Infectious Disease,General,Infectious Disease,Unknown,Cantab Anti-infectives Ltd.,,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,33491,46257,4702,3484,N/A,$474.32M ,,
Preclinical,,,,,,Peptide,,CEL-SCI Corporation,CVM,LEAPS-H1N1-DC,,Infectious Disease,Antiviral,Influenza (including vaccines),"Immune System,Influenza Virus",,LEAPS H1N1 DC,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Vaccine,,,No,,Virginia,United States,North America,,21798,30834,519,237,N/A,$536.71M ,,
Suspended,,,,,,Peptide,,Arrevus Inc. ,,ARV-1502,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),"DnaK,Protein synthesis",,"ARV 1502, ARV1502, Chex-Arg20, Chex Arg20, Chex-Arg 20",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,North Carolina,United States,North America,,37737,52624,8302,440,N/A, ,,
Suspended,,,,,,Peptide,,Cantab Anti-infectives Ltd.,,NVB333,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Staphylococcal Vaccines and Other Staphylococcus-Specific Agents (Antibacterial),Staphylococcus,,NVB-333,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,United Kingdom,Europe,,33493,46259,7068,3109,N/A, ,,
Suspended,,,,,,Peptide,,"Akashi Therapeutics, Inc.",,AT-300,,Metabolic,Single-Gene Disorders (Non-Inborn Errors of Metabolism),Duchenne Muscular Dystrophy (DMD),,Tonus Therapeutics,"GsMTx-4, AT300, AT 300",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,"Orphan,Rare Disease",,No,,Massachusetts,United States,North America,,24618,34203,4188,3620,N/A, ,,
Preclinical,,,,,,Peptide,,Alexion Pharmaceuticals Inc.,ALXN,Peptide Therapeutic Program (Alexion/Zealand),,Metabolic,General,Metabolic - General,Complement Pathway,Zealand Pharma A/S,,Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Massachusetts,United States,North America,,40272,56356,21,3163,N/A,$34.07B ,,
Preclinical,,,,,,Peptide,,Zealand Pharma A/S,ZEAL,Peptide Therapeutic Program (Zealand/Orbit),,Metabolic,General,Metabolic - General,,Orbit Discovery Ltd.,Peptide Therapeutic Program (Zealand/Orbit),Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,35991,50037,748,3163,N/A,$1.48B ,,
Suspended,,,,,,Peptide,,"GP Pharm, S.A.",,Triptorelin (GP Pharm),triptorelin,Metabolic,General,Metabolic - General,Gonadotropin-Releasing Hormone (GnRH) Receptor,,triptorelin,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,Spain,Europe,,23258,31845,4354,3163,N/A, ,,
Suspended,,,,,,Peptide,,Zealand Pharma A/S,ZEAL,Peptide Therapeutic Program (Zealand/TPIMS),,Metabolic,General,Metabolic - General,,,Peptide Therapeutic Program (Zealand/TPIMS),Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,36225,50398,748,3163,N/A,$1.48B ,,
Suspended,,,,,03/30/2004,Peptide,,Bristol Myers Squibb Company,BMY,AC162352,,Metabolic,Obesity,Obesity,Neuropeptide Y (NPY)/Peptide YY (PYY) Receptors,"Curis, Inc.",PYY 3-36,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/30/2004,12/31/2003,New Molecular Entity (NME),,,No,,New York,United States,North America,95%,321,603,73,135,N/A,$140.92B ,,
Suspended,,,,,,Peptide,,"CohBar, Inc.",CWBR,CB4209,,Metabolic,Obesity,Obesity,Mitochondria,,"CB 4209, CB-4209, CB-211, CB211, CB 211",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,34915,48367,7466,135,N/A,$84.34M ,,
I/II,,,,01/12/2015,,Peptide,,Johnson & Johnson,JNJ,ACI-35,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),"Immune System,Tau proteins",AC Immune SA,"Anti-phospho-Tau Vaccine, Anti-pTau Vaccine, anti-phospho-Tau (anti-pTau) vaccine, ACI35, ACI 35, ACI-35.030, ACI35.030, ACI 35.030",Y,II,18% (1% Above Avg.), - , - , - ,,,,,,,,,Vaccine,,,No,,New Jersey,United States,North America,,23188,31734,223,141,N/A,$422.18B ,,
Preclinical,,,,,,Peptide,,"Cenna Biosciences, Inc.",,P8,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Amyloid Beta/Amyloid Plaques,,,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,29053,40340,6116,141,N/A, ,,
Suspended,,,,,,Peptide,,"Neurotez, Inc.",,NT1,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),"Cytoplasmic linker protein 170 (CLIP-170) ,Presenilin 1 (PS1)",,NT-1,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,New Jersey,United States,North America,,24130,33371,3798,141,N/A, ,,
Preclinical,,,,,,Peptide,,"Angiochem, Inc.",,ANG2002,,Neurology,Pain,Chronic Pain,"NT1 (Neurotensin receptor type 1),NT2 (Neurotensin receptor type 2)",,ANG2002,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Canada,North America,,23774,32746,2712,3128,N/A, ,,
Suspended,,,,03/31/2018,,Peptide,,"Assertio Therapeutics, Inc.",ASRT,Synthetic ACTH Depot,cosyntropin,Neurology,Seizure Disorders (Epilepsy),Infantile Spasms (West Syndrome; Epilepsy),Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),Slán Medicinal Holdings Limited,"injectable formulation of cosyntropin (synthetic adrenocorticotropic hormone, or ACTH) depot",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,"Orphan,Rare Disease",,No,,Illinois,United States,North America,,36555,50904,120,3007,N/A,$76.07M ,,
Suspended,,,,,,Peptide,,"Travere Therapeutics, Inc.",TVTX,RE-034,cosyntropin,Neurology,Seizure Disorders (Epilepsy),Infantile Spasms (West Syndrome; Epilepsy),Melanocortin (MC) receptors,,tetracosactide,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,California,United States,North America,,23442,32160,3579,3007,N/A,$1.41B ,,
II,,,09/11/2020,09/11/2020,07/31/2017,Peptide,,"Lumosa Therapeutics Co., Ltd.",6535.TWO,LT3001,,Neurology,Stroke,Ischemic Stroke,Tissue Plasminogen Activator (TPA),,"LT 3001, LT-3001, PAK01",Y,II,17% (Same As Avg.), - , - , - ,,,,,,,07/28/2017,,New Molecular Entity (NME),,,No,,,Taiwan,Asia,,35891,49888,7749,145,N/A, ,,
Suspended,,,,,,Peptide,,"Constant Therapeutics, LLC",,TXA302,,Neurology,Stroke,Ischemic Stroke,"Angiotensin II Receptor Type 1 (AT1),Angiotensin II Receptor Type 2 (AT2)",,"TXA-302, TXA 302",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Massachusetts,United States,North America,,37515,52318,2872,145,N/A, ,,
Suspended,,,,,,Peptide,,"AnGes, Inc.",4563,AGMG0201,,Neurology,Stroke,Ischemic Stroke,"Angiotensins (I-IV),Immune System",,"Ang II vaccine, Angiotensin II DNA Vaccine",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Vaccine,,,No,,,Japan,Asia,,26129,48012,858,145,N/A,$1.60B ,,
Preclinical,,,,,,Peptide,,Axoltis Pharma,,NX218,,Neurology,General,Neurology - Other,Unknown,,"NX 218, NX-218",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Unknown,,,No,,,France,Europe,,42368,59609,8285,192,N/A, ,,
Preclinical,,,,,,Peptide,,"ReAlta Life Sciences, Inc.",,RLS-0071,,Neurology,General,Neurology - Other,"Complement Component 1q (C1q),Complement Pathway",,"PIC1 01, PIC101, PIC1-01, RLS0071, RLS 0071, PIC1-dPEG24, PIC1dPEG24, PIC1 dPEG24",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Orphan,,No,,Virginia,United States,North America,,41339,58019,9429,192,N/A, ,,
I,,,,,,Peptide,,Stragen Pharm SA,,STR-324,,Neurology,Pain,Pain Indications,Nociceptin/Orphanin FQ Peptide (NOP) Receptor,,"STR 324, STR324",N,I,10% (Same As Avg.), - , - , - ,,,,,,,02/23/2018,,Biologic,,,No,,,Switzerland,Europe,,41575,58322,10017,450,N/A, ,,
Suspended,,,,,,Peptide,,BioLineRx Ltd.,BLRX,EDP 32,,Neurology,Neurodegenerative,Parkinson's Disease (PD),Alpha-synuclein,,EDP-32,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Israel,Asia,,22195,30038,1248,194,N/A,$58.92M ,,
I,,,,,,Peptide,,Takeda Pharmaceutical Co. Ltd.,TAK,TAK-951,,Not Specified,Other,Emesis,,,,N,I,16% (Same As Avg.), - , - , - ,,,,,,,05/14/2019,,New Molecular Entity (NME),,,No,,,Japan,Asia,,40837,57294,826,594,N/A,$46.05B ,,
Program Hold,,,,,,Peptide,,Pantarhei Bioscience B.V.,,OTE-F,,Obstetrics/Gynecology,Gynecology,Reproductive Disorder,"Estrogen Receptor Beta (ER2 or ER beta),Oxytocin Receptor",,OTE-F,Y,I,16% (Same As Avg.), - , - , - ,,,,,,,03/06/2013,,New Molecular Entity (NME),,,No,,,Netherlands,Europe,,22032,29811,2094,241,N/A, ,,
Suspended,,,,01/14/2010,,Peptide,,Gedeon Richter Plc.,RICHT,PGL3001,,Obstetrics/Gynecology,Gynecology,Reproductive Disorder,Unknown,,PGL-3001,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,Hungary,Europe,,16790,21740,850,241,N/A,$4.75B ,,
Preclinical,,,,,,Peptide,,"Sapience Therapeutics, Inc.",,ST101 (Sapience),,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),,,"ST-101, ST 101",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,"Orphan,Rare Disease",,No,,New York,United States,North America,,41422,58134,9445,97,N/A, ,,
Suspended,,,,,,Peptide,,"OncoImmune, Inc.",,Echinomycin,echinomycin,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),DNA,,,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,Maryland,United States,North America,,36608,50982,6512,97,N/A, ,,
Suspended,,,,,,Peptide,,CytRx Corporation,CYTR,INNO-305,,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),"Immune System,Wilms' Tumor Protein 1 (WT1)",,INNO-305,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,10/27/2006,,New Molecular Entity (NME),Rare Disease,,No,,California,United States,North America,,8542,10612,709,97,N/A,$64.93M ,,
Investigator Initiated,,,12/13/2016,,,Peptide,,IMV Inc.,IMV,DPX-E7,,Oncology,Solid,Anal Cancer,"Human Papillomavirus (HPV),Immune System",,"DPXE7, DPX E7",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Nova Scotia,Canada,North America,,34570,47796,3704,3246,N/A,$231.59M ,,
II,,,01/26/2016,12/31/2015,,Peptide,,"Cleveland BioLabs, Inc.",CBLI,CBLB612,,Oncology,"Surgical, Interventional Radiological, and Other Invasive Procedures",Bone Marrow Transplant and Stem Cell Transplant,Toll-Like Receptor 2 (TLR2),,Protecan CBLB612,N,II,10% (Same As Avg.), - , - , - ,,,,,,,11/05/2014,,New Molecular Entity (NME),,,No,,New York,United States,North America,,20732,27730,920,300,  7%,$50.41M ,Tumor Type,N/A
Preclinical,,,,,,Peptide,,Arch Biopartners Inc.,ACHFF,MetaMx,,Oncology,Solid,Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM)),Tumor Cells,,"ACT0932, ACT 0932, ACT-0932",Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Canada,North America,,27847,39039,5869,228,N/A, ,,
IND,,,,,,Peptide,,"Neon Therapeutics, Inc.",,NEO-SV-01,,Oncology,Solid,Breast Cancer,Immune System,BioNTech SE,"NEO SV-01, NEO SV01, NEO SV 01",N,IND,0% (Same As Avg.), - , - , - ,,,,,,,,08/06/2019,Biologic,,,No,,Massachusetts,United States,North America,,38125,53224,6931,214,N/A, ,,
Suspended,,,,,,Peptide,,Treos Bio Limited,,PolyPEPI915,,Oncology,Solid,Breast Cancer,"Immune System,T lymphocytes",,"PolyPEPI 915, PolyPEPI-915, PolyPEPI 1",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,37191,51876,8133,214,N/A, ,,
IND,,,,,,Peptide,,"Clovis Oncology, Inc.",CLVS,FAP-2286,,Oncology,General,Cancer,"Fibroblast Activation Protein (FAP),Radiopharmaceutical",3B Pharmaceuticals GmbH,"PTRT Imaging Agent (Clovis/3B), FAP2286, FAP 2286",N,IND,0% (Same As Avg.), - , - , - ,,,,,,,,12/29/2020,New Molecular Entity (NME),,,Yes,,Colorado,United States,North America,,40906,57409,2737,313,N/A,$439.83M ,,
Preclinical,,,,,,Peptide,,Soricimed Biopharma Inc.,,SBI-1301,,Oncology,General,Cancer,"TRPV6, transient receptor potential vanilloid receptor 6, VR-6",,"SBI1301, SBI 1301",Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,New Brunswick,Canada,North America,,41577,58324,3674,313,N/A, ,,
Preclinical,,,,,,Peptide,,Portage Biotech Inc.,PTGEF,NLG PD1 Aptamer,,Oncology,General,Cancer,Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),,Nanolipogel Aptamer,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,42384,59632,4630,313,N/A, ,,
Preclinical,,,,,,Peptide,,Roche Holding AG,RHHBY,Roche Bicycle Program,,Oncology,General,Cancer,Unknown,,,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,41941,58930,149,313,N/A,$227.10B ,,
Preclinical,,,,,,Peptide,,Theratechnologies Inc.,THTX,TH1901,,Oncology,General,Cancer,Sortilin 1 (SORT1),,"TH 1901, TH-1901",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Quebec,Canada,North America,,42495,59778,459,313,N/A, ,,
Suspended,,,,,,Peptide,,Vaxon Biotech,,Vbx-016,,Oncology,General,Cancer,"Carcinoembryonic antigen (CEA),HER2/neu or ErbB-2,Immune System,Melanoma antigen-encoding gene (MAGE),Telomerase",,Vbx-016,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,France,Europe,,29126,40460,6138,313,N/A, ,,
Suspended,,,,,,Peptide,,Altimmune Inc. ,ALT,Oncosyn,,Oncology,General,Cancer,"Immune System,T-Cell Receptor (TCR)",,Oncosyn,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Maryland,United States,North America,,33305,45987,5116,313,N/A,$459.69M ,,
Investigator Initiated,,,12/13/2016,,,Peptide,,IMV Inc.,IMV,DPX-E7,,Oncology,Solid,Cervical Cancer,"Human Papillomavirus (HPV),Immune System",,"DPXE7, DPX E7",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Nova Scotia,Canada,North America,,34570,47781,3704,255,N/A,$231.59M ,,
Preclinical,,,,,,Peptide,,Hamlet Pharma AB,HAMLET,Alpha1H,,Oncology,Solid,Gastric Cancer,Tumor Cells,,Human Alpha-Lactalbumin,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Sweden,Europe,,40709,57077,9258,223,N/A,$79.95M ,,
Suspended,,,,,,Peptide,,Roche Holding AG,RHHBY,IMA942,,Oncology,Solid,Gastric Cancer,"Immune System,Tumor Cells",Immatics N.V.,IMA942,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,22641,30789,149,223,N/A,$227.10B ,,
Investigator Initiated,,,12/13/2016,,,Peptide,,IMV Inc.,IMV,DPX-E7,,Oncology,Solid,Head and Neck Cancer,"Human Papillomavirus (HPV),Immune System",,"DPXE7, DPX E7",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Nova Scotia,Canada,North America,,34570,47797,3704,230,N/A,$231.59M ,,
Suspended,,,,,,Peptide,,"Ono Pharmaceutical Company, Ltd.",4528:JP,ONO-7268MX2,,Oncology,Solid,Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases),Immune System,"OncoTherapy Science, Inc.","ONO-7268 MX2, peptide cocktail vaccine",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Japan,Asia,,23388,32074,844,297,N/A,$14.88B ,,
Preclinical,,,,,,Peptide,,"CohBar, Inc.",CWBR,CXCR4 Inhibitor (CohBar),,Oncology,Solid,Melanoma,Chemokine (C-X-C motif) Receptor 4 (CXCR4),,,Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,41654,58476,7466,221,N/A,$84.34M ,,
IND,,,,,,Peptide,,Oncopeptides AB,ONKO:SS,OPD5,,Oncology,Hematologic,Multiple Myeloma (MM),Aminopeptidase,,OPD-5,N,IND,0% (Same As Avg.), - , - , - ,,,,,,,,10/19/2020,Non-NME,Rare Disease,,No,,,Sweden,Europe,,43546,61398,4386,207,N/A, ,,
Suspended,,,,,,Peptide,,Andarix Pharmaceuticals,,Tozaride,Re188 P2045 somatostatin analog,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),"Radiopharmaceutical,Somatostatin Receptors","Bayer AG, Wuxi Fortune Pharmaceutical Co., Ltd.","Rhenium, P 2045, P-2045, 188 Re P2045, BAY865284, BAY86-5284, BAY86 5284",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,06/03/2007,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,13073,16471,2678,211,N/A, ,,
Suspended,,,,,,Peptide,,Roche Holding AG,RHHBY,IMA930,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),"Immune System,Tumor Cells",Immatics N.V.,IMA930,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,22642,30790,149,211,N/A,$227.10B ,,
Preclinical,,,,,,Peptide,,Theratechnologies Inc.,THTX,TH-1902,,Oncology,Solid,Ovarian Cancer,"Microtubules (Tubulin),Sortilin 1 (SORT1)",,"Theratechnologies/Katana Oncology Peptide Program, TH1902, TH 1902",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,Quebec,Canada,North America,,40176,60229,459,224,N/A, ,,
Preclinical,,,,,,Peptide,,Theratechnologies Inc.,THTX,TH-1904,,Oncology,Solid,Ovarian Cancer,"Sortilin 1 (SORT1),Topoisomerase II (DNA gyrase)",,"TH1904, TH 1904",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,Quebec,Canada,North America,,41089,57678,459,224,N/A, ,,
Suspended,,,,,,Peptide,,Treos Bio Limited,,PolyPEPI1211,,Oncology,Solid,Ovarian Cancer,"Immune System,T lymphocytes",,"PolyPEPI 5, PolyPEPI-1211, PolyPEPI 1211",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,United Kingdom,Europe,,37192,51877,8133,224,N/A, ,,
Suspended,,,,,01/17/2019,Peptide,,IMV Inc.,IMV,DPX-NEO Program,,Oncology,Solid,Ovarian Cancer,Tumor Cells,,DepoVax-Cancer,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,01/17/2019,,New Molecular Entity (NME),Rare Disease,,No,,Nova Scotia,Canada,North America,,29270,40632,3704,224,N/A,$231.59M ,,
Preclinical,,,,,,Peptide,,Andarix Pharmaceuticals,,Tozaride,Re188 P2045 somatostatin analog,Oncology,Solid,Pancreatic Cancer,"Radiopharmaceutical,Somatostatin Receptors","Bayer AG, Wuxi Fortune Pharmaceutical Co., Ltd.","Rhenium, P 2045, P-2045, 188 Re P2045, BAY865284, BAY86-5284, BAY86 5284",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,Massachusetts,United States,North America,,13073,46590,2678,220,N/A, ,,
Suspended,,,,,,Peptide,,"Aileron Therapeutics, Inc",ALRN,ATSP-9172,,Oncology,Solid,Prostate Cancer,Hypoxia Inducible Factor-1 alpha (HIF-1a),,ATSP-9172,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,22274,30167,4074,215,N/A,$50.04M ,,
Suspended,,,,,,Peptide,,"Inspyr Therapeutics, Inc.",NSPX,G-115,,Oncology,Solid,Prostate Cancer,"Prostate-Specific Antigen (PSA),Sarcoplasmic reticulum Ca2+-ATPase (SERCA)",,"G 115, G115",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Texas,United States,North America,,22842,31143,3640,215,N/A,$804.44K ,,
I,,,,,,Peptide,,Debiopharm S.A.,,Debio 1124,,Oncology,Solid,Small Cell Lung Cancer (SCLC),"Cholecystokinin 2 (CCK2 or CCKB) / Gastrin receptor,Radiopharmaceutical",,"Debio1124, Debio-1124, radioconjugated minigastrin analogue",Y,I,6% (Same As Avg.), - , - , - ,,,,,,,08/26/2020,,Biologic,Rare Disease,,Yes,,,Switzerland,Europe,,39280,60858,856,111,N/A, ,,
I/II,,,,01/31/2004,,Peptide,,Andarix Pharmaceuticals,,Tozaride,Re188 P2045 somatostatin analog,Oncology,Solid,Small Cell Lung Cancer (SCLC),"Radiopharmaceutical,Somatostatin Receptors","Bayer AG, Wuxi Fortune Pharmaceutical Co., Ltd.","Rhenium, P 2045, P-2045, 188 Re P2045, BAY865284, BAY86-5284, BAY86 5284",N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,Massachusetts,United States,North America,,13073,46589,2678,111, 17%, ,Orphan Drug designation,Yes
I,,,,,11/28/2017,Peptide,,"Vigeo Therapeutics, Inc.",,VT1021,,Oncology,Solid,Solid Tumors,,,"VT-1021, VT 1021",N,I,6% (Same As Avg.), - , - , - ,,,,,,,12/06/2017,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,36852,51346,8028,197,  2%, ,Indication,"Cancer, solid, unspecified"
I,,,,,,Peptide,,Vaxon Biotech,,Vx-006,,Oncology,Solid,Solid Tumors,"HER2/neu or ErbB-2,Immune System,Melanoma antigen-encoding gene (MAGE),Telomerase",,Vx006,Y,I,6% (Same As Avg.), - , - , - ,,,,,,,11/12/2014,,Biologic,,,No,,,France,Europe,,29125,40459,6138,197,N/A, ,,
I/II,,,07/01/2020,07/01/2020,,Peptide,,"Sapience Therapeutics, Inc.",,ST101 (Sapience),,Oncology,Solid,Solid Tumors,,,"ST-101, ST 101",N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,New York,United States,North America,,41422,58111,9445,197,  4%, ,Orphan Drug designation,N/A
I/II,,,,11/13/2019,11/13/2019,Peptide,,"Bicycle Therapeutics, plc",BCYC,BT5528,,Oncology,Solid,Solid Tumors,"Antibody-drug Conjugate (ADC),Ephrin Receptor EphA2 ",,"BT-5528, BT 5528",Y,II,10% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,38440,53672,6753,197,  8%,$251.55M ,Lead Indication,Yes
Preclinical,,,,,,Peptide,,"Sapience Therapeutics, Inc.",,Beta-Catenin Antagonist,,Oncology,Solid,Solid Tumors,,,"B-Catenin Antagonist,",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,New York,United States,North America,,41431,58120,9445,197,N/A, ,,
Preclinical,,,,,,Peptide,,Altimmune Inc. ,ALT,ALT-702,,Oncology,Solid,Solid Tumors,"Immune System,Toll-like receptor 7 (TLR7),Toll-like receptor 8 (TLR8)",,"ALT702, ALT 702",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Maryland,United States,North America,,40537,56793,5116,197,N/A,$459.69M ,,
Preclinical,,,,,,Peptide,,Scancell,SCLP,Modi-2,,Oncology,Solid,Solid Tumors,"Cluster of Differentiation 4 (CD4),Immune System,Vimentin",,Moditope vaccine,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,39428,55145,3349,197,N/A,$174.53M ,,
Preclinical,,,,,,Peptide,,Theratechnologies Inc.,THTX,TH-1902,,Oncology,Solid,Solid Tumors,"Microtubules (Tubulin),Sortilin 1 (SORT1)",,"Theratechnologies/Katana Oncology Peptide Program, TH1902, TH 1902",N,IND,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Quebec,Canada,North America,,40176,56200,459,197,N/A, ,,
Suspended,,,,,08/16/2018,Peptide,,Biosceptre International Limited,,BIL06v,,Oncology,Solid,Solid Tumors,"Immune System,Purinergic receptor P2X ligand-gated ion channel 7 (P2RX7)",,"peptide mimetic cancer vaccine, BIL-06v, BIL 06v",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,United Kingdom,Europe,,38842,54272,8639,197,N/A, ,,
Suspended,,,,,,Peptide,,Mediolanum Farmaceutici SpA,,GX 301,,Oncology,Solid,Solid Tumors,Telomerase,Genovax S.r.l.,GX301,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Italy,Europe,,22374,30333,4262,197,N/A, ,,
Suspended,,,,,,Peptide,,Aeterna Zentaris Inc.,AEZS,AEZS-125,,Oncology,Solid,Solid Tumors,Gonadotropin-Releasing Hormone (GnRH) Receptor,,Disorazol Z-D-Lys6-LHRH conjugate,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Canada,North America,,21324,28725,14,197,N/A,$33.59M ,,
Preclinical,,,,,,Peptide,,Debiopharm S.A.,,Debio 1124,,Oncology,Solid,Thyroid Cancer - Imaging,"Cholecystokinin 2 (CCK2 or CCKB) / Gastrin receptor,Radiopharmaceutical",,"Debio1124, Debio-1124, radioconjugated minigastrin analogue",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,Yes,,,Switzerland,Europe,,39280,54943,856,3383,N/A, ,,
I/II,,,,12/16/2019,12/16/2019,Peptide,,Allysta Pharmaceuticals,,ALY688,,Ophthalmology,Other,Dry Eye (Ophthalmology),Adiponectin receptors,,"ALY 688, ALY-688",Y,II,24% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,39057,54610,8703,548,N/A, ,,
Suspended,,,,,05/15/2017,Peptide,,Takeda Pharmaceutical Co. Ltd.,TAK,SHP639,,Ophthalmology,Glaucoma,Glaucoma / Ocular Hypertension (Ophthalmology),,,"SHP 639, SHP-639, TAK639, TAK-639, TAK 639",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,05/15/2017,03/31/2017,New Molecular Entity (NME),,,No,,,Japan,Asia,,27147,37954,826,278,N/A,$46.05B ,,
Suspended,,,,,,Peptide,,"Santen Pharmaceutical Co., Ltd.",4536,PDPS Program (Santen/PeptiDream),,Ophthalmology,Other,Other Ophthalmological Indications (Ophthalmology),Unknown,PeptiDream Inc.,Peptide Discovery Platform System,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Japan,Asia,,39127,54720,564,2569,N/A,$6.43B ,,
Suspended,,,,,,Peptide,,BioDiem Ltd,,BDM-E,epitalon,Ophthalmology,Congenital Blindness,Retinitis Pigmentosa (RP) (Ophthalmology),Unknown,,epitalon,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Australia,Oceania,,22242,30110,3483,2875,N/A, ,,
Suspended,,,,,,Peptide,,"Thrasos Theraputics, Inc.",,THR-8590,,Renal,Chronic Renal Failure,Renal Disease / Renal Failure,,,THR8590,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Canada,North America,,39183,54797,3989,149,N/A, ,,
Suspended,,,,,,Peptide,,Spotlight Innovation Inc.,STLT,Cardiotoxin,,Renal,Chronic Renal Failure,Renal Disease / Renal Failure,Potassium channels,,Cardiotoxin,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Iowa,United States,North America,,27476,38475,5456,149,N/A,$894.05K ,,
Suspended,,,,,,Peptide,,"Travere Therapeutics, Inc.",TVTX,RE-034,cosyntropin,Renal,Chronic Renal Failure,Renal Disease / Renal Failure,Melanocortin (MC) receptors,,tetracosactide,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,23442,32161,3579,149,N/A,$1.41B ,,
Suspended,,,,,,Peptide,,"Windtree Therapeutics, Inc.",WINT,DSC-104,,Respiratory,Asthma,Asthma,Alveolar Surface,,Inhaled Surfactant,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/09/2004,,Biologic,,,No,,Pennsylvania,United States,North America,,1340,4225,685,72,N/A,$74.83M ,,
Preclinical,,,,,,Peptide,,"CohBar, Inc.",CWBR,MBT2 Analog (CohBar),,Respiratory,Other,Idiopathic Pulmonary Fibrosis (IPF),Mitochondria,,,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,California,United States,North America,,42370,59611,7466,387,N/A,$84.34M ,,
Suspended,,,,,,Peptide,,Compugen Ltd.,CGEN,CGEN-25009,,Respiratory,Other,Idiopathic Pulmonary Fibrosis (IPF),Relaxin Family Peptide Receptors 1-4 (RXFP1-4),,CGEN25009,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,,Israel,Asia,,22603,30739,3500,387,N/A,$1.10B ,,
Preclinical,,,,,,Peptide,,Eli Lilly and Company,LLY,DACRA-056,,Rheumatology (Non Autoimmune),Osteoarthritis,Osteoarthritis and Osteoarthritis Pain,"Amylin Receptor,Calcitonin Gene-Related Peptide (CGRP) / Receptor",Nordic Bioscience A/S,"KBP056, KBP 056, KBP-056",Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Indiana,United States,North America,,35203,48828,136,249,N/A,$158.63B ,,
Development Outside U.S.,,,,,,Peptide,,Hamlet Pharma AB,HAMLET,Alpha1H,,Oncology,Solid,Bladder Cancer,Tumor Cells,,Human Alpha-Lactalbumin,N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Sweden,Europe,,40709,57076,9258,217,N/A,$79.95M ,,
Development Outside U.S.,,,,,,Peptide,,Strongbridge Biopharma plc,SBBP,COR-005,somatoprim,Endocrine,Other,Cushing's Syndrome,Somatostatin Receptors,Evotec SE,"DG3173, Somatoprim, COR 005, COR005, DG-3173, DG 3173, PTR-3173, Veldoreotide, somatostatin analogue, Peptor, Biomeas",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Pennsylvania,United States,North America,,22479,30512,5262,637,N/A,$188.28M ,,
Development Outside U.S.,,,,,,Peptide,,Strongbridge Biopharma plc,SBBP,COR-005,somatoprim,Ophthalmology,Retinopathy,Diabetic Retinopathy (Ophthalmology),Somatostatin Receptors,Evotec SE,"DG3173, Somatoprim, COR 005, COR005, DG-3173, DG 3173, PTR-3173, Veldoreotide, somatostatin analogue, Peptor, Biomeas",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Pennsylvania,United States,North America,,22479,30511,5262,364,N/A,$188.28M ,,
Development Outside U.S.,,,,,,Peptide,,Amolyt Pharma,,AZP-3404,,Endocrine,General,Endocrine Disorder,Insulin-Like Growth Factor Family ,,"AZP 3404, AZP3404",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,France,Europe,,40279,56367,9118,182,N/A, ,,
Development Outside U.S.,,,,,,Peptide,,"OncoTherapy Science, Inc.",4564:JP,OTSGC-A24,,Oncology,Solid,Gastric Cancer,T lymphocytes,,OTSGC-A24,N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Vaccine,,,No,,,Japan,Asia,,39822,55693,3322,223,N/A,$203.86M ,,
Development Outside U.S.,,,,,04/12/2018,Peptide,,"AnGes, Inc.",4563,AGMG0201,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),"Angiotensins (I-IV),Immune System",,"Ang II vaccine, Angiotensin II DNA Vaccine",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Vaccine,,,No,,,Japan,Asia,,26129,36419,858,244,N/A,$1.60B ,,
Development Outside U.S.,,,,,10/26/2016,Peptide,,Apitope Technology (Bristol) Ltd,,ATX-GD-459,,Endocrine,Thyroid,Hyperthyroidism / Graves' Disease,Thyroid stimulating hormone receptor (TSHR),,"ATX-GD-459, ATX-GD 459, ATX-GD-59",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Belgium,Europe,,23120,31612,1403,3371,N/A, ,,
Development Outside U.S.,,,,,,Peptide,,WntResearch AB,WNT.ST,Box-5,,Oncology,Solid,Melanoma,WNT Signaling Pathway,,"Box 5, Box5",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Sweden,Europe,,31126,43052,6117,221,N/A, ,,
Development Outside U.S.,,,,,,Peptide,,"JCR Pharmaceuticals Co., Ltd.",4552,JR-171,,Metabolic,Inborn Errors Of Metabolism,Mucopolysaccharidosis I (MPS I; Hurler Syndrome),Unsulfated alpha-L-iduronic acid,,"JR 171, JR171",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Japan,Asia,,36415,50706,2837,289,N/A,$2.94B ,,
Development Outside U.S.,,,,,,Peptide,,FunPep Co. Ltd.,,FPP003,,Autoimmune/immunology,Psoriasis,Psoriasis,,,"FPP 003 , FPP-003",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Japan,Asia,,40183,56214,5567,155,N/A, ,,
Development Outside U.S.,,,,,,Peptide,,Strongbridge Biopharma plc,SBBP,COR-005,somatoprim,Oncology,Solid,Solid Tumors,Somatostatin Receptors,Evotec SE,"DG3173, Somatoprim, COR 005, COR005, DG-3173, DG 3173, PTR-3173, Veldoreotide, somatostatin analogue, Peptor, Biomeas",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Pennsylvania,United States,North America,,22479,30513,5262,197,N/A,$188.28M ,,
Suspended,,,04/17/2013,04/17/2013,,Peptide,Inhaled,APEPTICO GmbH,,AP301,solnatide,Autoimmune/immunology,Transplant Rejection,Lung Transplant Rejection,Tumor Necrosis Factor-alpha (TNF-alpha),,Human tumour necrosis factor alpha-derived peptide,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Austria,Europe,,18205,30251,3254,627,N/A, ,,
II,,,,10/12/2006,,Peptide,Inhaled,"NeuroRx, Inc.",,Aviptadil,,Autoimmune/immunology,Other,Sarcoidosis,Vasoactive Intestinal Peptide (VIP) Receptor,"Bachem Holding AG, Biogen, Inc., Relief Therapeutics Holding AG","Vasoactive Intestinal Peptide; VIP, DasKloster 1000-01, RLF-100, RLF100, RLF 100",N,II,20% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Delaware,United States,North America,,8244,10194,6943,1506,N/A, ,,
Suspended,,,,09/14/2006,,Peptide,Inhaled,"NeuroRx, Inc.",,Aviptadil,,Cardiovascular,Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH),Vasoactive Intestinal Peptide (VIP) Receptor,"Bachem Holding AG, Biogen, Inc., Relief Therapeutics Holding AG","Vasoactive Intestinal Peptide; VIP, DasKloster 1000-01, RLF-100, RLF100, RLF 100",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,12/22/2003,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,Delaware,United States,North America,,8244,34269,6943,245,N/A, ,,
Suspended,,,,04/05/2005,,Peptide,Inhaled,"Biogen, Inc.",BIIB,Aviptadil (PAH),,Cardiovascular,Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH),Vasoactive Intestinal Peptide (VIP) Receptor,"Bachem Holding AG, Relief Therapeutics Holding AG",Vasoactive Intestinal Peptide; VIP,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/28/2004,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,Massachusetts,United States,North America,,2814,4796,64,245,N/A,$38.54B ,,
I/II,,,03/28/2013,11/30/2013,,Peptide,Inhaled,Aerami Therapeutics,,AER-501,human insulin,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,"Harmony Asset Ltd, Hikma Pharmaceuticals plc","Inhaled Insulin, inhaled preservative-free human insulin, Adagio, Dance501, Dance 501, Dance-501, AER501, AER 501",Y,II,19% (5% Below Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,North Carolina,United States,North America,,23989,33116,4675,157,N/A, ,,
Suspended,,,,09/20/2005,,Peptide,Inhaled,AbbVie Inc.,ABBV,ABT Inhaled Insulin,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,s,"KI02212, Kos Inhaled Insulin",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/24/2003,,Non-NME,,,No,,Illinois,United States,North America,,2213,3933,5,157,N/A,$188.39B ,,
Suspended,,,,,,Peptide,Inhaled,Allergan plc,AGN,MAP0001,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,MAP-0001,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/20/2008,,Non-NME,,,No,,,Ireland,Europe,,11047,13878,395,157,N/A,$63.66B ,,
Suspended,08/10/2004,07/19/2005,11/27/2000,08/10/2004,,Peptide,Inhaled,Eli Lilly and Company,LLY,AIR Insulin,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,Alkermes plc,Human Insulin Inhalation Powder (HIIP),N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,11/27/2000,,Non-NME,,,No,,Indiana,United States,North America,90%,1253,3249,136,157,N/A,$158.63B ,,
Withdrawn from Market,11/10/1998,05/02/2002,,06/16/1998,,Peptide,Inhaled,Nektar Therapeutics,NKTR,Exubera,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,Pfizer Inc.,"inhaled insulin, CP-464,005",N,Approved,100% (Same As Avg.), - , - , - ,01/27/2006,01/26/2006,,,,03/02/2005,,,Non-NME,,,No,,California,United States,North America,,1226,3254,210,157,N/A,$3.34B ,,
II,,,09/24/2013,11/30/2013,,Peptide,Inhaled,Aerami Therapeutics,,AER-501,human insulin,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,"Harmony Asset Ltd, Hikma Pharmaceuticals plc","Inhaled Insulin, inhaled preservative-free human insulin, Adagio, Dance501, Dance 501, Dance-501, AER501, AER 501",Y,II,19% (5% Below Avg.), - , - , - ,,,,,,,,,Non-NME,505b2,,No,,North Carolina,United States,North America,,23989,33117,4675,137,N/A, ,,
Suspended,,,,08/26/2004,,Peptide,Inhaled,AbbVie Inc.,ABBV,ABT Inhaled Insulin,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"KI02212, Kos Inhaled Insulin",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,Illinois,United States,North America,,2213,3714,5,137,N/A,$188.39B ,,
Suspended,,,,,,Peptide,Inhaled,Allergan plc,AGN,MAP0001,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,MAP-0001,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/20/2008,,Non-NME,,,No,,,Ireland,Europe,,11047,13879,395,137,N/A,$63.66B ,,
Suspended,07/19/2005,07/19/2005,,,,Peptide,Inhaled,Eli Lilly and Company,LLY,AIR Insulin,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,Alkermes plc,Human Insulin Inhalation Powder (HIIP),Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,Indiana,United States,North America,90%,1253,3927,136,137,N/A,$158.63B ,,
Suspended,,,,,,Peptide,Inhaled,MannKind Corporation,MNKD,MKC-253,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,Technosphere GLP-1; MKC253,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,05/11/2007,,Non-NME,,,No,,California,United States,North America,,6025,6492,809,137,N/A,$837.36M ,,
Withdrawn from Market,11/10/1998,11/10/1998,,06/16/1998,,Peptide,Inhaled,Nektar Therapeutics,NKTR,Exubera,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,Pfizer Inc.,"inhaled insulin, CP-464,005",Y,Approved,100% (Same As Avg.), - , - , - ,01/27/2006,01/26/2006,,,,11/30/2004,,,Non-NME,,,No,,California,United States,North America,,1226,1866,210,137,N/A,$3.34B ,,
Suspended,,,,,,Peptide,Inhaled,Azelon Pharmaceuticals,,Ostabolin-C (inhalable),,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Parathyroid Hormone Receptor (PTHR),,"Inhalable cyclic PTH-(1-31), Inhalable ZT-031",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,09/21/2006,,New Molecular Entity (NME),,,No,,Pennsylvania,United States,North America,,2818,4806,552,242,N/A, ,,
Suspended,,,,,06/07/2007,Peptide,Inhaled,Alkermes plc,ALKS,AIR PTH,teriparatide ,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Parathyroid Hormone Receptor (PTHR),,"AIR parathyroid hormone, AIR PTH [1-34]",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,06/07/2007,,Biologic,,,No,,,Ireland,Europe,,6979,7429,22,242,N/A,$3.28B ,,
II/III,,11/13/2020,04/07/2020,04/07/2020,,Peptide,Inhaled,"NeuroRx, Inc.",,Aviptadil,,Infectious Disease,Antiviral,COVID-19 Treatment,Vasoactive Intestinal Peptide (VIP) Receptor,"Bachem Holding AG, Biogen, Inc., Relief Therapeutics Holding AG","Vasoactive Intestinal Peptide; VIP, DasKloster 1000-01, RLF-100, RLF100, RLF 100",N,III,61% (Same As Avg.), - , - , - ,,,,,,,,03/26/2020,New Molecular Entity (NME),Fast Track,,No,,Delaware,United States,North America,,8244,59086,6943,3651,N/A, ,,
IND,,,,,,Peptide,Inhaled,Synairgen plc,SNG,SNG001,,Infectious Disease,Antiviral,COVID-19 Treatment,Interferon Receptor,Rentschler Biopharma SE ,"inhaled interferon beta, SNG 001, AZD9412, Interferon Beta-1A",N,IND,0% (Same As Avg.), - , - , - ,,,,,,,,12/18/2020,Biologic,Fast Track,,No,,,United Kingdom,Europe,,19960,59096,3680,3651,N/A,$413.05M ,,
Preclinical,,,,,,Peptide,Inhaled,"Windtree Therapeutics, Inc.",WINT,Aerosurf,lucinactant,Infectious Disease,Antiviral,Influenza (excluding vaccines),Alveolar Surface,Lee's Pharmaceutical Holdings Limited,"aSRT, Aerosolized KL4 Surfactant, lucinactant",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Pennsylvania,United States,North America,,2669,46654,685,3302,N/A,$74.83M ,,
Suspended,,,,,,Peptide,Inhaled,Synairgen plc,SNG,SNG001,,Infectious Disease,Antiviral,Influenza (including vaccines),Interferon Receptor,Rentschler Biopharma SE ,"inhaled interferon beta, SNG 001, AZD9412, Interferon Beta-1A",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,United Kingdom,Europe,,19960,26496,3680,237,N/A,$413.05M ,,
Preclinical,,,,,,Peptide,Inhaled,Santhera Pharmaceuticals,SANN,POL6014,,Metabolic,General,Metabolic - General,Human Neutrophil elastase (hNE),"PARI GmbH, Polyphor AG","POL-6014, POL 6014",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,22263,41096,1374,3163,N/A,$45.09M ,,
II,,,01/23/2018,01/23/2018,,Peptide,Inhaled,"BioMarck Pharmaceuticals, Ltd.",,BIO-11006,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),MARCKS (Myristoylated alanine-rich C-kinase substrate),,"BIO11006, BIO 11006",N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,North Carolina,United States,North America,,23815,51822,4631,211,  4%, ,Orphan Drug designation,N/A
II,,,,06/16/2005,,Peptide,Inhaled,"NeuroRx, Inc.",,Aviptadil,,Respiratory,Other,"Acute Respiratory Failure, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS)",Vasoactive Intestinal Peptide (VIP) Receptor,"Bachem Holding AG, Biogen, Inc., Relief Therapeutics Holding AG","Vasoactive Intestinal Peptide; VIP, DasKloster 1000-01, RLF-100, RLF100, RLF 100",N,II,18% (Same As Avg.), - , - , - ,,,,,,,07/28/2004,,New Molecular Entity (NME),Orphan,,No,,Delaware,United States,North America,,8244,10192,6943,685,N/A, ,,
II,,,10/03/2017,10/03/2017,,Peptide,Inhaled,"BioMarck Pharmaceuticals, Ltd.",,BIO-11006,,Respiratory,Other,"Acute Respiratory Failure, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS)",MARCKS (Myristoylated alanine-rich C-kinase substrate),,"BIO11006, BIO 11006",N,II,18% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,North Carolina,United States,North America,,23815,49178,4631,685,N/A, ,,
Suspended,,,06/29/2012,06/29/2012,04/07/2011,Peptide,Inhaled,APEPTICO GmbH,,AP301,solnatide,Respiratory,Other,"Acute Respiratory Failure, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS)",Tumor Necrosis Factor-alpha (TNF-alpha),,Human tumour necrosis factor alpha-derived peptide,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,04/07/2011,,New Molecular Entity (NME),Orphan,,No,,,Austria,Europe,,18205,27407,3254,685,N/A, ,,
Preclinical,,,,,,Peptide,Inhaled,"Antlia Bioscience, Inc.",,LANA-AS,,Respiratory,Asthma,Asthma,Unknown,,LANA AS,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,43530,61379,25965,72,N/A, ,,
Suspended,,,,,,Peptide,Inhaled,"Longevity Biotech, Inc.",,5A ApoA-I Mimetic Peptide Program,,Respiratory,Asthma,Asthma," ATP-Binding Cassette Transporter G1 (ABCG1),Reactive Oxygen Species/Free Radicals",,5A Apolipoprotein A-I Mimetic Peptide Program,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Pennsylvania,United States,North America,,36950,51518,7927,72,N/A, ,,
Suspended,,,04/01/2010,04/01/2010,,Peptide,Inhaled,Synairgen plc,SNG,SNG001,,Respiratory,Asthma,Asthma,Interferon Receptor,Rentschler Biopharma SE ,"inhaled interferon beta, SNG 001, AZD9412, Interferon Beta-1A",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,06/12/2007,,Biologic,,,No,,,United Kingdom,Europe,,19960,26493,3680,72,N/A,$413.05M ,,
Preclinical,,,,,06/06/2016,Peptide,Inhaled,Santhera Pharmaceuticals,SANN,POL6014,,Respiratory,Other,Bronchiectasis,Human Neutrophil elastase (hNE),"PARI GmbH, Polyphor AG","POL-6014, POL 6014",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,06/06/2016,,New Molecular Entity (NME),Rare Disease,,No,,,Switzerland,Europe,,22263,41095,1374,561,N/A,$45.09M ,,
Program Hold,,,02/07/2018,07/30/2015,,Peptide,Inhaled,Synairgen plc,SNG,SNG001,,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),Interferon Receptor,Rentschler Biopharma SE ,"inhaled interferon beta, SNG 001, AZD9412, Interferon Beta-1A",Y,II,18% (Same As Avg.), - , - , - ,,,,,,,06/12/2007,,Biologic,,,No,,,United Kingdom,Europe,,19960,26494,3680,73,N/A,$413.05M ,,
Suspended,,,,06/26/2008,,Peptide,Inhaled,"BioMarck Pharmaceuticals, Ltd.",,BIO-11006,,Respiratory,COPD,Chronic Obstructive Pulmonary Disease (COPD),MARCKS (Myristoylated alanine-rich C-kinase substrate),,"BIO11006, BIO 11006",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,North Carolina,United States,North America,,23815,32810,4631,73,N/A, ,,
I,,,,,09/01/2015,Peptide,Inhaled,Santhera Pharmaceuticals,SANN,POL6014,,Respiratory,Cystic Fibrosis,Cystic Fibrosis (CF),Human Neutrophil elastase (hNE),"PARI GmbH, Polyphor AG","POL-6014, POL 6014",N,I,12% (Same As Avg.), - , - , - ,,,,,,,09/01/2015,,New Molecular Entity (NME),Rare Disease,,No,,,Switzerland,Europe,,22263,30146,1374,74,N/A,$45.09M ,,
Program Hold,,,09/03/2008,09/03/2008,,Peptide,Inhaled,"Windtree Therapeutics, Inc.",WINT,Aerosurf,lucinactant,Respiratory,Cystic Fibrosis,Cystic Fibrosis (CF),Alveolar Surface,Lee's Pharmaceutical Holdings Limited,"aSRT, Aerosolized KL4 Surfactant, lucinactant",N,II,18% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,Pennsylvania,United States,North America,,2669,22861,685,74,N/A,$74.83M ,,
Suspended,,,08/31/2017,08/31/2017,,Peptide,Inhaled,"Spyryx Biosciences, Inc.",,SPX-101,,Respiratory,Cystic Fibrosis,Cystic Fibrosis (CF),Sodium Channels,,"SPX101, SPX 101",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/18/2016,,New Molecular Entity (NME),Rare Disease,,No,,North Carolina,United States,North America,,26033,36281,5297,74,N/A, ,,
Suspended,,,,,,Peptide,Inhaled,"RegeneRx Biopharmaceuticals, Inc.",RGRX,RGN-457,,Respiratory,Cystic Fibrosis,Cystic Fibrosis (CF),"Actin Filaments,ATP Synthase,Integrin-linked kinase (ILK)",,"RGN457, RGN 457",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,Maryland,United States,North America,,23304,31923,460,74,N/A,$62.06M ,,
f,,,,04/01/2007,,Peptide,Inhaled,"NeuroRx, Inc.",,Aviptadil,,Respiratory,Other,Idiopathic Pulmonary Fibrosis (IPF),Vasoactive Intestinal Peptide (VIP) Receptor,"Bachem Holding AG, Biogen, Inc., Relief Therapeutics Holding AG","Vasoactive Intestinal Peptide; VIP, DasKloster 1000-01, RLF-100, RLF100, RLF 100",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Delaware,United States,North America,,8244,10193,6943,387,N/A, ,,
Suspended,,,,,,Peptide,Inhaled,"Moerae Matrix, Inc.",,MMI-0100,,Respiratory,Other,Idiopathic Pulmonary Fibrosis (IPF),Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2),,MMI-0100,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/05/2014,,New Molecular Entity (NME),Rare Disease,,No,,New Jersey,United States,North America,,24482,33983,4796,387,N/A, ,,
Suspended,,,,,01/12/2016,Peptide,Inhaled,GlaxoSmithKline plc,GSK,GSK3008348,,Respiratory,Other,Idiopathic Pulmonary Fibrosis (IPF),Integrin Alpha-V Family,,"GSK 3008348, GSK-3008348",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,01/12/2016,,New Molecular Entity (NME),Rare Disease,,No,,,United Kingdom,Europe,,27470,38459,180,387,N/A,$94.89B ,,
Preclinical,,,,,,Peptide,Inhaled,Santhera Pharmaceuticals,SANN,POL6014,,Respiratory,General,Respiratory Disease,Human Neutrophil elastase (hNE),"PARI GmbH, Polyphor AG","POL-6014, POL 6014",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,22263,47379,1374,234,N/A,$45.09M ,,
IIb,,,,08/08/2008,,Peptide,Inhaled,"Windtree Therapeutics, Inc.",WINT,Aerosurf,lucinactant,Respiratory,Other,Respiratory Distress Syndrome (RDS),Alveolar Surface,Lee's Pharmaceutical Holdings Limited,"aSRT, Aerosolized KL4 Surfactant, lucinactant",Y,II,13% (5% Below Avg.), - , - , - ,,,,,,,05/01/2006,,New Molecular Entity (NME),"Fast Track,Rare Disease",,No,,Pennsylvania,United States,North America,,2669,4555,685,616,N/A,$74.83M ,,
Preclinical,,,,,,Peptide,Inhaled,"Acorda Therapeutics, Inc.",ACOR,CVT-717,surfactant,Respiratory,Other,Respiratory Distress Syndrome (RDS),Alveolar Surface,,"Surfactant Inhaled Formulation, Inhaled Surfactant",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,New York,United States,North America,,26463,36914,8,616,N/A,$33.25M ,,
Development Outside U.S.,,,,,,Peptide,Inhaled,APEPTICO GmbH,,AP301,solnatide,Infectious Disease,Antiviral,COVID-19 Treatment,Tumor Necrosis Factor-alpha (TNF-alpha),,Human tumour necrosis factor alpha-derived peptide,N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Austria,Europe,,18205,59046,3254,3651,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Inhaled,Polyphor AG,POLN,Inhaled Murepavadin,murepavadin,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Pseudomonas-Specific Agents (Antibacterial),"Cell Membrane,Pseudomonas aeruginosa",,Murepavadin (IH),N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,Switzerland,Europe,,36287,50516,3395,3119,N/A,$102.79M ,,
Approved (Generic Competition),,11/01/2002,,,,Peptide,Inhaled,"Sawai Pharmaceutical Co., Ltd.",4555,Fortical,,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Calcitonin Receptor,"Unigene Laboratories, Inc.",calcitonin salmon nasal spray,N,Approved,100% (Same As Avg.), - , - , - ,08/12/2005,,,,,,,,Non-NME,,,No,,,Japan,Asia,,21683,29269,2817,242,N/A,$2.00B ,,
Approved,06/29/2005,06/29/2005,,11/10/2004,,Peptide,Inhaled,MannKind Corporation,MNKD,Afrezza,human insulin,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,Cipla Limited,"Technosphere Insulin System, TIA, Afresa",Y,Approved,100% (Same As Avg.), - , - , - ,06/27/2014,,,,,03/16/2009,,,Non-NME,,,No,,California,United States,North America,,2214,3925,809,157,N/A,$837.36M ,,
Approved,06/29/2005,06/29/2005,,11/10/2004,,Peptide,Inhaled,MannKind Corporation,MNKD,Afrezza,human insulin,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,Cipla Limited,"Technosphere Insulin System, TIA, Afresa",Y,Approved,100% (Same As Avg.), - , - , - ,06/27/2014,,,,,03/16/2009,,,Non-NME,SPA,,No,,California,United States,North America,,2214,3715,809,137,N/A,$837.36M ,,
II,,,01/23/2014,08/16/2013,,Peptide,Intraarticular,"OrthoTrophix, Inc.",,TPX-100,,Rheumatology (Non Autoimmune),Osteoarthritis,Osteoarthritis and Osteoarthritis Pain,Integrin Alpha 2 beta 1/VLA-2,,"TPX100, TPX 100",Y,II,21% (3% Below Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,22818,31101,4391,249,N/A, ,,
Suspended,,,02/10/2009,02/10/2009,02/29/2008,Peptide,Intradermal,Capstone Therapeutics Corp.,CAPS,AZX100,,Autoimmune/immunology,General,Wound Healing,Actin Filaments,,AZX-100,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,02/29/2008,01/28/2008,New Molecular Entity (NME),,,No,,Arizona,United States,North America,,18262,23896,3280,1578,N/A,$1.84M ,,
II,,,04/25/2016,07/05/2017,,Peptide,Intradermal,"Sumitomo Dainippon Pharma Co., Ltd.",4506,DSP-7888,nelatimotide/adegramotide,Oncology,Solid,Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM)),"Immune System,Wilms' Tumor Protein 1 (WT1)",,"DSP7888, DSP 7888, nelatimotide and adegramotide, adegramotide/nelatimotide, ombipepimut-S",Y,II,10% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Japan,Asia,,26609,44922,686,228,  8%,$5.96B ,Orphan Drug designation,Yes
II,,,,05/29/2020,,Peptide,Intradermal,Greenwich LifeSciences,GLSI,GP2,,Oncology,Solid,Breast Cancer,HER2/neu or ErbB-2,,GP2,N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Texas,United States,North America,,43364,61151,12026,214,N/A,$458.74M ,,
IIb,,,02/01/2007,02/01/2007,03/22/2005,Peptide,Intradermal,Generex Biotechnology Corporation,GNBT,AE37,,Oncology,Solid,Breast Cancer,"HER2/neu or ErbB-2,Immune System","Shenzhen Boshengkang Biotechnology Co., Ltd","AE 37, AE-37",Y,II,8% (2% Below Avg.), - , - , - ,,,,,,,03/22/2005,,Biologic,,,No,,Florida,United States,North America,,2174,3617,164,214, 18%,$21.36M ,Lead Indication,Yes
IIb,11/23/2011,06/19/2009,,01/22/2008,,Peptide,Intradermal,"SELLAS Life Sciences Group, Inc.",SLS,NeuVax,nelipepimut-S,Oncology,Solid,Breast Cancer,"Granulocyte Macrophage Colony-Stimulating Factor Receptor (GM-CSFR)/CD116,HER2/neu or ErbB-2,Immune System","Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd.","nelipepimut-S (NPS), E 75, E-75, E75",Y,II,13% (3% Above Avg.), - , - , - ,,,,,,,,,Biologic,"Fast Track,SPA",,No,,New York,United States,North America,,18410,24117,5266,214, 30%,$79.06M ,Fast Track,Yes
Suspended,,,,04/19/2016,,Peptide,Intradermal,"SELLAS Life Sciences Group, Inc.",SLS,GALE-301/302,,Oncology,Solid,Breast Cancer,"Folate Binding Protein,Immune System",,"GALE-301/GALE-302, GALE-301/302 Combination",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,09/30/2013,,New Molecular Entity (NME),,,No,,New York,United States,North America,,27369,38279,5266,214,N/A,$79.06M ,,
Suspended,,,,,10/15/2010,Peptide,Intradermal,Lytix Biopharma AS,,LTX-315/GV1001,,Oncology,General,Cancer,"Cell Membrane,Immune System,Telomerase",KAEL Co. Ltd.,LTX-315/GV1001,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,06/09/2010,,New Molecular Entity (NME),,,No,,,Norway,Europe,,17532,22836,2958,313,N/A, ,,
Suspended,,,,04/22/2008,,Peptide,Intradermal,Immatics N.V.,IMTX,IMA910,,Oncology,Solid,Colorectal Cancer (CRC),"Immune System,Tumor Cells",,IMA910,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Germany,Europe,,19572,25832,2921,213,N/A, ,,
Suspended,,,,,,Peptide,Intradermal,"SELLAS Life Sciences Group, Inc.",SLS,NeuVax,nelipepimut-S,Oncology,Solid,Gastric Cancer,"Granulocyte Macrophage Colony-Stimulating Factor Receptor (GM-CSFR)/CD116,HER2/neu or ErbB-2,Immune System","Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd.","nelipepimut-S (NPS), E 75, E-75, E75",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,New York,United States,North America,,18410,32426,5266,223,N/A,$79.06M ,,
I,,,,,05/11/2016,Peptide,Intradermal,"BrightPath Biotherapeutics Co., Ltd",,GRN-1201,,Oncology,Solid,Melanoma,"HLA-A,Immune System",,"GRN1201, GRN 1201",Y,I,6% (Same As Avg.), - , - , - ,,,,,,,05/11/2016,10/06/2015,Biologic,,,No,,,Japan,Asia,,27649,38785,5772,221,  5%, ,Lead Indication,Yes
Suspended,,,,,,Peptide,Intradermal,"Sumitomo Dainippon Pharma Co., Ltd.",4506,WT4869,,Oncology,Hematologic,Multiple Myeloma (MM),"Immune System,Wilms' Tumor Protein 1 (WT1)","Chugai Pharmaceutical Co., Ltd.",WT4869,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Japan,Asia,,17786,23203,686,207,N/A,$5.96B ,,
I,,,,,07/21/2015,Peptide,Intradermal,"Sumitomo Dainippon Pharma Co., Ltd.",4506,DSP-7888,nelatimotide/adegramotide,Oncology,Hematologic,Myelodysplastic Syndrome (MDS),"Immune System,Wilms' Tumor Protein 1 (WT1)",,"DSP7888, DSP 7888, nelatimotide and adegramotide, adegramotide/nelatimotide, ombipepimut-S",Y,I,6% (Same As Avg.), - , - , - ,,,,,,,07/21/2015,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Japan,Asia,,26609,37140,686,206, 13%,$5.96B ,Orphan Drug designation,Yes
Suspended,,,,,,Peptide,Intradermal,"Sumitomo Dainippon Pharma Co., Ltd.",4506,WT4869,,Oncology,Hematologic,Myelodysplastic Syndrome (MDS),"Immune System,Wilms' Tumor Protein 1 (WT1)","Chugai Pharmaceutical Co., Ltd.",WT4869,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Japan,Asia,,17786,23459,686,206,N/A,$5.96B ,,
II,,,06/13/2018,01/30/2018,,Peptide,Intradermal,"BrightPath Biotherapeutics Co., Ltd",,GRN-1201,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),"HLA-A,Immune System",,"GRN1201, GRN 1201",N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Japan,Asia,,27649,52700,5772,211,  3%, ,Drug Modality,Peptide; Vaccine
Suspended,,,,,08/07/2008,Peptide,Intradermal,Generex Biotechnology Corporation,GNBT,AE37,,Oncology,Solid,Ovarian Cancer,"HER2/neu or ErbB-2,Immune System","Shenzhen Boshengkang Biotechnology Co., Ltd","AE 37, AE-37",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/07/2008,07/09/2008,Biologic,Rare Disease,,No,,Florida,United States,North America,,2174,14958,164,224,N/A,$21.36M ,,
Suspended,,,,,,Peptide,Intradermal,"SELLAS Life Sciences Group, Inc.",SLS,GALE-301/302,,Oncology,Solid,Ovarian Cancer,"Folate Binding Protein,Immune System",,"GALE-301/GALE-302, GALE-301/302 Combination",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,09/30/2013,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,New York,United States,North America,,27369,38280,5266,224,N/A,$79.06M ,,
Suspended,,,,,,Peptide,Intradermal,"SELLAS Life Sciences Group, Inc.",SLS,NeuVax,nelipepimut-S,Oncology,Solid,Ovarian Cancer,"Granulocyte Macrophage Colony-Stimulating Factor Receptor (GM-CSFR)/CD116,HER2/neu or ErbB-2,Immune System","Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd.","nelipepimut-S (NPS), E 75, E-75, E75",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,New York,United States,North America,,18410,43269,5266,224,N/A,$79.06M ,,
I,,,,,,Peptide,Intradermal,Generex Biotechnology Corporation,GNBT,AE37,,Oncology,Solid,Prostate Cancer,"HER2/neu or ErbB-2,Immune System","Shenzhen Boshengkang Biotechnology Co., Ltd","AE 37, AE-37",N,I,6% (Same As Avg.), - , - , - ,,,,,,,08/08/2006,,Biologic,,,No,,Florida,United States,North America,,2174,4732,164,215,  6%,$21.36M ,Target,HER2
Suspended,,,,,,Peptide,Intradermal,"SELLAS Life Sciences Group, Inc.",SLS,NeuVax,nelipepimut-S,Oncology,Solid,Prostate Cancer,"Granulocyte Macrophage Colony-Stimulating Factor Receptor (GM-CSFR)/CD116,HER2/neu or ErbB-2,Immune System","Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd.","nelipepimut-S (NPS), E 75, E-75, E75",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/21/2012,,Biologic,,,No,,New York,United States,North America,,18410,27968,5266,215,N/A,$79.06M ,,
Suspended,12/22/2010,12/22/2010,,09/25/2007,,Peptide,Intradermal,Immatics N.V.,IMTX,IMA901,,Oncology,Solid,Renal Cell Cancer (RCC),Immune System,,IMA901,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,11/29/2005,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Germany,Europe,,17339,22538,2921,216,N/A, ,,
I/II,,,,02/26/2015,02/26/2015,Peptide,Intradermal,ISA Pharmaceuticals B.V.,,ISA201,,Oncology,Solid,Solid Tumors,"Human Papillomavirus (HPV),Immune System,Toll-Like Receptor (TLR) Family,Toll-Like Receptor 2 (TLR2)",,ISA-201,N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Netherlands,Europe,,35404,49155,3000,197,N/A, ,,
I/II,,,07/30/2019,07/30/2019,12/24/2017,Peptide,Intradermal,"Sumitomo Dainippon Pharma Co., Ltd.",4506,DSP-7888,nelatimotide/adegramotide,Oncology,Solid,Solid Tumors,"Immune System,Wilms' Tumor Protein 1 (WT1)",,"DSP7888, DSP 7888, nelatimotide and adegramotide, adegramotide/nelatimotide, ombipepimut-S",N,II,10% (Same As Avg.), - , - , - ,,,,,,,12/24/2017,,New Molecular Entity (NME),,,No,,,Japan,Asia,,26609,50597,686,197,  3%,$5.96B ,Drug Modality,Peptide; Vaccine
Suspended,,,,,,Peptide,Intradermal,"Sumitomo Dainippon Pharma Co., Ltd.",4506,WT4869,,Oncology,Solid,Solid Tumors,"Immune System,Wilms' Tumor Protein 1 (WT1)","Chugai Pharmaceutical Co., Ltd.",WT4869,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Japan,Asia,,17786,24460,686,197,N/A,$5.96B ,,
Development Outside U.S.,,,,,,Peptide,Intradermal,"PassPort Technologies, Inc.",,Alzheimer's Peptide Program (PassPort/Hokkaido),,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Unknown,Hokkaido University,,N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,43500,61341,25946,141,N/A, ,,
Development Outside U.S.,,,,,11/17/2016,Peptide,Intradermal,Targovax ASA,TRVX,TG02 (Targovax),,Oncology,Solid,Colorectal Cancer (CRC),"Immune System,Ras",IOVaxis Therapeutics,"TG02 (Targovax), TG 02",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,11/17/2016,,New Molecular Entity (NME),,,No,,,Norway,Europe,,25185,35033,3386,213,N/A,$94.91M ,,
Development Outside U.S.,,,,,,Peptide,Intradermal,"CYTLIMIC, Inc.",,CYT001,,Oncology,Solid,Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases),Immune System,Immutep Ltd.,"CYT-001, CYT 001",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,,Japan,Asia,,37779,52684,8315,297,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Intradermal,Targovax ASA,TRVX,TG02 (Targovax),,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),"Immune System,Ras",IOVaxis Therapeutics,"TG02 (Targovax), TG 02",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Norway,Europe,,25185,35592,3386,211,N/A,$94.91M ,,
Development Outside U.S.,,,,01/30/2013,01/30/2013,Peptide,Intradermal,Targovax ASA,TRVX,TG01,,Oncology,Solid,Pancreatic Cancer,"Immune System,Ras",IOVaxis Therapeutics,"TG-01, TG 01",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Norway,Europe,,18680,24532,3386,220,N/A,$94.91M ,,
IIb,,,,12/31/2003,,Peptide,"Intradermal, Intranasal",Bionor Holding AS,,Vacc-4x,,Infectious Disease,Antiviral,HIV / AIDS,"HIV p24 protein,Immune System",,Vacc-4x,Y,II,27% (Same As Avg.), - , - , - ,,,,,,,,,Vaccine,,,No,,,Norway,Europe,,17248,22384,2910,78,N/A, ,,
Preclinical,,,,,,Peptide,Intramuscular (IM),ImCyse S.A.,,NMO Imotope Program (Imcyse),,Autoimmune/immunology,Other,"Neuromyelitis Optica (Devic's Syndrome, NMO)","HLA-DR,Immune System,T lymphocytes,T-Cell Receptor (TCR)",,,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Belgium,Europe,,42994,60588,5279,703,N/A, ,,
Preclinical,,,,,,Peptide,Intramuscular (IM),ImCyse S.A.,,RA Imotope Program (ImCyse/Pfizer),,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),"HLA-DR,Immune System,T lymphocytes,T-Cell Receptor (TCR)",Pfizer Inc.,,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Belgium,Europe,,37096,51726,5279,154,N/A, ,,
Suspended,,,03/31/2005,03/31/2005,,Peptide,Intramuscular (IM),"Urigen Pharmaceuticals, Inc.",,VLTS 934,,Cardiovascular,Peripheral Vascular Disease,Peripheral Arterial Disease (PAD),Cell Membrane,,"VLTS-934, poloxamer 188",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,New Jersey,United States,North America,,2142,3549,386,390,N/A, ,,
Suspended,,10/26/2006,,,,Peptide,Intramuscular (IM),"Ambrilia Biopharma, Inc.",AMB,C2L,octreotide acetate,Endocrine,Other,Acromegaly,Somatostatin Receptors,"Kyowa Kirin Co., Ltd., Teva Pharmaceutical Industries Ltd.","Prolonged-release formulation of Octreotide, C2L-OCT-01 PR",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,Rare Disease,,No,"EQ 0.05MG BASE/ML (INJECTABLE;INJECTION), EQ 0.1MG BASE/ML (INJECTABLE;INJECTION), EQ 0.2MG BASE/ML (INJECTABLE;INJECTION), EQ 0.5MG BASE/ML (INJECTABLE;INJECTION), EQ 10MG BASE/VIAL (INJECTABLE;INJECTION), EQ 1MG BASE/ML (INJECTABLE;INJECTION), EQ 20MG BASE/VIAL (INJECTABLE;INJECTION), EQ 30MG BASE/VIAL (INJECTABLE;INJECTION)",Quebec,Canada,North America,,11853,14928,613,680,N/A, ,,
Suspended,,,,02/02/2009,,Peptide,Intramuscular (IM),"Cancer Advances, Inc.",,Polyclonal Antibody Stimulator,,Gastroenterology (Non Inflammatory Bowel Disease),General,Gastroesophageal Reflux Disease (GERD),"gastrin1-17 (G17),Immune System",,"Polyclonal Antibody Stimulator (PAS), Insegia, G17DT, Anti-Gastrin 17, Anti-Gastrin Immunogen",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,North Carolina,United States,North America,,21270,28645,3988,644,N/A, ,,
II,,,12/08/2015,12/08/2015,08/24/2009,Peptide,Intramuscular (IM),"United Biomedical, Inc. ",,UB-311,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Amyloid Beta/Amyloid Plaques,,"UB311, UB 311, UBITh AD",Y,II,18% (1% Above Avg.), - , - , - ,,,,,,,08/24/2009,,New Molecular Entity (NME),,,No,,New York,United States,North America,,25175,35020,5048,141,N/A, ,,
III,09/04/2019,09/04/2019,12/17/2014,12/17/2014,,Peptide,Intramuscular (IM),Viatris Inc.,VTRS,Glatiramer Acetate (GA) Depot,glatiramer acetate,Neurology,Neurodegenerative,Multiple Sclerosis (MS),"Myelin,T lymphocytes",Mapi Pharma Ltd.,"glatiramer acetate long-acting injection, Glatiramer Acetate (Copaxone) Depot, GA Depot",Y,III,52% (Same As Avg.), - , - , - ,,,,,Now - 03/31/2021,,,,Non-NME,,,No,,Pennsylvania,United States,North America,,26133,36424,266,153,N/A, ,,
Suspended,,06/19/2002,,,,Peptide,Intramuscular (IM),GlaxoSmithKline plc,GSK,Plenaxis,abarelix,Obstetrics/Gynecology,Gynecology,Endometriosis,Gonadotropin-Releasing Hormone (GnRH) Receptor,,abarelix for injectable suspension,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,820,956,180,349,N/A,$94.89B ,,
I,,,,,11/28/2016,Peptide,Intramuscular (IM),"OncoPep, Inc.",,PVX-410,,Oncology,Solid,Breast Cancer,"CS1/SLAMF7,Immune System",,"PVX-410, Multi-peptide cancer vaccine (OncoPep)",N,I,6% (Same As Avg.), - , - , - ,,,,,,,11/28/2016,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,22454,44740,4289,214,  5%, ,Target has prior approval,Yes
Suspended,,,,02/02/2009,,Peptide,Intramuscular (IM),"Cancer Advances, Inc.",,Polyclonal Antibody Stimulator,,Oncology,Solid,Colorectal Cancer (CRC),"gastrin1-17 (G17),Immune System",,"Polyclonal Antibody Stimulator (PAS), Insegia, G17DT, Anti-Gastrin 17, Anti-Gastrin Immunogen",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,North Carolina,United States,North America,,21270,28644,3988,213,N/A, ,,
Suspended,,02/02/2009,,07/08/2003,,Peptide,Intramuscular (IM),"Cancer Advances, Inc.",,Polyclonal Antibody Stimulator,,Oncology,Solid,Gastric Cancer,"gastrin1-17 (G17),Immune System",,"Polyclonal Antibody Stimulator (PAS), Insegia, G17DT, Anti-Gastrin 17, Anti-Gastrin Immunogen",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,North Carolina,United States,North America,,21270,28643,3988,223,N/A, ,,
I/II,,,,01/29/2013,,Peptide,Intramuscular (IM),"OncoPep, Inc.",,PVX-410,,Oncology,Hematologic,Multiple Myeloma (MM),"CS1/SLAMF7,Immune System",,"PVX-410, Multi-peptide cancer vaccine (OncoPep)",Y,II,10% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,Massachusetts,United States,North America,,22454,30466,4289,207, 28%, ,Orphan Drug designation,Yes
III,,08/14/2000,,,,Peptide,Intramuscular (IM),"Cancer Advances, Inc.",,Polyclonal Antibody Stimulator,,Oncology,Solid,Pancreatic Cancer,"gastrin1-17 (G17),Immune System",,"Polyclonal Antibody Stimulator (PAS), Insegia, G17DT, Anti-Gastrin 17, Anti-Gastrin Immunogen",Y,III,35% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Fast Track,Rare Disease",,No,,North Carolina,United States,North America,,21270,28641,3988,220,N/A, ,,
III,,05/29/2008,,,,Peptide,Intramuscular (IM),"GP Pharm, S.A.",,Lutrate,leuprolide acetate,Oncology,Solid,Prostate Cancer,,"Hikma Pharmaceuticals plc, Lee's Pharmaceutical Holdings Limited, PharmaMar, S.A.","leuprolide acetate, Politrate (Italy), Leuprorelin, Lutrate Depot 22.5 mg, Lutrate Depot 3.75 mg",Y,III,35% (Same As Avg.), - , - , - ,,09/28/2011,,,,,,,Non-NME,,,No,,,Spain,Europe,,23244,31828,4354,215, 60%, ,Biosimilar,Yes
Withdrawn from Market,,12/03/2001,,,,Peptide,Intramuscular (IM),GlaxoSmithKline plc,GSK,Plenaxis,abarelix,Oncology,Solid,Prostate Cancer,Gonadotropin-Releasing Hormone (GnRH) Receptor,,abarelix for injectable suspension,Y,Approved,100% (Same As Avg.), - , - , - ,11/25/2003,09/29/2005,,,,12/11/2000,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,820,1939,180,215,N/A,$94.89B ,,
Development Outside U.S.,,,,,,Peptide,Intramuscular (IM),Alliance Pharma plc,APH,Syntometrine,oxytocin and ergometrine,Obstetrics/Gynecology,Obstetrics,Labor Induction,"Alpha Adrenergic Receptors,Dopamine Receptor - Unspecified,Oxytocin Receptor,Serotonin 5-HT2 receptor",Phebra Pty Ltd,"oxytocin/ergometrine, Syntometrine Ampoules",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,United Kingdom,Europe,,23055,31478,4450,2909,N/A,$633.85M ,,
Development Outside U.S.,,,,,,Peptide,Intramuscular (IM),ImCyse S.A.,,Autologous CD4+T Cells,,Neurology,Neurodegenerative,Multiple Sclerosis (MS),"HLA-DR,Immune System,T lymphocytes,T-Cell Receptor (TCR)",Pfizer Inc.,Autologous CD4+T Cells,Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Belgium,Europe,,25962,36191,5279,153,N/A, ,,
Approved,,,,,,Peptide,Intramuscular (IM),Novartis AG,NVS,Sandostatin LAR,octreotide acetate,Endocrine,Other,Acromegaly,Somatostatin Receptors,,"Sandostatin LAR Depot, octreotide acetate",Y,Approved,100% (Same As Avg.), - , - , - ,11/25/1998,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,"EQ 10MG BASE/VIAL (INJECTABLE;INJECTION), EQ 20MG BASE/VIAL (INJECTABLE;INJECTION), EQ 30MG BASE/VIAL (INJECTABLE;INJECTION)",,Switzerland,Europe,,2916,4968,289,680,N/A,$183.31B ,,
Approved,05/30/2012,05/30/2012,,,,Peptide,Intramuscular (IM),"Arbor Pharmaceuticals, LLC",,Triptodur,triptorelin pamoate,Endocrine,General,Endocrine Disorder,Gonadotropin-Releasing Hormone (GnRH),"Debiopharm S.A., Ipsen SA","Decapeptyl (EU), Pamorelin (EU), Triptorelin (Endocrine), AR 24, AR24, AR-24",Y,Approved,100% (Same As Avg.), - , - , - ,06/30/2017,01/09/2017,,,,08/29/2016,,,Non-NME,,,No,,Georgia,United States,North America,,34481,47652,4042,182,N/A, ,,
Approved,,,,,,Peptide,Intramuscular (IM),Fresenius SE & Co. KGaA,FSNUY,Glucagon Emergency Kit (Fresenius),,Endocrine,Other,Hyperinsulinemia/Hypoglycemia,Glucagon Receptor,,Glucagon for Injection (Fresenius),Y,Approved,100% (Same As Avg.), - , - , - ,05/08/2015,,,,,09/30/2010,,,Non-NME,505b2,,No,,,Germany,Europe,,41863,58791,882,3358,N/A, ,,
Approved,,,,,,Peptide,Intramuscular (IM),Novartis AG,NVS,Sandostatin LAR,octreotide acetate,Oncology,Solid,Neuroendocrine Tumors (NET),Somatostatin Receptors,,"Sandostatin LAR Depot, octreotide acetate",Y,Approved,100% (Same As Avg.), - , - , - ,11/25/1998,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,"EQ 10MG BASE/VIAL (INJECTABLE;INJECTION), EQ 20MG BASE/VIAL (INJECTABLE;INJECTION), EQ 30MG BASE/VIAL (INJECTABLE;INJECTION)",,Switzerland,Europe,,2916,17934,289,347,100%,$183.31B ,,
Approved,,,,,,Peptide,Intramuscular (IM),Recordati SpA,REC:IM,Cosmegen,,Oncology,Solid,Solid Tumors,RNA synthesis,,Dactinomycin for injection,N,Approved,100% (Same As Avg.), - , - , - ,12/10/1964,,,,,,,,New Molecular Entity (NME),,,No,,,Italy,Europe,,21756,29377,1008,197,100%,$10.59B ,,
Approved,09/30/2013,09/30/2013,03/31/2012,03/31/2012,,Peptide,"Intramuscular (IM), Intranasal",Eli Lilly and Company,LLY,Baqsimi,glucagon,Endocrine,Other,Hyperinsulinemia/Hypoglycemia,Glucagon Receptor,Locemia Solutions ULC,"intranasal glucagon, Baqsimi nasal powder, dry-mist nasal glucagon, LY900018, LY-900018, LY 900018, AMG5041, AMG504-1, AMG504 1, Baksumi (Japan)",Y,Approved,100% (Same As Avg.), - , - , - ,07/24/2019,12/16/2019,03/25/2020,,,06/28/2018,,,New Molecular Entity (NME),,,No,,Indiana,United States,North America,,25749,35846,136,3358,N/A,$158.63B ,,
Suspended,,,,05/23/2012,,Peptide,"Intramuscular (IM), Subcutaneous (SQ), Oral (PO)",Mallinckrodt plc,MNK,H.P. Acthar Gel,corticotropin,Endocrine,Diabetes Mellitus,Diabetic Nephropathy,Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),,"repository corticotropin injection, ACTH gel",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,80 UNITS/ML (INJECTABLE;INJECTION),,United Kingdom,Europe,,16222,26904,556,492,N/A,$63.44M ,,
Suspended,,,07/24/2013,07/24/2013,,Peptide,"Intramuscular (IM), Subcutaneous (SQ), Oral (PO)",Mallinckrodt plc,MNK,H.P. Acthar Gel,corticotropin,Neurology,Neurodegenerative,Amyotrophic Lateral Sclerosis (ALS),Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),,"repository corticotropin injection, ACTH gel",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,"Fast Track,Orphan,Rare Disease",,No,80 UNITS/ML (INJECTABLE;INJECTION),,United Kingdom,Europe,,16222,29923,556,193,N/A,$63.44M ,,
III,,05/17/2016,,,,Peptide,"Intramuscular (IM), Subcutaneous (SQ), Oral (PO)",Mallinckrodt plc,MNK,H.P. Acthar Gel,corticotropin,Renal,Chronic Renal Failure,Focal Segmental Glomerulosclerosis (FSGS),Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),,"repository corticotropin injection, ACTH gel",N,III,62% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,80 UNITS/ML (INJECTABLE;INJECTION),,United Kingdom,Europe,,16222,55792,556,3622,N/A,$63.44M ,,
Investigator Initiated,,,,,,Peptide,"Intramuscular (IM), Subcutaneous (SQ), Oral (PO)",Mallinckrodt plc,MNK,H.P. Acthar Gel,corticotropin,Renal,Chronic Renal Failure,Immunoglobulin A (IgA) Nephropathy (Berger's Disease),Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),,"repository corticotropin injection, ACTH gel",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,Rare Disease,,No,80 UNITS/ML (INJECTABLE;INJECTION),,United Kingdom,Europe,,16222,53476,556,3628,N/A,$63.44M ,,
Suspended,,,10/22/2013,10/22/2013,,Peptide,"Intramuscular (IM), Subcutaneous (SQ), Oral (PO)",Mallinckrodt plc,MNK,H.P. Acthar Gel,corticotropin,Respiratory,Other,"Acute Respiratory Failure, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS)",Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),,"repository corticotropin injection, ACTH gel",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,80 UNITS/ML (INJECTABLE;INJECTION),,United Kingdom,Europe,,16222,31661,556,685,N/A,$63.44M ,,
Approved,,,,,,Peptide,"Intramuscular (IM), Subcutaneous (SQ), Oral (PO)",Mallinckrodt plc,MNK,H.P. Acthar Gel,corticotropin,Autoimmune/immunology,Other,Dermatomyositis,Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),,"repository corticotropin injection, ACTH gel",N,Approved,100% (Same As Avg.), - , - , - ,04/29/1952,,,,,,,,Non-NME,Rare Disease,,No,80 UNITS/ML (INJECTABLE;INJECTION),,United Kingdom,Europe,,16222,27310,556,377,N/A,$63.44M ,,
Approved,,07/31/2001,,,,Peptide,"Intramuscular (IM), Subcutaneous (SQ), Oral (PO)",Mallinckrodt plc,MNK,H.P. Acthar Gel,corticotropin,Neurology,Seizure Disorders (Epilepsy),Infantile Spasms (West Syndrome; Epilepsy),Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),,"repository corticotropin injection, ACTH gel",N,Approved,100% (Same As Avg.), - , - , - ,10/15/2010,,,,,06/23/2006,,,Non-NME,"Orphan,Rare Disease",,No,80 UNITS/ML (INJECTABLE;INJECTION),,United Kingdom,Europe,,16222,20873,556,3007,N/A,$63.44M ,,
Approved,,,,,,Peptide,"Intramuscular (IM), Subcutaneous (SQ), Oral (PO)",Mallinckrodt plc,MNK,H.P. Acthar Gel,corticotropin,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),,"repository corticotropin injection, ACTH gel",Y,Approved,100% (Same As Avg.), - , - , - ,04/29/1952,,,,,,,,Non-NME,,,No,80 UNITS/ML (INJECTABLE;INJECTION),,United Kingdom,Europe,,16222,20874,556,153,N/A,$63.44M ,,
Approved,,,,,,Peptide,"Intramuscular (IM), Subcutaneous (SQ), Oral (PO)",Mallinckrodt plc,MNK,H.P. Acthar Gel,corticotropin,Ophthalmology,Other,Ocular Pain and/or Inflammation (Ophthalmology),Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),,"repository corticotropin injection, ACTH gel",N,Approved,100% (Same As Avg.), - , - , - ,04/29/1952,,,,,,,,Non-NME,,,No,80 UNITS/ML (INJECTABLE;INJECTION),,United Kingdom,Europe,,16222,54564,556,554,N/A,$63.44M ,,
Approved,,,,,,Peptide,"Intramuscular (IM), Subcutaneous (SQ), Oral (PO)",Mallinckrodt plc,MNK,H.P. Acthar Gel,corticotropin,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),,"repository corticotropin injection, ACTH gel",N,Approved,100% (Same As Avg.), - , - , - ,04/29/1952,,,,,,,,Non-NME,,,No,80 UNITS/ML (INJECTABLE;INJECTION),,United Kingdom,Europe,,16222,29251,556,336,N/A,$63.44M ,,
Approved,,,,,,Peptide,"Intramuscular (IM), Subcutaneous (SQ), Oral (PO)",Mallinckrodt plc,MNK,H.P. Acthar Gel,corticotropin,Renal,Chronic Renal Failure,Renal Disease / Renal Failure,Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),,"repository corticotropin injection, ACTH gel",N,Approved,100% (Same As Avg.), - , - , - ,04/29/1952,,,,,,,,Non-NME,,,No,80 UNITS/ML (INJECTABLE;INJECTION),,United Kingdom,Europe,,16222,21728,556,149,N/A,$63.44M ,,
Approved,,,,,,Peptide,"Intramuscular (IM), Subcutaneous (SQ), Oral (PO)",Mallinckrodt plc,MNK,H.P. Acthar Gel,corticotropin,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),,"repository corticotropin injection, ACTH gel",N,Approved,100% (Same As Avg.), - , - , - ,04/29/1952,,,,,,,,Non-NME,,,No,80 UNITS/ML (INJECTABLE;INJECTION),,United Kingdom,Europe,,16222,29252,556,154,N/A,$63.44M ,,
Approved,,,,,,Peptide,"Intramuscular (IM), Subcutaneous (SQ), Oral (PO)",Mallinckrodt plc,MNK,H.P. Acthar Gel,corticotropin,Autoimmune/immunology,Other,Sarcoidosis,Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),,"repository corticotropin injection, ACTH gel",N,Approved,100% (Same As Avg.), - , - , - ,04/29/1952,,,,,,,,Non-NME,Rare Disease,,No,80 UNITS/ML (INJECTABLE;INJECTION),,United Kingdom,Europe,,16222,30724,556,1506,N/A,$63.44M ,,
Approved,,,,,,Peptide,"Intramuscular (IM), Subcutaneous (SQ), Oral (PO)",Mallinckrodt plc,MNK,H.P. Acthar Gel,corticotropin,Autoimmune/immunology,Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus (SLE),Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),,"repository corticotropin injection, ACTH gel",N,Approved,100% (Same As Avg.), - , - , - ,04/29/1952,,,,,,,,Non-NME,,,No,80 UNITS/ML (INJECTABLE;INJECTION),,United Kingdom,Europe,,16222,24440,556,282,N/A,$63.44M ,,
Approved,,,,,,Peptide,"Intramuscular (IM), Subcutaneous (SQ), Oral (PO)",Mallinckrodt plc,MNK,H.P. Acthar Gel,corticotropin,Ophthalmology,Uveitis,Uveitis (Ophthalmology),Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),,"repository corticotropin injection, ACTH gel",N,Approved,100% (Same As Avg.), - , - , - ,04/29/1952,,,,,,,,Non-NME,Rare Disease,,No,80 UNITS/ML (INJECTABLE;INJECTION),,United Kingdom,Europe,,16222,55104,556,307,N/A,$63.44M ,,
I,,,,,01/24/2017,Peptide,Intranasal,"Dauntless Pharmaceuticals, Inc.",,DP1038,octreotide acetate,Endocrine,Other,Acromegaly,Somatostatin Receptors,,"Dauntless 1, Dauntless1, Dauntless-1, DP-1038, DP 1038, Intranasal Octreotide",N,I,14% (Same As Avg.), - , - , - ,,,,,,,01/24/2017,,Non-NME,"Orphan,Rare Disease",,No,,California,United States,North America,,26569,51920,5437,680,N/A, ,,
Suspended,,,,,09/19/2006,Peptide,Intranasal,AstraZeneca PLC,AZN,Intranasal exenatide,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,"Adhera Therapeutics, Inc., Bristol Myers Squibb Company, Eli Lilly and Company",intranasal exenatide,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,09/19/2006,,Non-NME,,,No,,,United Kingdom,Europe,,2704,4623,45,137,N/A,$133.38B ,,
Suspended,,,,,04/15/2014,Peptide,Intranasal,Critical Pharmaceuticals,,CP046,teriparatide,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Parathyroid Hormone Receptor (PTHR),,teriparatide nasal spray,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,04/15/2014,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,19552,25805,3403,242,N/A, ,,
Suspended,,,,12/04/2006,07/05/2005,Peptide,Intranasal,"Adhera Therapeutics, Inc.",ATRX,Teriparatide Nasal Spray,teriparatide,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Parathyroid Hormone Receptor (PTHR),,"Intranasal Parathyroid Hormone, PTH1-34 Nasal Spray",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/05/2005,,New Molecular Entity (NME),,,No,,North Carolina,United States,North America,,2242,3764,467,242,N/A,$543.48K ,,
Preclinical,,,,10/31/2018,10/23/2015,Peptide,Intranasal,Monash Institute of Pharmaceutical Science (MIPS),,Oxytocin Dry Powder Inhaler,oxytocin,Hematology,Other,Acute Hemorrhage,Oxytocin Receptor,Vectura Group plc,GR121619,Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,10/23/2015,,Non-NME,,,No,,,Australia,Oceania,,24675,34283,4849,3189,N/A, ,,
Preclinical,,,,,,Peptide,Intranasal,"Sotira, LLC",,Keptide Covid,,Infectious Disease,Antiviral,COVID-19 Treatment,"Angiotensin Converting Enzyme- Related Carbopeptidase2 (ACE2),SARS-CoV-2",,,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Arizona,United States,North America,,43585,61453,26000,3651,N/A, ,,
Preclinical,,,,,,Peptide,Intranasal,NovaBiotics Ltd,,Luminaderm,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Staphylococcal Vaccines and Other Staphylococcus-Specific Agents (Antibacterial),Unknown,,"NP108, NP 108, NP-108",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,35303,48993,5540,3109,N/A, ,,
Suspended,,,08/14/2006,08/14/2006,09/23/2003,Peptide,Intranasal,"Adhera Therapeutics, Inc.",ATRX,PYY3-36,,Metabolic,Obesity,Obesity,Neuropeptide Y (NPY)/Peptide YY (PYY) Receptors,Pfizer Inc.,PYY,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,01/20/2004,,New Molecular Entity (NME),,,No,,North Carolina,United States,North America,,1363,1694,467,135,N/A,$543.48K ,,
Suspended,,,,10/05/2015,,Peptide,Intranasal,"Impel NeuroPharma, Inc.",,INP-102,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Insulin Receptor,3M,"INP102, INP 102, POD Insulin",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,Washington,United States,North America,,30992,42885,6091,141,N/A, ,,
Suspended,,,,,,Peptide,Intranasal,"ProteoTech, Inc.",,PeptiClere,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Amyloid Beta/Amyloid Plaques,,PeptiClere,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Washington,United States,North America,,20404,27195,2323,141,N/A, ,,
Suspended,,,12/06/2006,12/06/2006,01/25/2005,Peptide,Intranasal,Endo International plc,ENDP,Davunetide,davunetide,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Microtubules (Tubulin),,"NAP (intranasal), davunetide intranasal, AL-108",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,01/25/2005,,New Molecular Entity (NME),,,No,,,Ireland,Europe,,8124,10031,142,141,N/A,$1.82B ,,
Suspended,,,08/12/2014,08/16/2013,,Peptide,Intranasal,"Vyera Pharmaceuticals, LLC",,Syntocinon Nasal Spray,oxytocin,Neurology,Neurodevelopmental Disorders,Autism Spectrum Disorders (Autism),Oxytocin Receptor,"Alfasigma S.p.A., Novartis AG",Syntocinon Nasal Spray,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New York,United States,North America,,23745,32703,5136,619,N/A, ,,
Preclinical,,,,,,Peptide,Intranasal,Tonix Pharmaceuticals Holding Corp.,TNXP,TNX-1900,,Neurology,Headache,Migraine and Other Headaches,Oxytocin Receptor,,"oxytocin, intranasal oxytocin, TI001, TI 001, TI-001, TNX1900, TNX 1900",Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,New York,United States,North America,,17144,22242,3362,288,N/A,$151.02M ,,
Preclinical,,,,,,Peptide,Intranasal,"Nanomerics, Ltd.",,NM127,,Neurology,Pain,Moderate to Severe Pain,Opioid receptors,,"NM-127, NM 127, NM0127",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,United Kingdom,Europe,,37461,52245,6986,3134,N/A, ,,
Program Hold,,,,,,Peptide,Intranasal,"Trigemina, Inc.",,TI-002,,Neurology,Pain,Pain Indications,,,TI-002,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,20545,27386,2900,450,N/A, ,,
Suspended,,,,,,Peptide,Intranasal,Endo International plc,ENDP,Davunetide,davunetide,Neurology,Neurodegenerative,Parkinson's Disease (PD),Microtubules (Tubulin),,"NAP (intranasal), davunetide intranasal, AL-108",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Ireland,Europe,,8124,25995,142,194,N/A,$1.82B ,,
Suspended,,01/04/2011,,,,Peptide,Intranasal,Endo International plc,ENDP,Davunetide,davunetide,Neurology,Neurodegenerative,Progressive Supranuclear Palsy,Microtubules (Tubulin),,"NAP (intranasal), davunetide intranasal, AL-108",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,01/12/2009,,New Molecular Entity (NME),"Fast Track,Orphan,Rare Disease,SPA",,No,,,Ireland,Europe,,8124,17900,142,3024,N/A,$1.82B ,,
Withdrawn from Market,,,,,,Peptide,Intranasal,"Vyera Pharmaceuticals, LLC",,Syntocinon Nasal Spray,oxytocin,Obstetrics/Gynecology,Obstetrics,Milk Letdown,Oxytocin Receptor,"Alfasigma S.p.A., Novartis AG",Syntocinon Nasal Spray,Y,Approved,100% (Same As Avg.), - , - , - ,08/31/1960,,,,,01/31/1960,,,New Molecular Entity (NME),,,No,,New York,United States,North America,,23745,32708,5136,3415,N/A, ,,
I,,,,,01/24/2017,Peptide,Intranasal,"Dauntless Pharmaceuticals, Inc.",,DP1038,octreotide acetate,Oncology,Solid,Neuroendocrine Tumors (NET),Somatostatin Receptors,,"Dauntless 1, Dauntless1, Dauntless-1, DP-1038, DP 1038, Intranasal Octreotide",N,I,6% (Same As Avg.), - , - , - ,,,,,,,01/24/2017,,Non-NME,Rare Disease,,No,,California,United States,North America,,26569,37060,5437,347,N/A, ,,
I,,,,,08/05/2018,Peptide,Intranasal,"Impel NeuroPharma, Inc.",,INP-105,olanzapine,Psychiatry,Bipolar,Bipolar Disorder,"Dopamine 1 (D1) Receptor,Dopamine 2 (D2) Receptor",3M,"INP105, INP 105, I105, I 105, POD olanzapine",Y,I,7% (Same As Avg.), - , - , - ,,,,,,,08/05/2018,,Non-NME,,,No,,Washington,United States,North America,,31056,54281,6091,168,N/A, ,,
Suspended,,,,,,Peptide,Intranasal,"Impel NeuroPharma, Inc.",,INP-105,olanzapine,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),"Dopamine 1 (D1) Receptor,Dopamine 2 (D2) Receptor",3M,"INP105, INP 105, I105, I 105, POD olanzapine",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,Washington,United States,North America,,31056,42970,6091,167,N/A, ,,
I,,,,,08/05/2018,Peptide,Intranasal,"Impel NeuroPharma, Inc.",,INP-105,olanzapine,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,"Dopamine 1 (D1) Receptor,Dopamine 2 (D2) Receptor",3M,"INP105, INP 105, I105, I 105, POD olanzapine",N,I,7% (Same As Avg.), - , - , - ,,,,,,,08/05/2018,,Non-NME,,,No,,Washington,United States,North America,,31056,54383,6091,170,N/A, ,,
Suspended,,,,12/08/2009,,Peptide,Intranasal,"Vyera Pharmaceuticals, LLC",,Syntocinon Nasal Spray,oxytocin,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Oxytocin Receptor,"Alfasigma S.p.A., Novartis AG",Syntocinon Nasal Spray,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New York,United States,North America,,23745,32702,5136,170,N/A, ,,
Suspended,,,03/27/2007,03/27/2007,,Peptide,Intranasal,Endo International plc,ENDP,Davunetide,davunetide,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Microtubules (Tubulin),,"NAP (intranasal), davunetide intranasal, AL-108",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Ireland,Europe,,8124,10029,142,170,N/A,$1.82B ,,
Development Outside U.S.,,,,,,Peptide,Intranasal,"OptiNose, Inc.",OPTN,OPN300,,Neurology,Neurodevelopmental Disorders,Autism Spectrum Disorders (Autism),Oxytocin Receptor,,"OPN 300, OPN-300",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,Pennsylvania,United States,North America,,26415,36859,4325,619,N/A,$223.95M ,,
Development Outside U.S.,,,,,,Peptide,Intranasal,Ovoca Bio plc,OVB,BP-101,,Obstetrics/Gynecology,Female Sexual Arousal Disorder,Female Sexual Arousal Disorder,Unknown,,"BP 101, BP101",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Ireland,Europe,,40872,57348,9314,275,N/A,$12.20M ,,
Approved (Generic Competition),,,,,,Peptide,Intranasal,Novartis AG,NVS,Miacalcin,calcitonin-salmon,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Calcitonin Receptor,,"Miacalcic, calcitonin-salmon",Y,Approved,100% (Same As Avg.), - , - , - ,08/17/1995,,,,,,,,Non-NME,,,No,"200 IU/ML (INJECTABLE;INJECTION), 200 IU/SPRAY (SPRAY, METERED;NASAL)",,Switzerland,Europe,,2914,4966,289,242,N/A,$183.31B ,,
Approved,,07/10/2009,,11/17/2008,,Peptide,Intranasal,Avadel Pharmaceuticals plc,AVDL,Noctiva,desmopressin acetate,Urology,Other,"Urinary Symptoms (e.g. Nocturia, Polyuria)",Vasopressin receptors,"CPEX Pharmaceuticals, Inc., Serenity Pharmaceuticals, Inc.","SER120, SER-120, SER 120, desmopressin acetate, AV002, AV 002, AV-002",Y,Approved,100% (Same As Avg.), - , - , - ,03/03/2017,,,,,02/04/2016,11/06/2008,,Non-NME,505b2,,No,,,Ireland,Europe,,16127,20703,831,2291,N/A,$275.40M ,,
II,,,09/01/2020,09/01/2020,05/25/2018,Peptide,Intraocular/Subretinal/Subconjunctival,Oxurion NV,OXUR,THR-149,,Ophthalmology,Retinopathy,Diabetic Macular Edema (Ophthalmology),Kinin-Kallikrein System ,"Bicycle Therapeutics, plc, Pepscan Therapeutics","ThromboGenics Bicycle Program, THR149, THR 149",N,II,24% (Same As Avg.), - , - , - ,,,,,,,05/25/2018,,New Molecular Entity (NME),,,No,,,Belgium,Europe,,32465,44840,2293,476,N/A,$124.37M ,,
IIb,,,,12/20/2011,,Peptide,Intraocular/Subretinal/Subconjunctival,"Allegro Ophthalmics, LLC.",,Luminate,risuteganib,Ophthalmology,Retinopathy,Diabetic Macular Edema (Ophthalmology),"Angiogenesis,Integrins","Hanmi Pharmaceutical Co., Ltd.","ALG 1001, ALG-1001, ALG1001, Risuteganib",Y,II,26% (2% Above Avg.), - , - , - ,,,,,,,10/21/2011,,New Molecular Entity (NME),,,No,,California,United States,North America,,19970,26510,3683,476,N/A, ,,
Preclinical,,,,,,Peptide,Intraocular/Subretinal/Subconjunctival,"OcuNexus Therapeutics, Inc.",,Peptagon,,Ophthalmology,Retinopathy,Diabetic Macular Edema (Ophthalmology),Connexin / Connexon / Hemichannel,,Peptagon (Intravitreal),N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,35259,48965,4436,476,N/A, ,,
Preclinical,,,,,,Peptide,Intraocular/Subretinal/Subconjunctival,"OcuNexus Therapeutics, Inc.",,Peptagon,,Ophthalmology,Retinopathy,Diabetic Retinopathy (Ophthalmology),Connexin / Connexon / Hemichannel,,Peptagon (Intravitreal),N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,35259,48934,4436,364,N/A, ,,
Suspended,,,05/04/2015,05/04/2015,,Peptide,Intraocular/Subretinal/Subconjunctival,"Allegro Ophthalmics, LLC.",,Luminate,risuteganib,Ophthalmology,Retinopathy,Diabetic Retinopathy (Ophthalmology),"Angiogenesis,Integrins","Hanmi Pharmaceutical Co., Ltd.","ALG 1001, ALG-1001, ALG1001, Risuteganib",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,19970,36221,3683,364,N/A, ,,
II,,,08/09/2018,08/09/2018,,Peptide,Intraocular/Subretinal/Subconjunctival,"Allegro Ophthalmics, LLC.",,Luminate,risuteganib,Ophthalmology,Macular Degeneration,Dry Age-Related Macular Degeneration (Dry AMD)/Geographic Atrophy (Ophthalmology),"Angiogenesis,Integrins","Hanmi Pharmaceutical Co., Ltd.","ALG 1001, ALG-1001, ALG1001, Risuteganib",N,II,27% (3% Above Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,19970,54292,3683,2870,N/A, ,,
Preclinical,,,,,,Peptide,Intraocular/Subretinal/Subconjunctival,"OcuNexus Therapeutics, Inc.",,Peptagon,,Ophthalmology,Macular Degeneration,Dry Age-Related Macular Degeneration (Dry AMD)/Geographic Atrophy (Ophthalmology),Connexin / Connexon / Hemichannel,,Peptagon (Intravitreal),N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,35259,48963,4436,2870,N/A, ,,
Suspended,,,07/09/2012,07/09/2012,,Peptide,Intraocular/Subretinal/Subconjunctival,Novartis AG,NVS,APL-1,,Ophthalmology,Macular Degeneration,Dry Age-Related Macular Degeneration (Dry AMD)/Geographic Atrophy (Ophthalmology),Complement Pathway,"Apellis Pharmaceuticals, Inc.","POT-4, AL-78898A",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,11075,30519,289,2870,N/A,$183.31B ,,
II,,,,02/07/2017,,Peptide,Intraocular/Subretinal/Subconjunctival,"BRIM Biotechnology, Inc.",,BRM421,,Ophthalmology,Other,Dry Eye (Ophthalmology),PEDF (pigment epithelium-derived factor),"Grandpharma Co., Ltd.","BRM-421, BRM 421",N,II,24% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Taiwan,Asia,,42314,59526,10781,548,N/A, ,,
II,,,02/19/2020,02/19/2020,,Peptide,Intraocular/Subretinal/Subconjunctival,"Palatin Technologies, Inc.",PTN,PL-9643,,Ophthalmology,Other,Dry Eye (Ophthalmology),Melanocortin (MC) receptors,,"PL 9643, PL9643",N,II,23% (1% Below Avg.), - , - , - ,,,,,,,,12/31/2019,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,41281,57955,504,548,N/A,$162.89M ,,
II,,,,02/17/2020,,Peptide,Intraocular/Subretinal/Subconjunctival,Recordati SpA,REC:IM,REC 0559,,Ophthalmology,Other,Ophthalmic Wound Healing (Ophthalmology),Nerve growth factor (NGF)/receptor,,"NGF, Human Nerve Growth Factor (Recordati), REC0559, REC-0559",N,II,24% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Orphan,,No,,,Italy,Europe,,35295,48985,1008,265,N/A,$10.59B ,,
I,,,,,10/23/2019,Peptide,Intraocular/Subretinal/Subconjunctival,ONL Therapeutics ,,ONL1204,,Ophthalmology,Other,Rhegmatogenous Retinal Detachment (RRD) (Ophthalmology),Fas receptor (FasR)/CD95/Apo-1/TNFRSf6),,"ONL-1204, ONL 1204",N,I,21% (Same As Avg.), - , - , - ,,,,,,,10/23/2019,,New Molecular Entity (NME),Orphan,,No,,Michigan,United States,North America,,43958,62044,13662,589,N/A, ,,
II,,,,06/02/2014,,Peptide,Intraocular/Subretinal/Subconjunctival,"Allegro Ophthalmics, LLC.",,Luminate,risuteganib,Ophthalmology,Other,Vitreomacular Adhesion (Ophthalmology),"Angiogenesis,Integrins","Hanmi Pharmaceutical Co., Ltd.","ALG 1001, ALG-1001, ALG1001, Risuteganib",N,II,26% (2% Above Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,19970,33493,3683,2892,N/A, ,,
II,,,12/31/2019,09/20/2018,,Peptide,Intraocular/Subretinal/Subconjunctival,"RIBOMIC, Inc.",4591,RBM-007,,Ophthalmology,Macular Degeneration,Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology),Fibroblast Growth Factor Receptor-2,AJU Pharm Korea,"RBM007, RBM 007",Y,II,24% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Japan,Asia,,41897,58852,10891,162,N/A,$98.68M ,,
Preclinical,,,,,,Peptide,Intraocular/Subretinal/Subconjunctival,"OcuNexus Therapeutics, Inc.",,Peptagon,,Ophthalmology,Macular Degeneration,Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology),Connexin / Connexon / Hemichannel,,Peptagon (Intravitreal),N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,35259,48964,4436,162,N/A, ,,
Suspended,,,07/06/2011,07/06/2011,03/20/2007,Peptide,Intraocular/Subretinal/Subconjunctival,Novartis AG,NVS,APL-1,,Ophthalmology,Macular Degeneration,Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology),Complement Pathway,"Apellis Pharmaceuticals, Inc.","POT-4, AL-78898A",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/20/2007,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,11075,13916,289,162,N/A,$183.31B ,,
Development Outside U.S.,,,,,,Peptide,Intraocular/Subretinal/Subconjunctival,"RIBOMIC, Inc.",4591,RBM-007,,Endocrine,Short Stature,Achondroplasia,Fibroblast Growth Factor Receptor-2,AJU Pharm Korea,"RBM007, RBM 007",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Japan,Asia,,41897,60347,10891,3084,N/A,$98.68M ,,
Development Outside U.S.,,,03/31/2012,,,Peptide,Intraocular/Subretinal/Subconjunctival,"Allegro Ophthalmics, LLC.",,Luminate,risuteganib,Ophthalmology,Macular Degeneration,Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology),"Angiogenesis,Integrins","Hanmi Pharmaceutical Co., Ltd.","ALG 1001, ALG-1001, ALG1001, Risuteganib",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,19970,43915,3683,162,N/A, ,,
Approved,,09/30/2014,,,,Peptide,Intraocular/Subretinal/Subconjunctival,Sun Pharmaceutical Industries Ltd.,524715,Cequa,cyclosporine,Ophthalmology,Other,Dry Eye (Ophthalmology),Calcineurin phosphatase ,China Medical System Holdings Limited,"OTX-101 0.05%, OTX101, OTX 101, Seciera, Cyclosporine A",N,Approved,100% (Same As Avg.), - , - , - ,08/14/2018,,,,,,,,Non-NME,505b2,,No,,,India,Asia,,27691,38831,3285,548,N/A, ,,
NDA,06/26/2018,05/09/2018,,,11/25/2014,Peptide,"Intraocular/Subretinal/Subconjunctival, Intravenous (IV), Subcutaneous (SQ)","Apellis Pharmaceuticals, Inc.",APLS,Pegcetacoplan,pegcetacoplan,Autoimmune/immunology,Paroxysmal Nocturnal Hemoglobinuria,Paroxysmal Nocturnal Hemoglobinuria (PNH),Complement Pathway,"SFJ Pharmaceuticals, Inc, Swedish Orphan Biovitrum AB","APL 2, APL2, pegcetacoplan, APL-2",N,NDA/BLA,94% (7% Above Avg.),09/15/2021 - 09/15/2021,08/01/2021 - 02/28/2022, - ,,,,05/14/2021,,09/15/2020,04/20/2014,,New Molecular Entity (NME),"Fast Track,Orphan,Rare Disease",,No,,Massachusetts,United States,North America,,24958,34690,2089,394,N/A,$4.15B ,,
II,,,08/31/2017,08/31/2017,,Peptide,"Intraocular/Subretinal/Subconjunctival, Intravenous (IV), Subcutaneous (SQ)","Apellis Pharmaceuticals, Inc.",APLS,Pegcetacoplan,pegcetacoplan,Hematology,Marrow Or Peripheral Blood Stimulator,Autoimmune Hemolytic Anemia (AIHA),Complement Pathway,"SFJ Pharmaceuticals, Inc, Swedish Orphan Biovitrum AB","APL 2, APL2, pegcetacoplan, APL-2",N,II,30% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,Massachusetts,United States,North America,,24958,49534,2089,3647,N/A,$4.15B ,,
Preclinical,,,,10/27/2020,,Peptide,"Intraocular/Subretinal/Subconjunctival, Intravenous (IV), Subcutaneous (SQ)","Apellis Pharmaceuticals, Inc.",APLS,Pegcetacoplan,pegcetacoplan,Hematology,General,Transplant-Associated Thrombotic Microangiopathy (TA-TMA),Complement Pathway,"SFJ Pharmaceuticals, Inc, Swedish Orphan Biovitrum AB","APL 2, APL2, pegcetacoplan, APL-2",N,II,30% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,24958,61489,2089,3641,N/A,$4.15B ,,
II,,,11/19/2020,11/19/2020,,Peptide,"Intraocular/Subretinal/Subconjunctival, Intravenous (IV), Subcutaneous (SQ)","Apellis Pharmaceuticals, Inc.",APLS,Pegcetacoplan,pegcetacoplan,Neurology,Neurodegenerative,Amyotrophic Lateral Sclerosis (ALS),Complement Pathway,"SFJ Pharmaceuticals, Inc, Swedish Orphan Biovitrum AB","APL 2, APL2, pegcetacoplan, APL-2",N,II,17% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Massachusetts,United States,North America,,24958,61239,2089,193,N/A,$4.15B ,,
III,09/12/2018,09/12/2018,10/14/2015,10/14/2015,,Peptide,"Intraocular/Subretinal/Subconjunctival, Intravenous (IV), Subcutaneous (SQ)","Apellis Pharmaceuticals, Inc.",APLS,Pegcetacoplan,pegcetacoplan,Ophthalmology,Macular Degeneration,Dry Age-Related Macular Degeneration (Dry AMD)/Geographic Atrophy (Ophthalmology),Complement Pathway,"SFJ Pharmaceuticals, Inc, Swedish Orphan Biovitrum AB","APL 2, APL2, pegcetacoplan, APL-2",N,III,57% (6% Above Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Fast Track,,No,,Massachusetts,United States,North America,,24958,35382,2089,2870,N/A,$4.15B ,,
I/II,,,03/13/2018,03/13/2018,02/10/2015,Peptide,"Intraocular/Subretinal/Subconjunctival, Intravenous (IV), Subcutaneous (SQ)","Apellis Pharmaceuticals, Inc.",APLS,Pegcetacoplan,pegcetacoplan,Ophthalmology,Macular Degeneration,Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology),Complement Pathway,"SFJ Pharmaceuticals, Inc, Swedish Orphan Biovitrum AB","APL 2, APL2, pegcetacoplan, APL-2",N,II,24% (Same As Avg.), - , - , - ,,,,,,,02/10/2015,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,24958,34689,2089,162,N/A,$4.15B ,,
II,,,02/27/2018,02/27/2018,,Peptide,"Intraocular/Subretinal/Subconjunctival, Intravenous (IV), Subcutaneous (SQ)","Apellis Pharmaceuticals, Inc.",APLS,Pegcetacoplan,pegcetacoplan,Renal,Chronic Renal Failure,"C3 Glomerulopathy (C3G), including Dense Deposit Disease (DDD) and C3 Glomerulonephritis (C3GN)",Complement Pathway,"SFJ Pharmaceuticals, Inc, Swedish Orphan Biovitrum AB","APL 2, APL2, pegcetacoplan, APL-2",N,II,25% (1% Above Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,Massachusetts,United States,North America,,24958,53472,2089,3655,N/A,$4.15B ,,
Investigator Initiated,,,,,,Peptide,Intrathecal,TerSera Therapeutics LLC,,Prialt,ziconotide,Neurology,Pain,Neuropathic Pain,Calcium Channel,RIEMSER Pharma GmbH,"ziconotide, omegaconotoxin, SNX111, SNX 111, SNX-111",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,"100MCG/1ML (100MCG/ML) (INJECTABLE;INTRATHECAL), 500MCG/20ML (25MCG/ML) (INJECTABLE;INTRATHECAL), 500MCG/5ML (100MCG/ML) (INJECTABLE;INTRATHECAL)",Illinois,United States,North America,,1387,33759,7142,362,N/A, ,,
Preclinical,,,,,,Peptide,Intrathecal,Axoltis Pharma,,NX210,,Neurology,Other,Spinal Cord Injury (SCI),,,"NX 210, NX-210",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,,France,Europe,,37662,52505,8285,707,N/A, ,,
Approved,,01/13/1998,,,,Peptide,Intrathecal,TerSera Therapeutics LLC,,Prialt,ziconotide,Neurology,Pain,Chronic Pain,Calcium Channel,RIEMSER Pharma GmbH,"ziconotide, omegaconotoxin, SNX111, SNX 111, SNX-111",Y,Approved,100% (Same As Avg.), - , - , - ,12/28/2004,02/21/2005,,,,12/29/1999,,,New Molecular Entity (NME),,,No,"100MCG/1ML (100MCG/ML) (INJECTABLE;INTRATHECAL), 500MCG/20ML (25MCG/ML) (INJECTABLE;INTRATHECAL), 500MCG/5ML (100MCG/ML) (INJECTABLE;INTRATHECAL)",Illinois,United States,North America,,1387,1799,7142,3128,N/A, ,,
IND,,,,,,Peptide,Intratracheal,"Windtree Therapeutics, Inc.",WINT,Surfaxin,lucinactant,Infectious Disease,Antiviral,COVID-19 Treatment,Alveolar Surface,"Dompé Farmaceutici S.p.A., Esteve Pharmaceuticals, S.A., Lee's Pharmaceutical Holdings Limited","lucinactant, Surfaxin LS",N,IND,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Pennsylvania,United States,North America,,1790,59145,685,3651,N/A,$74.83M ,,
Program Hold,,,,12/07/2004,,Peptide,Intratracheal,"Windtree Therapeutics, Inc.",WINT,Surfaxin,lucinactant,Respiratory,Other,"Acute Respiratory Failure, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS)",Alveolar Surface,"Dompé Farmaceutici S.p.A., Esteve Pharmaceuticals, S.A., Lee's Pharmaceutical Holdings Limited","lucinactant, Surfaxin LS",N,II,6% (12% Below Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Pennsylvania,United States,North America,,1790,4453,685,685,N/A,$74.83M ,,
Suspended,,,,01/06/2005,,Peptide,Intratracheal,"Windtree Therapeutics, Inc.",WINT,Surfaxin,lucinactant,Respiratory,Other,Bronchopulmonary Dysplasia (BPD),Alveolar Surface,"Dompé Farmaceutici S.p.A., Esteve Pharmaceuticals, S.A., Lee's Pharmaceutical Holdings Limited","lucinactant, Surfaxin LS",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Fast Track,Orphan",,No,,Pennsylvania,United States,North America,,1790,2982,685,628,N/A,$74.83M ,,
Suspended,,,,01/30/2013,,Peptide,Intratracheal,Chiesi Farmaceutici S.p.A.,,CHF 5633,synthetic surfactant,Respiratory,Other,Respiratory Distress Syndrome (RDS),Alveolar Surface,,CHF-5633,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Italy,Europe,,23769,32736,851,616,N/A, ,,
Approved,,,,,,Peptide,Intratracheal,"Windtree Therapeutics, Inc.",WINT,Surfaxin,lucinactant,Respiratory,Other,Respiratory Distress Syndrome (RDS),Alveolar Surface,"Dompé Farmaceutici S.p.A., Esteve Pharmaceuticals, S.A., Lee's Pharmaceutical Holdings Limited","lucinactant, Surfaxin LS",Y,Approved,100% (Same As Avg.), - , - , - ,03/06/2012,,,,,04/13/2004,,,New Molecular Entity (NME),Rare Disease,,No,,Pennsylvania,United States,North America,,1790,2854,685,616,N/A,$74.83M ,,
Suspended,,,,,,Peptide,Intratumoral,Lytix Biopharma AS,,Oncopore,,Oncology,Solid,Breast Cancer,Cell Membrane,"Verrica Pharmaceuticals, Inc.","LTX-315, LTX315, LTX 315",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Norway,Europe,,17531,46233,2958,214,N/A, ,,
II,,,03/01/2012,03/01/2012,,Peptide,Intratumoral,Nymox Pharmaceutical Corporation,NYMX,NX-1207,fexapotide triflutate,Oncology,Solid,Prostate Cancer,"Apoptosis (Cell Death),Mitochondria",Recordati SpA,"Fexapotide Triflutate (FT), NX1207, NX 1207, NYM4805, NYM-4805, NYM 4805, REC0482, REC 0482, REC-0482",N,II,2% (8% Below Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Quebec,Canada,North America,,866,20416,296,215,  4%,$215.42M ,Orphan Drug designation,N/A
Preclinical,,,,,,Peptide,Intratumoral,Lytix Biopharma AS,,Oncopore,,Oncology,Solid,Skin Cancer - Basal Cell Carcinoma (BCC),Cell Membrane,"Verrica Pharmaceuticals, Inc.","LTX-315, LTX315, LTX 315",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Norway,Europe,,17531,60742,2958,360,N/A, ,,
I/II,,,,02/05/2020,,Peptide,Intratumoral,Olatec Therapeutics LLC,,CyPep-1 (Intratumoral),,Oncology,Solid,Solid Tumors,Tumor Cells,,"CyPep1, CyPep 1",N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New York,United States,North America,,40270,56351,9108,197,N/A, ,,
III,06/09/2008,06/09/2008,,01/26/2004,,Peptide,Intratumoral,Nymox Pharmaceutical Corporation,NYMX,NX-1207,fexapotide triflutate,Urology,General,Benign Prostatic Hyperplasia (BPH),"Apoptosis (Cell Death),Mitochondria",Recordati SpA,"Fexapotide Triflutate (FT), NX1207, NX 1207, NYM4805, NYM-4805, NYM 4805, REC0482, REC 0482, REC-0482",Y,III,58% (4% Below Avg.), - , - , - ,,,,,Now - 03/31/2021,,,,New Molecular Entity (NME),,,No,,Quebec,Canada,North America,,866,1904,296,569,N/A,$215.42M ,,
Development Outside U.S.,,,,,,Peptide,Intratumoral,Lytix Biopharma AS,,Oncopore,,Oncology,Solid,Sarcoma,Cell Membrane,"Verrica Pharmaceuticals, Inc.","LTX-315, LTX315, LTX 315",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Norway,Europe,,17531,54767,2958,610,N/A, ,,
Development Outside U.S.,,,,,02/01/2010,Peptide,Intratumoral,Lytix Biopharma AS,,Oncopore,,Oncology,Solid,Solid Tumors,Cell Membrane,"Verrica Pharmaceuticals, Inc.","LTX-315, LTX315, LTX 315",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Norway,Europe,,17531,22835,2958,197,N/A, ,,
III,11/13/2015,11/13/2015,06/16/2005,06/16/2005,,Peptide,"Intratympanic, Intraocular/Subretinal/Subconjunctival",Zilentin AG,,Sonsuvi,brimapitide,ENT/Dental,General,Hearing Loss - General,c-Jun N-terminal kinase (JNK),"Auris Medical Holding AG, Xigen SA","D-JNKI-1, XG-102, XG102, AM111, AM-111, AM 111, brimapitide",Y,III,49% (13% Below Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Fast Track,Orphan",,No,,,Switzerland,Europe,,19877,26353,12278,3074,N/A, ,,
Suspended,,09/10/2014,,,,Peptide,"Intratympanic, Intraocular/Subretinal/Subconjunctival",Zilentin AG,,Sonsuvi,brimapitide,Ophthalmology,Other,Ocular Pain and/or Inflammation (Ophthalmology),c-Jun N-terminal kinase (JNK),"Auris Medical Holding AG, Xigen SA","D-JNKI-1, XG-102, XG102, AM111, AM-111, AM 111, brimapitide",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,19877,34938,12278,554,N/A, ,,
Suspended,,,,,,Peptide,Intravenous (IV),"Araim Pharmaceuticals, Inc.",,Cibinetide,cibinetide,Autoimmune/immunology,Inflammatory Bowel Disease,Inflammatory Bowel Disease (IBD),"CSF2RB (common ß subunit, CD131),Erythropoietin Receptor (EPOR)",,"pHBSP, ARA290, ARA 290",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,New York,United States,North America,,20147,53193,3718,464,N/A, ,,
Suspended,,,,,,Peptide,Intravenous (IV),"Soligenix, Inc.",SNGX,SGX942,dusquetide,Autoimmune/immunology,General,Inflammatory Disorders,Immune System,"SciClone Pharmaceuticals, Inc.","susquetide, SGX94, SGX-942, SGX 942, IMX 942, IMX942, IMX-942, IMX-001, IMX001, IMX 001",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Orphan,,No,,New Jersey,United States,North America,,21570,34933,143,422,N/A,$42.68M ,,
III,07/27/2017,07/27/2017,12/05/2013,12/05/2013,,Peptide,Intravenous (IV),"Soligenix, Inc.",SNGX,SGX942,dusquetide,Autoimmune/immunology,Other,Mucositis,Immune System,"SciClone Pharmaceuticals, Inc.","susquetide, SGX94, SGX-942, SGX 942, IMX 942, IMX942, IMX-942, IMX-001, IMX001, IMX 001",Y,III,53% (6% Below Avg.), - , - , - ,,,,,,,12/18/2012,,New Molecular Entity (NME),Fast Track,,No,,New Jersey,United States,North America,,21570,29089,143,348,N/A,$42.68M ,,
Suspended,,,,12/02/2010,,Peptide,Intravenous (IV),"Araim Pharmaceuticals, Inc.",,Cibinetide,cibinetide,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),"CSF2RB (common ß subunit, CD131),Erythropoietin Receptor (EPOR)",,"pHBSP, ARA290, ARA 290",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,New York,United States,North America,,20147,26811,3718,154,N/A, ,,
II,,,10/01/2011,09/13/2011,,Peptide,Intravenous (IV),"Araim Pharmaceuticals, Inc.",,Cibinetide,cibinetide,Autoimmune/immunology,Other,Sarcoidosis,"CSF2RB (common ß subunit, CD131),Erythropoietin Receptor (EPOR)",,"pHBSP, ARA290, ARA 290",N,II,20% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,"Fast Track,Orphan,Rare Disease",,No,,New York,United States,North America,,20147,28920,3718,1506,N/A, ,,
Suspended,,,,,,Peptide,Intravenous (IV),"Araim Pharmaceuticals, Inc.",,Cibinetide,cibinetide,Autoimmune/immunology,Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus (SLE),"CSF2RB (common ß subunit, CD131),Erythropoietin Receptor (EPOR)",,"pHBSP, ARA290, ARA 290",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,New York,United States,North America,,20147,53196,3718,282,N/A, ,,
Suspended,,,,,,Peptide,Intravenous (IV),"Astellas Pharma, Inc.",4503:JP,ASP2409,,Autoimmune/immunology,Transplant Rejection,Transplant Rejection,,,ASP-2409,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,02/01/2012,,Biologic,,,No,,,Japan,Asia,,19555,25808,814,3086,N/A,$28.31B ,,
Suspended,,,,,,Peptide,Intravenous (IV),"Esperion Therapeutics, Inc.",ESPR,4WF,,Cardiovascular,Acute Coronary Syndrome,Acute Coronary Syndrome (ACS),Reverse Cholesterol Transport (RCT),,"apoA1 mimetic, apolipoprotein A1-4WF",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Michigan,United States,North America,,23948,33042,2098,179,N/A,$860.27M ,,
Suspended,,,,02/10/2011,,Peptide,Intravenous (IV),"RegeneRx Biopharmaceuticals, Inc.",RGRX,RGN-352,timbetasin,Cardiovascular,Acute Coronary Syndrome,Acute Coronary Syndrome (ACS),"Actin Filaments,ATP Synthase,Integrin-linked kinase (ILK)",Lee's Pharmaceutical Holdings Limited,"thymosin beta 4 (TB4) peptide, Thymosin beta 4 (Tβ4), RGN352, RGN 352",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/31/2007,,Biologic,,,No,,Maryland,United States,North America,,10782,13508,460,179,N/A,$62.06M ,,
Suspended,,,07/01/2010,07/01/2010,,Peptide,Intravenous (IV),Renova Therapeutics,,RT-400,,Cardiovascular,Congestive Heart Failure,Acute Decompensated Heart Failure,Corticotropin Releasing Factor -Receptor2 (CRF-R2),,"stresscopin, JNJ-39588146, JNJ39588146, JNJ 39588146, RT400, RT 400",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,18296,23951,5718,575,N/A, ,,
Suspended,08/10/2012,08/10/2012,03/16/2006,03/16/2006,,Peptide,Intravenous (IV),Cardiorentis AG,,Ularitide,recombinant urodilatin,Cardiovascular,Congestive Heart Failure,Acute Decompensated Heart Failure,Natriuretic Peptide Receptors,"PDL BioPharma, Inc., Pharis Biotec GmbH","ESP-305, recombinant urodilatin",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Fast Track,,No,,,Switzerland,Europe,,2163,3591,3904,575,N/A, ,,
Suspended,,,10/28/2009,04/28/2005,02/10/2005,Peptide,Intravenous (IV),"Neurocrine Biosciences, Inc.",NBIX,Urocortin 2,,Cardiovascular,Congestive Heart Failure,Acute Decompensated Heart Failure,Corticotropin Releasing Factor -Receptor2 (CRF-R2),,"Stresscopin Related Peptide, NBI-69734",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,02/10/2005,,New Molecular Entity (NME),,,No,,California,United States,North America,,2042,4281,276,575,N/A,$9.61B ,,
Suspended,10/01/2009,10/01/2009,11/01/2005,11/01/2005,,Peptide,Intravenous (IV),Novartis AG,NVS,Reasanz,serelaxin,Cardiovascular,Congestive Heart Failure,Acute Decompensated Heart Failure,Relaxin Family Peptide Receptors 1-4 (RXFP1-4),,"Relaxin (recombinant), serelaxin, RLX-030, rhRIx, RLX030",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,05/31/2013,,,New Molecular Entity (NME),"Breakthrough,Fast Track",,No,,,Switzerland,Europe,,16214,20857,289,575,N/A,$183.31B ,,
Suspended,,,,,,Peptide,Intravenous (IV),"Artery Therapeutics, Inc.",,ATI-5261,,Cardiovascular,General,Atherosclerosis,Apolipoprotein A-I,,"ATI5261, ATI 5261, AT-5261, Artpep",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,24555,34104,4816,650,N/A, ,,
Suspended,,12/28/2004,,,,Peptide,Intravenous (IV),The Medicines Company,MDCO,Angiomax,bivalirudin,Cardiovascular,"Surgical, Interventional Radiological, and Other Invasive Procedures",Cardiac Valve Surgery,Thrombin (Coagulation Factor IIa),"AstraZeneca PLC, Biogen, Inc., Daiichi Sankyo Co., Ltd., SciClone Pharmaceuticals, Inc.","bivalirudin, Hirulog,  Angiox",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,250MG/VIAL (INJECTABLE;INTRAVENOUS),New Jersey,United States,North America,88%,238,3910,248,678,N/A, ,,
Preclinical,,,,,,Peptide,Intravenous (IV),"Araim Pharmaceuticals, Inc.",,Cibinetide,cibinetide,Cardiovascular,General,Cardiovascular Disease,"CSF2RB (common ß subunit, CD131),Erythropoietin Receptor (EPOR)",,"pHBSP, ARA290, ARA 290",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,New York,United States,North America,,20147,52954,3718,181,N/A, ,,
Suspended,,,,,06/01/2003,Peptide,Intravenous (IV),Pfizer Inc.,PFE,ETC-642,,Cardiovascular,General,Cardiovascular Disease,Reverse Cholesterol Transport (RCT),Arbutus Biopharma Corporation,RLT Peptide,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,06/30/2003,,Biologic,,,No,,New York,United States,North America,,593,1297,312,181,N/A,$205.99B ,,
Suspended,,,11/20/2011,11/20/2011,,Peptide,Intravenous (IV),Johnson & Johnson,JNJ,JNJ-54452840,,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,Beta Adrenergic Receptors,,COR-1,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,11/25/2009,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,19813,26255,223,264,N/A,$422.18B ,,
Suspended,,,05/15/2014,11/12/2013,,Peptide,Intravenous (IV),Novartis AG,NVS,Reasanz,serelaxin,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,Relaxin Family Peptide Receptors 1-4 (RXFP1-4),,"Relaxin (recombinant), serelaxin, RLX-030, rhRIx, RLX030",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,16214,31475,289,264,N/A,$183.31B ,,
Suspended,,02/11/2003,,,,Peptide,Intravenous (IV),The Medicines Company,MDCO,Angiomax,bivalirudin,Cardiovascular,"Surgical, Interventional Radiological, and Other Invasive Procedures",Coronary Artery Bypass Graft (CABG),Thrombin (Coagulation Factor IIa),"AstraZeneca PLC, Biogen, Inc., Daiichi Sankyo Co., Ltd., SciClone Pharmaceuticals, Inc.","bivalirudin, Hirulog,  Angiox",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,250MG/VIAL (INJECTABLE;INTRAVENOUS),New Jersey,United States,North America,88%,238,589,248,303,N/A, ,,
Suspended,,,,,,Peptide,Intravenous (IV),"Artery Therapeutics, Inc.",,CS-6253,,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia, ATP-Binding Cassette Transporter G1 (ABCG1),,"CS6253, CS 6253",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,24554,34102,4816,506,N/A, ,,
Suspended,,,,12/16/2014,,Peptide,Intravenous (IV),Capstone Therapeutics Corp.,CAPS,AEM-28,,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Lipoproteins,"Anji Pharmaceuticals, Inc., LipimetiX Development Inc",AEM-28-14,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,04/08/2014,,New Molecular Entity (NME),Orphan,,No,,Arizona,United States,North America,,20775,27800,3280,506,N/A,$1.84M ,,
Suspended,,,06/30/2005,07/27/2005,03/04/2005,Peptide,Intravenous (IV),Pfizer Inc.,PFE,Rotigaptide,,Cardiovascular,Dysrythmia (Arrythmia),Dysrhythmia (Arrhythmia),Gap Junction,Zealand Pharma A/S,"GAP-486, ZP123, ZP-123",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/04/2005,,New Molecular Entity (NME),,,No,,New York,United States,North America,,8342,10342,312,86,N/A,$205.99B ,,
Suspended,,,03/04/2010,03/04/2010,,Peptide,Intravenous (IV),"Araim Pharmaceuticals, Inc.",,Cibinetide,cibinetide,Cardiovascular,Peripheral Vascular Disease,Peripheral Arterial Disease (PAD),"CSF2RB (common ß subunit, CD131),Erythropoietin Receptor (EPOR)",,"pHBSP, ARA290, ARA 290",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,New York,United States,North America,,20147,26805,3718,390,N/A, ,,
Suspended,,08/07/2003,,,,Peptide,Intravenous (IV),The Medicines Company,MDCO,Angiomax,bivalirudin,Cardiovascular,Peripheral Vascular Disease,Peripheral Arterial Disease (PAD),Thrombin (Coagulation Factor IIa),"AstraZeneca PLC, Biogen, Inc., Daiichi Sankyo Co., Ltd., SciClone Pharmaceuticals, Inc.","bivalirudin, Hirulog,  Angiox",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,250MG/VIAL (INJECTABLE;INTRAVENOUS),New Jersey,United States,North America,88%,238,590,248,390,N/A, ,,
I,,,,,09/12/2017,Peptide,Intravenous (IV),"Bioniz Therapeutics, Inc.",,BNZ-1,,Dermatology,General,Alopecia Areata,"IL-15 (Interleukin-15)/IL-15 Receptor,IL-2 (Interleukin-2),IL-9 (Interleukin-9)",,"BNZ132-1-40, BNZ132-1, BNZ1, BNZ 1",N,I,16% (Same As Avg.), - , - , - ,,,,,,,09/12/2017,,Biologic,,,No,,California,United States,North America,,33684,53121,7115,733,N/A, ,,
Suspended,,,,,,Peptide,Intravenous (IV),"Araim Pharmaceuticals, Inc.",,Cibinetide,cibinetide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I","CSF2RB (common ß subunit, CD131),Erythropoietin Receptor (EPOR)",,"pHBSP, ARA290, ARA 290",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Orphan,,No,,New York,United States,North America,,20147,42122,3718,157,N/A, ,,
Suspended,,,,,12/02/2014,Peptide,Intravenous (IV),"Merck & Co., Inc.",MRK,MK-2640,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,MK2640,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/18/2016,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,31717,43792,254,157,N/A,$212.57B ,,
III,06/01/2004,11/10/2004,,,,Peptide,Intravenous (IV),Mallinckrodt plc,MNK,Terlipressin,terlipressin,Endocrine,Other,Hepatorenal Syndrome (HRS),Vasopressin receptors,"Orphan Therapeutics, LLC, Sinclair Pharma Ltd","terlipressin, Haemopressin, Glipressina, Glycylpressin, Variquel (EU), Lucassin (Australia), FE999908, FE 999908, FE-999908",Y,III,58% (2% Below Avg.), - , - , - ,,,,,,05/28/2008,,,New Molecular Entity (NME),"Fast Track,Orphan,Rare Disease",,No,,,United Kingdom,Europe,,2166,3600,556,668,N/A,$63.44M ,,
Suspended,,,,,07/02/2013,Peptide,Intravenous (IV),La Jolla Pharmaceutical Company,LJPC,Giapreza,angiotensin II,Endocrine,Other,Hepatorenal Syndrome (HRS),"Angiotensin II Receptor Type 1 (AT1),Angiotensin II Receptor Type 2 (AT2)",HealthCare Royalty Partners,"angiotensin II, LJPC501, LJPC 501, LJPC-501",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/02/2013,06/04/2013,New Molecular Entity (NME),Rare Disease,,No,,California,United States,North America,,22551,30657,453,668,N/A,$113.63M ,,
Withdrawn from Market,,,,,,Peptide,Intravenous (IV),Sanofi,SNY,Parathar,teriparatide acetate,Endocrine,Other,Hypoparathyroidism,Parathyroid Hormone Receptor (PTHR),,PTH 1-34,Y,Approved,100% (Same As Avg.), - , - , - ,12/23/1987,,,,,,,,New Molecular Entity (NME),Orphan,,No,,,France,Europe,,22048,29838,51,2557,N/A,$107.55B ,,
II,,,07/12/2017,07/12/2017,,Peptide,Intravenous (IV),"BioVie, Inc.",BIVI,BIV201,terlipressin acetate,Gastroenterology (Non Inflammatory Bowel Disease),Other,Liver Failure / Cirrhosis,Vasopressin receptors,,"BIV-201, BIV 201, terlipressin acetate continuous infusion",Y,II,24% (Same As Avg.), - , - , - ,,,,,,,,11/29/2016,Non-NME,"Fast Track,Orphan,Rare Disease",,No,,California,United States,North America,,31406,43410,4065,2866,N/A,$348.04M ,,
Suspended,,,05/05/2008,05/05/2008,,Peptide,Intravenous (IV),Helsinn Healthcare SA,,Ipamorelin,Ipamorelin,Gastroenterology (Non Inflammatory Bowel Disease),General,Postoperative Ileus,Ghrelin Receptor,Novo Nordisk A/S,Ipamorelin,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,09/19/2006,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,16104,20656,462,555,N/A, ,,
Preclinical,,,,,,Peptide,Intravenous (IV),"Soligenix, Inc.",SNGX,SGX942,dusquetide,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Antibacterial - General,Immune System,"SciClone Pharmaceuticals, Inc.","susquetide, SGX94, SGX-942, SGX 942, IMX 942, IMX942, IMX-942, IMX-001, IMX001, IMX 001",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,21570,39481,143,3121,N/A,$42.68M ,,
Suspended,,,,,02/17/2009,Peptide,Intravenous (IV),"Merck & Co., Inc.",MRK,"CB-182,804",,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Antibacterial - General,Cell Membrane,,"CB-182,804",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,02/17/2009,12/31/2008,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,14485,18339,254,3121,N/A,$212.57B ,,
Suspended,,,,,,Peptide,Intravenous (IV),Takeda Pharmaceutical Co. Ltd.,TAK,Mifamurtide,muramyl tripeptide phosphatidyl ethanolamine,Infectious Disease,"Other (I.E. Antiparasitic, Etc.)",Anti-Parasitic and Anti-Protozoal,Immune System,"GENESIS Pharma S.A., Novartis AG","Junovan, L-MTP-PE, Mepact (EU), liposomal muramyl tripeptide, CGP 19835A, CGP-19835A, CGP19835A",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Japan,Asia,,2405,42562,826,81,N/A,$46.05B ,,
Preclinical,,,,,,Peptide,Intravenous (IV),"OncoTherapy Science, Inc.",4564:JP,COVID-19 Peptide Vaccine (OncoTherapy),,Infectious Disease,Antiviral,COVID-19 Prevention,SARS-CoV-2,,"Peptide Therapy, Peptide Vaccine",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Vaccine,,,No,,,Japan,Asia,,43412,61209,3322,3665,N/A,$203.86M ,,
II,,,09/22/2020,07/23/2020,,Peptide,Intravenous (IV),INOTREM S.A.,,Nangibotide,nangibotide,Infectious Disease,Antiviral,COVID-19 Treatment,"Immune System,Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1)",,"LR12, LR-12, LR 12, MOTREM, CardioTREM",N,II,27% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,France,Europe,,36618,60527,7972,3651,N/A, ,,
II,,,10/07/2020,10/07/2020,,Peptide,Intravenous (IV),Arch Biopartners Inc.,ACHFF,Metablok,,Infectious Disease,Antiviral,COVID-19 Treatment,Dipeptidase 1 (DPEP-1),,LSALT peptide,N,II,27% (Same As Avg.), - , - , - ,,,,,,,,06/08/2020,New Molecular Entity (NME),,,No,,,Canada,North America,,27850,59509,5869,3651,N/A, ,,
Preclinical,,,,,,Peptide,Intravenous (IV),Soricimed Biopharma Inc.,,SOR-C13,,Infectious Disease,Antiviral,COVID-19 Treatment,"TRPV6, transient receptor potential vanilloid receptor 6, VR-6",,"SORC13, SOR C13",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New Brunswick,Canada,North America,,19934,62018,3674,3651,N/A, ,,
Preclinical,,,,,,Peptide,Intravenous (IV),"Orgenesis, Inc.",ORGS,Onconase,,Infectious Disease,Antiviral,COVID-19 Treatment,RNA,"BL&H Co., Ltd., GENESIS Pharma S.A., Leidos, Inc., MegaPharm Ltd., US Pharmacia",Ranpirnase,Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Maryland,United States,North America,,1984,60176,20060,3651,N/A,$118.12M ,,
Suspended,,,,,,Peptide,Intravenous (IV),"Orgenesis, Inc.",ORGS,Onconase,,Infectious Disease,Antiviral,Cytomegalovirus (CMV) Infection (Antiviral),RNA,"BL&H Co., Ltd., GENESIS Pharma S.A., Leidos, Inc., MegaPharm Ltd., US Pharmacia",Ranpirnase,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Maryland,United States,North America,,1984,30326,20060,411,N/A,$118.12M ,,
Suspended,,,,,,Peptide,Intravenous (IV),"Orgenesis, Inc.",ORGS,Onconase,,Infectious Disease,Antiviral,Ebola,RNA,"BL&H Co., Ltd., GENESIS Pharma S.A., Leidos, Inc., MegaPharm Ltd., US Pharmacia",Ranpirnase,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Maryland,United States,North America,,1984,42212,20060,688,N/A,$118.12M ,,
Suspended,10/24/2018,10/24/2018,08/19/2013,08/19/2013,,Peptide,Intravenous (IV),Polyphor AG,POLN,Murepavadin,murepavadin,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Hospital Acquired (Nosocomial) Pneumonia (HAP) (Antibacterial),"Cell wall synthesis,Pseudomonas aeruginosa",,"LptD program, POL-7080, POL7080, POL 7080, RG 7929, RG7929, RG-7929",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Fast Track,QIDP",,No,,,Switzerland,Europe,,22262,56518,3395,673,N/A,$102.79M ,,
II,,,,02/25/2016,,Peptide,Intravenous (IV),"Orgenesis, Inc.",ORGS,Onconase,,Infectious Disease,Antiviral,Human Papillomavirus (HPV) Treatment (Antiviral),RNA,"BL&H Co., Ltd., GENESIS Pharma S.A., Leidos, Inc., MegaPharm Ltd., US Pharmacia",Ranpirnase,Y,II,27% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Maryland,United States,North America,,1984,30325,20060,238,N/A,$118.12M ,,
Suspended,10/24/2018,10/24/2018,08/19/2013,08/19/2013,,Peptide,Intravenous (IV),Polyphor AG,POLN,Murepavadin,murepavadin,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Pseudomonas-Specific Agents (Antibacterial),"Cell wall synthesis,Pseudomonas aeruginosa",,"LptD program, POL-7080, POL7080, POL 7080, RG 7929, RG7929, RG-7929",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/04/2013,,New Molecular Entity (NME),"Fast Track,QIDP",,No,,,Switzerland,Europe,,22262,30145,3395,3119,N/A,$102.79M ,,
IIb,,,11/14/2019,11/14/2019,,Peptide,Intravenous (IV),INOTREM S.A.,,Nangibotide,nangibotide,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Sepsis and Septic Shock,"Immune System,Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1)",,"LR12, LR-12, LR 12, MOTREM, CardioTREM",N,II,27% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,France,Europe,,36618,51005,7972,76,N/A, ,,
Suspended,07/27/2015,07/27/2015,,11/25/2009,,Peptide,Intravenous (IV),Ferring Pharmaceuticals,,Selepressin,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Sepsis and Septic Shock,Vasopressin receptors,,FE 202158,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,21223,28572,582,76,N/A, ,,
NDA,10/05/2015,10/05/2015,12/13/2011,12/13/2011,09/14/2010,Peptide,Intravenous (IV),Atox Bio,,Reltecimod,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),"Cluster of Differentiation 28 (CD28) /ICOS and B7RP-1 Pathway,Immune System",,"p2TA, AB103, AB 103, AB-103",N,NDA/BLA,94% (6% Above Avg.),09/30/2021 - 09/30/2021, - , - ,,,,09/30/2021,,12/10/2020,09/14/2010,,New Molecular Entity (NME),"Fast Track,Orphan",,No,,,Israel,Asia,,18329,23996,3296,440,N/A, ,,
Suspended,,,,,,Peptide,Intravenous (IV),"Soligenix, Inc.",SNGX,SGX942,dusquetide,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),Immune System,"SciClone Pharmaceuticals, Inc.","susquetide, SGX94, SGX-942, SGX 942, IMX 942, IMX942, IMX-942, IMX-001, IMX001, IMX 001",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,12/18/2012,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,21570,29092,143,440,N/A,$42.68M ,,
I,,,,,10/01/2018,Peptide,Intravenous (IV),"Attralus, Inc.",,AT-01,AT01,Metabolic,Other,Amyloidosis,,,"AT 01, 124I-p5+14",N,I,16% (Same As Avg.), - , - , - ,,,,,,,10/01/2018,,Biologic,Rare Disease,,Yes,,California,United States,North America,,43702,61619,25565,625,N/A, ,,
Suspended,,,,,,Peptide,Intravenous (IV),"9 Meters Biopharma, Inc. ",NMTR,INN-329,,Metabolic,Single-Gene Disorders (Non-Inborn Errors of Metabolism),Spinal Muscular Atrophy,Secretin receptor,Repligen Corp.,"Secretin, SecreFlo, INN329, INN 329, RG1068, RG-1068, RG 1068",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,11/08/2012,,New Molecular Entity (NME),Rare Disease,,Yes,,North Carolina,United States,North America,,8283,29122,7614,3065,N/A,$288.83M ,,
Suspended,,,,,,Peptide,Intravenous (IV),"ArmaGen, Inc.",,AGT-3100,,Neurology,Neurodegenerative,Alzheimer's Disease - Imaging,"Amyloid Beta/Amyloid Plaques,Radiopharmaceutical",,"AGT-3 [N-biotinyl, 125I]-Abeta(1-40)",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,Yes,,California,United States,North America,,21467,28930,4018,1329,N/A, ,,
Suspended,,,,,,Peptide,Intravenous (IV),"Genervon Biopharmaceuticals, LLC",,GM605,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),"Insulin Receptor,Melanocortin (MC) receptors,Neuropeptide Y (NPY)/Peptide YY (PYY) Receptors,Nociceptin/Orphanin FQ Peptide (NOP) Receptor,Notch Receptors,Somatostatin Receptors",,"GM6, GM600",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,01/04/2013,,Biologic,,,No,,California,United States,North America,,22194,30037,4203,141,N/A, ,,
II,,,05/29/2013,05/29/2013,,Peptide,Intravenous (IV),"Genervon Biopharmaceuticals, LLC",,GM604,,Neurology,Neurodegenerative,Amyotrophic Lateral Sclerosis (ALS),,,"GM6, GM-604",Y,II,17% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,"Fast Track,Orphan,Rare Disease",,No,,California,United States,North America,,22451,30462,4203,193,N/A, ,,
Suspended,02/14/2002,02/14/2002,,,,Peptide,Intravenous (IV),"9 Meters Biopharma, Inc. ",NMTR,INN-329,,Neurology,Neurodevelopmental Disorders,Autism Spectrum Disorders (Autism),Secretin receptor,Repligen Corp.,"Secretin, SecreFlo, INN329, INN 329, RG1068, RG-1068, RG 1068",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,Yes,,North Carolina,United States,North America,,8283,28183,7614,619,N/A,$288.83M ,,
Suspended,,,,06/02/2006,,Peptide,Intravenous (IV),Endo International plc,ENDP,AL-208,davunetide,Neurology,Other,Cognitive Dysfunction,Microtubules (Tubulin),,"NAP (intravenous), davunetide intravenous",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/22/2005,,New Molecular Entity (NME),,,No,,,Ireland,Europe,,10809,13544,142,429,N/A,$1.82B ,,
Preclinical,,,,,,Peptide,Intravenous (IV),"RegeneRx Biopharmaceuticals, Inc.",RGRX,RGN-352,timbetasin,Neurology,Pain,Diabetic Peripheral Neuropathy (DPN),"Actin Filaments,ATP Synthase,Integrin-linked kinase (ILK)",Lee's Pharmaceutical Holdings Limited,"thymosin beta 4 (TB4) peptide, Thymosin beta 4 (Tβ4), RGN352, RGN 352",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Maryland,United States,North America,,10782,28061,460,671,N/A,$62.06M ,,
Suspended,,,,,,Peptide,Intravenous (IV),"9 Meters Biopharma, Inc. ",NMTR,INN-329,,Neurology,Other,Friedreich's Ataxia,Secretin receptor,Repligen Corp.,"Secretin, SecreFlo, INN329, INN 329, RG1068, RG-1068, RG 1068",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,11/08/2012,,New Molecular Entity (NME),Rare Disease,,Yes,,North Carolina,United States,North America,,8283,29121,7614,2826,N/A,$288.83M ,,
III,03/26/2015,03/26/2015,08/04/2008,08/04/2008,,Peptide,Intravenous (IV),NoNO Inc.,,NA-1,nerinetide,Neurology,Stroke,Ischemic Stroke,PSD-95 (postsynaptic density protein 95)/SAP-90 (synapse-associated protein 90),,"NA 1, NA1",Y,III,52% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Fast Track,,No,,,Canada,North America,,19440,25630,3559,145,N/A, ,,
Suspended,,,04/14/2011,04/14/2011,,Peptide,Intravenous (IV),"Genervon Biopharmaceuticals, LLC",,GM602,,Neurology,Stroke,Ischemic Stroke,Unknown,,"GM6, GM600",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,22192,30035,4203,145,N/A, ,,
Suspended,,,,12/02/2010,,Peptide,Intravenous (IV),D-Pharm Ltd.,DPRM,THR-18,,Neurology,Stroke,Ischemic Stroke,"Plasminogen Activator Inhibitor-1 (PAI-1, PLANH1)",,THR-18,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,02/04/2010,,Biologic,,,No,,,Israel,Asia,,19616,25882,128,145,N/A, ,,
Suspended,,10/09/2013,,,,Peptide,Intravenous (IV),The Medicines Company,MDCO,Angiomax,bivalirudin,Neurology,Stroke,Ischemic Stroke,Thrombin (Coagulation Factor IIa),"AstraZeneca PLC, Biogen, Inc., Daiichi Sankyo Co., Ltd., SciClone Pharmaceuticals, Inc.","bivalirudin, Hirulog,  Angiox",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,250MG/VIAL (INJECTABLE;INTRAVENOUS),New Jersey,United States,North America,88%,238,31563,248,145,N/A, ,,
Suspended,,,,,,Peptide,Intravenous (IV),"Artielle ImmunoTherapeutics, Inc.",,RTL1000,,Neurology,Neurodegenerative,Multiple Sclerosis (MS),T-Cell Receptor (TCR),,RTL 1000,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/14/2007,,Biologic,,,No,,Oregon,United States,North America,,8468,10528,1383,153,N/A, ,,
Suspended,12/12/2003,12/08/2004,,09/05/2001,,Peptide,Intravenous (IV),Medwell Capital Corp.,MWC:CN,Dirucotide,dirucotide,Neurology,Neurodegenerative,Multiple Sclerosis (MS),"Immune System,Myelin Basic Protein (MBP)",AutoImmune Inc.,MBP8298,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Fast Track,,No,,Alberta,Canada,North America,97%,991,1142,622,153,N/A, ,,
Suspended,,,,,,Peptide,Intravenous (IV),"RegeneRx Biopharmaceuticals, Inc.",RGRX,RGN-352,timbetasin,Neurology,Neurodegenerative,Multiple Sclerosis (MS),"Actin Filaments,ATP Synthase,Integrin-linked kinase (ILK)",Lee's Pharmaceutical Holdings Limited,"thymosin beta 4 (TB4) peptide, Thymosin beta 4 (Tβ4), RGN352, RGN 352",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Maryland,United States,North America,,10782,22540,460,153,N/A,$62.06M ,,
Preclinical,,,,,,Peptide,Intravenous (IV),Vect-Horus S.A.S.,,VH-N439,,Neurology,General,Neurology - Other,NT1 (Neurotensin receptor type 1),,"VHN439, VH N439",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,France,Europe,,35480,49282,7620,192,N/A, ,,
Suspended,,,,06/25/2010,,Peptide,Intravenous (IV),"Araim Pharmaceuticals, Inc.",,Cibinetide,cibinetide,Neurology,Pain,Neuropathic Pain,"CSF2RB (common ß subunit, CD131),Erythropoietin Receptor (EPOR)",,"pHBSP, ARA290, ARA 290",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,New York,United States,North America,,20147,26810,3718,362,N/A, ,,
Suspended,,,,,,Peptide,Intravenous (IV),Allergan plc,AGN,Rapastinel,rapastinel,Neurology,Pain,Neuropathic Pain,NMDA Receptor - Glycine Site,,"GLYX13, GLYX 13, GLYX-13, ThrProProThr",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,09/27/2011,,New Molecular Entity (NME),,,No,,,Ireland,Europe,,17642,24813,395,362,N/A,$63.66B ,,
Suspended,,,,01/04/2013,,Peptide,Intravenous (IV),"Genervon Biopharmaceuticals, LLC",,GM608,,Neurology,Neurodegenerative,Parkinson's Disease (PD),Unknown,,"GM6, GM600",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,22196,30039,4203,194,N/A, ,,
Suspended,,,,,,Peptide,Intravenous (IV),"RegeneRx Biopharmaceuticals, Inc.",RGRX,RGN-352,timbetasin,Neurology,Other,Traumatic Brain Injury (TBI),"Actin Filaments,ATP Synthase,Integrin-linked kinase (ILK)",Lee's Pharmaceutical Holdings Limited,"thymosin beta 4 (TB4) peptide, Thymosin beta 4 (Tβ4), RGN352, RGN 352",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Maryland,United States,North America,,10782,25798,460,547,N/A,$62.06M ,,
Suspended,,,,,,Peptide,Intravenous (IV),"Soligenix, Inc.",SNGX,SGX942,dusquetide,Not Specified,Other,Acute Radiation Syndrome (ARS),Immune System,"SciClone Pharmaceuticals, Inc.","susquetide, SGX94, SGX-942, SGX 942, IMX 942, IMX942, IMX-942, IMX-001, IMX001, IMX 001",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Orphan,,No,,New Jersey,United States,North America,,21570,31358,143,666,N/A,$42.68M ,,
I/II,,,,06/18/2020,06/18/2020,Peptide,Intravenous (IV),"Alume Biosciences, Inc.",,ALM-488,,Not Specified,Other,Surgical and Procedure Complications,Unknown,,"ALM488, ALM 488",N,II,24% (Same As Avg.), - , - , - ,,,,,,,,05/04/2020,New Molecular Entity (NME),,,Yes,,California,United States,North America,,42371,59612,24957,2887,N/A, ,,
Suspended,,,,03/27/2012,,Peptide,Intravenous (IV),Novartis AG,NVS,Reasanz,serelaxin,Obstetrics/Gynecology,Obstetrics,Eclampsia/Pre-Eclampsia,Relaxin Family Peptide Receptors 1-4 (RXFP1-4),,"Relaxin (recombinant), serelaxin, RLX-030, rhRIx, RLX030",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,12/22/2009,,New Molecular Entity (NME),Rare Disease,,No,,,Switzerland,Europe,,16214,20865,289,2908,N/A,$183.31B ,,
Suspended,,,,04/23/2008,,Peptide,Intravenous (IV),Novartis AG,NVS,Reasanz,serelaxin,Obstetrics/Gynecology,Obstetrics,Labor Induction,Relaxin Family Peptide Receptors 1-4 (RXFP1-4),,"Relaxin (recombinant), serelaxin, RLX-030, rhRIx, RLX030",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,16214,20866,289,2909,N/A,$183.31B ,,
I,,,07/08/2018,07/08/2018,,Peptide,Intravenous (IV),Immune System Key Ltd.,,Nerofe,,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),"Angiogenesis,Apoptosis (Cell Death),Immune System",,dTCApFs,N,I,6% (Same As Avg.), - , - , - ,,,,,,,07/29/2020,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Israel,Asia,,38811,54227,8628,97, 11%, ,Orphan Drug designation,Yes
Investigator Initiated,,,,,,Peptide,Intravenous (IV),Tiziana Life Sciences plc,TLSA,Dactinomycin,,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),RNA synthesis,,"actinomycin D, Act D",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,Rare Disease,,No,,,United Kingdom,Europe,,40125,56117,5019,97,N/A,$55.20M ,,
Preclinical,,,,,,Peptide,Intravenous (IV),"Rasna Therapeutics, Inc. ",RASP,RASP-101,dactinomycin,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),RNA synthesis,,RASP 101,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,Rare Disease,,No,,New York,United States,North America,,34850,48281,7449,97,N/A,$4.48M ,,
Suspended,,,09/15/2014,09/15/2014,,Peptide,Intravenous (IV),"Genus Oncology, LLC",,GO-203-2c,,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),Mucin 1 (MUC-1),,"GO-203-2c, GO-203",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,Illinois,United States,North America,,17992,46453,3024,97,N/A, ,,
Suspended,,,,,09/20/2016,Peptide,Intravenous (IV),"Aileron Therapeutics, Inc",ALRN,ALRN-6924,,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),"Mdm2,Mdmx/Mdm4",Roche Holding AG,"ALRN6924, ALRN 6924, ATSP7041 Successor, ATSP-7041 Successor, ATSP 7041 Successor",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,09/20/2016,,Biologic,"Orphan,Rare Disease",,No,,Massachusetts,United States,North America,,22802,48792,4074,97,N/A,$50.04M ,,
Preclinical,,,,,,Peptide,Intravenous (IV),"Bioniz Therapeutics, Inc.",,BNZ-1,,Oncology,Hematologic,Adult T-cell Leukemia/Lymphoma (ATL),"IL-15 (Interleukin-15)/IL-15 Receptor,IL-2 (Interleukin-2),IL-9 (Interleukin-9)",,"BNZ132-1-40, BNZ132-1, BNZ1, BNZ 1",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,33684,51366,7115,3349,N/A, ,,
Suspended,,,,01/22/2013,,Peptide,Intravenous (IV),Spectrum Pharmaceuticals Inc.,SPPI,SPI-1620,,Oncology,Solid,Biliary Tract Cancer,Endothelin Receptor Type B (EDNRB),,SPI-1620,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,02/08/2008,,New Molecular Entity (NME),Rare Disease,,No,,Nevada,United States,North America,,10554,29435,270,580,N/A,$547.21M ,,
Suspended,,,11/03/2010,11/03/2010,,Peptide,Intravenous (IV),Aeterna Zentaris Inc.,AEZS,Zoptrex,zoptarelin doxorubicin,Oncology,Solid,Bladder Cancer,"DNA,DNA synthesis,Gonadotropin-Releasing Hormone (GnRH) Receptor,Topoisomerase I (Topo-I)","Ergomed plc, Orient EuroPharma Co., Ltd., Rafa Laboratories, Ltd., Sinopharm Group Co. Ltd., Specialised Therapeutics","AN-152, ZEN-008, Zoptarelin Doxorubicin, AEZS-108",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Canada,North America,,980,21689,14,217,N/A,$33.59M ,,
Suspended,,,,,,Peptide,Intravenous (IV),University of Texas MD Anderson Cancer Center,,BMTP-11,,Oncology,Solid,Bone Cancer,IL-11R (interleukin-11 receptor),,"BMTP11, BMTP 11, bone metastasis targeting peptide-11",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Texas,United States,North America,,35471,49266,3791,684,N/A, ,,
Suspended,,,,04/13/2010,,Peptide,Intravenous (IV),Polyphor AG,POLN,POL6326,balixafortide,Oncology,"Surgical, Interventional Radiological, and Other Invasive Procedures",Bone Marrow Transplant and Stem Cell Transplant,Chemokine (C-X-C motif) Receptor 4 (CXCR4),"Shanghai Fosun Pharmaceutical (Group) Co., Ltd.","POL-6326, POL 6326, Balixafortide",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,18714,24585,3395,300,N/A,$102.79M ,,
III,11/28/2018,11/28/2018,,,09/25/2014,Peptide,Intravenous (IV),"Blaze Bioscience, Inc. ",,BLZ-100,tozuleristide,Oncology,Solid,Brain Cancer - Imaging,,"Eisai Co., Ltd.","BLZ100, BLZ 100, tumor paint",N,III,35% (Same As Avg.), - , - , - ,,,,,,,09/25/2014,,Non-NME,"Fast Track,Orphan",,Yes,,Washington,United States,North America,,26400,36834,5398,3203, 52%, ,Tumor Type,N/A
II,,,12/06/2007,12/06/2007,,Peptide,Intravenous (IV),"Angiochem, Inc.",,ANG1005,,Oncology,Solid,Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM)),"Cluster of Differentiation 91 (CD91) / Low density lipoprotein receptor-related protein 1 (LRP1),Microtubules (Tubulin)",Shenogen Pharma Group Ltd.,"ANG-1005, ANG 1005, GRN1005, GRM-1005, GRN 1005, SNG 1005, SNG1005, SNG-1005",N,II,10% (Same As Avg.), - , - , - ,,,,,,,,09/14/2007,New Molecular Entity (NME),"Fast Track,Orphan,Rare Disease",,No,,,Canada,North America,,15919,20395,2712,228, 16%, ,Fast Track,Yes
III,12/01/2011,12/01/2011,06/01/1996,06/01/1996,,Peptide,Intravenous (IV),"Burzynski Research Institute, Inc.",BZYR,Antineoplastons,,Oncology,Solid,Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM)),Tumor Cells,,"A10 (atengenal) / AS2-1 (astugenal), ANP",N,III,35% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Texas,United States,North America,,25734,35820,5212,228,N/A,$3.15M ,,
Suspended,,02/20/2008,,11/22/2004,,Peptide,Intravenous (IV),EspeRare Foundation,,EspoiR-003,Cilengitide,Oncology,Solid,Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM)),Integrin Alpha-V Family,,EMD 121974,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Switzerland,Europe,,2584,4389,7990,228,N/A, ,,
Suspended,,12/02/2008,,04/01/2002,,Peptide,Intravenous (IV),"TransMolecular, Inc.",,TM-601,,Oncology,Solid,Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM)),"MMP-2 (Metalloproteinase-2) Receptor ,Radiopharmaceutical",,"131Iodine-TM601, 131I-TM601, Chlorotoxin",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Fast Track,Orphan,Rare Disease,SPA",,No,,Massachusetts,United States,North America,,2929,4993,956,228,N/A, ,,
Suspended,,,02/19/2014,02/19/2014,,Peptide,Intravenous (IV),"Inspyr Therapeutics, Inc.",NSPX,Mipsagargin,,Oncology,Solid,Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM)),"Prostate-specific Membrane Antigen (PSMA),Sarcoplasmic reticulum Ca2+-ATPase (SERCA)",,"C66H100N6O27, Thapsigargin pro-drug, G-202, G202, G 202",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Texas,United States,North America,,19781,32772,3640,228,N/A,$804.44K ,,
II,,,12/06/2007,12/06/2007,,Peptide,Intravenous (IV),"Angiochem, Inc.",,ANG1005,,Oncology,Solid,Brain Cancer (Secondary; Metastases),"Cluster of Differentiation 91 (CD91) / Low density lipoprotein receptor-related protein 1 (LRP1),Microtubules (Tubulin)",Shenogen Pharma Group Ltd.,"ANG-1005, ANG 1005, GRN1005, GRM-1005, GRN 1005, SNG 1005, SNG1005, SNG-1005",Y,II,12% (2% Above Avg.), - , - , - ,,,,,,,,09/14/2007,New Molecular Entity (NME),SPA,,No,,,Canada,North America,,15919,20399,2712,713,  6%, ,Target with previous approval,No
I/II,,,09/06/2018,09/06/2018,,Peptide,Intravenous (IV),Immune System Key Ltd.,,Nerofe,,Oncology,Solid,Breast Cancer,"Angiogenesis,Apoptosis (Cell Death),Immune System",,dTCApFs,N,II,10% (Same As Avg.), - , - , - ,,,,,,,12/01/2013,,New Molecular Entity (NME),,,No,,,Israel,Asia,,38811,54225,8628,214,N/A, ,,
III,,03/15/2019,,,11/29/2013,Peptide,Intravenous (IV),Polyphor AG,POLN,POL6326,balixafortide,Oncology,Solid,Breast Cancer,Chemokine (C-X-C motif) Receptor 4 (CXCR4),"Shanghai Fosun Pharmaceutical (Group) Co., Ltd.","POL-6326, POL 6326, Balixafortide",N,III,38% (3% Above Avg.),01/01/2022 - 01/31/2022, - , - ,,,,,,,11/29/2013,,New Molecular Entity (NME),Fast Track,,No,,,Switzerland,Europe,,18714,52362,3395,214, 33%,$102.79M ,Tumor Type,Solid
Suspended,,,,10/25/2011,,Peptide,Intravenous (IV),Aeterna Zentaris Inc.,AEZS,Zoptrex,zoptarelin doxorubicin,Oncology,Solid,Breast Cancer,"DNA,DNA synthesis,Gonadotropin-Releasing Hormone (GnRH) Receptor,Topoisomerase I (Topo-I)","Ergomed plc, Orient EuroPharma Co., Ltd., Rafa Laboratories, Ltd., Sinopharm Group Co. Ltd., Specialised Therapeutics","AN-152, ZEN-008, Zoptarelin Doxorubicin, AEZS-108",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,06/05/2006,,New Molecular Entity (NME),,,No,,,Canada,North America,,980,914,14,214,N/A,$33.59M ,,
Suspended,06/22/2009,06/22/2009,,,,Peptide,Intravenous (IV),Merck KGaA,MKKGY,Tecemotide,tecemotide,Oncology,Solid,Breast Cancer,"Immune System,Mucin 1 (MUC-1)","Ono Pharmaceutical Company, Ltd., Seagen Inc. ","BLP25 liposome vaccine, EMD531444, L-BLP25, ONO-7165, Stimuvax, emepepimut-S",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Germany,Europe,,1146,19653,255,214,N/A,$12.69B ,,
II/III,08/02/2018,08/02/2018,06/30/2017,06/30/2017,04/16/2015,Peptide,Intravenous (IV),"Avelas Biosciences, Inc.",,AVB-620,,Oncology,Solid,Breast Cancer - Imaging,Protease,,"AVB 620, AVB620",N,III,35% (Same As Avg.), - , - , - ,,,,,,,03/17/2015,,New Molecular Entity (NME),Breakthrough,,Yes,,California,United States,North America,,25679,35758,5198,800, 63%, ,Breakthrough Therapy designation,Yes
Suspended,,,,,,Peptide,Intravenous (IV),ISA Pharmaceuticals B.V.,,ISA203,,Oncology,General,Cancer,Immune System,,"ISA203, PRAME (PReferentially expressed Antigen in MElanoma)",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Netherlands,Europe,,22991,31363,3000,313,N/A, ,,
Suspended,,,,09/16/2013,,Peptide,Intravenous (IV),ISA Pharmaceuticals B.V.,,ISA102,,Oncology,Solid,Colorectal Cancer (CRC),"Immune System,p53",,"ISA102, p53-SLP",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Netherlands,Europe,,22990,31362,3000,213,N/A, ,,
Suspended,,,,08/01/1998,,Peptide,Intravenous (IV),"Burzynski Research Institute, Inc.",BZYR,Antineoplastons,,Oncology,Solid,Colorectal Cancer (CRC),Tumor Cells,,"A10 (atengenal) / AS2-1 (astugenal), ANP",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Texas,United States,North America,,25734,35819,5212,213,N/A,$3.15M ,,
Suspended,,,01/06/2012,01/06/2012,,Peptide,Intravenous (IV),Merck KGaA,MKKGY,Tecemotide,tecemotide,Oncology,Solid,Colorectal Cancer (CRC),"Immune System,Mucin 1 (MUC-1)","Ono Pharmaceutical Company, Ltd., Seagen Inc. ","BLP25 liposome vaccine, EMD531444, L-BLP25, ONO-7165, Stimuvax, emepepimut-S",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Germany,Europe,,1146,25436,255,213,N/A,$12.69B ,,
I/II,,,,09/13/2017,02/07/2017,Peptide,Intravenous (IV),"Bioniz Therapeutics, Inc.",,BNZ-1,,Oncology,Hematologic,Cutaneous T-Cell Lymphoma (CTCL) - NHL,"IL-15 (Interleukin-15)/IL-15 Receptor,IL-2 (Interleukin-2),IL-9 (Interleukin-9)",,"BNZ132-1-40, BNZ132-1, BNZ1, BNZ 1",N,II,10% (Same As Avg.), - , - , - ,,,,,,,02/07/2017,,Biologic,"Orphan,Rare Disease",,No,,California,United States,North America,,33684,46521,7115,417, 13%, ,Lead Indication,Yes
Suspended,,,,,,Peptide,Intravenous (IV),"PharmaMar, S.A.",PHM,Irvalec,,Oncology,Solid,Esophageal Cancer,ErbB3/HER3,,"PM-02734, elisidepsin",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Spain,Europe,,19809,26265,775,273,N/A,$5.22M ,,
Suspended,,,,,,Peptide,Intravenous (IV),"Inspyr Therapeutics, Inc.",NSPX,Mipsagargin,,Oncology,Solid,Gastric Cancer,"Prostate-specific Membrane Antigen (PSMA),Sarcoplasmic reticulum Ca2+-ATPase (SERCA)",,"C66H100N6O27, Thapsigargin pro-drug, G-202, G202, G 202",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Texas,United States,North America,,19781,49861,3640,223,N/A,$804.44K ,,
Suspended,,,,,,Peptide,Intravenous (IV),"PharmaMar, S.A.",PHM,Irvalec,,Oncology,Solid,Gastric Cancer,ErbB3/HER3,,"PM-02734, elisidepsin",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Spain,Europe,,19809,26264,775,223,N/A,$5.22M ,,
Suspended,,,11/03/2008,11/03/2008,,Peptide,Intravenous (IV),EspeRare Foundation,,EspoiR-003,Cilengitide,Oncology,Solid,Head and Neck Cancer,Integrin Alpha-V Family,,EMD 121974,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,2584,4388,7990,230,N/A, ,,
Suspended,,,,05/02/2006,,Peptide,Intravenous (IV),Pertinax Therapeutics,,PTX-9908,,Oncology,Solid,Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases),Chemokine (C-X-C motif) Receptor 4 (CXCR4),"MicroConstants, Inc., TCM Biotech International Corp.","CTCE-9908, CTCE9908, CTCE 9908, PTX 9908, PTX9908",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,12/11/2003,,New Molecular Entity (NME),Rare Disease,,No,,,United Kingdom,Europe,,6577,6790,4425,297,N/A, ,,
Suspended,,,,,,Peptide,Intravenous (IV),Horizon Therapeutics plc,HZNP,HepTide Program,,Oncology,Solid,Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases),Cluster of Differentiation 91 (CD91) / Low density lipoprotein receptor-related protein 1 (LRP1),,HepTide Program,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,,Ireland,Europe,,24262,33597,2878,297,N/A,$17.57B ,,
Suspended,,,02/21/2013,11/19/2012,,Peptide,Intravenous (IV),"Inspyr Therapeutics, Inc.",NSPX,Mipsagargin,,Oncology,Solid,Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases),"Prostate-specific Membrane Antigen (PSMA),Sarcoplasmic reticulum Ca2+-ATPase (SERCA)",,"C66H100N6O27, Thapsigargin pro-drug, G-202, G202, G 202",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,01/25/2010,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,Texas,United States,North America,,19781,28626,3640,297,N/A,$804.44K ,,
Suspended,,,,,,Peptide,Intravenous (IV),Takeda Pharmaceutical Co. Ltd.,TAK,Mifamurtide,muramyl tripeptide phosphatidyl ethanolamine,Oncology,Solid,Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases),Immune System,"GENESIS Pharma S.A., Novartis AG","Junovan, L-MTP-PE, Mepact (EU), liposomal muramyl tripeptide, CGP 19835A, CGP-19835A, CGP19835A",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Japan,Asia,,2405,42561,826,297,N/A,$46.05B ,,
Suspended,,,,,,Peptide,Intravenous (IV),Mallinckrodt plc,MNK,Terlipressin,terlipressin,Oncology,Solid,Malignant Ascites,Vasopressin receptors,"Orphan Therapeutics, LLC, Sinclair Pharma Ltd","terlipressin, Haemopressin, Glipressina, Glycylpressin, Variquel (EU), Lucassin (Australia), FE999908, FE 999908, FE-999908",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Orphan,,No,,,United Kingdom,Europe,,2166,43142,556,2782,N/A,$63.44M ,,
Program Hold,,,,06/05/2004,,Peptide,Intravenous (IV),ExperGen Drug Development GmbH,,TLN-232,,Oncology,Solid,Melanoma,M2PK (pyruvate kinase),,"CAP-232, TT-232",N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Austria,Europe,,10207,12762,2865,221,N/A, ,,
Suspended,,,,,,Peptide,Intravenous (IV),"SolaranRx, Inc",,SRX-1117,,Oncology,Solid,Melanoma,"Melanocortin (MC) receptors,Radiopharmaceutical",,"SRX1117, SRX 1117",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Orphan,,No,,New Mexico,United States,North America,,24802,34464,4905,221,N/A, ,,
Suspended,,,,06/02/2008,,Peptide,Intravenous (IV),"TransMolecular, Inc.",,TM-601,,Oncology,Solid,Melanoma,"MMP-2 (Metalloproteinase-2) Receptor ,Radiopharmaceutical",,"131Iodine-TM601, 131I-TM601, Chlorotoxin",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Orphan,,No,,Massachusetts,United States,North America,,2929,14353,956,221,N/A, ,,
II,,,,06/03/2008,,Peptide,Intravenous (IV),"CanBas Co., Ltd.",4575,CBP501,,Oncology,Solid,Mesothelioma,Cell Cycle Checkpoint Kinase 1 (Chk1),,"CBP-501, CBP 501",Y,II,10% (Same As Avg.), - , - , - ,,,,,,,01/06/2006,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Japan,Asia,,11652,14676,2215,652,N/A,$30.70M ,,
Suspended,05/15/1997,04/26/1999,,05/15/1997,,Peptide,Intravenous (IV),"Orgenesis, Inc.",ORGS,Onconase,,Oncology,Solid,Mesothelioma,RNA,"BL&H Co., Ltd., GENESIS Pharma S.A., Leidos, Inc., MegaPharm Ltd., US Pharmacia",Ranpirnase,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,03/12/2007,,,New Molecular Entity (NME),"Fast Track,Orphan,Rare Disease",,No,,Maryland,United States,North America,,1984,3206,20060,652,N/A,$118.12M ,,
Suspended,,,,03/23/2010,,Peptide,Intravenous (IV),Merck KGaA,MKKGY,Tecemotide,tecemotide,Oncology,Hematologic,Multiple Myeloma (MM),"Immune System,Mucin 1 (MUC-1)","Ono Pharmaceutical Company, Ltd., Seagen Inc. ","BLP25 liposome vaccine, EMD531444, L-BLP25, ONO-7165, Stimuvax, emepepimut-S",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Germany,Europe,,1146,21351,255,207,N/A,$12.69B ,,
Suspended,,,,,09/20/2016,Peptide,Intravenous (IV),"Aileron Therapeutics, Inc",ALRN,ALRN-6924,,Oncology,Hematologic,Myelodysplastic Syndrome (MDS),"Mdm2,Mdmx/Mdm4",Roche Holding AG,"ALRN6924, ALRN 6924, ATSP7041 Successor, ATSP-7041 Successor, ATSP 7041 Successor",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,09/20/2016,,Biologic,Rare Disease,,No,,Massachusetts,United States,North America,,22802,43807,4074,206,N/A,$50.04M ,,
I,,,,02/19/2017,,Peptide,Intravenous (IV),Ipsen SA,IPSEY,SOMTher,satoreotide,Oncology,Solid,Neuroendocrine Tumors (NET),"Radiopharmaceutical,Somatostatin Receptors",,"177Lu-OPS-201, OPS-201, 177Lu OPSC001, OPS201, 177Lu-OPS201, IPN-01072, IPN01072, IPN 01072, Lu-IPN01072",N,I,6% (Same As Avg.), - , - , - ,,,,,,,07/30/2020,,Non-NME,Rare Disease,,No,,,France,Europe,,32227,44512,220,347, 13%,$4.57B ,Target with previous approval,Yes
I/II,,,04/24/2018,04/24/2018,11/24/2016,Peptide,Intravenous (IV),"Tarveda Therapeutics, Inc.",,PEN-221,,Oncology,Solid,Neuroendocrine Tumors (NET),"Somatostatin Receptors,Tumor Cells",,"Pentarin, PEN221, PEN 221, BTP277, BTP-277, BTP 277",N,II,10% (Same As Avg.), - , - , - ,,,,,,,11/24/2016,,Biologic,Rare Disease,,No,,Massachusetts,United States,North America,,25535,45574,4047,347, 15%, ,Indication Group,NET
Suspended,,,,01/24/2007,,Peptide,Intravenous (IV),"Progenics Pharmaceuticals, Inc.",PGNX,Onalta,,Oncology,Solid,Neuroendocrine Tumors (NET),"Radiopharmaceutical,Somatostatin Receptors","Biomedica Life Sciences, S.A., Novartis AG","Yttrium-90 edotreotide, OctreoTher, Y-90 SMT487, Y-90 SMT-487, Y-90 SMT 487",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,New York,United States,North America,100%,15128,19231,321,347,N/A,$355.05M ,,
Suspended,,,,,,Peptide,Intravenous (IV),"Esperance Pharmaceuticals, Inc.",,EP-100,,Oncology,Hematologic,Non-Hodgkin's Lymphoma (NHL),Luteinizing Hormone Receptor (LHR) ,,EP-100,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Louisiana,United States,North America,,18401,26257,3311,205,N/A, ,,
II,,,07/07/2009,07/07/2009,,Peptide,Intravenous (IV),"CanBas Co., Ltd.",4575,CBP501,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),Cell Cycle Checkpoint Kinase 1 (Chk1),,"CBP-501, CBP 501",N,II,6% (4% Below Avg.), - , - , - ,,,,,,,01/06/2006,,New Molecular Entity (NME),,,No,,,Japan,Asia,,11652,14677,2215,211,N/A,$30.70M ,,
Suspended,,,02/11/2009,02/11/2009,,Peptide,Intravenous (IV),EspeRare Foundation,,EspoiR-003,Cilengitide,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),Integrin Alpha-V Family,,EMD 121974,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,2584,19101,7990,211,N/A, ,,
Suspended,,,,05/02/2005,,Peptide,Intravenous (IV),Yakult Honsha Co. Ltd. ,2267:JP,Soblidotin,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),Microtubules (Tubulin),,"TZT-1027, YHI-501",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,10/31/2001,,New Molecular Entity (NME),,,No,,,Japan,Asia,,2102,3462,1273,211,N/A, ,,
Suspended,01/02/2007,01/02/2007,11/13/2002,11/13/2002,,Peptide,Intravenous (IV),Merck KGaA,MKKGY,Tecemotide,tecemotide,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),"Immune System,Mucin 1 (MUC-1)","Ono Pharmaceutical Company, Ltd., Seagen Inc. ","BLP25 liposome vaccine, EMD531444, L-BLP25, ONO-7165, Stimuvax, emepepimut-S",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Fast Track,SPA",,No,,,Germany,Europe,,1146,1467,255,211,N/A,$12.69B ,,
Suspended,,,,02/08/2005,02/08/2005,Peptide,Intravenous (IV),"Orgenesis, Inc.",ORGS,Onconase,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),RNA,"BL&H Co., Ltd., GENESIS Pharma S.A., Leidos, Inc., MegaPharm Ltd., US Pharmacia",Ranpirnase,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Maryland,United States,North America,,1984,3202,20060,211,N/A,$118.12M ,,
Suspended,,,,12/18/2008,,Peptide,Intravenous (IV),"PharmaMar, S.A.",PHM,Irvalec,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),ErbB3/HER3,,"PM-02734, elisidepsin",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Spain,Europe,,19809,26260,775,211,N/A,$5.22M ,,
Suspended,,,,12/03/2012,02/08/2008,Peptide,Intravenous (IV),Spectrum Pharmaceuticals Inc.,SPPI,SPI-1620,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),Endothelin Receptor Type B (EDNRB),,SPI-1620,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,02/08/2008,,New Molecular Entity (NME),,,No,,Nevada,United States,North America,,10554,13217,270,211,N/A,$547.21M ,,
I,,,,,08/06/2019,Peptide,Intravenous (IV),Soricimed Biopharma Inc.,,SOR-C13,,Oncology,Solid,Ovarian Cancer,"TRPV6, transient receptor potential vanilloid receptor 6, VR-6",,"SORC13, SOR C13",N,I,6% (Same As Avg.), - , - , - ,,,,,,,08/06/2019,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,New Brunswick,Canada,North America,,19934,43604,3674,224,  9%, ,Orphan Drug designation,Yes
I/II,,,09/06/2018,09/06/2018,,Peptide,Intravenous (IV),Immune System Key Ltd.,,Nerofe,,Oncology,Solid,Ovarian Cancer,"Angiogenesis,Apoptosis (Cell Death),Immune System",,dTCApFs,N,II,10% (Same As Avg.), - , - , - ,,,,,,,12/01/2013,,New Molecular Entity (NME),Rare Disease,,No,,,Israel,Asia,,38811,54226,8628,224,N/A, ,,
Suspended,,,02/16/2012,02/16/2012,,Peptide,Intravenous (IV),"Esperance Pharmaceuticals, Inc.",,EP-100,,Oncology,Solid,Ovarian Cancer,Luteinizing Hormone Receptor (LHR) ,,EP-100,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,06/01/2011,,New Molecular Entity (NME),Rare Disease,,No,,Louisiana,United States,North America,,18401,24100,3311,224,N/A, ,,
Suspended,,,,10/01/2009,,Peptide,Intravenous (IV),ISA Pharmaceuticals B.V.,,ISA102,,Oncology,Solid,Ovarian Cancer,"Immune System,p53",,"ISA102, p53-SLP",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Netherlands,Europe,,22990,31361,3000,224,N/A, ,,
Suspended,,,,,,Peptide,Intravenous (IV),"CanBas Co., Ltd.",4575,CBP501,,Oncology,Solid,Ovarian Cancer,Cell Cycle Checkpoint Kinase 1 (Chk1),,"CBP-501, CBP 501",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,10/29/2007,,New Molecular Entity (NME),Rare Disease,,No,,,Japan,Asia,,11652,30244,2215,224,N/A,$30.70M ,,
Suspended,,,,12/06/2007,,Peptide,Intravenous (IV),Aeterna Zentaris Inc.,AEZS,Zoptrex,zoptarelin doxorubicin,Oncology,Solid,Ovarian Cancer,"DNA,DNA synthesis,Gonadotropin-Releasing Hormone (GnRH) Receptor,Topoisomerase I (Topo-I)","Ergomed plc, Orient EuroPharma Co., Ltd., Rafa Laboratories, Ltd., Sinopharm Group Co. Ltd., Specialised Therapeutics","AN-152, ZEN-008, Zoptarelin Doxorubicin, AEZS-108",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,06/05/2006,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Canada,North America,,980,4645,14,224,N/A,$33.59M ,,
I,,,,,08/13/2018,Peptide,Intravenous (IV),Cend Therapeutics,,CEND-1,,Oncology,Solid,Pancreatic Cancer,"Integrin Alpha-V Family,Neuropilin 1 (NRP1)",,"CEND1, CEND 1, iRGD, CEND-001, CEND001, CEND 001",N,I,6% (Same As Avg.), - , - , - ,,,,,,,08/13/2018,,Biologic,"Orphan,Rare Disease",,No,,California,United States,North America,,42093,59171,12188,220,  6%, ,Orphan Drug designation,Yes
I,,,,,08/06/2019,Peptide,Intravenous (IV),Soricimed Biopharma Inc.,,SOR-C13,,Oncology,Solid,Pancreatic Cancer,"TRPV6, transient receptor potential vanilloid receptor 6, VR-6",,"SORC13, SOR C13",N,I,6% (Same As Avg.), - , - , - ,,,,,,,08/06/2019,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,New Brunswick,Canada,North America,,19934,43605,3674,220,  8%, ,Orphan Drug designation,Yes
IND,,,,,,Peptide,Intravenous (IV),"Immune Therapeutics, Inc.",IMUN,MENK,,Oncology,Solid,Pancreatic Cancer,Opioid receptors,Cytocom Inc.,"IRT-101, IRT101, Met-enkephalin, Opioid Growth Factor, OGF, CYTO-401, Menkophian",N,IND,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,Florida,United States,North America,,34926,48384,7470,220,N/A,$7.90K ,,
Program Hold,,,,,,Peptide,Intravenous (IV),ExperGen Drug Development GmbH,,TLN-232,,Oncology,Solid,Pancreatic Cancer,M2PK (pyruvate kinase),,"CAP-232, TT-232",N,I,6% (Same As Avg.), - , - , - ,,,,,,,03/14/2006,,New Molecular Entity (NME),Rare Disease,,No,,,Austria,Europe,,10207,12761,2865,220,N/A, ,,
Suspended,12/06/1995,12/06/1995,,,,Peptide,Intravenous (IV),"Orgenesis, Inc.",ORGS,Onconase,,Oncology,Solid,Pancreatic Cancer,RNA,"BL&H Co., Ltd., GENESIS Pharma S.A., Leidos, Inc., MegaPharm Ltd., US Pharmacia",Ranpirnase,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Maryland,United States,North America,,1984,3205,20060,220,N/A,$118.12M ,,
Suspended,03/26/2008,03/26/2008,,,,Peptide,Intravenous (IV),"9 Meters Biopharma, Inc. ",NMTR,INN-329,,Oncology,Diagnostics,Pancreatic Cancer - Imaging,Secretin receptor,Repligen Corp.,"Secretin, SecreFlo, INN329, INN 329, RG1068, RG-1068, RG 1068",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,12/21/2011,,,New Molecular Entity (NME),"Fast Track,Orphan",,Yes,,North Carolina,United States,North America,,8283,10255,7614,3193,N/A,$288.83M ,,
Suspended,,,08/31/2016,08/31/2016,,Peptide,Intravenous (IV),"Aileron Therapeutics, Inc",ALRN,ALRN-6924,,Oncology,Hematologic,Peripheral T-Cell Lymphoma (PTCL) - NHL,"Mdm2,Mdmx/Mdm4",Roche Holding AG,"ALRN6924, ALRN 6924, ATSP7041 Successor, ATSP-7041 Successor, ATSP 7041 Successor",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,Massachusetts,United States,North America,,22802,48793,4074,3097,N/A,$50.04M ,,
Suspended,,,,,,Peptide,Intravenous (IV),University of Texas MD Anderson Cancer Center,,BMTP-11,,Oncology,Solid,Prostate Cancer,IL-11R (interleukin-11 receptor),,"BMTP11, BMTP 11, bone metastasis targeting peptide-11",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/30/2009,,New Molecular Entity (NME),,,No,,Texas,United States,North America,,35471,49263,3791,215,N/A, ,,
Suspended,,,,12/22/2003,,Peptide,Intravenous (IV),"Kotinos Pharmaceuticals, Inc.",,PCK3145,tigapotide triflutate,Oncology,Solid,Prostate Cancer,Follicle-stimulating hormone (FSH),"Ambrilia Biopharma, Inc.",tigapotide triflutate,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New York,United States,North America,,11863,14939,2673,215,N/A, ,,
Suspended,,,11/12/2010,11/12/2010,,Peptide,Intravenous (IV),Aeterna Zentaris Inc.,AEZS,Zoptrex,zoptarelin doxorubicin,Oncology,Solid,Prostate Cancer,"DNA,DNA synthesis,Gonadotropin-Releasing Hormone (GnRH) Receptor,Topoisomerase I (Topo-I)","Ergomed plc, Orient EuroPharma Co., Ltd., Rafa Laboratories, Ltd., Sinopharm Group Co. Ltd., Specialised Therapeutics","AN-152, ZEN-008, Zoptarelin Doxorubicin, AEZS-108",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/05/2010,,New Molecular Entity (NME),,,No,,,Canada,North America,,980,19248,14,215,N/A,$33.59M ,,
Suspended,,,,,01/13/2015,Peptide,Intravenous (IV),Aptevo Therapeutics Inc.,APVO,APVO414,,Oncology,Solid,Prostate Cancer,"Cluster of Differentiation 3 (CD3),Prostate-specific Membrane Antigen (PSMA),T-Cell Receptor (TCR)",,"ES414, ES-414, T-Scorp, MOR 209, MOR209/ES414, APVO-414, APVO 414",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,01/13/2015,11/20/2014,Biologic,,,No,,Washington,United States,North America,100%,22282,30181,6381,215,N/A,$160.13M ,,
Suspended,,,10/19/2001,10/19/2001,,Peptide,Intravenous (IV),Merck KGaA,MKKGY,Tecemotide,tecemotide,Oncology,Solid,Prostate Cancer,"Immune System,Mucin 1 (MUC-1)","Ono Pharmaceutical Company, Ltd., Seagen Inc. ","BLP25 liposome vaccine, EMD531444, L-BLP25, ONO-7165, Stimuvax, emepepimut-S",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Germany,Europe,,1146,1468,255,215,N/A,$12.69B ,,
Suspended,,,11/27/2012,11/27/2012,,Peptide,Intravenous (IV),"Inspyr Therapeutics, Inc.",NSPX,Mipsagargin,,Oncology,Solid,Prostate Cancer,"Prostate-specific Membrane Antigen (PSMA),Sarcoplasmic reticulum Ca2+-ATPase (SERCA)",,"C66H100N6O27, Thapsigargin pro-drug, G-202, G202, G 202",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,09/11/2009,,New Molecular Entity (NME),,,No,,Texas,United States,North America,,19781,26200,3640,215,N/A,$804.44K ,,
Program Hold,,,,04/04/2007,,Peptide,Intravenous (IV),ExperGen Drug Development GmbH,,TLN-232,,Oncology,Solid,Renal Cell Cancer (RCC),M2PK (pyruvate kinase),,"CAP-232, TT-232",Y,II,10% (Same As Avg.), - , - , - ,,,,,,,03/14/2006,,New Molecular Entity (NME),Rare Disease,,No,,,Austria,Europe,,10207,12760,2865,216,N/A, ,,
Suspended,,,07/05/2016,07/05/2016,,Peptide,Intravenous (IV),"Inspyr Therapeutics, Inc.",NSPX,Mipsagargin,,Oncology,Solid,Renal Cell Cancer (RCC),"Prostate-specific Membrane Antigen (PSMA),Sarcoplasmic reticulum Ca2+-ATPase (SERCA)",,"C66H100N6O27, Thapsigargin pro-drug, G-202, G202, G 202",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,06/24/2014,,New Molecular Entity (NME),Rare Disease,,No,,Texas,United States,North America,,19781,33637,3640,216,N/A,$804.44K ,,
Suspended,,,,08/01/2001,,Peptide,Intravenous (IV),"Orgenesis, Inc.",ORGS,Onconase,,Oncology,Solid,Renal Cell Cancer (RCC),RNA,"BL&H Co., Ltd., GENESIS Pharma S.A., Leidos, Inc., MegaPharm Ltd., US Pharmacia",Ranpirnase,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Maryland,United States,North America,,1984,3204,20060,216,N/A,$118.12M ,,
Suspended,,,,,09/22/2015,Peptide,Intravenous (IV),"Blaze Bioscience, Inc. ",,BLZ-100,tozuleristide,Oncology,Solid,Sarcoma - Imaging,,"Eisai Co., Ltd.","BLZ100, BLZ 100, tumor paint",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,09/22/2015,,Non-NME,,,Yes,,Washington,United States,North America,,26400,36835,5398,3600,N/A, ,,
Suspended,,,,,12/19/2013,Peptide,Intravenous (IV),"Blaze Bioscience, Inc. ",,BLZ-100,tozuleristide,Oncology,Solid,Skin Cancer - Imaging,,"Eisai Co., Ltd.","BLZ100, BLZ 100, tumor paint",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,12/19/2013,,Non-NME,,,Yes,,Washington,United States,North America,,26400,36839,5398,3601,N/A, ,,
I/II,,,04/24/2018,04/24/2018,11/24/2016,Peptide,Intravenous (IV),"Tarveda Therapeutics, Inc.",,PEN-221,,Oncology,Solid,Small Cell Lung Cancer (SCLC),"Somatostatin Receptors,Tumor Cells",,"Pentarin, PEN221, PEN 221, BTP277, BTP-277, BTP 277",N,II,10% (Same As Avg.), - , - , - ,,,,,,,11/24/2016,,Biologic,Rare Disease,,No,,Massachusetts,United States,North America,,25535,35563,4047,111,  7%, ,Target has prior approval,Yes
I/II,,,,11/20/2017,11/20/2017,Peptide,Intravenous (IV),Novartis AG,NVS,Lutathera,lutetium Lu 177 dotatate,Oncology,Solid,Small Cell Lung Cancer (SCLC),"Radiopharmaceutical,Somatostatin Receptors",FUJIFILM Holdings Corp.,"177Lutetium-DOTA0-Tyr3-Octreotate, Lutate, 77Lu-DOTATATE, Lutetium Lu 177 dotatate, lutetium (177Lu) oxodotreotide, F-1515, F1515, F 1515",N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Switzerland,Europe,,19928,51493,289,111,N/A,$183.31B ,,
I,,,,,,Peptide,Intravenous (IV),"PIN Pharma, Inc.",,PIN-2,,Oncology,Solid,Solid Tumors,"Cluster of Differentiation 80 (CD80),Cluster of Differentiation 86 (CD86),Immune System,T lymphocytes",,"PIN2, PIN 2",N,I,6% (Same As Avg.), - , - , - ,,,,,,,11/15/2017,,Biologic,,,No,,New York,United States,North America,,38758,54131,8606,197,  2%, ,Indication,"Cancer, solid, unspecified"
I,,,,,07/26/2012,Peptide,Intravenous (IV),Soricimed Biopharma Inc.,,SOR-C13,,Oncology,Solid,Solid Tumors,"TRPV6, transient receptor potential vanilloid receptor 6, VR-6",,"SORC13, SOR C13",Y,I,6% (Same As Avg.), - , - , - ,,,,,,,07/26/2012,,New Molecular Entity (NME),,,No,,New Brunswick,Canada,North America,,19934,26445,3674,197,  5%, ,Indication,"Cancer, solid, unspecified"
II,,,01/16/2019,01/16/2019,02/12/2015,Peptide,Intravenous (IV),"Aileron Therapeutics, Inc",ALRN,ALRN-6924,,Oncology,Solid,Solid Tumors,"Mdm2,Mdmx/Mdm4",Roche Holding AG,"ALRN6924, ALRN 6924, ATSP7041 Successor, ATSP-7041 Successor, ATSP 7041 Successor",N,II,10% (Same As Avg.), - , - , - ,,,,,,,02/12/2015,,Biologic,,,No,,Massachusetts,United States,North America,,22802,31068,4074,197,N/A,$50.04M ,,
Suspended,,,,,,Peptide,Intravenous (IV),CytImmune Sciences Inc.,,CYT-6091,,Oncology,Solid,Solid Tumors,Tumor Necrosis Factor-alpha (TNF-alpha),,"CYT 6091, CYT-6091, Aurimune",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/26/2006,,Biologic,,,No,,Maryland,United States,North America,,33077,45674,6968,197,N/A, ,,
Suspended,,,,,02/15/2011,Peptide,Intravenous (IV),"Genus Oncology, LLC",,GO-203-2c,,Oncology,Solid,Solid Tumors,Mucin 1 (MUC-1),,"GO-203-2c, GO-203",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,02/15/2011,,New Molecular Entity (NME),Orphan,,No,,Illinois,United States,North America,,17992,23503,3024,197,N/A, ,,
Suspended,,,,,,Peptide,Intravenous (IV),"Eisai Co., Ltd.",4523:JP,E7974,,Oncology,Solid,Solid Tumors,Microtubules (Tubulin),,E7974,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/15/2005,,New Molecular Entity (NME),,,No,,,Japan,Asia,,7847,9639,134,197,N/A,$20.09B ,,
Suspended,,,,12/31/2008,,Peptide,Intravenous (IV),"PharmaMar, S.A.",PHM,Irvalec,,Oncology,Solid,Solid Tumors,ErbB3/HER3,,"PM-02734, elisidepsin",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,10/04/2005,,New Molecular Entity (NME),,,No,,,Spain,Europe,,19809,26251,775,197,N/A,$5.22M ,,
I,,,,,07/14/2015,Peptide,Intravenous (IV),"Blaze Bioscience, Inc. ",,BLZ-100,tozuleristide,Oncology,General,Solid Tumors - Imaging,,"Eisai Co., Ltd.","BLZ100, BLZ 100, tumor paint",N,I,6% (Same As Avg.), - , - , - ,,,,,,,07/14/2015,,Non-NME,,,Yes,,Washington,United States,North America,,26400,36844,5398,3183, 62%, ,Indication,"Diagnosis, cancer"
Suspended,05/30/2013,12/28/2012,12/06/2007,12/06/2007,,Peptide,Intravenous (IV),Aeterna Zentaris Inc.,AEZS,Zoptrex,zoptarelin doxorubicin,Oncology,Solid,Uterine (Endometrial) Cancer,"DNA,DNA synthesis,Gonadotropin-Releasing Hormone (GnRH) Receptor,Topoisomerase I (Topo-I)","Ergomed plc, Orient EuroPharma Co., Ltd., Rafa Laboratories, Ltd., Sinopharm Group Co. Ltd., Specialised Therapeutics","AN-152, ZEN-008, Zoptarelin Doxorubicin, AEZS-108",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,06/05/2006,,New Molecular Entity (NME),"Rare Disease,SPA",,No,,,Canada,North America,,980,4646,14,219,N/A,$33.59M ,,
Investigator Initiated,,,,,05/10/2016,Peptide,Intravenous (IV),"Araim Pharmaceuticals, Inc.",,Cibinetide,cibinetide,Ophthalmology,Retinopathy,Diabetic Macular Edema (Ophthalmology),"CSF2RB (common ß subunit, CD131),Erythropoietin Receptor (EPOR)",,"pHBSP, ARA290, ARA 290",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,New York,United States,North America,,20147,40792,3718,476,N/A, ,,
Program Hold,,,,04/25/2012,,Peptide,Intravenous (IV),Allergan plc,AGN,Rapastinel,rapastinel,Psychiatry,Bipolar,Bipolar Disorder,NMDA Receptor - Glycine Site,,"GLYX13, GLYX 13, GLYX-13, ThrProProThr",N,II,12% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Ireland,Europe,,17642,26571,395,168,N/A,$63.66B ,,
Suspended,11/01/2016,10/28/2016,05/09/2011,05/09/2011,,Peptide,Intravenous (IV),Allergan plc,AGN,Rapastinel,rapastinel,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),NMDA Receptor - Glycine Site,,"GLYX13, GLYX 13, GLYX-13, ThrProProThr",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,12/16/2009,,New Molecular Entity (NME),"Breakthrough,Fast Track",,No,,,Ireland,Europe,,17642,22982,395,167,N/A,$63.66B ,,
Suspended,,,,,,Peptide,Intravenous (IV),Allergan plc,AGN,Rapastinel,rapastinel,Psychiatry,Other,Obsessive-Compulsive Disorder (OCD),NMDA Receptor - Glycine Site,,"GLYX13, GLYX 13, GLYX-13, ThrProProThr",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Ireland,Europe,,17642,36461,395,2051,N/A,$63.66B ,,
Suspended,,,,,,Peptide,Intravenous (IV),"9 Meters Biopharma, Inc. ",NMTR,INN-329,,Psychiatry,Other,Obsessive-Compulsive Disorder (OCD),Secretin receptor,Repligen Corp.,"Secretin, SecreFlo, INN329, INN 329, RG1068, RG-1068, RG 1068",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,05/25/2005,,New Molecular Entity (NME),,,Yes,,North Carolina,United States,North America,,8283,28185,7614,2051,N/A,$288.83M ,,
Suspended,,,,12/10/2003,,Peptide,Intravenous (IV),"9 Meters Biopharma, Inc. ",NMTR,INN-329,,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,Secretin receptor,Repligen Corp.,"Secretin, SecreFlo, INN329, INN 329, RG1068, RG-1068, RG 1068",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,Yes,,North Carolina,United States,North America,,8283,28184,7614,170,N/A,$288.83M ,,
Suspended,,,,,,Peptide,Intravenous (IV),Allergan plc,AGN,Rapastinel,rapastinel,Psychiatry,Other,Substance Use Disorder,NMDA Receptor - Glycine Site,,"GLYX13, GLYX 13, GLYX-13, ThrProProThr",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Ireland,Europe,,17642,56478,395,560,N/A,$63.66B ,,
Suspended,,,,,,Peptide,Intravenous (IV),EspeRare Foundation,,EspoiR-003,Cilengitide,Renal,Chronic Renal Failure,Focal Segmental Glomerulosclerosis (FSGS),Integrin Alpha-V Family,,EMD 121974,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,2584,51085,7990,3622,N/A, ,,
Suspended,,,,12/04/2017,,Peptide,Intravenous (IV),Atox Bio,,Reltecimod,,Renal,Chronic Renal Failure,Renal Disease / Renal Failure,"Cluster of Differentiation 28 (CD28) /ICOS and B7RP-1 Pathway,Immune System",,"p2TA, AB103, AB 103, AB-103",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Israel,Asia,,18329,51270,3296,149,N/A, ,,
Suspended,,,,06/25/2008,,Peptide,Intravenous (IV),AbbVie Inc.,ABBV,ABT-719,,Renal,Chronic Renal Failure,Renal Disease / Renal Failure,Melanocortin (MC) receptors,Zealand Pharma A/S,"AP214, ZP1480",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Illinois,United States,North America,,18413,24122,5,149,N/A,$188.39B ,,
Suspended,,,,,,Peptide,Intravenous (IV),Relief Therapeutics Holding AG,RLFTF,DK0141,,Respiratory,Other,"Acute Respiratory Failure, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS)",,,"DasKloster 0141-01, Adrenomedullin",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Switzerland,Europe,,23797,32780,6373,685,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Intravenous (IV),Araclon Biotech S.L.,,ABvac40,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),"Amyloid Beta/Amyloid Plaques,Immune System","Grifols, S.A.",amyloid beta peptide vaccine 40,Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Spain,Europe,,20256,26978,3739,141,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Intravenous (IV),Invectys,,UCPVax,,Oncology,Solid,Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM)),"Immune System,Telomerase",,Universal Cancer Peptide Vaccine,N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,France,Europe,,27125,61801,5609,228,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Intravenous (IV),Invectys,,UCPVax,,Oncology,General,Cancer,"Immune System,Telomerase",,Universal Cancer Peptide Vaccine,N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,France,Europe,,27125,37922,5609,313,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Intravenous (IV),WntResearch AB,WNT.ST,Foxy-5,,Oncology,Solid,Colorectal Cancer (CRC),WNT Signaling Pathway,,"Foxy5, Foxy 5",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Sweden,Europe,,29057,40346,6117,213,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Intravenous (IV),INOTREM S.A.,,Nangibotide,nangibotide,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,"Immune System,Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1)",,"LR12, LR-12, LR 12, MOTREM, CardioTREM",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,France,Europe,,36618,57159,7972,264,N/A, ,,
Development Outside U.S.,,,,,07/10/2017,Peptide,Intravenous (IV),"Beijing Northland Biotechnology Co., Ltd",,NL-005,,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,"Actin Filaments,ATP Synthase,Integrin-linked kinase (ILK)","Huons Co., Ltd.","NL005, NL 005, Human Thymosin β4, rh-Tβ4, Thymosin beta 4 (TB4), HU024, HU-024, HU 024",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,China,Asia,,38470,53719,3903,264,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Intravenous (IV),La Jolla Pharmaceutical Company,LJPC,Giapreza,angiotensin II,Infectious Disease,Antiviral,COVID-19 Treatment,"Angiotensin II Receptor Type 1 (AT1),Angiotensin II Receptor Type 2 (AT2)",HealthCare Royalty Partners,"angiotensin II, LJPC501, LJPC 501, LJPC-501",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,22551,59241,453,3651,N/A,$113.63M ,,
Development Outside U.S.,,,,,,Peptide,Intravenous (IV),"Beijing Northland Biotechnology Co., Ltd",,NL-005,,Ophthalmology,Other,Dry Eye (Ophthalmology),"Actin Filaments,ATP Synthase,Integrin-linked kinase (ILK)","Huons Co., Ltd.","NL005, NL 005, Human Thymosin β4, rh-Tβ4, Thymosin beta 4 (TB4), HU024, HU-024, HU 024",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,China,Asia,,38470,61829,3903,548,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Intravenous (IV),Shionogi & Co. Ltd.,4507,S-488210,,Oncology,Solid,Head and Neck Cancer,Unknown,"OncoTherapy Science, Inc.","S 488210, S488210",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Vaccine,,,No,,,Japan,Asia,,20512,27345,618,230,N/A,$17.14B ,,
Development Outside U.S.,,,,,,Peptide,Intravenous (IV),Invectys,,UCPVax,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),"Immune System,Telomerase",,Universal Cancer Peptide Vaccine,N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,France,Europe,,27125,61802,5609,211,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Intravenous (IV),Arch Biopartners Inc.,ACHFF,Metablok,,Renal,Chronic Renal Failure,Renal Disease / Renal Failure,Dipeptidase 1 (DPEP-1),,LSALT peptide,Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Canada,North America,,27850,39042,5869,149,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Intravenous (IV),Ferring Pharmaceuticals,,Tractocile ,atosiban,Obstetrics/Gynecology,Gynecology,Reproductive Disorder,Oxytocin Receptor,,Atosiban,N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,12719,16088,582,241,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Intravenous (IV),amcure GmbH,,AMC303,,Oncology,Solid,Solid Tumors,Cluster of Differentiation 44 (CD44),,"AMC 303 , AMC-303",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Germany,Europe,,38869,54319,8649,197,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Intravenous (IV),"OncoTherapy Science, Inc.",4564:JP,S-588210,,Oncology,Solid,Solid Tumors,,Shionogi & Co. Ltd.,"S588210, S 588210",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Japan,Asia,,40085,56047,3322,197,N/A,$203.86M ,,
Approved in other than U.S./E.U.,,,,10/01/2005,,Peptide,Intravenous (IV),"Daiichi Sankyo Co., Ltd.",4568,Carperitide,carperitide,Cardiovascular,Congestive Heart Failure,Acute Decompensated Heart Failure,Natriuretic Peptide Receptors,,"SUN 4936h, HANP Injection 1000, recombinant alfa-human atrial natriuretic peptide",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,01/20/1995,,,,,,Biologic,,,No,,,Japan,Asia,,2407,4116,343,575,N/A,$67.72B ,,
Approved in other than U.S./E.U.,02/18/2015,,,,,Peptide,Intravenous (IV),Frontier Biotechnologies Inc,,Aikening,albuvirtide,Infectious Disease,Antiviral,HIV / AIDS,gp41,,ABT,N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,China,Asia,,25505,35513,5139,78,N/A, ,,
Approved in Europe,,04/01/1995,,,,Peptide,Intravenous (IV),Takeda Pharmaceutical Co. Ltd.,TAK,Mifamurtide,muramyl tripeptide phosphatidyl ethanolamine,Oncology,Solid,Bone Cancer,Immune System,"GENESIS Pharma S.A., Novartis AG","Junovan, L-MTP-PE, Mepact (EU), liposomal muramyl tripeptide, CGP 19835A, CGP-19835A, CGP19835A",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,03/06/2009,,,,10/26/2006,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Japan,Asia,,2405,4072,826,684,N/A,$46.05B ,,
Approved in Europe,,,,,,Peptide,Intravenous (IV),Ferring Pharmaceuticals,,Tractocile ,atosiban,Obstetrics/Gynecology,Obstetrics,Preterm Labor,Oxytocin Receptor,,Atosiban,Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,01/20/2000,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,12719,16065,582,2546,N/A, ,,
Approved (Generic Competition),,11/18/1998,,,,Peptide,Intravenous (IV),The Medicines Company,MDCO,Angiomax,bivalirudin,Cardiovascular,Acute Coronary Syndrome,Acute Coronary Syndrome (ACS),Thrombin (Coagulation Factor IIa),"AstraZeneca PLC, Biogen, Inc., Daiichi Sankyo Co., Ltd., SciClone Pharmaceuticals, Inc.","bivalirudin, Hirulog,  Angiox",Y,Approved,100% (Same As Avg.), - , - , - ,12/15/2000,09/22/2004,,,,12/23/1997,,,New Molecular Entity (NME),,,No,250MG/VIAL (INJECTABLE;INTRAVENOUS),New Jersey,United States,North America,88%,238,2647,248,179,N/A, ,,
Approved (Generic Competition),,,,,,Peptide,Intravenous (IV),"Astellas Pharma, Inc.",4503:JP,Mycamine,micafungin sodium,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Fungal Infections - Non-Systemic,"Beta (1,3)-D-Glucan",,"micafungin, Funguard, Fungard, FK463",N,Approved,100% (Same As Avg.), - , - , - ,03/16/2005,05/07/2008,,,,,,,New Molecular Entity (NME),,,No,"EQ 100MG BASE/VIAL (INJECTABLE;IV (INFUSION)), EQ 50MG BASE/VIAL (INJECTABLE;IV (INFUSION))",,Japan,Asia,,3245,25909,814,3117,N/A,$28.31B ,,
Approved (Generic Competition),,,,,,Peptide,Intravenous (IV),"Astellas Pharma, Inc.",4503:JP,Mycamine,micafungin sodium,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Fungal Infections - Systemic,"Beta (1,3)-D-Glucan",,"micafungin, Funguard, Fungard, FK463",Y,Approved,100% (Same As Avg.), - , - , - ,03/16/2005,05/07/2008,,,,04/29/2002,,,New Molecular Entity (NME),,,No,"EQ 100MG BASE/VIAL (INJECTABLE;IV (INFUSION)), EQ 50MG BASE/VIAL (INJECTABLE;IV (INFUSION))",,Japan,Asia,,3245,5570,814,3116,N/A,$28.31B ,,
Approved (Generic Competition),,11/18/1998,,,,Peptide,Intravenous (IV),The Medicines Company,MDCO,Angiomax,bivalirudin,Cardiovascular,"Surgical, Interventional Radiological, and Other Invasive Procedures",Percutaneous Coronary Interventions (PCIs) for Stable Angina,Thrombin (Coagulation Factor IIa),"AstraZeneca PLC, Biogen, Inc., Daiichi Sankyo Co., Ltd., SciClone Pharmaceuticals, Inc.","bivalirudin, Hirulog,  Angiox",Y,Approved,100% (Same As Avg.), - , - , - ,12/15/2000,09/20/2004,,,,12/23/1997,,,New Molecular Entity (NME),,,No,250MG/VIAL (INJECTABLE;INTRAVENOUS),New Jersey,United States,North America,88%,238,320,248,358,N/A, ,,
Approved,,11/07/1996,,01/12/1994,,Peptide,Intravenous (IV),Johnson & Johnson,JNJ,Natrecor,nesiritide,Cardiovascular,Congestive Heart Failure,Acute Decompensated Heart Failure,Natriuretic Peptide Receptors,"Pharma Services Holding, Inc.",nesiritide,Y,Approved,100% (Same As Avg.), - , - , - ,08/10/2001,,,,,04/27/1998,,,New Molecular Entity (NME),,,No,1.5MG/VIAL (FOR SOLUTION;INTRAVENOUS),New Jersey,United States,North America,,192,3072,223,575,N/A,$422.18B ,,
Approved,,12/20/2000,,,,Peptide,Intravenous (IV),CSL Limited,CSL,Zemaira,,Metabolic,Inborn Errors Of Metabolism,Alpha-1 Antitrypsin Deficiency (A1AD or AATD),"Alpha-1-antitrypsin (A1AT),Protease",,"A1AT, A1-PI, A1PI, Alpha1-Proteinase Inhibitor (Human), Respreeza (EU)",Y,Approved,100% (Same As Avg.), - , - , - ,07/08/2003,08/20/2015,,,,01/06/2003,,,Biologic,Fast Track,,No,,,Australia,Oceania,,20783,27812,870,3654,N/A,$97.36B ,,
Approved,,,,,,Peptide,Intravenous (IV),Bayer AG,BAYN,NeoTect,,Oncology,General,Cancer - Imaging,,,"NeoSpect,  Somatostatin-Tc99m ligand, Tc-99m depreotide",Y,Approved,100% (Same As Avg.), - , - , - ,08/03/1999,12/12/2000,,,,06/15/1998,,,New Molecular Entity (NME),,,Yes,,,Germany,Europe,,41484,58182,59,3579,100%,$63.00B ,,
Approved,,,,,,Peptide,Intravenous (IV),Baxter International Inc.,BAX,Myxredlin,human insulin (regular),Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,"Celerity Pharmaceuticals, LLC",Insulin Human in 0.9% Sodium Chloride Injection,N,Approved,100% (Same As Avg.), - , - , - ,06/20/2019,,,,,08/22/2018,,,Non-NME,505b2,,No,,Illinois,United States,North America,,40703,57065,58,157,N/A,$41.63B ,,
Approved,,,,,,Peptide,Intravenous (IV),Baxter International Inc.,BAX,Myxredlin,human insulin (regular),Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,"Celerity Pharmaceuticals, LLC",Insulin Human in 0.9% Sodium Chloride Injection,N,Approved,100% (Same As Avg.), - , - , - ,06/20/2019,,,,,08/22/2018,,,Non-NME,505b2,,No,,Illinois,United States,North America,,40703,57066,58,137,N/A,$41.63B ,,
Approved,07/01/2008,09/13/2005,,,,Peptide,Intravenous (IV),CSL Limited,CSL,Kcentra,"Prothrombin Complex Concentrate, Human",Hematology,Other,Hemostasis,"Coagulation Factor IX,Coagulation Factor VII,Coagulation Factor X,Protein C,Protein S,Thrombin (Coagulation Factor IIa)",,"Beriplex, Confidex, human 4-factor prothrombin complex concentrate (PCC), Beriplex P/N",Y,Approved,100% (Same As Avg.), - , - , - ,04/29/2013,01/11/2008,03/30/2017,,,03/30/2012,,,Biologic,Orphan,,No,,,Australia,Oceania,,20115,26746,870,672,N/A,$97.36B ,,
Approved,,,,,,Peptide,Intravenous (IV),Bristol Myers Squibb Company,BMY,Refludan,lepirudin recombinant,Cardiovascular,Other,Heparin-Induced Thrombocytopenia (HIT),Thrombin (Coagulation Factor IIa),Bayer AG,lepirudin ([DNA for injection] for injection,Y,Approved,100% (Same As Avg.), - , - , - ,03/06/1998,03/17/1997,,,,,,,Biologic,,,No,,New York,United States,North America,,880,949,73,407,N/A,$140.92B ,,
Approved,02/05/2013,02/05/2013,03/14/2011,03/14/2011,,Peptide,Intravenous (IV),"Amgen, Inc.",AMGN,Parsabiv,velcalcetide,Endocrine,Hyperparathyroidism,Hyperparathyroidism (Secondary),Protein Kinase C (PKC),"Ono Pharmaceutical Company, Ltd.","AMG 416, ONO-5163, KAI-4169, Etelcalcetide Hydrochloride",Y,Approved,100% (Same As Avg.), - , - , - ,02/07/2017,11/11/2016,12/19/2016,,,08/25/2015,07/20/2010,,New Molecular Entity (NME),Rare Disease,,No,,California,United States,North America,,18110,23661,30,367,N/A,$136.24B ,,
Approved,,,,,,Peptide,Intravenous (IV),Endo International plc,ENDP,Vasostrict,,Cardiovascular,Other,Hypotension/Shock,,,Vasopressin,Y,Approved,100% (Same As Avg.), - , - , - ,04/17/2014,,,,,09/26/2012,,,New Molecular Entity (NME),505b2,,No,,,Ireland,Europe,,24914,34629,142,3577,N/A,$1.82B ,,
Approved,,01/13/2015,,,,Peptide,Intravenous (IV),La Jolla Pharmaceutical Company,LJPC,Giapreza,angiotensin II,Cardiovascular,Other,Hypotension/Shock,"Angiotensin II Receptor Type 1 (AT1),Angiotensin II Receptor Type 2 (AT2)",HealthCare Royalty Partners,"angiotensin II, LJPC501, LJPC 501, LJPC-501",Y,Approved,100% (Same As Avg.), - , - , - ,12/21/2017,08/29/2019,,,,08/28/2017,07/23/2012,,New Molecular Entity (NME),SPA,,No,,California,United States,North America,,22551,33726,453,3577,N/A,$113.63M ,,
Approved,,,,,,Peptide,Intravenous (IV),"ANI Pharmaceuticals, Inc.",ANIP,Cortrophin-Zinc,corticotropin-zinc hydroxide,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),"Merck & Co., Inc.",Corticotropin-Zinc Hydroxide,N,Approved,100% (Same As Avg.), - , - , - ,07/29/1955,,,,,,,,Non-NME,,,No,,Minnesota,United States,North America,,31691,43754,523,153,N/A,$392.13M ,,
Approved,,,,,,Peptide,Intravenous (IV),"ANI Pharmaceuticals, Inc.",ANIP,Purified Cortrophin Gel,corticotropin,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),"Merck & Co., Inc.","Corticotropin Gel, Purified Corticotropin Gel",N,Approved,100% (Same As Avg.), - , - , - ,06/16/1954,,,,,,,,Non-NME,,,No,,Minnesota,United States,North America,,31690,43753,523,153,N/A,$392.13M ,,
Approved,09/30/2012,09/30/2012,01/31/2008,01/31/2008,,Peptide,Intravenous (IV),Novartis AG,NVS,Lutathera,lutetium Lu 177 dotatate,Oncology,Solid,Neuroendocrine Tumors (NET),"Radiopharmaceutical,Somatostatin Receptors",FUJIFILM Holdings Corp.,"177Lutetium-DOTA0-Tyr3-Octreotate, Lutate, 77Lu-DOTATATE, Lutetium Lu 177 dotatate, lutetium (177Lu) oxodotreotide, F-1515, F1515, F 1515",Y,Approved,100% (Same As Avg.), - , - ,05/01/2021 - 11/30/2021,01/26/2018,09/29/2017,,,,04/28/2016,,,New Molecular Entity (NME),"Fast Track,Orphan,Rare Disease",,No,,,Switzerland,Europe,,19928,26432,289,347,100%,$183.31B ,,
Development Outside U.S.,,,,,,Peptide,"Intravenous (IV), Intradermal",BioNTech SE,BNTX,GAPVAC,,Oncology,Solid,Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM)),Immune System,Immatics N.V.,"APVAC, APVAC1, APVAC2, APVAC Glioblastoma Vaccine (immatics), Biomarker-guided actively personalized vaccine (APVAC)",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Germany,Europe,,25968,36197,5277,228,N/A,$12.00B ,,
Suspended,,,01/16/2018,01/16/2018,08/25/2016,Peptide,"Intravenous (IV), Intramuscular (IM)",Marathon Pharmaceuticals LLC ,,Synacthen Depot,tetracosactide,Metabolic,Single-Gene Disorders (Non-Inborn Errors of Metabolism),Duchenne Muscular Dystrophy (DMD),Melanocortin (MC) receptors,"Mallinckrodt plc, Novartis AG","tetracosactrin, MNK-1411, MNK1411, MNK 1411, Cosyntropin, Tetracosactide",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/25/2016,,Biologic,"Fast Track,Orphan,Rare Disease",,No,,Illinois,United States,North America,,22504,41205,5122,3620,N/A, ,,
Approved in Europe,,,,,,Peptide,"Intravenous (IV), Intramuscular (IM)",Marathon Pharmaceuticals LLC ,,Synacthen Depot,tetracosactide,Allergy,General,Atopic Dermatitis (Eczema),Melanocortin (MC) receptors,"Mallinckrodt plc, Novartis AG","tetracosactrin, MNK-1411, MNK1411, MNK 1411, Cosyntropin, Tetracosactide",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Illinois,United States,North America,,22504,30578,5122,385,N/A, ,,
Approved in Europe,,,,,,Peptide,"Intravenous (IV), Intramuscular (IM)",Marathon Pharmaceuticals LLC ,,Synacthen Depot,tetracosactide,Not Specified,Other,Drug Toxicity,Melanocortin (MC) receptors,"Mallinckrodt plc, Novartis AG","tetracosactrin, MNK-1411, MNK1411, MNK 1411, Cosyntropin, Tetracosactide",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Illinois,United States,North America,,22504,30581,5122,726,N/A, ,,
Approved in Europe,,,,,,Peptide,"Intravenous (IV), Intramuscular (IM)",Marathon Pharmaceuticals LLC ,,Synacthen Depot,tetracosactide,Endocrine,General,Endocrine Disorder,Melanocortin (MC) receptors,"Mallinckrodt plc, Novartis AG","tetracosactrin, MNK-1411, MNK1411, MNK 1411, Cosyntropin, Tetracosactide",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Illinois,United States,North America,,22504,30571,5122,182,N/A, ,,
Approved in Europe,,,,,,Peptide,"Intravenous (IV), Intramuscular (IM)",Mallinckrodt plc,MNK,Synacthen (IR),tetracosactide,Endocrine,General,Endocrine Disorder,Melanocortin (MC) receptors,"Alfasigma S.p.A., Novartis AG","tetracosactrin, Synacthen Immediate Release (IR)",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,United Kingdom,Europe,,22490,30535,556,182,N/A,$63.44M ,,
Approved in Europe,,,,,,Peptide,"Intravenous (IV), Intramuscular (IM)",Marathon Pharmaceuticals LLC ,,Synacthen Depot,tetracosactide,Neurology,Seizure Disorders (Epilepsy),Infantile Spasms (West Syndrome; Epilepsy),Melanocortin (MC) receptors,"Mallinckrodt plc, Novartis AG","tetracosactrin, MNK-1411, MNK1411, MNK 1411, Cosyntropin, Tetracosactide",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,Illinois,United States,North America,,22504,30575,5122,3007,N/A, ,,
Approved in Europe,,,,,,Peptide,"Intravenous (IV), Intramuscular (IM)",Marathon Pharmaceuticals LLC ,,Synacthen Depot,tetracosactide,Autoimmune/immunology,General,Inflammatory Disorders,Melanocortin (MC) receptors,"Mallinckrodt plc, Novartis AG","tetracosactrin, MNK-1411, MNK1411, MNK 1411, Cosyntropin, Tetracosactide",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Illinois,United States,North America,,22504,30564,5122,422,N/A, ,,
Approved in Europe,,,,,,Peptide,"Intravenous (IV), Intramuscular (IM)",Marathon Pharmaceuticals LLC ,,Synacthen Depot,tetracosactide,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Melanocortin (MC) receptors,"Mallinckrodt plc, Novartis AG","tetracosactrin, MNK-1411, MNK1411, MNK 1411, Cosyntropin, Tetracosactide",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Illinois,United States,North America,,22504,30573,5122,153,N/A, ,,
Approved in Europe,,,,,,Peptide,"Intravenous (IV), Intramuscular (IM)",Marathon Pharmaceuticals LLC ,,Synacthen Depot,tetracosactide,Autoimmune/immunology,Other,Pemphigus Vulgaris,Melanocortin (MC) receptors,"Mallinckrodt plc, Novartis AG","tetracosactrin, MNK-1411, MNK1411, MNK 1411, Cosyntropin, Tetracosactide",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Illinois,United States,North America,,22504,30577,5122,392,N/A, ,,
Approved in Europe,,,,,,Peptide,"Intravenous (IV), Intramuscular (IM)",Marathon Pharmaceuticals LLC ,,Synacthen Depot,tetracosactide,Autoimmune/immunology,Psoriasis,Psoriasis,Melanocortin (MC) receptors,"Mallinckrodt plc, Novartis AG","tetracosactrin, MNK-1411, MNK1411, MNK 1411, Cosyntropin, Tetracosactide",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Illinois,United States,North America,,22504,30579,5122,155,N/A, ,,
Approved in Europe,,,,,,Peptide,"Intravenous (IV), Intramuscular (IM)",Marathon Pharmaceuticals LLC ,,Synacthen Depot,tetracosactide,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),Melanocortin (MC) receptors,"Mallinckrodt plc, Novartis AG","tetracosactrin, MNK-1411, MNK1411, MNK 1411, Cosyntropin, Tetracosactide",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Illinois,United States,North America,,22504,30580,5122,321,N/A, ,,
NDA,06/29/2016,06/29/2016,08/06/2014,08/06/2014,,Peptide,"Intravenous (IV), Oral (PO)","Cara Therapeutics, Inc.",CARA,Korsuva,difelikefalin,Allergy,General,Pruritus,Opioid receptors,"Chong Kun Dang Pharmaceutical Corp., Enteris BioPharma Inc., Fresenius SE & Co. KGaA, Kissei Pharmaceutical Co., Ltd, Maruishi Pharmaceutical Co., Ltd., Unigene Laboratories, Inc., Vifor Pharma Group ","difelikefalin injection, CR-845, CR845, CR 845, MR13A9, MR 13A9, MR-13A9, IV Korsuva, IV-Korsuva",N,NDA/BLA,98% (9% Above Avg.),08/27/2021 - 08/27/2021, - , - ,,,,08/27/2021,,12/28/2020,04/29/2013,,New Molecular Entity (NME),Breakthrough,,No,,Connecticut,United States,North America,,16383,30732,2778,3196,N/A,$802.30M ,,
Suspended,,,,,,Peptide,"Intravenous (IV), Oral (PO)",Cyxone AB,CYXO,T20K,cyclotide,Autoimmune/immunology,Inflammatory Bowel Disease,Inflammatory Bowel Disease (IBD),IL-2 (Interleukin-2),,"T 20K, T-20K",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Sweden,Europe,,37743,52633,8303,464,N/A,$32.16M ,,
Suspended,,,,,,Peptide,"Intravenous (IV), Oral (PO)",Novo Nordisk A/S,NVO,NN1954,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,Merrion Pharmaceuticals Plc.,"Insulin 362, NNC 0148-0000-0362, OI362GT",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,05/01/2013,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,20183,30341,292,157,N/A,$108.42B ,,
Suspended,,,,,05/10/2012,Peptide,"Intravenous (IV), Oral (PO)",Novo Nordisk A/S,NVO,NN1954,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,Merrion Pharmaceuticals Plc.,"Insulin 362, NNC 0148-0000-0362, OI362GT",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,05/10/2012,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,20183,26861,292,137,N/A,$108.42B ,,
Suspended,,,,02/08/2010,,Peptide,"Intravenous (IV), Oral (PO)","Cara Therapeutics, Inc.",CARA,Korsuva,difelikefalin,Neurology,Pain,Neuropathic Pain,Opioid receptors,"Chong Kun Dang Pharmaceutical Corp., Enteris BioPharma Inc., Fresenius SE & Co. KGaA, Kissei Pharmaceutical Co., Ltd, Maruishi Pharmaceutical Co., Ltd., Unigene Laboratories, Inc., Vifor Pharma Group ","difelikefalin injection, CR-845, CR845, CR 845, MR13A9, MR 13A9, MR-13A9, IV Korsuva, IV-Korsuva",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Connecticut,United States,North America,,16383,21124,2778,362,N/A,$802.30M ,,
III,09/09/2015,09/09/2015,01/12/2009,01/12/2009,04/28/2008,Peptide,"Intravenous (IV), Oral (PO)","Cara Therapeutics, Inc.",CARA,Korsuva,difelikefalin,Neurology,Pain,Postsurgical Pain,Opioid receptors,"Chong Kun Dang Pharmaceutical Corp., Enteris BioPharma Inc., Fresenius SE & Co. KGaA, Kissei Pharmaceutical Co., Ltd, Maruishi Pharmaceutical Co., Ltd., Unigene Laboratories, Inc., Vifor Pharma Group ","difelikefalin injection, CR-845, CR845, CR 845, MR13A9, MR 13A9, MR-13A9, IV Korsuva, IV-Korsuva",Y,III,60% (8% Above Avg.), - , - , - ,,,,,,,04/28/2008,,New Molecular Entity (NME),,,No,,Connecticut,United States,North America,,16383,21123,2778,3130,N/A,$802.30M ,,
Suspended,,,08/17/2015,08/17/2015,11/30/2011,Peptide,"Intravenous (IV), Oral (PO)","Cara Therapeutics, Inc.",CARA,Korsuva,difelikefalin,Rheumatology (Non Autoimmune),Osteoarthritis,Osteoarthritis and Osteoarthritis Pain,Opioid receptors,"Chong Kun Dang Pharmaceutical Corp., Enteris BioPharma Inc., Fresenius SE & Co. KGaA, Kissei Pharmaceutical Co., Ltd, Maruishi Pharmaceutical Co., Ltd., Unigene Laboratories, Inc., Vifor Pharma Group ","difelikefalin injection, CR-845, CR845, CR 845, MR13A9, MR 13A9, MR-13A9, IV Korsuva, IV-Korsuva",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,05/19/2011,,New Molecular Entity (NME),,,No,,Connecticut,United States,North America,,16383,26733,2778,249,N/A,$802.30M ,,
Development Outside U.S.,,,,,,Peptide,"Intravenous (IV), Oral (PO)",Cyxone AB,CYXO,T20K,cyclotide,Neurology,Neurodegenerative,Multiple Sclerosis (MS),IL-2 (Interleukin-2),,"T 20K, T-20K",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Sweden,Europe,,37743,52630,8303,153,N/A,$32.16M ,,
Suspended,,,,,,Peptide,"Intravenous (IV), Oral (PO), Topical",Takeda Pharmaceutical Co. Ltd.,TAK,Actovegin,actovegin,Neurology,Pain,Diabetic Peripheral Neuropathy (DPN),Unknown,,Deproteinised hemoderivative of calf blood,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Japan,Asia,,19976,26528,826,671,N/A,$46.05B ,,
Suspended,,,,,,Peptide,"Intravenous (IV), Oral (PO), Topical",Takeda Pharmaceutical Co. Ltd.,TAK,Actovegin,actovegin,Neurology,Stroke,Ischemic Stroke,Unknown,,Deproteinised hemoderivative of calf blood,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Japan,Asia,,19976,26520,826,145,N/A,$46.05B ,,
I,,,,,11/30/2017,Peptide,"Intravenous (IV), Subcutaneous (SQ)","Apellis Pharmaceuticals, Inc.",APLS,APL-9,,Autoimmune/immunology,Other,Complement Deficiencies / Abnormalities,Complement Pathway,,"APL9, APL 9",Y,I,14% (Same As Avg.), - , - , - ,,,,,,,11/30/2017,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,37038,51641,2089,738,N/A,$4.15B ,,
Suspended,,,,,,Peptide,"Intravenous (IV), Subcutaneous (SQ)","Anexon, Inc.",,ANX-042,,Cardiovascular,Congestive Heart Failure,Acute Decompensated Heart Failure,Natriuretic Peptide Receptors,,ANX-042,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/10/2012,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,20639,27569,3864,575,N/A, ,,
Suspended,,,07/11/2008,07/11/2008,05/31/2007,Peptide,"Intravenous (IV), Subcutaneous (SQ)",Mayo Clinic,,Cenderitide,,Cardiovascular,Congestive Heart Failure,Acute Decompensated Heart Failure,Natriuretic Peptide Receptors,,CD-NP,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,01/20/2006,,New Molecular Entity (NME),Fast Track,,No,,Minnesota,United States,North America,,10521,13167,3928,575,N/A, ,,
II,,,,11/17/2010,,Peptide,"Intravenous (IV), Subcutaneous (SQ)","Zensun Sci & Tech Co., Ltd.",,Neucardin,human neuregulin-1,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,"ErbB4/HER4,HER2/neu or ErbB-2","SciClone Pharmaceuticals, Inc.",Recombinant Human Neuregulin-1 (rhNRG-1),Y,II,13% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Fast Track,,No,,,China,Asia,,18289,23941,3287,264,N/A, ,,
II,,,05/10/2016,05/10/2016,,Peptide,"Intravenous (IV), Subcutaneous (SQ)","Eiger BioPharmaceuticals, Inc.",EIGR,Avexitide,avexitide,Endocrine,Other,Hyperinsulinemia/Hypoglycemia,GLP-1 Receptor,,"exendin (9-39), exendin 9-39",Y,II,24% (Same As Avg.), - , - , - ,,,,,,,09/14/2015,,Non-NME,"Breakthrough,Orphan",,No,,California,United States,North America,,27047,37811,2982,3358,N/A,$378.67M ,,
Withdrawn from Market,10/11/2007,10/11/2007,07/11/2005,07/11/2005,10/04/2004,Peptide,"Intravenous (IV), Subcutaneous (SQ)","Affymax, Inc.",AFFY,Omontys,peginesatide,Hematology,Marrow Or Peripheral Blood Stimulator,"Anemia Due to Chronic Renal Failure, Dialysis-Dependent",Erythropoietin Receptor (EPOR),"Nektar Therapeutics, Takeda Pharmaceutical Co. Ltd.","AF-37702, Hematide, peginesatide",Y,Approved,100% (Same As Avg.), - ,06/27/2013 - 09/02/2013, - ,03/27/2012,,,,,05/31/2011,10/04/2004,,New Molecular Entity (NME),,,No,,New York,United States,North America,,3077,5264,990,187,N/A, ,,
Suspended,10/11/2007,10/11/2007,04/07/2005,04/07/2005,10/04/2004,Peptide,"Intravenous (IV), Subcutaneous (SQ)","Affymax, Inc.",AFFY,Omontys,peginesatide,Hematology,Marrow Or Peripheral Blood Stimulator,"Anemia Due to Chronic Renal Failure, Dialysis-Independent",Erythropoietin Receptor (EPOR),"Nektar Therapeutics, Takeda Pharmaceutical Co. Ltd.","AF-37702, Hematide, peginesatide",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,10/04/2004,,New Molecular Entity (NME),,,No,,New York,United States,North America,,3077,5263,990,371,N/A, ,,
Suspended,,,01/30/2006,01/30/2006,10/04/2004,Peptide,"Intravenous (IV), Subcutaneous (SQ)","Affymax, Inc.",AFFY,Omontys,peginesatide,Hematology,Marrow Or Peripheral Blood Stimulator,Anemia Due to Oncology Treatment,Erythropoietin Receptor (EPOR),"Nektar Therapeutics, Takeda Pharmaceutical Co. Ltd.","AF-37702, Hematide, peginesatide",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,10/04/2004,,New Molecular Entity (NME),,,No,,New York,United States,North America,,3077,5265,990,372,N/A, ,,
I/II,,,05/28/2020,05/28/2020,,Peptide,"Intravenous (IV), Subcutaneous (SQ)","Apellis Pharmaceuticals, Inc.",APLS,APL-9,,Infectious Disease,Antiviral,COVID-19 Treatment,Complement Pathway,,"APL9, APL 9",Y,II,27% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,37038,59878,2089,3651,N/A,$4.15B ,,
Preclinical,,,,,,Peptide,"Intravenous (IV), Subcutaneous (SQ)","Zensun Sci & Tech Co., Ltd.",,Neucardin,human neuregulin-1,Neurology,Other,Neurofibromatosis (NF),"ErbB4/HER4,HER2/neu or ErbB-2","SciClone Pharmaceuticals, Inc.",Recombinant Human Neuregulin-1 (rhNRG-1),N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,,China,Asia,,18289,59111,3287,3621,N/A, ,,
II,,,09/14/2005,09/14/2005,,Peptide,"Intravenous (IV), Subcutaneous (SQ)",Ferring Pharmaceuticals,,Barusiban,,Obstetrics/Gynecology,Gynecology,Reproductive Disorder,Oxytocin Receptor,,"FE 200440, FE200440, FE-200440, FE200 440",N,II,24% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,41039,57603,582,241,N/A, ,,
Approved in other than U.S./E.U.,,,,,,Peptide,"Intravenous (IV), Subcutaneous (SQ)",Novartis AG,NVS,Sandostatin,octreotide acetate,Endocrine,Other,Hyperinsulinemia/Hypoglycemia,Somatostatin Receptors,,Octreotide acetate,N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,"EQ 0.05MG BASE/ML (INJECTABLE;INJECTION), EQ 0.1MG BASE/ML (INJECTABLE;INJECTION), EQ 0.2MG BASE/ML (INJECTABLE;INJECTION), EQ 0.5MG BASE/ML (INJECTABLE;INJECTION), EQ 10MG BASE/VIAL (INJECTABLE;INJECTION), EQ 1MG BASE/ML (INJECTABLE;INJECTION), EQ 20MG BASE/VIAL (INJECTABLE;INJECTION), EQ 30MG BASE/VIAL (INJECTABLE;INJECTION)",,Switzerland,Europe,,18172,60831,289,3358,N/A,$183.31B ,,
Approved (Generic Competition),,,,,,Peptide,"Intravenous (IV), Subcutaneous (SQ)",Novartis AG,NVS,Sandostatin,octreotide acetate,Endocrine,Other,Acromegaly,Somatostatin Receptors,,Octreotide acetate,N,Approved,100% (Same As Avg.), - , - , - ,10/21/1988,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,"EQ 0.05MG BASE/ML (INJECTABLE;INJECTION), EQ 0.1MG BASE/ML (INJECTABLE;INJECTION), EQ 0.2MG BASE/ML (INJECTABLE;INJECTION), EQ 0.5MG BASE/ML (INJECTABLE;INJECTION), EQ 10MG BASE/VIAL (INJECTABLE;INJECTION), EQ 1MG BASE/ML (INJECTABLE;INJECTION), EQ 20MG BASE/VIAL (INJECTABLE;INJECTION), EQ 30MG BASE/VIAL (INJECTABLE;INJECTION)",,Switzerland,Europe,,18172,23773,289,680,N/A,$183.31B ,,
Approved (Generic Competition),,,,,,Peptide,"Intravenous (IV), Subcutaneous (SQ)",Novartis AG,NVS,Sandostatin,octreotide acetate,Oncology,Solid,Neuroendocrine Tumors (NET),Somatostatin Receptors,,Octreotide acetate,N,Approved,100% (Same As Avg.), - , - , - ,10/21/1988,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,"EQ 0.05MG BASE/ML (INJECTABLE;INJECTION), EQ 0.1MG BASE/ML (INJECTABLE;INJECTION), EQ 0.2MG BASE/ML (INJECTABLE;INJECTION), EQ 0.5MG BASE/ML (INJECTABLE;INJECTION), EQ 10MG BASE/VIAL (INJECTABLE;INJECTION), EQ 1MG BASE/ML (INJECTABLE;INJECTION), EQ 20MG BASE/VIAL (INJECTABLE;INJECTION), EQ 30MG BASE/VIAL (INJECTABLE;INJECTION)",,Switzerland,Europe,,18172,23774,289,347,N/A,$183.31B ,,
Approved,,02/05/2003,,,,Peptide,"Intravenous (IV), Subcutaneous (SQ)",Sanofi,SNY,Apidra,insulin glulisine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"insulin glulisine, HMR 1964, HMR1964, HMR-1964",N,Approved,100% (Same As Avg.), - , - , - ,04/16/2004,09/27/2004,04/22/2009,,,06/18/2003,,,New Molecular Entity (NME),,,No,"1000 UNITS/10ML (100 UNITS/ML) (INJECTABLE;IV (INFUSION), SUBC), 300 UNITS/3ML (INJECTABLE;SUBCUTANEOUS), 300 UNITS/3ML (100 UNITS/ML) (INJECTABLE;IV (INFUSION), SUBC)",,France,Europe,,1699,3255,51,157,N/A,$107.55B ,,
Approved,,02/05/2003,,,,Peptide,"Intravenous (IV), Subcutaneous (SQ)",Sanofi,SNY,Apidra,insulin glulisine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"insulin glulisine, HMR 1964, HMR1964, HMR-1964",Y,Approved,100% (Same As Avg.), - , - , - ,04/19/2004,09/27/2004,04/22/2009,,,06/18/2003,,,New Molecular Entity (NME),,,No,"1000 UNITS/10ML (100 UNITS/ML) (INJECTABLE;IV (INFUSION), SUBC), 300 UNITS/3ML (INJECTABLE;SUBCUTANEOUS), 300 UNITS/3ML (100 UNITS/ML) (INJECTABLE;IV (INFUSION), SUBC)",,France,Europe,,1699,2726,51,137,N/A,$107.55B ,,
Approved,,,,,,Peptide,"Intravenous (IV), Subcutaneous (SQ), Intramuscular (IM)",Novo Nordisk A/S,NVO,GlucaGen,,Endocrine,Other,Hyperinsulinemia/Hypoglycemia,Glucagon Receptor,"Boehringer Ingelheim GmbH, Bristol Myers Squibb Company, EA Pharma Co., Ltd.",Glucagon for injection; Glucagon G Novo,Y,Approved,100% (Same As Avg.), - , - , - ,06/24/1998,,,,,,,,Non-NME,,,No,,,Denmark,Europe,,735,3251,292,3358,N/A,$108.42B ,,
Preclinical,,,,,,Peptide,N/A,Anergis SA,,Der p 2 COPs SVLP,,Allergy,General,Allergy,Toll-Like Receptor (TLR) Family,,,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,42879,60398,3236,152,N/A, ,,
Preclinical,,,,,,Peptide,N/A,"selectION, Inc.",,si-544,,Autoimmune/immunology,General,Autoimmune Disorders,Potassium channels,,"si 544, si544",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,40526,56774,9193,180,N/A, ,,
Suspended,,,,,,Peptide,N/A,Medicenna Therapeutics Corp.,MDNAF,MDNA209,,Autoimmune/immunology,General,Autoimmune Disorders,"Cluster of Differentiation 122 (CD122),IL-2 Receptor (IL-2R) ",,"MDNA209, MDNA 209, MDNA-209",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Ontario,Canada,North America,,38699,54027,6304,180,N/A, ,,
Preclinical,,,,,,Peptide,N/A,"RegeneRx Biopharmaceuticals, Inc.",RGRX,Thymosin beta 4 Program (RegeneRx),,Autoimmune/immunology,Other,Chronic Granulomatous Disease,"Actin Filaments,ATP Synthase,Hypoxia Inducible Factor-1 alpha (HIF-1a),Integrin-linked kinase (ILK)",,"thymosin beta 4 (TB4), Thymosin beta 4 (Tβ4)",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,Maryland,United States,North America,,41299,57973,460,353,N/A,$62.06M ,,
Suspended,,,,,,Peptide,N/A,"Biogen, Inc.",BIIB,CB 2782,,Autoimmune/immunology,Transplant Rejection,Delayed Graft Function (DGF),Complement Pathway,"Catalyst Biosciences, Inc., Mosaic Biosciences, Inc.","CB2782, CB-2782, CB 2782-PEG",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,26771,37398,64,3494,N/A,$38.54B ,,
Suspended,,,,,,Peptide,N/A,NephRx Corporation,,NX002,,Autoimmune/immunology,Inflammatory Bowel Disease,Inflammatory Bowel Disease (IBD),,,NX002,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Michigan,United States,North America,,19118,25180,2903,464,N/A, ,,
Suspended,,,,,,Peptide,N/A,Celtaxsys Inc.,,CRC-4273,,Autoimmune/immunology,General,Inflammatory Disorders,,,CTX-4273,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,09/09/2013,,Biologic,,,No,,Georgia,United States,North America,,21100,28369,3951,422,N/A, ,,
Suspended,,,,,,Peptide,N/A,BioLineRx Ltd.,BLRX,BL-7060,,Autoimmune/immunology,General,Inflammatory Disorders,"FPRL1 - Formyl peptide receptor homolog-1,MAS G-protein coupled receptor ",Compugen Ltd.,"CGEN-855/CGEN-856, BL-7070, EDP29",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Israel,Asia,,19182,25266,1248,422,N/A,$58.92M ,,
Suspended,,,,,11/18/2010,Peptide,N/A,NephRx Corporation,,NX001,,Autoimmune/immunology,Transplant Rejection,Kidney Transplant Rejection,Unknown,,NX001,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,11/18/2010,,New Molecular Entity (NME),Orphan,,No,,Michigan,United States,North America,,17182,22291,2903,380,N/A, ,,
Suspended,,,,,,Peptide,N/A,NephRx Corporation,,NX002,,Autoimmune/immunology,Other,Mucositis,,,NX002,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Michigan,United States,North America,,19118,25179,2903,348,N/A, ,,
Preclinical,,,,,,Peptide,N/A,CEL-SCI Corporation,CVM,CEL-2000,,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Immune System,,"CEL 2000, CEL2000",Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Vaccine,,,No,,Virginia,United States,North America,,22966,31325,519,154,N/A,$536.71M ,,
Preclinical,,,,,,Peptide,N/A,Silver Creek Pharmaceuticals,,SGF-1,,Cardiovascular,General,Atherosclerosis,"Apoptosis (Cell Death),IGF-1R (Insulin-like Growth Factor-1 Receptor) ",,,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,37263,51971,8153,650,N/A, ,,
Preclinical,,,,,,Peptide,N/A,"Palatin Technologies, Inc.",PTN,PL-5028,,Cardiovascular,General,Cardiovascular Disease,Natriuretic Peptide Receptors,,NPR-A/C Agonist,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,33718,46571,504,181,N/A,$162.89M ,,
Preclinical,,,,,,Peptide,N/A,Corvidia Therapeutics,,COR-003,,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,"Apolipoprotein C-II (apoCII, apo-CII, apo-C2),Apolipoprotein C-III (apoCIII, apo-CIII, apo-C3)",,"COR003, COR 003, D6PV",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Massachusetts,United States,North America,,41817,58723,6645,506,N/A, ,,
Suspended,,,,,,Peptide,N/A,Thrombotargets Europe SL,,TT-120,,Cardiovascular,Peripheral Vascular Disease,Peripheral Arterial Disease (PAD),,,TT-120,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,Spain,Europe,,23500,32283,3717,390,N/A, ,,
Suspended,,,,08/16/2004,,Peptide,N/A,XOMA Corporation,XOMA,XOMA 629,,Dermatology,General,Acne,Unknown,,XMP.629,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,1676,2694,401,603,N/A,$453.01M ,,
Preclinical,,,,,,Peptide,N/A,Serodus ASA,,SER140,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",IL-1 Receptor (IL-1R),,SER140,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Norway,Europe,,22669,31233,2987,157,N/A, ,,
Suspended,,,,,,Peptide,N/A,Perle Bioscience,,PRL002,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Regenerating Protein Family (REG Family) Receptors,,PRL002,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,South Carolina,United States,North America,,25951,36179,5273,157,N/A, ,,
Suspended,,,,,,Peptide,N/A,Serpin Pharma LLC,,SP16,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Alpha-1-antitrypsin (A1AT),,"SP-16, Alpha-1-antitrypsin (AAT)",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Virginia,United States,North America,,23272,31860,4511,157,N/A, ,,
I,,,,,08/22/2017,Peptide,N/A,Zealand Pharma A/S,ZEAL,BI 473494,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Amylin Receptor,,"Boehringer Ingelheim/Zealand Cardio-Metabolic Program, BI473494, BI-473494, Long-acting amylin analog",N,I,14% (Same As Avg.), - , - , - ,,,,,,,08/22/2017,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,26854,37531,748,137,N/A,$1.48B ,,
Preclinical,,,,,,Peptide,N/A,Serodus ASA,,SER140,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",IL-1 Receptor (IL-1R),,SER140,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Norway,Europe,,22669,30832,2987,137,N/A, ,,
Preclinical,,,,,,Peptide,N/A,"Velocity Pharmaceutical Development, LLC",,SP-1373,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GLP-1 Receptor,Glucagon Receptor",Altimmune Inc. ,"ALT-801, ALT801, ALT 801, VPD107, VPD-107, VPD 107, SP1373, SP 1373",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,35198,48813,6401,137,N/A, ,,
Preclinical,,,,,,Peptide,N/A,"CohBar, Inc.",CWBR,CB4211,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Mitochondria,,CB 4211,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,34916,48372,7466,137,N/A,$84.34M ,,
Preclinical,,,,,,Peptide,N/A,"CohBar, Inc.",CWBR,CB5064,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Apelin Receptor (APJ),,"CB 5064, CB-5064,",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,40545,56812,7466,137,N/A,$84.34M ,,
Preclinical,,,,,,Peptide,N/A,"Intarcia Therapeutics, Inc.",ITCA,ITCA 650/Peptide 1 Program,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,"ITCA 650 + Optimized Peptide 1,",Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,26783,37418,1376,137,N/A, ,,
Preclinical,,,,,,Peptide,N/A,"Intarcia Therapeutics, Inc.",ITCA,ITCA 650/Peptide 2 Program,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,ITCA 650 + Optimized Peptide 2,Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,26784,37419,1376,137,N/A, ,,
Suspended,,,,,,Peptide,N/A,Perle Bioscience,,PRL002,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Regenerating Protein Family (REG Family) Receptors,,PRL002,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,South Carolina,United States,North America,,25951,36181,5273,137,N/A, ,,
Suspended,,,,,,Peptide,N/A,"Intarcia Therapeutics, Inc.",ITCA,ITCA 650/Calibr Peptide Program,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,Massachusetts,United States,North America,,33109,45724,1376,137,N/A, ,,
Suspended,,,,,05/06/2009,Peptide,N/A,Pfizer Inc.,PFE,OAP-189,oxyntomodulin,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GLP-1 Receptor,Glucagon Receptor",,"PF-05212389, TKS-1225, Oxyntomodulin Analogue",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,01/26/2009,,New Molecular Entity (NME),,,No,,New York,United States,North America,,3199,23879,312,137,N/A,$205.99B ,,
I,,,,,02/21/2017,Peptide,N/A,MorphoSys AG,MOR,MOR107,,Endocrine,Diabetes Mellitus,Diabetic Nephropathy,Angiotensin II Receptor Type 2 (AT2),,LP2,N,I,14% (Same As Avg.), - , - , - ,,,,,,,02/21/2017,,Biologic,,,No,,,Germany,Europe,,26025,36272,264,492,N/A,$3.88B ,,
Preclinical,,,,,,Peptide,N/A,Pfenex Inc.,PFNX,PF810,,Endocrine,General,Endocrine Disorder,Unknown,,"PF-810, PF 810",Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,43136,60806,4727,182,N/A,$437.28M ,,
Suspended,,,,,,Peptide,N/A,APEPTICO GmbH,,Enaritide,enaritide,Endocrine,General,Endocrine Disorder,Sodium Channels,,"enaritide, AP318",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Orphan,,No,,,Austria,Europe,,25129,34939,3254,182,N/A, ,,
Suspended,,,,,,Peptide,N/A,"EpiVax, Inc.",,Treg-BT,,Endocrine,Thyroid,Hyperthyroidism / Graves' Disease,"Immune System,T-Cell Receptor (TCR),Thyroid stimulating hormone receptor (TSHR)",,Tregitope-biotherapeutic,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Rhode Island,United States,North America,,36919,51465,7859,3371,N/A, ,,
I,,,,,12/08/2020,Peptide,N/A,Altimmune Inc. ,ALT,ALT-801,,Endocrine,Other,Non-Alcoholic Steatohepatitis (NASH),"GLP-1 Receptor,Glucagon Receptor",,"ALT801, ALT 801",N,I,14% (Same As Avg.), - , - , - ,,,,,,,12/08/2020,,Biologic,,,No,,Maryland,United States,North America,,43172,60861,5116,683,N/A,$459.69M ,,
I,,,,,07/12/2018,Peptide,N/A,"CohBar, Inc.",CWBR,CB4211,,Endocrine,Other,Non-Alcoholic Steatohepatitis (NASH),Mitochondria,,CB 4211,N,I,14% (Same As Avg.), - , - , - ,,,,,,,07/12/2018,,Biologic,,,No,,California,United States,North America,,34916,48371,7466,683,N/A,$84.34M ,,
I,,,,,,Peptide,N/A,Novo Nordisk A/S,NVO,NN6177,,Endocrine,Other,Non-Alcoholic Steatohepatitis (NASH),"GLP-1 Receptor,Glucagon Receptor",,"NN 6177, NN-6177",N,I,14% (Same As Avg.), - , - , - ,,,,,,,02/05/2020,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,41903,58863,292,683,N/A,$108.42B ,,
Preclinical,,,,,,Peptide,N/A,"Velocity Pharmaceutical Development, LLC",,SP-1373,,Endocrine,Other,Non-Alcoholic Steatohepatitis (NASH),"GLP-1 Receptor,Glucagon Receptor",Altimmune Inc. ,"ALT-801, ALT801, ALT 801, VPD107, VPD-107, VPD 107, SP1373, SP 1373",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,35198,52893,6401,683,N/A, ,,
II,,,,11/02/2020,,Peptide,N/A,D&D Pharmatech,,P4M01,,ENT/Dental,General,Periodontitis,antimicrobial,,"P4-M01, P4M01",N,II,24% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Korea (South),Asia,,43654,61554,9709,621,N/A, ,,
II,,,,03/07/2014,,Peptide,N/A,"Armata Pharmaceuticals, Inc.",ARMP,C16G2,,ENT/Dental,General,Periodontitis,Streptococcus mutans,,C-16G2,N,II,24% (Same As Avg.), - , - , - ,,,,,,,02/19/2013,05/24/2012,New Molecular Entity (NME),,,No,,California,United States,North America,,19622,25890,3593,621,N/A,$59.47M ,,
Suspended,,,,,,Peptide,N/A,Thrombotargets Europe SL,,TT-120,,Hematology,Antithrombotic,Anticoagulation,,,TT-120,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,Spain,Europe,,23500,32282,3717,88,N/A, ,,
Preclinical,,,,,,Peptide,N/A,ContraFect Corporation.,CFRX,App2-M1,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Antibacterial - General,,,"App2M1, App2 M1",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,New York,United States,North America,,40827,57275,4424,3121,N/A,$147.95M ,,
Suspended,,,,,,Peptide,N/A,"NovoBiotic Pharmaceuticals, LLC",,Lassomycin,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Antibacterial - General,Protease,,Lassomycin,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,25716,35797,5207,3121,N/A, ,,
Suspended,,,,,,Peptide,N/A,Nektar Therapeutics,NKTR,NKTR-223,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Antibacterial - General,Unknown,,NKTR-223,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,22951,31301,210,3121,N/A,$3.34B ,,
Suspended,,,,,,Peptide,N/A,VG Life Sciences Inc.,VGLS,VGV-L,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Antibacterial and Antifungal - Miscellaneous Vaccines and Treatments,Borrelia (Lyme disease),,APi1177,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,21517,28995,4030,77,N/A,$571.78K ,,
Preclinical,,,,,,Peptide,N/A,"Peptilogics, Inc.",,PLG0206,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Bone and Joint Infections (Antibacterial),Cell Membrane,,"PLG 0206, PLG-0206",Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Orphan,,No,,Pennsylvania,United States,North America,,43245,60969,25454,3122,N/A, ,,
Preclinical,,,,,,Peptide,N/A,"Bolder BioTechnology, Inc.",,BBT-032,,Infectious Disease,Antiviral,COVID-19 Treatment,"Interferon-beta (IFNb),SARS-CoV-2",,"BBT032, BBT 032",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Colorado,United States,North America,,43168,60855,7670,3651,N/A, ,,
Preclinical,,,,,,Peptide,N/A,"Kalos Therapeutics, Inc.",,KTH 222,,Infectious Disease,Antiviral,COVID-19 Treatment,MAPK/ERK (mitogen-activated protein kinases/extracellular signal-regulated kinases; Ras-Raf-MEK-ERK pathway),"Oncology Pharma, Inc.","KTH-222, KTH222, Leu-Lys-Gly-Gln-Leu-Arg-Cys-Ile",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Arizona,United States,North America,,40787,61114,9281,3651,N/A, ,,
Preclinical,,,,,,Peptide,N/A,"48Hour Discovery, Inc.",,Peptide-Based COVID-19 Anti-Viral Program (48Hour),,Infectious Disease,Antiviral,COVID-19 Treatment,"Immune System,SARS-CoV-2",,Peptide-Based COVID-19 Program (48Hour),N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Canada,North America,,42197,59354,24869,3651,N/A, ,,
Preclinical,,,,,,Peptide,N/A,"CohBar, Inc.",CWBR,CB5064,,Infectious Disease,Antiviral,COVID-19 Treatment,Apelin Receptor (APJ),,"CB 5064, CB-5064,",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,40545,59648,7466,3651,N/A,$84.34M ,,
Suspended,,,,,,Peptide,N/A,ISA Pharmaceuticals B.V.,,ISA204,,Infectious Disease,Antiviral,Hepatitis B (HBV) Treatment (Antiviral),"Immune System,Toll-Like Receptor 1 (TLR1),Toll-Like Receptor 2 (TLR2)",,ISA-204,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Netherlands,Europe,,35403,49154,3000,319,N/A, ,,
Suspended,,,,,,Peptide,N/A,Alexion Pharmaceuticals Inc.,ALXN,TRI-1144,,Infectious Disease,Antiviral,HIV / AIDS,gp41,Roche Holding AG,TR-0291144,Y,Approved,100% (Same As Avg.), - , - , - ,,,,,,,05/08/2008,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,11270,14151,21,78,N/A,$34.07B ,,
Suspended,,,,,,Peptide,N/A,VG Life Sciences Inc.,VGLS,VGX-X,,Infectious Disease,Antiviral,HIV / AIDS,,,APi1177,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,21516,28994,4030,78,N/A,$571.78K ,,
Preclinical,,,,,,Peptide,N/A,Adenium Biotech ApS,,AA139,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Hospital Acquired (Nosocomial) Pneumonia (HAP) (Antibacterial),"Cell wall,DNA,Gram-Negative Bacteria",,"AA 139, AA-139",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,35852,49830,7738,673,N/A, ,,
Suspended,,,,,,Peptide,N/A,"EnBiotix, Inc.",,EBX-004,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Hospital Acquired (Nosocomial) Pneumonia (HAP) (Antibacterial),Penicillin Binding Proteins (PBP),,"EBX004, EBX 004",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,36240,50427,7870,673,N/A, ,,
Suspended,,,,,,Peptide,N/A,IMV Inc.,IMV,DepoVax-HPV16,,Infectious Disease,Antiviral,Human Papillomavirus (HPV) Treatment (Antiviral),"Human Papillomavirus (HPV),Immune System",,"DepoVax-HPV, DepoVax-HPV16 Peptide Vaccine",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Vaccine,,,No,,Nova Scotia,Canada,North America,,34349,47456,3704,238,N/A,$231.59M ,,
Preclinical,,,,,,Peptide,N/A,Tokyo Metropolitan Institute of Medical Science,,PD-001,,Infectious Disease,Antiviral,Influenza (including vaccines),Influenza Virus,PeptiDream Inc.,"iHA-24, HA Program, PD001, PD 001",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Japan,Asia,,23943,33034,4668,237,N/A, ,,
Suspended,,,,,,Peptide,N/A,Serpin Pharma LLC,,SP14,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Sepsis and Septic Shock,Protease,,SP-14,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Virginia,United States,North America,,23274,31862,4511,76,N/A, ,,
Suspended,,,07/24/2008,07/24/2008,,Peptide,N/A,XOMA Corporation,XOMA,XOMA 629,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),Unknown,,XMP.629,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,1676,13700,401,440,N/A,$453.01M ,,
Preclinical,,,,,,Peptide,N/A,Adenium Biotech ApS,,AP-138,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Staphylococcal Vaccines and Other Staphylococcus-Specific Agents (Antibacterial),Cell wall synthesis,,"AP138, AP 138",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,35871,49855,7738,3109,N/A, ,,
Preclinical,,,,,,Peptide,N/A,Adenium Biotech ApS,,AA139,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Urinary Tract and Reproductive Tract Infections (Antibacterial),"Cell wall,DNA,Gram-Negative Bacteria",,"AA 139, AA-139",Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,35852,49828,7738,534,N/A, ,,
I,,,,,,Peptide,N/A,Antag Therapeutics ApS,,GIP Receptor Antagonist Program (Antag),,Metabolic,General,Metabolic - General,GIP Receptor (GIPR)/Glucose-Dependent Insulinotropic Polypeptide Receptor,,,N,I,16% (Same As Avg.), - , - , - ,,,,,,,06/26/2017,,Biologic,,,No,,,Denmark,Europe,,38252,53407,8449,3163,N/A, ,,
Preclinical,,,,,,Peptide,N/A,"Palatin Technologies, Inc.",PTN,PL-8905,,Metabolic,General,Metabolic - General,Melanocortin (MC) receptors,,"PL8905, PL 8905, MC4r Agonist",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,26881,38583,504,3163,N/A,$162.89M ,,
Preclinical,,,,,,Peptide,N/A,Zealand Pharma A/S,ZEAL,Peptide Therapeutic Program (Zealand/UniQuest),,Metabolic,General,Metabolic - General,,Uniquest,,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,37411,52183,748,3163,N/A,$1.48B ,,
I,,,,,07/12/2018,Peptide,N/A,"CohBar, Inc.",CWBR,CB4211,,Metabolic,Obesity,Obesity,Mitochondria,,CB 4211,N,I,16% (Same As Avg.), - , - , - ,,,,,,,07/12/2018,,Biologic,,,No,,California,United States,North America,,34916,48370,7466,135,N/A,$84.34M ,,
I,,,,,08/22/2017,Peptide,N/A,Zealand Pharma A/S,ZEAL,BI 473494,,Metabolic,Obesity,Obesity,Amylin Receptor,,"Boehringer Ingelheim/Zealand Cardio-Metabolic Program, BI473494, BI-473494, Long-acting amylin analog",N,I,16% (Same As Avg.), - , - , - ,,,,,,,08/22/2017,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,26854,49836,748,135,N/A,$1.48B ,,
Preclinical,,,,,,Peptide,N/A,Kallyope Inc.,,Gut-Brain Axis Program (Kallyope),,Metabolic,Obesity,Obesity,,Novo Nordisk A/S,Peptide Therapeutic Program (Kallyope/Novo Nordisk),N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New York,United States,North America,,38274,53439,8456,135,N/A, ,,
Preclinical,,,,,,Peptide,N/A,"Palatin Technologies, Inc.",PTN,PL-8905,,Metabolic,Obesity,Obesity,Melanocortin (MC) receptors,,"PL8905, PL 8905, MC4r Agonist",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,26881,38582,504,135,N/A,$162.89M ,,
Suspended,,,,,,Peptide,N/A,Pfizer Inc.,PFE,OAP-189,oxyntomodulin,Metabolic,Obesity,Obesity,"GLP-1 Receptor,Glucagon Receptor",,"PF-05212389, TKS-1225, Oxyntomodulin Analogue",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/31/2005,,New Molecular Entity (NME),,,No,,New York,United States,North America,,3199,5474,312,135,N/A,$205.99B ,,
Preclinical,,,,,,Peptide,N/A,"Neurotez, Inc.",,NT2,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),"Cytoplasmic linker protein 170 (CLIP-170) ,Presenilin 1 (PS1)",,NT-2,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,New Jersey,United States,North America,,24131,33372,3798,141,N/A, ,,
Preclinical,,,,,,Peptide,N/A,NervGen Pharma Corp.,NGENF,NVG-291,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),PTP-1b (Tyrosine phosphatase 1B inhibitor),,"NVG291, NVG 291",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Canada,North America,,42965,60526,25240,141,N/A, ,,
Suspended,,,,,,Peptide,N/A,"New World Laboratories, Inc.",,NWL-154,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Caspases,,NWL-154,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Canada,North America,,22201,30044,4204,141,N/A, ,,
Suspended,,,,,,Peptide,N/A,"New World Laboratories, Inc.",,NWL-53,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Caspases,,NWL-53,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Canada,North America,,22207,30051,4204,141,N/A, ,,
Suspended,,,,,,Peptide,N/A,Araclon Biotech S.L.,,S-14,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Somatostatin Receptors,"Grifols, S.A.",Somatastatin-14,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,Spain,Europe,,23231,31802,3739,141,N/A, ,,
Suspended,,,,,,Peptide,N/A,Senexis Ltd.,,SEN304,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Amyloid Beta/Amyloid Plaques,,SEN304,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,21301,28684,3799,141,N/A, ,,
Suspended,,,,,,Peptide,N/A,Alzinova AB,ALZ,ALZ-301,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Amyloid Beta/Amyloid Plaques,,ALZ-301,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Sweden,Europe,,22168,30002,4194,141,N/A,$15.45M ,,
Suspended,,,,,,Peptide,N/A,"New World Laboratories, Inc.",,NWL-154,,Neurology,Neurodegenerative,Huntington's Disease,Caspases,,NWL-154,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,,Canada,North America,,22201,30045,4204,296,N/A, ,,
Preclinical,,,,,,Peptide,N/A,NervGen Pharma Corp.,NGENF,NVG-291,,Neurology,Neurodegenerative,Multiple Sclerosis (MS),PTP-1b (Tyrosine phosphatase 1B inhibitor),,"NVG291, NVG 291",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Canada,North America,,42965,60525,25240,153,N/A, ,,
Suspended,,,,,,Peptide,N/A,"Xenetic Biosciences, Inc.",XBIO,MyeloXen,,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Mannose,,"Liposomal Multiple Sclerosis vaccine, Xemys",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Massachusetts,United States,North America,,21687,29274,3211,153,N/A,$20.11M ,,
Preclinical,,,,,,Peptide,N/A,PeptiDream Inc.,4587,PDPS Program (JCR/PeptiDream),,Neurology,General,Neurology - Other,,,Peptide Discovery Platform System,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Japan,Asia,,40472,56669,4665,192,N/A,$6.95B ,,
Suspended,,,,07/31/2003,,Peptide,N/A,Horizon Therapeutics plc,HZNP,Prosaptide,,Neurology,Pain,Neuropathic Pain,,Ferring Pharmaceuticals,Prosaptide,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Ireland,Europe,,872,1028,2878,362,N/A,$17.57B ,,
Preclinical,,,,,,Peptide,N/A,"Seelos Therapeutics, Inc.",SEEL,SLS-007,,Neurology,Neurodegenerative,Parkinson's Disease (PD),Alpha-synuclein,,"SLS007, SLS 007",Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,New York,United States,North America,,41791,58681,3009,194,N/A,$75.15M ,,
Suspended,,,,,,Peptide,N/A,"New World Laboratories, Inc.",,NWL-53,,Neurology,Neurodegenerative,Parkinson's Disease (PD),Caspases,,NWL-53,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Canada,North America,,22207,30052,4204,194,N/A, ,,
IND,,,,,,Peptide,N/A,NervGen Pharma Corp.,NGENF,NVG-291,,Neurology,Other,Spinal Cord Injury (SCI),PTP-1b (Tyrosine phosphatase 1B inhibitor),,"NVG291, NVG 291",N,IND,0% (Same As Avg.), - , - , - ,,,,,,,,12/31/2019,Biologic,Rare Disease,,No,,,Canada,North America,,42965,60524,25240,707,N/A, ,,
Preclinical,,,,,,Peptide,N/A,Silver Creek Pharmaceuticals,,SGF-1,,Neurology,Other,Traumatic Brain Injury (TBI),"Apoptosis (Cell Death),IGF-1R (Insulin-like Growth Factor-1 Receptor) ",,,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,37263,51975,8153,547,N/A, ,,
Suspended,,,,,,Peptide,N/A,VG Life Sciences Inc.,VGLS,VG1177,,Neurology,Other,Traumatic Brain Injury (TBI),Immune System,,VG1177,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,23198,34425,4030,547,N/A,$571.78K ,,
Preclinical,,,,,,Peptide,N/A,ValiRx Plc,VAL,VAL301,,Obstetrics/Gynecology,Gynecology,Endometriosis,"Androgen receptors,Src Kinase Family",,"VAL 301, VAL-301",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,38534,53801,3920,349,N/A,$18.30M ,,
Suspended,,,,,,Peptide,N/A,"S1 Biopharma, Inc.",,S1B-307,,Obstetrics/Gynecology,Female Sexual Arousal Disorder,Female Sexual Arousal Disorder,Unknown,,S1B-307,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,New York,United States,North America,,24689,34310,4857,275,N/A, ,,
Suspended,,,,,,Peptide,N/A,"Palatin Technologies, Inc.",PTN,PL-8905,,Obstetrics/Gynecology,Female Sexual Arousal Disorder,Female Sexual Arousal Disorder,Melanocortin (MC) receptors,,"PL8905, PL 8905, MC4r Agonist",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,26881,37569,504,275,N/A,$162.89M ,,
II,,,,07/13/2015,,Peptide,N/A,Ferring Pharmaceuticals,,FE-202767,,Obstetrics/Gynecology,Obstetrics,Milk Letdown,Oxytocin Receptor,,"FE202767, FE 202767, merotocin",N,II,24% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,26384,36812,582,3415,N/A, ,,
Investigator Initiated,,,,12/23/2010,,Peptide,N/A,"Formula Pharmaceuticals, Inc.",,FPI-01,,Oncology,Hematologic,Acute Lymphoblastic Leukemia (ALL),"Immune System,Wilms' Tumor Protein 1 (WT1)",,"FPI-01, WT-1-vaccine",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Pennsylvania,United States,North America,,19152,27479,3495,199,N/A, ,,
Suspended,,,,,,Peptide,N/A,Polyphor AG,POLN,POL5551,,Oncology,Hematologic,Acute Lymphoblastic Leukemia (ALL),Chemokine (C-X-C motif) Receptor 4 (CXCR4),,POL5551,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Switzerland,Europe,,21534,29019,3395,199,N/A,$102.79M ,,
Investigator Initiated,,,,12/23/2010,,Peptide,N/A,"Formula Pharmaceuticals, Inc.",,FPI-01,,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),"Immune System,Wilms' Tumor Protein 1 (WT1)",,"FPI-01, WT-1-vaccine",Y,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Pennsylvania,United States,North America,,19152,25225,3495,97,N/A, ,,
Suspended,,,,,,Peptide,N/A,Modulation Therapeutics,,MTI-101,,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),Cluster of Differentiation 44 (CD44),,"MTI101, MTI 101",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,California,United States,North America,,21539,29046,4035,97,N/A, ,,
Preclinical,,,,,,Peptide,N/A,Neumedicines Inc.,,NMHSS1-1,,Oncology,Solid,Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM)),Hematopoietic Signal peptide-containing Secreted 1 (HSS1),,"NMHSS1-1, HSS-1",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,California,United States,North America,,21536,29023,4033,228,N/A, ,,
Preclinical,,,,,,Peptide,N/A,"PepVax, Inc.",,PVX-009,,Oncology,Solid,Breast Cancer,Melanoma antigen-encoding gene (MAGE),,"PVX 009, PVX009",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Maryland,United States,North America,,35530,49355,7638,214,N/A, ,,
Preclinical,,,,,,Peptide,N/A,CEL-SCI Corporation,CVM,J-HER,,Oncology,Solid,Breast Cancer,"HER2/neu or ErbB-2,Immune System",,"JHER, J HER",Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Virginia,United States,North America,,22968,31327,519,214,N/A,$536.71M ,,
Preclinical,,,,,,Peptide,N/A,EpiVax Therapeutics,,Ancer Epitope Platform,,Oncology,General,Cancer,Tumor Cells,,,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New York,United States,North America,,36133,50256,7841,313,N/A, ,,
Preclinical,,,,,,Peptide,N/A,Apeiron Biologics AG,,APN431,,Oncology,General,Cancer,"CBL-B,E3 ubiquitin ligase",,"APN 431, APN-431",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Austria,Europe,,43714,61638,3484,313,N/A, ,,
Suspended,,,,,,Peptide,N/A,PeptiMimesis Pharma,,Ipsen/PeptiMimesis Oncology Peptide Program,,Oncology,General,Cancer,Unknown,Ipsen SA,,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,France,Europe,,27778,38941,5852,313,N/A, ,,
Suspended,,,,,,Peptide,N/A,AbbVie Inc.,ABBV,AbbVie/Pure	MHC Peptide Program,,Oncology,General,Cancer,Unknown,,,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Illinois,United States,North America,,33097,45704,5,313,N/A,$188.39B ,,
Suspended,,,,,,Peptide,N/A,Ipsen SA,IPSEY,IPN-01087,,Oncology,General,Cancer - Imaging,"NT1 (Neurotensin receptor type 1),Radiopharmaceutical",3B Pharmaceuticals GmbH,"3BP227, 3BP 227, 3BP-227, IPN01087, IPN-01087A, 177Lu-IPN01087, 177Lu-3BP-227",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,France,Europe,,35826,49794,220,3579,N/A,$4.57B ,,
Suspended,,01/04/2001,,12/10/1998,,Peptide,N/A,"Sarepta Therapeutics, Inc.",SRPT,Avicine,,Oncology,Solid,Colorectal Cancer (CRC),"Human chorionic gonadotropin (hCG) ,Immune System","Otsuka Holdings Co., Ltd.",CTP-37,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,577,1096,52,213,N/A,$13.33B ,,
Preclinical,,,,,,Peptide,N/A,"selectION, Inc.",,si-544,,Oncology,Hematologic,Cutaneous T-Cell Lymphoma (CTCL) - NHL,Potassium channels,,"si 544, si544",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,California,United States,North America,,40526,56773,9193,417,N/A, ,,
Suspended,,,,,,Peptide,N/A,Shionogi & Co. Ltd.,4507,S-488410,,Oncology,Solid,Esophageal Cancer,Immune System,"OncoTherapy Science, Inc.",S-488410,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Japan,Asia,,17628,22964,618,273,N/A,$17.14B ,,
Preclinical,,,,,,Peptide,N/A,Neumedicines Inc.,,NMHSS1-1,,Oncology,Hematologic,Hematologic Cancer,Hematopoietic Signal peptide-containing Secreted 1 (HSS1),,"NMHSS1-1, HSS-1",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,21536,29024,4033,196,N/A, ,,
Suspended,,,,,,Peptide,N/A,"Sumitomo Dainippon Pharma Co., Ltd.",4506,WT2725,,Oncology,Hematologic,Hematologic Cancer,"Immune System,Wilms' Tumor Protein 1 (WT1)","Chugai Pharmaceutical Co., Ltd., Roche Holding AG",WT2725,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/31/2013,,New Molecular Entity (NME),,,No,,,Japan,Asia,,20495,31145,686,196,N/A,$5.96B ,,
Suspended,,,,,,Peptide,N/A,Relief Therapeutics Holding AG,RLFTF,DasKloster 0014,,Oncology,Solid,Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases),,,"DasKloster 0014-01, DasKloster-0014, DasKloster0014, DasKloster 0014 01, DasKloster 001401",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,"Orphan,Rare Disease",,No,,,Switzerland,Europe,,23798,32781,6373,297,N/A, ,,
I/II,,,12/15/2020,12/15/2020,,Peptide,N/A,IO Biotech ApS,,IO103,,Oncology,Solid,Melanoma,Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2),,"IO 103, IO-103",N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Breakthrough,,No,,,Denmark,Europe,,35928,49944,7764,221,N/A, ,,
Preclinical,,,,,,Peptide,N/A,"9 Meters Biopharma, Inc. ",NMTR,NM-102,,Oncology,Solid,Melanoma,Unknown,,"NM102, NM 102",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,North Carolina,United States,North America,,43768,61720,7614,221,N/A,$288.83M ,,
Suspended,,,,,,Peptide,N/A,Modulation Therapeutics,,MTI-101,,Oncology,Hematologic,Multiple Myeloma (MM),Cluster of Differentiation 44 (CD44),,"MTI101, MTI 101",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,California,United States,North America,,21539,29030,4035,207,N/A, ,,
I,,,,,,Peptide,N/A,"RadioMedix, Inc.",,AlphaMedix,,Oncology,Solid,Neuroendocrine Tumors (NET),"Radiopharmaceutical,Somatostatin Receptors",Orano Med,203Pb-AR-RMX,N,I,6% (Same As Avg.), - , - , - ,,,,,,,05/31/2017,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,Texas,United States,North America,,37075,51692,8094,347,  5%, ,Indication Group,NET
Suspended,,08/03/2016,,,,Peptide,N/A,"Adlai Nortye Biopharma Co., Ltd.",,AN-2109,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),Unknown,,AN2109,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,China,Asia,,30570,42344,6388,211,N/A, ,,
Suspended,,,02/14/2012,02/14/2012,,Peptide,N/A,"SELLAS Life Sciences Group, Inc.",SLS,GALE-301,,Oncology,Solid,Ovarian Cancer,"Folate Binding Protein,Immune System",,"E39, FBP Vaccine, Folate Binding Protein-E39",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,New York,United States,North America,,18853,24787,5266,224,  5%,$79.06M ,Tumor Type,Solid
I/II,,,02/15/2018,02/15/2018,,Peptide,N/A,Ipsen SA,IPSEY,IPN-01087,,Oncology,Solid,Pancreatic Cancer,"NT1 (Neurotensin receptor type 1),Radiopharmaceutical",3B Pharmaceuticals GmbH,"3BP227, 3BP 227, 3BP-227, IPN01087, IPN-01087A, 177Lu-IPN01087, 177Lu-3BP-227",N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,France,Europe,,35826,49809,220,220,N/A,$4.57B ,,
Preclinical,,,,,,Peptide,N/A,"Kalos Therapeutics, Inc.",,KTH 222,,Oncology,Solid,Pancreatic Cancer,MAPK/ERK (mitogen-activated protein kinases/extracellular signal-regulated kinases; Ras-Raf-MEK-ERK pathway),"Oncology Pharma, Inc.","KTH-222, KTH222, Leu-Lys-Gly-Gln-Leu-Arg-Cys-Ile",Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,Arizona,United States,North America,,40787,57208,9281,220,N/A, ,,
Suspended,,,,,06/14/2011,Peptide,N/A,"Otsuka Holdings Co., Ltd.",4578,OCV-105,,Oncology,Solid,Pancreatic Cancer,Immune System,"OncoTherapy Science, Inc.",OCV-105,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Japan,Asia,,18437,24161,636,220,N/A,$22.58B ,,
Suspended,,,,06/02/1999,,Peptide,N/A,"Sarepta Therapeutics, Inc.",SRPT,Avicine,,Oncology,Solid,Pancreatic Cancer,"Human chorionic gonadotropin (hCG) ,Immune System","Otsuka Holdings Co., Ltd.",CTP-37,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Massachusetts,United States,North America,,577,1095,52,220,N/A,$13.33B ,,
I/II,,,,06/22/2018,06/22/2018,Peptide,N/A,Novartis AG,NVS,177Lu-PSMA-SR6,,Oncology,Solid,Prostate Cancer,"Prostate-specific Membrane Antigen (PSMA),Radiopharmaceutical",,"PSMA-SR6, 177Lu PSMA-R2",Y,II,10% (Same As Avg.), - , - , - ,,,,,01/01/2024 - 12/31/2025,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,27295,38185,289,215, 10%,$183.31B ,Lead Indication,Yes
Suspended,,,,,,Peptide,N/A,ValiRx Plc,VAL,VAL101,,Oncology,Solid,Prostate Cancer,"B-cell lymphoma 2 (Bcl-2)/Bcl-2 Family,Histone Deacetylase (HDAC)",,VAL 101,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,20953,28104,3920,215,N/A,$18.30M ,,
I,,,,,,Peptide,N/A,"Sumitomo Dainippon Pharma Co., Ltd.",4506,WT2725,,Oncology,Solid,Solid Tumors,"Immune System,Wilms' Tumor Protein 1 (WT1)","Chugai Pharmaceutical Co., Ltd., Roche Holding AG",WT2725,N,I,6% (Same As Avg.), - , - , - ,,,,,,,06/06/2012,,New Molecular Entity (NME),,,No,,,Japan,Asia,,20495,27322,686,197,N/A,$5.96B ,,
I/II,,,03/27/2018,03/27/2018,,Peptide,N/A,"Bicycle Therapeutics, plc",BCYC,BT1718,,Oncology,Solid,Solid Tumors,"Antibody-drug Conjugate (ADC),Microtubules (Tubulin),MMP (metalloproteinase)",Pepscan Therapeutics,"BT 1718, BT-1718",N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,32458,44832,6753,197,N/A,$251.55M ,,
I/II,,,,09/10/2020,09/10/2020,Peptide,N/A,"Bicycle Therapeutics, plc",BCYC,BT8009,,Oncology,Solid,Solid Tumors,"Antibody-drug Conjugate (ADC),Nectin-4",,"BT-8009, BT 8009",Y,II,10% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,41051,57622,6753,197, 15%,$251.55M ,Lead Indication,Yes
Preclinical,,,,,,Peptide,N/A,Neumedicines Inc.,,NMHSS1-1,,Oncology,Solid,Solid Tumors,Hematopoietic Signal peptide-containing Secreted 1 (HSS1),,"NMHSS1-1, HSS-1",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,21536,29025,4033,197,N/A, ,,
Preclinical,,,,,,Peptide,N/A,Alkermes plc,ALKS,IL-10-Fc program (Alkermes),,Oncology,Solid,Solid Tumors,IL-10 (Interleukin-10) and IL-10 Receptor (IL-10R),,,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Ireland,Europe,,41715,58568,22,197,N/A,$3.28B ,,
Preclinical,,,,,,Peptide,N/A,Scancell,SCLP,AMPLIVANT:Modi-1 Conjugate Therapy,,Oncology,Solid,Solid Tumors,"Dendritic cells,Immune System,T lymphocytes,Toll-Like Receptor (TLR) Family,Toll-Like Receptor 1 (TLR1),Toll-Like Receptor 2 (TLR2),Vimentin",ISA Pharmaceuticals B.V.,"Modi-1/AMPLIVANT, Modi-1-AMPLIVANT, Moditope, Modi-1 - AMPLIVANT conjugate",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,37369,52123,3349,197,N/A,$174.53M ,,
Preclinical,,,,,,Peptide,N/A,Scancell,SCLP,Modi-1,,Oncology,Solid,Solid Tumors,"Immune System,Vimentin",,Moditope vaccine,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,24753,34394,3349,197,N/A,$174.53M ,,
Suspended,,,,,,Peptide,N/A,Pierre Fabre,,AUNP-12,,Oncology,Solid,Solid Tumors,"Immune System,Programmed death-1 receptor (PD-1) / Programmed death ligands (PD-L1 and PD-L2)",Dr. Reddy's Laboratories Ltd.,"AUNP12, AUR-012, Aurigene-012",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,France,Europe,,22442,30449,906,197,N/A, ,,
Suspended,,,,,,Peptide,N/A,"Biscayne Pharmaceuticals, Inc.",,BIS-1602,,Oncology,Solid,Solid Tumors,Growth Hormone Releasing Hormone (GHRH) Receptor,,BIS-1602,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Florida,United States,North America,,27181,38012,5628,197,N/A, ,,
Suspended,,,,,,Peptide,N/A,CytImmune Sciences Inc.,,CYT-61000,interferon,Oncology,Solid,Solid Tumors,"Interferon-alpha (IFNa),Protein synthesis,RNA synthesis",,"CYT 61000, CYT61000",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Maryland,United States,North America,,33081,45678,6968,197,N/A, ,,
Suspended,,,,,,Peptide,N/A,Aeterna Zentaris Inc.,AEZS,AEZS-138,,Oncology,Solid,Solid Tumors,Gonadotropin-Releasing Hormone (GnRH),,"Disorazol Z-D-Lys6-LHRH conjugate, AEZS138, AEZS 138",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Canada,North America,,26662,37224,14,197,N/A,$33.59M ,,
Suspended,,,,,,Peptide,N/A,"Aileron Therapeutics, Inc",ALRN,ATSP-7041,,Oncology,Solid,Solid Tumors,"Mdm2,Mdmx/Mdm4",Roche Holding AG,"ATSP 7041, ATSP7041",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Massachusetts,United States,North America,,22518,30590,4074,197,N/A,$50.04M ,,
Suspended,,,,,03/14/2012,Peptide,N/A,Seagen Inc. ,SGEN,ONT-10,,Oncology,Solid,Solid Tumors,"Immune System,Mucin 1 (MUC-1),Toll-like receptor 4 (TLR4)",,ONT-10,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/14/2012,12/20/2011,New Molecular Entity (NME),,,No,,Washington,United States,North America,,19218,25317,351,197,N/A,$31.80B ,,
Suspended,,,,,,Peptide,N/A,Targovax ASA,TRVX,TG03,,Oncology,Solid,Solid Tumors,Immune System,,"TG 03, TG-03",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Norway,Europe,,28343,39571,3386,197,N/A,$94.91M ,,
Suspended,,,02/14/2012,09/26/2011,,Peptide,N/A,"SELLAS Life Sciences Group, Inc.",SLS,GALE-301,,Oncology,Solid,Uterine (Endometrial) Cancer,"Folate Binding Protein,Immune System",,"E39, FBP Vaccine, Folate Binding Protein-E39",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,New York,United States,North America,,18853,25789,5266,219,  5%,$79.06M ,Tumor Type,Solid
Preclinical,,,,,,Peptide,N/A,"Biogen, Inc.",BIIB,CB 2782,,Ophthalmology,Macular Degeneration,Dry Age-Related Macular Degeneration (Dry AMD)/Geographic Atrophy (Ophthalmology),Complement Pathway,"Catalyst Biosciences, Inc., Mosaic Biosciences, Inc.","CB2782, CB-2782, CB 2782-PEG",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,26771,52862,64,2870,N/A,$38.54B ,,
Preclinical,,,,,,Peptide,N/A,OKYO Pharma Limited,OKYO,OKYO-0201,,Ophthalmology,Other,Ocular Pain and/or Inflammation (Ophthalmology),MAS-Related G Protein-Coupled Receptors (MRGPR) ,,"OKYO0201, OKYO 0201, Bam8 Analog, Bovine Adrenal Medulla Analog",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,40789,57210,9283,554,N/A,$75.42M ,,
Suspended,,,,,,Peptide,N/A,"Palatin Technologies, Inc.",PTN,PL-8331,,Ophthalmology,Other,Ocular Pain and/or Inflammation (Ophthalmology),Melanocortin (MC) receptors,,"MC1/5r Agonist, PL8331, PL 8331",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,33722,46577,504,554,N/A,$162.89M ,,
Suspended,,,,,,Peptide,N/A,BioLineRx Ltd.,BLRX,BL-8010,,Ophthalmology,Retinopathy,Other Retinopathy (Ophthalmology),Angiopoietin Receptors (TIE-1 and TIE-2),Compugen Ltd.,"CGEN-25017, BL-8010/EDP30",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Israel,Asia,,19184,25268,1248,2761,N/A,$58.92M ,,
Preclinical,,,,,,Peptide,N/A,"Protagenic Therapeutics, Inc.",OTCQB:PTIX,PT00114,,Psychiatry,Anxiety,Generalized Anxiety Disorder (GAD),Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),,"PT-00114, PT 00114",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New York,,,,43937,62010,26228,169,N/A, ,,
Preclinical,,,,,,Peptide,N/A,"Protagenic Therapeutics, Inc.",OTCQB:PTIX,PT00114,,Psychiatry,Unipolar Depression,Major Depressive Disorder (MDD),Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),,"PT-00114, PT 00114",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New York,,,,43937,62009,26228,167,N/A, ,,
Preclinical,,,,,,Peptide,N/A,"Protagenic Therapeutics, Inc.",OTCQB:PTIX,PT00114,,Psychiatry,Other,Post-Traumatic Stress Disorder (PTSD),Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH),,"PT-00114, PT 00114",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New York,,,,43937,62007,26228,659,N/A, ,,
Preclinical,,,,,,Peptide,N/A,"OrthoTrophix, Inc.",,TPX-200,,Renal,Chronic Renal Failure,Renal Disease / Renal Failure,Phosphate,,TPX-200,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,22820,31103,4391,149,N/A, ,,
Suspended,,,07/03/2013,07/03/2013,,Peptide,N/A,"Thrasos Theraputics, Inc.",,THR-184,,Renal,Chronic Renal Failure,Renal Disease / Renal Failure,"Apoptosis (Cell Death),Bone morphogenetic protein (BMP),Smad",,THR-184,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,10/25/2012,,New Molecular Entity (NME),Fast Track,,No,,,Canada,North America,,21271,28642,3989,149,N/A, ,,
Suspended,,,,,,Peptide,N/A,Synairgen plc,SNG,Synairgen IL4/IL13 Peptide,,Respiratory,Asthma,Asthma,"IL-13 (Interleukin-13),IL-4 (Interleukin-4)",,Synairgen IL4/IL13 Peptide,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,United Kingdom,Europe,,22305,30217,3680,72,N/A,$413.05M ,,
Suspended,,,,,,Peptide,N/A,Serpin Pharma LLC,,SP9,,Respiratory,Cystic Fibrosis,Cystic Fibrosis (CF),,,SP-9,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,Virginia,United States,North America,,23273,31861,4511,74,N/A, ,,
Suspended,,,,,,Peptide,N/A,"PhaseBio Pharmaceuticals, Inc.",PHAS,PB1120,,Respiratory,Cystic Fibrosis,Cystic Fibrosis (CF),Vasoactive Intestinal Peptide (VIP) Receptor,,"PB 1120, PB-1120",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,Pennsylvania,United States,North America,,35980,50018,3581,74,N/A,$118.93M ,,
Preclinical,,,,,,Peptide,N/A,AstraZeneca PLC,AZN,AstraZeneca Bicycle Program,,Respiratory,General,Respiratory Disease,Unknown,"Bicycle Therapeutics, plc",,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,32466,44841,45,234,N/A,$133.38B ,,
Suspended,,,,,,Peptide,N/A,"Palatin Technologies, Inc.",PTN,PL-8905,,Urology,Male Sexual Dysfunction,Erectile Dysfunction (ED),Melanocortin (MC) receptors,,"PL8905, PL 8905, MC4r Agonist",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,26881,37570,504,160,N/A,$162.89M ,,
Development Outside U.S.,,,,,,Peptide,N/A,Vaxeal Holding SA,,CBX-1,,Oncology,General,Cancer,"Cyclin B1,Immune System",,"CBX1, CBX 1, CBX-1 Vaccine Vaxeal",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,36980,51568,8076,313,N/A, ,,
Development Outside U.S.,,,,,,Peptide,N/A,"Edinburgh Molecular Imaging, Ltd.",,EMT-100,,Oncology,General,Cancer,"Hepatocyte growth factor receptor (c-Met, HGFR)",,"EMT100, EMT 100",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,United Kingdom,Europe,,42639,60018,7825,313,N/A, ,,
Development Outside U.S.,,,,,,Peptide,N/A,"Edinburgh Molecular Imaging, Ltd.",,EMT‑101,,Oncology,General,Cancer,"Hepatocyte growth factor receptor (c-Met, HGFR)",,"EMT101, EMT 101",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,United Kingdom,Europe,,42640,60019,7825,313,N/A, ,,
Development Outside U.S.,,,,,,Peptide,N/A,Vaxeal Holding SA,,SVX-1,,Oncology,General,Cancer,"Immune System,Survivin",,"SVX 1, SVX1, SVX-1 Vaccine Vaxeal",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,36981,51569,8076,313,N/A, ,,
Development Outside U.S.,,,,,,Peptide,N/A,ImmuPharma PLC,IMM,IPP-204106,,Oncology,General,Cancer,Nucleolin,,"IPP 204106, N6L",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,16880,21891,2061,313,N/A,$43.03M ,,
Development Outside U.S.,,,,,,Peptide,N/A,Cellivery Therapeutics Inc,,CV-15,,Infectious Disease,Antiviral,COVID-19 Treatment,"Immune System,SARS-CoV-2",,"iCP-NI, CV15, CV 15",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Korea (South),Asia,,42612,59979,11842,3651,N/A, ,,
Development Outside U.S.,,,,,,Peptide,N/A,ImCyse S.A.,,IMCY-0098,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Immune System,,IMCY 0098,N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Belgium,Europe,,35134,48670,5279,157,N/A, ,,
Development Outside U.S.,,,,,,Peptide,N/A,Sihuan Pharmaceutical Holdings Group Ltd,00460,Insulin Degludec (Sihuan),degludec,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,Long-acting Insulin Degludec (Sihuan),N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,China,Asia,,39004,54537,3605,137,N/A, ,,
Development Outside U.S.,,,,,,Peptide,N/A,Zion Medical,,Gammora,,Infectious Disease,Antiviral,HIV / AIDS,Human Immunodeficiency Virus (HIV) ,,,N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Israel,Asia,,39439,55164,8831,78,N/A, ,,
Development Outside U.S.,,,,,,Peptide,N/A,Vac-4-All,,Malaria Vaccine (PfPEBS),,Infectious Disease,"Other (I.E. Antiparasitic, Etc.)",Malaria,"Immune System,Plasmodium",,"Lyophilised PEBS synthetic protein, P. Falciparum Pre-Erythrocytic and Blood Stage",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Vaccine,,,No,,,France,Europe,,20293,27027,3754,467,N/A, ,,
Development Outside U.S.,,,,,,Peptide,N/A,"Hanmi Pharmaceutical Co., Ltd.",128940,HM15912,,Gastroenterology (Non Inflammatory Bowel Disease),Other,Short Bowel Syndrome (SBS),GLP-2 Receptor,,"HM 15912, HM-15912, LAPS GLP-2 Analog",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Korea (South),Asia,,41732,58588,3379,581,N/A,$4.34B ,,
Approved in Europe,,,,,,Peptide,N/A,Sanofi,SNY,Modustatine,somatostatin,Hematology,Other,Acute Hemorrhage,Somatostatin Receptors,,"CM-9357, GHRIH",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,France,Europe,,41506,58211,51,3189,N/A,$107.55B ,,
III,06/10/2019,06/10/2019,09/21/2006,09/21/2006,,Peptide,Oral (PO),"9 Meters Biopharma, Inc. ",NMTR,INN-202,larazotide acetate,Autoimmune/immunology,Inflammatory Bowel Disease,Celiac Disease,Zonulin and zonulin receptor,Alba Therapeutics Corporation,"SPD550, SPD-550, AT-1001 (Alba), EC AT-1001, INN202, INN 202",Y,III,54% (5% Below Avg.), - , - , - ,,,,,,,09/27/2005,,New Molecular Entity (NME),Fast Track,,No,,North Carolina,United States,North America,,10754,13463,7614,2304,N/A,$288.83M ,,
I,,,,,12/09/2020,Peptide,Oral (PO),Johnson & Johnson,JNJ,PN-235,,Autoimmune/immunology,Inflammatory Bowel Disease,Crohn's Disease,IL-23 (Interleukin-23)  ,"Protagonist Therapeutics, Inc.","PN 235, PN235, JNJ-77242113, JNJ 77242113, JNJ77242113",N,I,14% (Same As Avg.), - , - , - ,,,,,,,12/09/2020,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,43646,61544,223,156,N/A,$422.18B ,,
II,,,11/06/2019,11/06/2019,11/09/2017,Peptide,Oral (PO),Johnson & Johnson,JNJ,PTG-200,,Autoimmune/immunology,Inflammatory Bowel Disease,Crohn's Disease,IL-23 (Interleukin-23)  ,"Protagonist Therapeutics, Inc.","PTG200, PTG 200, JNJ-67864238, JNJ 67864238, JNJ67864238",Y,II,20% (Same As Avg.), - , - , - ,,,,,,,11/09/2017,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,29538,40934,223,156,N/A,$422.18B ,,
Preclinical,,,,,,Peptide,Oral (PO),Johnson & Johnson,JNJ,PN-232,,Autoimmune/immunology,Inflammatory Bowel Disease,Crohn's Disease,IL-23 (Interleukin-23)  ,"Protagonist Therapeutics, Inc.","PN232, PN 232, JNJ-75105186, JNJ75105186, JNJ 75105186",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,43647,61546,223,156,N/A,$422.18B ,,
Suspended,,,,,,Peptide,Oral (PO),"9 Meters Biopharma, Inc. ",NMTR,INN-289,larazotide acetate,Autoimmune/immunology,Inflammatory Bowel Disease,Crohn's Disease,Zonulin and zonulin receptor,Alba Therapeutics Corporation,"INN 289, INN289",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,North Carolina,United States,North America,,40063,56015,7614,156,N/A,$288.83M ,,
I,,,,,08/21/2019,Peptide,Oral (PO),"Ra Pharmaceuticals, Inc.",RARX,Cyclomimetic Program,,Autoimmune/immunology,Other,Hereditary Angioedema (HAE),Kinin-Kallikrein System ,"Merck & Co., Inc.",Cyclomimetic,Y,I,14% (Same As Avg.), - , - , - ,,,,,,,08/21/2019,,New Molecular Entity (NME),Rare Disease,,No,,Massachusetts,United States,North America,,20200,26885,3732,556,N/A,$2.27B ,,
Preclinical,,,,,,Peptide,Oral (PO),Zealand Pharma A/S,ZEAL,ZP10000,,Autoimmune/immunology,Inflammatory Bowel Disease,Inflammatory Bowel Disease (IBD),Integrin Alpha-4 beta-7/LPAM,,"ET 3764, ET-3764, ET3764, ZP 10000, ZP-10000",Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,41070,57651,748,464,N/A,$1.48B ,,
Suspended,,,,,,Peptide,Oral (PO),"Amgen, Inc.",AMGN,Large Molecule Program (Entera/Amgen),,Autoimmune/immunology,General,Inflammatory Disorders,,Entera Bio Ltd.,Inflammatory Disease Program (Entera/Amgen),N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,39736,55575,30,422,N/A,$136.24B ,,
Suspended,,,,,,Peptide,Oral (PO),"Allostera Pharma, Inc.",,APG2305,,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),IL-23 (Interleukin-23)  ,,APG-2305,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Quebec,Canada,North America,,19157,25231,3498,336,N/A, ,,
Program Hold,,,,08/19/2008,,Peptide,Oral (PO),"Synthetic Biologics, Inc.",SYN,Oral dnaJP1,,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Immune System,,peptide dnaJP1,Y,II,20% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Maryland,United States,North America,,12413,15655,1252,154,N/A,$13.20M ,,
Suspended,,,,,11/12/2009,Peptide,Oral (PO),"arGentis Pharmaceuticals, LLC ",,ARG301,,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),T-Cell Receptor (TCR),,"ARG 301, ARG-301, APLA12, APL-A12, APL A12",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,11/12/2009,,Non-NME,,,No,,Tennessee,United States,North America,,18518,24283,3351,154,N/A, ,,
I,,,,,10/11/2012,Peptide,Oral (PO),Bausch Health Companies Inc.,BHC,Dolcanatide,dolcanatide,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),Guanylyl cyclase c Receptor,,"guanylyl cyclase c receptor agonist, SP-333",Y,I,14% (Same As Avg.), - , - , - ,,,,,,,10/11/2012,09/07/2012,New Molecular Entity (NME),,,No,,Quebec,Canada,North America,,19765,26179,470,321,N/A,$8.11B ,,
II,,,11/04/2020,11/04/2020,12/13/2018,Peptide,Oral (PO),"Protagonist Therapeutics, Inc.",PTGX,PN-943,,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),Integrin Alpha-4 beta-7/LPAM,,"PN-943, PN943, PN 943, PN-10943, PN10943, PN 10943",N,II,20% (Same As Avg.), - , - , - ,,,,,,,12/13/2018,,New Molecular Entity (NME),,,No,,California,United States,North America,,39645,55439,4983,321,N/A,$890.35M ,,
Suspended,,,,,,Peptide,Oral (PO),Dr Kurt Wolff GmbH & Co KG,,KdPT,,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),Melanocortin (MC) receptors,,K(D)PT,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Germany,Europe,,23101,31573,4466,321,N/A, ,,
Suspended,,,01/17/2017,01/17/2017,01/08/2016,Peptide,Oral (PO),"Protagonist Therapeutics, Inc.",PTGX,PTG-100,,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),Integrin Alpha-4 beta-7/LPAM,,"PTG100, PTG 100",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,01/08/2016,,New Molecular Entity (NME),,,No,,California,United States,North America,,24998,34747,4983,321,N/A,$890.35M ,,
Suspended,,,,,,Peptide,Oral (PO),Bruin Pharmaceuticals,,6F,,Cardiovascular,General,Atherosclerosis,Reverse Cholesterol Transport (RCT),,6F,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,21335,28742,918,650,N/A, ,,
Suspended,,,,,,Peptide,Oral (PO),Novartis AG,NVS,APP018,,Cardiovascular,General,Atherosclerosis,Reverse Cholesterol Transport (RCT),Bruin Pharmaceuticals,D-4F,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,04/21/2005,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,1889,3046,289,650,N/A,$183.31B ,,
III,02/23/2016,02/23/2016,,,,Peptide,Oral (PO),Novo Nordisk A/S,NVO,Rybelsus,semaglutide,Cardiovascular,General,Cardiovascular Disease,GLP-1 Receptor,"Emisphere Technologies, Inc., Merck & Co., Inc.","OG217SC, NN9924, NN 9924, NN-9924, Oral Semaglutide",N,III,47% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,Denmark,Europe,,16255,58664,292,181,N/A,$108.42B ,,
Suspended,,,,,,Peptide,Oral (PO),Dr Kurt Wolff GmbH & Co KG,,KdPT,,Dermatology,General,Dermatology,Melanocortin (MC) receptors,,K(D)PT,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Germany,Europe,,23101,31577,4466,151,N/A, ,,
II,,,,01/16/2014,,Peptide,Oral (PO),"Biocon, Ltd.",,IN-105,insulin tregopil,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,Bristol Myers Squibb Company,Oral Insulin,Y,II,24% (Same As Avg.), - , - , - ,,,,,,,08/19/2010,,New Molecular Entity (NME),,,No,,,India,Asia,,15238,23306,2652,157,N/A, ,,
II,,,,09/24/2008,,Peptide,Oral (PO),Oramed Pharmaceuticals Inc.,ORMP,ORMD-0801,human insulin,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,Sinopharm Group Co. Ltd.,"oral insulin, ORMD0801, ORMD 0801",N,II,24% (Same As Avg.), - , - , - ,,,,,,,09/09/2008,,Non-NME,,,No,,,Israel,Asia,,11388,16327,2118,157,N/A,$104.65M ,,
Suspended,,,,06/15/2005,,Peptide,Oral (PO),Diabetology Ltd.,,Capsulin IR,insulin,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,Capsulin IR,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,United Kingdom,Europe,,18038,23559,1280,157,N/A, ,,
Suspended,,,,,,Peptide,Oral (PO),DiaMedica Therapeutics Inc.,DMAC,DM99,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",,,DM-99,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Minnesota,United States,North America,,16645,26015,2825,157,N/A,$184.21M ,,
Suspended,,,,,,Peptide,Oral (PO),"9 Meters Biopharma, Inc. ",NMTR,INN-202,larazotide acetate,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Zonulin and zonulin receptor,Alba Therapeutics Corporation,"SPD550, SPD-550, AT-1001 (Alba), EC AT-1001, INN202, INN 202",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,North Carolina,United States,North America,,10754,13464,7614,157,N/A,$288.83M ,,
Suspended,,,,,12/07/2009,Peptide,Oral (PO),Novo Nordisk A/S,NVO,NN1952,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,Merrion Pharmaceuticals Plc.,NN1952,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,12/07/2009,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,16165,20773,292,157,N/A,$108.42B ,,
Suspended,,,,,04/28/2011,Peptide,Oral (PO),Novo Nordisk A/S,NVO,NN1953,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,Merrion Pharmaceuticals Plc.,"insulin 338, NNC0123-0000-0338, OI338GT, GIPET I",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,04/28/2011,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,18267,23902,292,157,N/A,$108.42B ,,
Suspended,,,,,11/20/2012,Peptide,Oral (PO),Novo Nordisk A/S,NVO,NN1956,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,Merrion Pharmaceuticals Plc.,"insulin 287, NNC0148-0000-0287, OI287GT",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/11/2013,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,22372,30330,292,157,N/A,$108.42B ,,
I,,,,,,Peptide,Oral (PO),Oramed Pharmaceuticals Inc.,ORMP,ORMD-0901,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,"ORMD0901, Oral Exenatide, ORMD 0901",Y,I,14% (Same As Avg.), - , - , - ,,,,,,,09/09/2009,,Non-NME,,,No,,,Israel,Asia,,15769,20138,2118,137,N/A,$104.65M ,,
II,,,12/26/2017,01/16/2014,,Peptide,Oral (PO),"Biocon, Ltd.",,IN-105,insulin tregopil,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,Bristol Myers Squibb Company,Oral Insulin,N,II,24% (Same As Avg.), - , - , - ,,,,,,,,12/31/2009,New Molecular Entity (NME),,,No,,,India,Asia,,15238,19364,2652,137,N/A, ,,
II/III,12/23/2008,12/23/2008,,08/23/2007,,Peptide,Oral (PO),Diasome Pharmaceuticals,,Oral HDV-I,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"Targeted oral insulin, Hepatic-directed vesicles insulin",Y,III,55% (5% Below Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,Ohio,United States,North America,,11367,14301,2113,137,N/A, ,,
III,,11/24/2020,07/08/2013,04/14/2008,,Peptide,Oral (PO),Oramed Pharmaceuticals Inc.,ORMP,ORMD-0801,human insulin,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,Sinopharm Group Co. Ltd.,"oral insulin, ORMD0801, ORMD 0801",N,III,58% (2% Below Avg.), - , - , - ,,,,,,,07/11/2006,12/31/2012,Non-NME,,,No,,,Israel,Asia,,11388,14308,2118,137,N/A,$104.65M ,,
Preclinical,,,,,,Peptide,Oral (PO),"Longevity Biotech, Inc.",,LBT-6030,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GIP Receptor (GIPR)/Glucose-Dependent Insulinotropic Polypeptide Receptor,GLP-1 Receptor",,"LBT6030, LBT 6030",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Pennsylvania,United States,North America,,36430,50732,7927,137,N/A, ,,
Suspended,,,,06/25/2007,,Peptide,Oral (PO),Diabetology Ltd.,,Capsulin OAD,insulin ,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,Capsulin OAD,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,United Kingdom,Europe,,7490,9200,1280,137,N/A, ,,
Suspended,,,,,,Peptide,Oral (PO),Zydus Cadila,CDH,ZYOG1,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,ZYOG1,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,India,Asia,,18648,24483,3380,137,N/A,$6.74B ,,
Suspended,,,,,,Peptide,Oral (PO),DiaMedica Therapeutics Inc.,DMAC,DM99,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",,,DM-99,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Minnesota,United States,North America,,16645,21503,2825,137,N/A,$184.21M ,,
Suspended,,,,,,Peptide,Oral (PO),"Emisphere Technologies, Inc.",EMIS,Oral GLP-1,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,Oral GLP-1,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/29/2007,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,3240,5557,140,137,N/A,$475.25M ,,
Suspended,,,,,12/07/2009,Peptide,Oral (PO),Novo Nordisk A/S,NVO,NN1952,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,Merrion Pharmaceuticals Plc.,NN1952,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,12/07/2009,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,16165,20769,292,137,N/A,$108.42B ,,
Suspended,,,06/11/2015,06/11/2015,04/28/2011,Peptide,Oral (PO),Novo Nordisk A/S,NVO,NN1953,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,Merrion Pharmaceuticals Plc.,"insulin 338, NNC0123-0000-0338, OI338GT, GIPET I",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,11/24/2008,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,18267,23903,292,137,N/A,$108.42B ,,
Suspended,,,,,03/11/2013,Peptide,Oral (PO),Novo Nordisk A/S,NVO,NN1956,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,Merrion Pharmaceuticals Plc.,"insulin 287, NNC0148-0000-0287, OI287GT",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/11/2013,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,22372,30329,292,137,N/A,$108.42B ,,
Suspended,,,,,06/25/2015,Peptide,Oral (PO),Novo Nordisk A/S,NVO,NN1957,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"Insulin 320, OI320GT, NN-1957",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,06/25/2015,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,26594,37111,292,137,N/A,$108.42B ,,
Suspended,,,,,,Peptide,Oral (PO),Novo Nordisk A/S,NVO,NN9926,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,"NNC 0113-0987, OG987GT",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/09/2011,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,19679,26019,292,137,N/A,$108.42B ,,
Suspended,,,,,,Peptide,Oral (PO),Novo Nordisk A/S,NVO,NN9928,semaglutide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,"OG217GT, NN 9928, NN-9928",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,05/30/2013,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,23075,31526,292,137,N/A,$108.42B ,,
Suspended,,,,,08/31/2018,Peptide,Oral (PO),Novo Nordisk A/S,NVO,OG2023SC,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,"OG 2023SC, OG-2023SC, NN9023, NN 9023, NN-9023",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/31/2018,,Non-NME,,,No,,,Denmark,Europe,,40291,56384,292,137,N/A,$108.42B ,,
Suspended,,,,,,Peptide,Oral (PO),Oramed Pharmaceuticals Inc.,ORMP,Insulin + GLP-1 Analog Combination (Oramed),exenatide/insulin,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GLP-1 Receptor,Insulin Receptor",,"ORMD-0801/ORMD-0901, ORMD-0801 + ORMD-0901, oral exenatide + insulin",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,Israel,Asia,,35380,49120,2118,137,N/A,$104.65M ,,
II,,,08/20/2014,08/20/2014,,Peptide,Oral (PO),Entera Bio Ltd.,ENTX,Oral PTH (1-34),teriparatide,Endocrine,Other,Hypoparathyroidism,Parathyroid Hormone Receptor (PTHR),,"EB 612, EB-612, EB612, PTH 1-34, PTH134, PTH1-34",Y,II,24% (Same As Avg.), - , - , - ,,,,,01/01/2022 - 12/31/2022,,,,Biologic,Orphan,,No,,Massachusetts,United States,North America,,36625,51015,7974,2557,N/A,$22.43M ,,
II,,,12/02/2020,12/02/2020,,Peptide,Oral (PO),Oramed Pharmaceuticals Inc.,ORMP,ORMD-0801,human insulin,Endocrine,Other,Non-Alcoholic Steatohepatitis (NASH),Insulin Receptor,Sinopharm Group Co. Ltd.,"oral insulin, ORMD0801, ORMD 0801",N,II,24% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,Israel,Asia,,11388,51051,2118,683,N/A,$104.65M ,,
Suspended,,,,,,Peptide,Oral (PO),"9 Meters Biopharma, Inc. ",NMTR,INN-202,larazotide acetate,Endocrine,Other,Non-Alcoholic Steatohepatitis (NASH),Zonulin and zonulin receptor,Alba Therapeutics Corporation,"SPD550, SPD-550, AT-1001 (Alba), EC AT-1001, INN202, INN 202",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,North Carolina,United States,North America,,10754,55118,7614,683,N/A,$288.83M ,,
Suspended,,,,,,Peptide,Oral (PO),"9 Meters Biopharma, Inc. ",NMTR,INN-217,larazotide acetate,Endocrine,Other,Non-Alcoholic Steatohepatitis (NASH),Zonulin and zonulin receptor,Alba Therapeutics Corporation,"INN 217, INN217",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,North Carolina,United States,North America,,40062,56014,7614,683,N/A,$288.83M ,,
IND,,,,,,Peptide,Oral (PO),Entera Bio Ltd.,ENTX,EB613,teriparatide,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Parathyroid Hormone Receptor (PTHR),,"EB 613, EB-613, PTH 1-34, PTH134, PTH1-34, EBP 05, EBP-05, EBP05, Oral PTH (1-34)",N,IND,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,505b2,,No,,Massachusetts,United States,North America,,36611,50988,7974,242,N/A,$22.43M ,,
Suspended,,,03/15/2011,03/15/2011,10/06/2008,Peptide,Oral (PO),"Unigene Laboratories, Inc.",,Oral PTH,,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Parathyroid Hormone Receptor (PTHR),,"GSK768974, oral parathyroid hormone, UGP131",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,10/06/2008,,Non-NME,,,No,,New Jersey,United States,North America,,17758,23159,2068,242,N/A, ,,
Suspended,,,,,,Peptide,Oral (PO),Nordic Bioscience A/S,,SAN 267,,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,GLP-2 Receptor,,SAN-267,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,22701,30882,2459,242,N/A, ,,
Suspended,08/14/2009,10/20/2009,,,,Peptide,Oral (PO),R-Pharm JSC,,Tbria,,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Calcitonin Receptor,"Unigene Laboratories, Inc.","Oral Recombinant Salmon Calcitonin, rsCT, Ostora",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,SPA,,No,,,Russia,Europe,,17832,23282,4264,242,N/A, ,,
Suspended,,,,09/29/2009,,Peptide,Oral (PO),Botanix Pharmaceuticals Limited,BOT:AU,Capsitonin,,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Calcitonin Receptor,,BN002,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,505b2,,No,,,Australia,Oceania,,21914,29621,6620,242,N/A,$90.87M ,,
Suspended,,,,02/01/2008,,Peptide,Oral (PO),Botanix Pharmaceuticals Limited,BOT:AU,CaPTHymone,,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Parathyroid Hormone Receptor (PTHR),,BN003,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Australia,Oceania,,21912,29619,6620,242,N/A,$90.87M ,,
Suspended,,,,,,Peptide,Oral (PO),Zydus Cadila,CDH,ZYPH0907,,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Parathyroid Hormone (PTH),,ZYPH0907,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,India,Asia,,19587,25851,3380,242,N/A,$6.74B ,,
Suspended,02/27/2007,02/27/2007,,02/26/2003,,Peptide,Oral (PO),"Emisphere Technologies, Inc.",EMIS,Oral Salmon Calcitonin,,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Calcitonin Receptor,"Nordic Bioscience A/S, Unigene Laboratories, Inc.",SMC021,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,SPA,,No,,New Jersey,United States,North America,,357,682,140,242,N/A,$475.25M ,,
Suspended,,,,,,Peptide,Oral (PO),Novartis AG,NVS,Oral PTH 1-34,,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Parathyroid Hormone Receptor (PTHR),"Emisphere Technologies, Inc.","Oral Recombinant Parathyroid Hormone, teriparatide",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,05/04/2007,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,5200,5687,289,242,N/A,$183.31B ,,
Preclinical,,,,,,Peptide,Oral (PO),Debiopharm S.A.,,Debio 025,alisporivir,Gastroenterology (Non Inflammatory Bowel Disease),General,Gastroenterologic Disorders,Cyclophilin,Solid Biosciences Inc.,"Debio-025, DEB025, Alisporivir",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,16385,56819,856,2944,N/A, ,,
Suspended,,,,,,Peptide,Oral (PO),"9 Meters Biopharma, Inc. ",NMTR,INN-202,larazotide acetate,Gastroenterology (Non Inflammatory Bowel Disease),Other,Liver Failure / Cirrhosis,Zonulin and zonulin receptor,Alba Therapeutics Corporation,"SPD550, SPD-550, AT-1001 (Alba), EC AT-1001, INN202, INN 202",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,North Carolina,United States,North America,,10754,55641,7614,2866,N/A,$288.83M ,,
II,,,,10/31/2013,,Peptide,Oral (PO),Bausch Health Companies Inc.,BHC,Dolcanatide,dolcanatide,Gastroenterology (Non Inflammatory Bowel Disease),Other,Opioid Induced Constipation (OIC),Guanylyl cyclase c Receptor,,"guanylyl cyclase c receptor agonist, SP-333",N,II,27% (3% Above Avg.), - , - , - ,,,,,,,10/02/2013,,New Molecular Entity (NME),,,No,,Quebec,Canada,North America,,19765,31496,470,551,N/A,$8.11B ,,
Suspended,,,10/16/2014,06/11/2013,,Peptide,Oral (PO),"Ironwood Pharmaceuticals, Inc.",IRWD,Linzess,linaclotide acetate,Gastroenterology (Non Inflammatory Bowel Disease),Other,Opioid Induced Constipation (OIC),Guanylyl cyclase c Receptor,"AbbVie Inc., Allergan plc, Astellas Pharma, Inc., AstraZeneca PLC","Constella (EU), linaclotide acetate, MD-1100, MD1100, MD 1100, ASP 0456, ASP0456, ASP-0456",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,"145MCG (CAPSULE;ORAL), 290MCG (CAPSULE;ORAL)",Massachusetts,United States,North America,50%,8466,30849,916,551,N/A,$1.89B ,,
Suspended,,04/06/2015,,,,Peptide,Oral (PO),Nutrinia Ltd.,,NTRA-9620,,Gastroenterology (Non Inflammatory Bowel Disease),Other,Short Bowel Syndrome (SBS),Insulin Receptor,,"NTRA 9620, NTRA9620",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,"Orphan,Rare Disease",,No,,,Israel,Asia,,30905,42737,6415,581,N/A, ,,
Preclinical,,,,,,Peptide,Oral (PO),"Oragenics, Inc.",OGEN,OG716,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Clostridium difficile-Associated Diarrhea/Infection (CDAD/CDI),Cell Membrane,"Precigen, Inc.","OG 716, OG-716, Lantibiotics",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Florida,United States,North America,,30930,42781,4110,487,N/A,$77.08M ,,
Suspended,,09/29/2011,04/08/2010,04/08/2010,02/13/2009,Peptide,Oral (PO),"Merck & Co., Inc.",MRK,Surotomycin,surotomycin,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Clostridium difficile-Associated Diarrhea/Infection (CDAD/CDI),Cell Membrane,,"CB-183,315, CB-315, MK-4261",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,12/23/2008,12/23/2008,New Molecular Entity (NME),"Fast Track,QIDP",,No,,New Jersey,United States,North America,,14458,18305,254,487,N/A,$212.57B ,,
Suspended,,,,01/25/2012,,Peptide,Oral (PO),Novartis AG,NVS,LFF571,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Clostridium difficile-Associated Diarrhea/Infection (CDAD/CDI),Protein synthesis,,LFF-571,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Switzerland,Europe,,19471,25677,289,487,N/A,$183.31B ,,
Suspended,,,,,,Peptide,Oral (PO),"Oragenics, Inc.",OGEN,OG253,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Clostridium difficile-Associated Diarrhea/Infection (CDAD/CDI),Cell Membrane,"Precigen, Inc.","MU 1140, MU 1140-S, MU1140",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Florida,United States,North America,,21868,29543,4110,487,N/A,$77.08M ,,
Preclinical,,,,,,Peptide,Oral (PO),"9 Meters Biopharma, Inc. ",NMTR,INN-202,larazotide acetate,Infectious Disease,Antiviral,COVID-19 Treatment,Zonulin and zonulin receptor,Alba Therapeutics Corporation,"SPD550, SPD-550, AT-1001 (Alba), EC AT-1001, INN202, INN 202",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,North Carolina,United States,North America,,10754,60590,7614,3651,N/A,$288.83M ,,
Suspended,,01/27/2011,,04/18/2007,,Peptide,Oral (PO),Debiopharm S.A.,,Debio 025,alisporivir,Infectious Disease,Antiviral,Hepatitis C (HCV) (Antiviral),Cyclophilin,Solid Biosciences Inc.,"Debio-025, DEB025, Alisporivir",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,10/31/2006,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,16385,21127,856,176,N/A, ,,
Program Hold,,,,,11/09/2009,Peptide,Oral (PO),"Concert Pharmaceuticals, Inc.",CNCE,CTP-518,,Infectious Disease,Antiviral,HIV / AIDS,HIV-1 protease (HIV PR),GlaxoSmithKline plc,CTP-518,Y,I,19% (Same As Avg.), - , - , - ,,,,,,,11/09/2009,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,16066,20603,2728,78,N/A,$391.08M ,,
Suspended,,,,,,Peptide,Oral (PO),Debiopharm S.A.,,Debio 025,alisporivir,Infectious Disease,Antiviral,HIV / AIDS,Cyclophilin,Solid Biosciences Inc.,"Debio-025, DEB025, Alisporivir",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,02/09/2006,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,16385,21126,856,78,N/A, ,,
Suspended,,,,,,Peptide,Oral (PO),"Concert Pharmaceuticals, Inc.",CNCE,CTP-298,,Infectious Disease,Antiviral,HIV / AIDS,HIV-1 protease (HIV PR),GlaxoSmithKline plc,CTP-298,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,06/20/2011,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,19620,25887,2728,78,N/A,$391.08M ,,
Preclinical,,,,,,Peptide,Oral (PO),"Ra Pharmaceuticals, Inc.",RARX,RA101295,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Sepsis and Septic Shock,Complement Pathway,,"C5 Inhibitor, RA 101295, RA-101295",Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,35371,49099,3732,76,N/A,$2.27B ,,
Suspended,,,,,,Peptide,Oral (PO),Debiopharm S.A.,,Debio 025,alisporivir,Metabolic,Single-Gene Disorders (Non-Inborn Errors of Metabolism),Duchenne Muscular Dystrophy (DMD),Cyclophilin,Solid Biosciences Inc.,"Debio-025, DEB025, Alisporivir",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Switzerland,Europe,,16385,37269,856,3620,N/A, ,,
Preclinical,,,,,,Peptide,Oral (PO),"Palatin Technologies, Inc.",PTN,PL-9610,,Metabolic,General,Metabolic - General,Melanocortin (MC) receptors,,"PL 9610, PL9610",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,41282,57956,504,3163,N/A,$162.89M ,,
Suspended,,,,,,Peptide,Oral (PO),"Unigene Laboratories, Inc.",,UGP281,,Metabolic,Obesity,Obesity,Amylin Receptor,,UGP281,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,18713,24584,2068,135,N/A, ,,
Suspended,,,,,,Peptide,Oral (PO),Zydus Cadila,CDH,ZYOG1,,Metabolic,Obesity,Obesity,GLP-1 Receptor,,ZYOG1,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,India,Asia,,18648,24484,3380,135,N/A,$6.74B ,,
Suspended,,,,,,Peptide,Oral (PO),"Emisphere Technologies, Inc.",EMIS,Oral PYY3-36,,Metabolic,Obesity,Obesity,Neuropeptide Y (NPY)/Peptide YY (PYY) Receptors,,Oral PYY3-36,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/29/2007,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,3241,5558,140,135,N/A,$475.25M ,,
Suspended,,,,,,Peptide,Oral (PO),PolyNovo Limited,PNV:AU,AOD9604,,Metabolic,Obesity,Obesity,Growth hormone receptor (GHR),,AOD9604,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Australia,Oceania,,2589,4397,8552,135,N/A,$1.82B ,,
Preclinical,,,,,,Peptide,Oral (PO),Neuren Pharmaceuticals Limited,NEU,NNZ-2591,,Metabolic,Single-Gene Disorders (Non-Inborn Errors of Metabolism),Phelan-McDermid Syndrome (PMS),Unknown,,"NNZ-2591, NNZ2591, NNZ 2591",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Australia,Oceania,,21227,56155,3978,3394,N/A,$129.95M ,,
III,12/16/2020,12/16/2020,,,,Peptide,Oral (PO),Novo Nordisk A/S,NVO,Rybelsus,semaglutide,Neurology,Neurodegenerative,Alzheimer's Disease (AD),GLP-1 Receptor,"Emisphere Technologies, Inc., Merck & Co., Inc.","OG217SC, NN9924, NN 9924, NN-9924, Oral Semaglutide",N,III,52% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,Denmark,Europe,,16255,62006,292,141,N/A,$108.42B ,,
Preclinical,,,,,,Peptide,Oral (PO),Neuren Pharmaceuticals Limited,NEU,NNZ-2591,,Neurology,General,Angelman Syndrome,Unknown,,"NNZ-2591, NNZ2591, NNZ 2591",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Australia,Oceania,,21227,56705,3978,3640,N/A,$129.95M ,,
Suspended,,,,,,Peptide,Oral (PO),Neuren Pharmaceuticals Limited,NEU,NNZ-2591,,Neurology,Neurodevelopmental Disorders,Fragile X Syndrome,Unknown,,"NNZ-2591, NNZ2591, NNZ 2591",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Australia,Oceania,,21227,31138,3978,2776,N/A,$129.95M ,,
Preclinical,,,,,,Peptide,Oral (PO),"Longevity Biotech, Inc.",,LBT-3627,,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Vasoactive Intestinal Peptide (VIP) Receptor,,"LBT3627, LBT 3627,",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Pennsylvania,United States,North America,,36432,50741,7927,153,N/A, ,,
Suspended,,,,,,Peptide,Oral (PO),Neuren Pharmaceuticals Limited,NEU,NNZ-2591,,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Unknown,,"NNZ-2591, NNZ2591, NNZ 2591",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Australia,Oceania,,21227,33482,3978,153,N/A,$129.95M ,,
I,,,,,01/21/2020,Peptide,Oral (PO),Stealth BioTherapeutics Inc.,MITO,SBT-272,,Neurology,General,Neurology - Other,Mitochondria,,"SBT272, SBT 272",N,I,10% (Same As Avg.), - , - , - ,,,,,,,01/21/2020,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,39862,55755,3274,192,N/A,$7.02M ,,
Preclinical,,,,,,Peptide,Oral (PO),"Creative Bio-Peptides, Inc.",,RAP-103,,Neurology,General,Neurology - Other,"Chemokine Receptor 2 (CCR2),Chemokine Receptor 5 (CCR5)",,"RAP103, RAP 103, R103, R-103, R 103",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Maryland,,,,43126,60789,25367,192,N/A, ,,
Preclinical,,,,,,Peptide,Oral (PO),Neuren Pharmaceuticals Limited,NEU,NNZ-2591,,Neurology,General,Neurology - Other,Unknown,,"NNZ-2591, NNZ2591, NNZ 2591",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Orphan,,No,,,Australia,Oceania,,21227,56708,3978,192,N/A,$129.95M ,,
Preclinical,,,,,,Peptide,Oral (PO),"Creative Bio-Peptides, Inc.",,RAP-103,,Neurology,Pain,Neuropathic Pain,"Chemokine Receptor 2 (CCR2),Chemokine Receptor 5 (CCR5)",,"RAP103, RAP 103, R103, R-103, R 103",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Maryland,,,,43126,60790,25367,362,N/A, ,,
Preclinical,,,,,,Peptide,Oral (PO),"Longevity Biotech, Inc.",,LBT-3627,,Neurology,Neurodegenerative,Parkinson's Disease (PD),Vasoactive Intestinal Peptide (VIP) Receptor,,"LBT3627, LBT 3627,",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Pennsylvania,United States,North America,,36432,50735,7927,194,N/A, ,,
Suspended,,,,,,Peptide,Oral (PO),Neuren Pharmaceuticals Limited,NEU,NNZ-2591,,Neurology,Neurodegenerative,Parkinson's Disease (PD),Unknown,,"NNZ-2591, NNZ2591, NNZ 2591",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Australia,Oceania,,21227,28577,3978,194,N/A,$129.95M ,,
Preclinical,,,,,,Peptide,Oral (PO),"Circle Pharma, Inc.",,Macrocycle Modulator of CXCR7 Program (Circle/Pfizer),,Not Specified,Other,Undisclosed,Chemokine (C-X-C motif) Receptor 7 (CXCR7),Pfizer Inc.,,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,37120,51767,8107,3338,N/A, ,,
Preclinical,,,,,,Peptide,Oral (PO),Ferring Pharmaceuticals,,Peptelligence Program (Ferring/Enteris),,Not Specified,Other,Undisclosed,Unknown,Enteris BioPharma Inc.,oral peptide program,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,33481,46235,582,3338,N/A, ,,
Suspended,,,,02/18/2013,,Peptide,Oral (PO),"Chiasma, Inc.",CHMA,Mycapssa,octreotide acetate,Oncology,Solid,Neuroendocrine Tumors (NET),Somatostatin Receptors,,"RG3806, Octreolin",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,Rare Disease,,No,,Massachusetts,United States,North America,,20701,29597,3884,347,N/A,$243.36M ,,
Suspended,,,09/03/2010,09/03/2010,,Peptide,Oral (PO),"Enzo Biochem, Inc.",ENZ,Optiquel,,Ophthalmology,Uveitis,Uveitis (Ophthalmology),,,B27PD,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/13/2007,,New Molecular Entity (NME),Rare Disease,,No,,New York,United States,North America,,13427,16935,650,307,N/A,$128.84M ,,
III,07/01/2010,07/01/2010,,09/02/2005,,Peptide,Oral (PO),Denovo Biopharma LLC,,Pomaglumetad Methionil,pomaglumetad methionil,Psychiatry,Psychosis/Schizophrenia,Schizophrenia,"Metabotropic Glutamate Receptor subtype 2  (mGluR2),Metabotropic Glutamate Receptor subtype 3 (mGluR3)",,"DB103, DB-103, DB 103, LY2140023, LY 2140023, LY-2140023, mGlu2/3 prodrug",Y,III,51% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,3171,5423,4836,170,N/A, ,,
Preclinical,,,,,,Peptide,Oral (PO),"9 Meters Biopharma, Inc. ",NMTR,INN-202,larazotide acetate,Respiratory,Other,"Acute Respiratory Failure, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS)",Zonulin and zonulin receptor,Alba Therapeutics Corporation,"SPD550, SPD-550, AT-1001 (Alba), EC AT-1001, INN202, INN 202",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,North Carolina,United States,North America,,10754,60586,7614,685,N/A,$288.83M ,,
Suspended,,,,09/29/2009,,Peptide,Oral (PO),Botanix Pharmaceuticals Limited,BOT:AU,Capsitonin,,Rheumatology (Non Autoimmune),Osteoarthritis,Osteoarthritis and Osteoarthritis Pain,Calcitonin Receptor,,BN002,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,505b2,,No,,,Australia,Oceania,,21914,29622,6620,249,N/A,$90.87M ,,
Suspended,05/24/2007,05/24/2007,,12/12/2005,,Peptide,Oral (PO),"Emisphere Technologies, Inc.",EMIS,Oral Salmon Calcitonin,,Rheumatology (Non Autoimmune),Osteoarthritis,Osteoarthritis and Osteoarthritis Pain,Calcitonin Receptor,"Nordic Bioscience A/S, Unigene Laboratories, Inc.",SMC021,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,New Jersey,United States,North America,,357,4197,140,249,N/A,$475.25M ,,
Approved in Europe,,,,,,Peptide,Oral (PO),"Merck & Co., Inc.",MRK,Renormax,spirapril hydrochloride,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Angiotensin Converting Enzyme (ACE),,"Quadropril, Renpress, Sandopril, Sch-33844, Setrilan, TI-211-950",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,New Jersey,United States,North America,,41628,58438,254,244,N/A,$212.57B ,,
Approved (Generic Competition),,,,,,Peptide,Oral (PO),AbbVie Inc.,ABBV,Gengraf,cyclosporine,Autoimmune/immunology,Transplant Rejection,Heart Transplant Rejection,Calcineurin phosphatase ,,"Gengraf Oral Solution, Gengraf Capsules, Cyclosporin",Y,Approved,100% (Same As Avg.), - , - , - ,05/12/2000,,,,,,,,Non-NME,,,No,"100MG (CAPSULE;ORAL), 25MG (CAPSULE;ORAL), 50MG (CAPSULE;ORAL)",Illinois,United States,North America,,3063,5237,5,608,N/A,$188.39B ,,
Approved (Generic Competition),,,,,,Peptide,Oral (PO),AbbVie Inc.,ABBV,Gengraf,cyclosporine,Autoimmune/immunology,Transplant Rejection,Kidney Transplant Rejection,Calcineurin phosphatase ,,"Gengraf Oral Solution, Gengraf Capsules, Cyclosporin",Y,Approved,100% (Same As Avg.), - , - , - ,05/12/2000,,,,,,,,Non-NME,,,No,"100MG (CAPSULE;ORAL), 25MG (CAPSULE;ORAL), 50MG (CAPSULE;ORAL)",Illinois,United States,North America,,3063,5238,5,380,N/A,$188.39B ,,
Approved (Generic Competition),,,,,,Peptide,Oral (PO),AbbVie Inc.,ABBV,Gengraf,cyclosporine,Autoimmune/immunology,Transplant Rejection,Liver Transplant Rejection,Calcineurin phosphatase ,,"Gengraf Oral Solution, Gengraf Capsules, Cyclosporin",Y,Approved,100% (Same As Avg.), - , - , - ,05/12/2000,,,,,,,,Non-NME,,,No,"100MG (CAPSULE;ORAL), 25MG (CAPSULE;ORAL), 50MG (CAPSULE;ORAL)",Illinois,United States,North America,,3063,5239,5,727,N/A,$188.39B ,,
Approved (Generic Competition),,,,,,Peptide,Oral (PO),AbbVie Inc.,ABBV,Gengraf,cyclosporine,Autoimmune/immunology,Psoriasis,Psoriasis,Calcineurin phosphatase ,,"Gengraf Oral Solution, Gengraf Capsules, Cyclosporin",Y,Approved,100% (Same As Avg.), - , - , - ,05/12/2000,,,,,,,,Non-NME,,,No,"100MG (CAPSULE;ORAL), 25MG (CAPSULE;ORAL), 50MG (CAPSULE;ORAL)",Illinois,United States,North America,,3063,5241,5,155,N/A,$188.39B ,,
Approved (Generic Competition),,,,,,Peptide,Oral (PO),AbbVie Inc.,ABBV,Gengraf,cyclosporine,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Calcineurin phosphatase ,,"Gengraf Oral Solution, Gengraf Capsules, Cyclosporin",N,Approved,100% (Same As Avg.), - , - , - ,05/12/2000,,,,,,,,Non-NME,,,No,"100MG (CAPSULE;ORAL), 25MG (CAPSULE;ORAL), 50MG (CAPSULE;ORAL)",Illinois,United States,North America,,3063,5240,5,154,N/A,$188.39B ,,
Approved,01/06/2012,01/06/2012,,,,Peptide,Oral (PO),"Chiasma, Inc.",CHMA,Mycapssa,octreotide acetate,Endocrine,Other,Acromegaly,Somatostatin Receptors,,"RG3806, Octreolin",Y,Approved,100% (Same As Avg.), - , - , - ,06/26/2020,,,,,06/15/2015,06/14/2010,,Non-NME,"505b2,Orphan,Rare Disease",,No,,Massachusetts,United States,North America,,20701,27676,3884,680,N/A,$243.36M ,,
Approved,10/07/2011,10/07/2011,02/19/2010,03/19/2010,,Peptide,Oral (PO),Bausch Health Companies Inc.,BHC,Trulance,plecanatide,Gastroenterology (Non Inflammatory Bowel Disease),Other,Chronic Idiopathic Constipation,Guanylyl cyclase c Receptor,"Cipher Pharmaceuticals Inc., Ironwood Pharmaceuticals, Inc., Luoxin Pharmaceutical Group Co., Ltd.","guanilib, SP-304, SP304, SP 304",Y,Approved,100% (Same As Avg.), - , - , - ,01/19/2017,,,,,01/29/2016,06/04/2008,,New Molecular Entity (NME),,,No,,Quebec,Canada,North America,,11867,14949,470,661,N/A,$8.11B ,,
Approved,,09/16/2008,,10/24/2006,,Peptide,Oral (PO),"Ironwood Pharmaceuticals, Inc.",IRWD,Linzess,linaclotide acetate,Gastroenterology (Non Inflammatory Bowel Disease),Other,Chronic Idiopathic Constipation,Guanylyl cyclase c Receptor,"AbbVie Inc., Allergan plc, Astellas Pharma, Inc., AstraZeneca PLC","Constella (EU), linaclotide acetate, MD-1100, MD1100, MD 1100, ASP 0456, ASP0456, ASP-0456",Y,Approved,100% (Same As Avg.), - , - , - ,08/30/2012,,08/21/2018,,,08/09/2011,05/23/2006,,New Molecular Entity (NME),,,No,"145MCG (CAPSULE;ORAL), 290MCG (CAPSULE;ORAL)",Massachusetts,United States,North America,50%,8466,10524,916,661,N/A,$1.89B ,,
Approved,02/16/2016,02/16/2016,12/02/2013,08/13/2013,12/21/2009,Peptide,Oral (PO),Novo Nordisk A/S,NVO,Rybelsus,semaglutide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,"Emisphere Technologies, Inc., Merck & Co., Inc.","OG217SC, NN9924, NN 9924, NN-9924, Oral Semaglutide",Y,Approved,100% (Same As Avg.), - , - , - ,09/20/2019,04/04/2020,06/29/2020,,,03/20/2019,01/13/2010,,Non-NME,,,No,,,Denmark,Europe,,16255,20926,292,137,N/A,$108.42B ,,
Approved,,,,,,Peptide,Oral (PO),AbbVie Inc.,ABBV,Norvir,ritonavir,Infectious Disease,Antiviral,HIV / AIDS,"Cytochrome p450,HIV-1 protease (HIV PR)",,"ritonavir, RTV",Y,Approved,100% (Same As Avg.), - , - , - ,03/01/1996,08/26/1996,,,,12/21/1995,,,New Molecular Entity (NME),,,No,"100MG (CAPSULE;ORAL), 100MG (TABLET;ORAL), 80MG/ML (SOLUTION;ORAL)",Illinois,United States,North America,100%,2136,3543,5,78,N/A,$188.39B ,,
Approved,,,,,,Peptide,Oral (PO),GlaxoSmithKline plc,GSK,Viracept,nelfinavir mesylate,Infectious Disease,Antiviral,HIV / AIDS,HIV-1 protease (HIV PR),"Japan Tobacco Inc., Pfizer Inc., Roche Holding AG","Nelfinavir mesylate, NFV",Y,Approved,100% (Same As Avg.), - , - , - ,03/14/1997,01/22/1998,03/06/1998,,,12/23/1996,,,New Molecular Entity (NME),,,No,"EQ 250MG BASE (TABLET;ORAL), EQ 625MG BASE (TABLET;ORAL)",,United Kingdom,Europe,,2135,3542,180,78,N/A,$94.89B ,,
Approved,,01/29/1996,,,,Peptide,Oral (PO),"Merck & Co., Inc.",MRK,Crixivan,indinavir,Infectious Disease,Antiviral,HIV / AIDS,HIV-1 protease (HIV PR),,"indinavir, IDV",Y,Approved,100% (Same As Avg.), - , - , - ,03/13/1996,10/04/1996,,,,01/31/1996,,,New Molecular Entity (NME),,,No,"EQ 200MG BASE (CAPSULE;ORAL), EQ 400MG BASE (CAPSULE;ORAL)",New Jersey,United States,North America,,2133,3539,254,78,N/A,$212.57B ,,
Approved,,,,,,Peptide,Oral (PO),Roche Holding AG,RHHBY,Invirase ,saquinavir,Infectious Disease,Antiviral,HIV / AIDS,HIV-1 protease (HIV PR),,"saquinavir, Fortovase, SQV ",Y,Approved,100% (Same As Avg.), - , - , - ,12/07/1995,04/10/1996,,,,,,,New Molecular Entity (NME),,,No,"EQ 200MG BASE (CAPSULE;ORAL), EQ 500MG BASE (TABLET;ORAL)",,Switzerland,Europe,,2138,3545,149,78,N/A,$227.10B ,,
Approved,12/18/2014,12/18/2014,12/27/2012,12/27/2012,,Peptide,Oral (PO),Bausch Health Companies Inc.,BHC,Trulance,plecanatide,Gastroenterology (Non Inflammatory Bowel Disease),Other,Irritable Bowel Syndrome (IBS),Guanylyl cyclase c Receptor,"Cipher Pharmaceuticals Inc., Ironwood Pharmaceuticals, Inc., Luoxin Pharmaceutical Group Co., Ltd.","guanilib, SP-304, SP304, SP 304",N,Approved,100% (Same As Avg.), - , - , - ,01/24/2018,,,,,03/27/2017,06/04/2008,,New Molecular Entity (NME),,,No,,Quebec,Canada,North America,,11867,14948,470,435,N/A,$8.11B ,,
Approved,01/14/2009,01/14/2009,,04/13/2007,,Peptide,Oral (PO),"Ironwood Pharmaceuticals, Inc.",IRWD,Linzess,linaclotide acetate,Gastroenterology (Non Inflammatory Bowel Disease),Other,Irritable Bowel Syndrome (IBS),Guanylyl cyclase c Receptor,"AbbVie Inc., Allergan plc, Astellas Pharma, Inc., AstraZeneca PLC","Constella (EU), linaclotide acetate, MD-1100, MD1100, MD 1100, ASP 0456, ASP0456, ASP-0456",Y,Approved,100% (Same As Avg.), - , - , - ,08/30/2012,11/26/2012,12/19/2016,,,08/09/2011,05/23/2006,,New Molecular Entity (NME),,,No,"145MCG (CAPSULE;ORAL), 290MCG (CAPSULE;ORAL)",Massachusetts,United States,North America,50%,8466,10522,916,435,N/A,$1.89B ,,
Suspended,,,03/08/2013,03/08/2013,10/10/2007,Peptide,"Oral (PO), Intravenous (IV)",Zealand Pharma A/S,ZEAL,Danegaptide,,Cardiovascular,Acute Coronary Syndrome,Acute Coronary Syndrome (ACS),Gap Junction,,"ZP1609, GAP-134",Y,Suspended,-10% (10% Below Avg.), - , - , - ,,,,,,,10/10/2007,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,11377,14295,748,179,N/A,$1.48B ,,
Suspended,,,,09/14/2010,,Peptide,"Oral (PO), Intravenous (IV), Subcutaneous (SQ)",Stealth BioTherapeutics Inc.,MITO,Elamipretide (Systemic Delivery),elamipretide,Cardiovascular,Acute Coronary Syndrome,Acute Coronary Syndrome (ACS),"Mitochondria,Reactive Oxygen Species/Free Radicals",Alexion Pharmaceuticals Inc.,"Bendavia, elamipretide (skeletal muscle/cardio-renal diseases), MTP131, MTP-131, MTP 131, SS31, SS-31, SS 31",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,05/17/2010,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,18253,23882,3274,179,N/A,$7.02M ,,
II/III,05/08/2017,05/08/2017,06/27/2016,06/27/2016,12/20/2012,Peptide,"Oral (PO), Intravenous (IV), Subcutaneous (SQ)",Stealth BioTherapeutics Inc.,MITO,Elamipretide (Systemic Delivery),elamipretide,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,"Mitochondria,Reactive Oxygen Species/Free Radicals",Alexion Pharmaceuticals Inc.,"Bendavia, elamipretide (skeletal muscle/cardio-renal diseases), MTP131, MTP-131, MTP 131, SS31, SS-31, SS 31",N,III,41% (6% Below Avg.), - , - , - ,,,,,Now - 03/31/2021,,12/20/2012,,New Molecular Entity (NME),"Fast Track,Orphan",,No,,Massachusetts,United States,North America,,18253,29379,3274,264,N/A,$7.02M ,,
Suspended,11/06/2017,11/06/2017,06/19/2015,02/17/2015,,Peptide,"Oral (PO), Intravenous (IV), Subcutaneous (SQ)",Stealth BioTherapeutics Inc.,MITO,Elamipretide (Systemic Delivery),elamipretide,Metabolic,Inborn Errors Of Metabolism,Mitochondrial Respiratory-Chain Diseases,"Mitochondria,Reactive Oxygen Species/Free Radicals",Alexion Pharmaceuticals Inc.,"Bendavia, elamipretide (skeletal muscle/cardio-renal diseases), MTP131, MTP-131, MTP 131, SS31, SS-31, SS 31",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Fast Track,Orphan,Rare Disease",,No,,Massachusetts,United States,North America,,18253,35418,3274,3142,N/A,$7.02M ,,
II,,,03/28/2019,03/28/2019,,Peptide,"Oral (PO), Intravenous (IV), Subcutaneous (SQ)",Stealth BioTherapeutics Inc.,MITO,Elamipretide (Systemic Delivery),elamipretide,Ophthalmology,Macular Degeneration,Dry Age-Related Macular Degeneration (Dry AMD)/Geographic Atrophy (Ophthalmology),"Mitochondria,Reactive Oxygen Species/Free Radicals",Alexion Pharmaceuticals Inc.,"Bendavia, elamipretide (skeletal muscle/cardio-renal diseases), MTP131, MTP-131, MTP 131, SS31, SS-31, SS 31",N,II,24% (Same As Avg.), - , - , - ,,,,,,,07/25/2016,,New Molecular Entity (NME),Fast Track,,No,,Massachusetts,United States,North America,,18253,43936,3274,2870,N/A,$7.02M ,,
Suspended,,,,10/14/2014,,Peptide,"Oral (PO), Intravenous (IV), Subcutaneous (SQ)",Stealth BioTherapeutics Inc.,MITO,Elamipretide (Systemic Delivery),elamipretide,Orthopedics,General,Orthopedic Disorder,"Mitochondria,Reactive Oxygen Species/Free Radicals",Alexion Pharmaceuticals Inc.,"Bendavia, elamipretide (skeletal muscle/cardio-renal diseases), MTP131, MTP-131, MTP 131, SS31, SS-31, SS 31",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,18253,35004,3274,164,N/A,$7.02M ,,
Suspended,,,11/19/2012,11/01/2012,,Peptide,"Oral (PO), Intravenous (IV), Subcutaneous (SQ)",Stealth BioTherapeutics Inc.,MITO,Elamipretide (Systemic Delivery),elamipretide,Renal,Chronic Renal Failure,Renal Disease / Renal Failure,"Mitochondria,Reactive Oxygen Species/Free Radicals",Alexion Pharmaceuticals Inc.,"Bendavia, elamipretide (skeletal muscle/cardio-renal diseases), MTP131, MTP-131, MTP 131, SS31, SS-31, SS 31",N,Approved,100% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,18253,28836,3274,149,N/A,$7.02M ,,
Suspended,,,,12/03/2009,,Peptide,"Oral (PO), Subcutaneous (SQ)","Constant Therapeutics, LLC",,TXA127,,Autoimmune/immunology,Transplant Rejection,Bone Marrow and Stem Cell Transplant - Graft vs. Host Disease (GVHD) Prophylaxis,"Angiotensin II Receptor Type 1 (AT1),Angiotensin II Receptor Type 2 (AT2)","Unigene Laboratories, Inc.","TXA127, Asp-Arg-Val-Tyr-Ile-His-Pro, TXA 127, TXA-127",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Orphan,,No,,Massachusetts,United States,North America,,16940,21970,2872,3643,N/A, ,,
Suspended,,,,,,Peptide,"Oral (PO), Subcutaneous (SQ)","Constant Therapeutics, LLC",,TXA127,,Cardiovascular,Peripheral Vascular Disease,Peripheral Arterial Disease (PAD),"Angiotensin II Receptor Type 1 (AT1),Angiotensin II Receptor Type 2 (AT2)","Unigene Laboratories, Inc.","TXA127, Asp-Arg-Val-Tyr-Ile-His-Pro, TXA 127, TXA-127",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Massachusetts,United States,North America,,16940,29791,2872,390,N/A, ,,
Suspended,,,,,,Peptide,"Oral (PO), Subcutaneous (SQ)","Constant Therapeutics, LLC",,TXA127,,Cardiovascular,Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH),"Angiotensin II Receptor Type 1 (AT1),Angiotensin II Receptor Type 2 (AT2)","Unigene Laboratories, Inc.","TXA127, Asp-Arg-Val-Tyr-Ile-His-Pro, TXA 127, TXA-127",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,"Orphan,Rare Disease",,No,,Massachusetts,United States,North America,,16940,24806,2872,245,N/A, ,,
Investigator Initiated,,,,,,Peptide,"Oral (PO), Subcutaneous (SQ)","Constant Therapeutics, LLC",,TXA127,,Infectious Disease,Antiviral,COVID-19 Treatment,"Angiotensin II Receptor Type 1 (AT1),Angiotensin II Receptor Type 2 (AT2)","Unigene Laboratories, Inc.","TXA127, Asp-Arg-Val-Tyr-Ile-His-Pro, TXA 127, TXA-127",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Massachusetts,United States,North America,,16940,60389,2872,3651,N/A, ,,
IND,,,,,,Peptide,"Oral (PO), Subcutaneous (SQ)","Constant Therapeutics, LLC",,TXA127,,Metabolic,Single-Gene Disorders (Non-Inborn Errors of Metabolism),Duchenne Muscular Dystrophy (DMD),"Angiotensin II Receptor Type 1 (AT1),Angiotensin II Receptor Type 2 (AT2)","Unigene Laboratories, Inc.","TXA127, Asp-Arg-Val-Tyr-Ile-His-Pro, TXA 127, TXA-127",N,IND,0% (Same As Avg.), - , - , - ,,,,,,,,10/06/2015,Biologic,"Fast Track,Orphan,Rare Disease",,No,,Massachusetts,United States,North America,,16940,56033,2872,3620,N/A, ,,
Preclinical,,,,,,Peptide,"Oral (PO), Subcutaneous (SQ)","Constant Therapeutics, LLC",,TXA127,,Metabolic,Single-Gene Disorders (Non-Inborn Errors of Metabolism),Epidermolysis Bullosa,"Angiotensin II Receptor Type 1 (AT1),Angiotensin II Receptor Type 2 (AT2)","Unigene Laboratories, Inc.","TXA127, Asp-Arg-Val-Tyr-Ile-His-Pro, TXA 127, TXA-127",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,"Orphan,Rare Disease",,No,,Massachusetts,United States,North America,,16940,49324,2872,657,N/A, ,,
Preclinical,,,,,,Peptide,"Oral (PO), Subcutaneous (SQ)","Constant Therapeutics, LLC",,TXA127,,Neurology,Stroke,Ischemic Stroke,"Angiotensin II Receptor Type 1 (AT1),Angiotensin II Receptor Type 2 (AT2)","Unigene Laboratories, Inc.","TXA127, Asp-Arg-Val-Tyr-Ile-His-Pro, TXA 127, TXA-127",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Massachusetts,United States,North America,,16940,29792,2872,145,N/A, ,,
Suspended,,,,,,Peptide,"Oral (PO), Subcutaneous (SQ)","Constant Therapeutics, LLC",,TXA127,,Oncology,Hematologic,Myelodysplastic Syndrome (MDS),"Angiotensin II Receptor Type 1 (AT1),Angiotensin II Receptor Type 2 (AT2)","Unigene Laboratories, Inc.","TXA127, Asp-Arg-Val-Tyr-Ile-His-Pro, TXA 127, TXA-127",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,06/28/2010,,Biologic,"Orphan,Rare Disease",,No,,Massachusetts,United States,North America,,16940,21969,2872,206,N/A, ,,
Suspended,,,,,,Peptide,"Oral (PO), Sublingual (SL)/Oral Transmucosal",Eastgate Biotech Corporation,ETBI,EGP-1214,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"EGP1214, EGP 1214, Intraoral Insulin (EastGate)",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,Ontario,Canada,North America,,34932,48391,7468,137,N/A,$6.77M ,,
Suspended,,,,,,Peptide,Rectal,Oramed Pharmaceuticals Inc.,ORMP,ORMD-0802,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"ORMD 0802, Insulin suppository",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,02/04/2009,,New Molecular Entity (NME),,,No,,,Israel,Asia,,13516,17060,2118,157,N/A,$104.65M ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),Mymetics Corporation,MYMX,Virosomes Allergy Program (Anergis/Mymetics),,Allergy,General,Allergic Rhinitis,Immune System,Anergis SA,"COP Virosome Allergy Program, COP Virosomes",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Switzerland,Europe,,37879,52860,3308,236,N/A,$19.74M ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Kineta, Inc.",,Dalazatide,dalazatide,Autoimmune/immunology,Vasculitis,Antineutrophil Cytoplasmic Antibodies (ANCA) Associated Vasculitis,Potassium channels,"Kv1.3 Therapeutics, Inc.","ShK186, ShK 186, ShK-186",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,05/10/2016,,New Molecular Entity (NME),,,No,,Washington,United States,North America,,20882,37785,3909,629,N/A, ,,
II,,,12/04/2019,10/10/2019,,Peptide,Subcutaneous (SQ),"Ra Pharmaceuticals, Inc.",RARX,Zilucoplan,zilucoplan,Autoimmune/immunology,General,Autoimmune Disorders,"C5a Receptor,Complement Pathway",,"RA-101495, RA 101495, RA101495, RA101495 SC, RA101495SC, RA101495-SC",N,II,20% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,26745,56788,3732,180,N/A,$2.27B ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),"Ra Pharmaceuticals, Inc.",RARX,Zilucoplan ER,zilucoplan,Autoimmune/immunology,Other,Complement Deficiencies / Abnormalities,"C5a Receptor,Complement Pathway",Camurus AB,"Zilucoplan XR, FluidCrystal Extended Release Zilucoplan, Long Acting Zilucoplan, zilucoplan extended release (XR)",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,40691,57049,3732,738,N/A,$2.27B ,,
Suspended,,,10/07/2003,10/07/2003,,Peptide,Subcutaneous (SQ),Takeda Pharmaceutical Co. Ltd.,TAK,Gattex,teduglutide,Autoimmune/immunology,Inflammatory Bowel Disease,Crohn's Disease,GLP-2 Receptor,,"Revestive (EU), ALX-0600, teduglutide, recombinant GLP-2, SHP633, SHP 633, SHP-633",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,5MG/VIAL (POWDER;SUBCUTANEOUS),,Japan,Asia,100%,698,1832,826,156,N/A,$46.05B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"SciClone Pharmaceuticals, Inc.",SCLN,Zadaxin,thymalfasin,Autoimmune/immunology,Other,DiGeorge Syndrome,Immune System,"Alfasigma S.p.A., Merck & Co., Inc.","thymosin alpha 1, thymalfasin",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,California,United States,North America,,883,60406,491,3659,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Pegilodecakin,pegilodecakin,Autoimmune/immunology,Inflammatory Bowel Disease,Inflammatory Bowel Disease (IBD),IL-10 (Interleukin-10) and IL-10 Receptor (IL-10R),,"AM-0010, AM 0010, PEGylated interleukin-10, LY3500518, LY 3500518, LY-3500518, AM0010",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Indiana,United States,North America,,23876,32911,136,464,N/A,$158.63B ,,
Suspended,,,,,02/03/2009,Peptide,Subcutaneous (SQ),Zealand Pharma A/S,ZEAL,Glepaglutide,glepaglutide,Autoimmune/immunology,Inflammatory Bowel Disease,Inflammatory Bowel Disease (IBD),GLP-2 Receptor,,"ZP1848, ZP 1848, ZP-1848",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,02/03/2009,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,14383,18204,748,464,N/A,$1.48B ,,
Suspended,,,,12/22/2008,,Peptide,Subcutaneous (SQ),"SciClone Pharmaceuticals, Inc.",SCLN,SCV-07,,Autoimmune/immunology,Other,Mucositis,STAT3 Transcription Factor,Verta Ltd.,gamma-D-glutamyl-L-tryptophan,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,884,17771,491,348,N/A, ,,
III,10/02/2019,10/02/2019,10/18/2017,10/11/2017,12/02/2015,Peptide,Subcutaneous (SQ),"Ra Pharmaceuticals, Inc.",RARX,Zilucoplan,zilucoplan,Autoimmune/immunology,Other,Myasthenia Gravis (MG),"C5a Receptor,Complement Pathway",,"RA-101495, RA 101495, RA101495, RA101495 SC, RA101495SC, RA101495-SC",N,III,66% (7% Above Avg.), - , - , - ,,,,,,,12/02/2015,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,Massachusetts,United States,North America,,26745,43720,3732,469,N/A,$2.27B ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),"Ra Pharmaceuticals, Inc.",RARX,RA101348,,Autoimmune/immunology,Paroxysmal Nocturnal Hemoglobinuria,Paroxysmal Nocturnal Hemoglobinuria (PNH),Complement Pathway,,RA101348,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Massachusetts,United States,North America,,26357,36771,3732,394,N/A,$2.27B ,,
Program Hold,,,04/26/2017,03/08/2017,12/02/2015,Peptide,Subcutaneous (SQ),"Ra Pharmaceuticals, Inc.",RARX,Zilucoplan,zilucoplan,Autoimmune/immunology,Paroxysmal Nocturnal Hemoglobinuria,Paroxysmal Nocturnal Hemoglobinuria (PNH),"C5a Receptor,Complement Pathway",,"RA-101495, RA 101495, RA101495, RA101495 SC, RA101495SC, RA101495-SC",N,II,22% (2% Above Avg.), - , - , - ,,,,,,,12/02/2015,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,Massachusetts,United States,North America,,26745,37348,3732,394,N/A,$2.27B ,,
Suspended,,,,,10/14/2014,Peptide,Subcutaneous (SQ),"Kineta, Inc.",,Dalazatide,dalazatide,Autoimmune/immunology,Psoriasis,Psoriasis,Potassium channels,"Kv1.3 Therapeutics, Inc.","ShK186, ShK 186, ShK-186",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,10/14/2014,,New Molecular Entity (NME),,,No,,Washington,United States,North America,,20882,34387,3909,155,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Kineta, Inc.",,Dalazatide,dalazatide,Autoimmune/immunology,Psoriasis,Psoriatic Arthritis (PA),Potassium channels,"Kv1.3 Therapeutics, Inc.","ShK186, ShK 186, ShK-186",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/21/2012,,New Molecular Entity (NME),,,No,,Washington,United States,North America,,20882,27965,3909,336,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Kineta, Inc.",,Dalazatide,dalazatide,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),Potassium channels,"Kv1.3 Therapeutics, Inc.","ShK186, ShK 186, ShK-186",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,05/10/2016,,New Molecular Entity (NME),,,No,,Washington,United States,North America,,20882,40680,3909,154,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Eton Pharmaceuticals, Inc.",ETON,CT-100,corticotropin,Autoimmune/immunology,Arthritis,Rheumatoid Arthritis (RA),"Corticotropin / Adrenocorticotropic Hormone (ACTH),Corticotropin Releasing Factor (CRF) / Corticotropin Releasing Hormone (CRH)",,"CT100, CT 100",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,05/09/2017,,Non-NME,,,No,,Illinois,United States,North America,,36388,50665,7916,154,N/A,$195.40M ,,
Suspended,,,12/01/2008,09/27/2010,,Peptide,Subcutaneous (SQ),Daval International Limited,,Aimspro,,Autoimmune/immunology,Other,Scleroderma,Unknown,,caprine hyperimmune serum against HIV lysate,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,"Orphan,Rare Disease",,No,,,United Kingdom,Europe,,18922,24898,3455,457,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),XTL Biopharmaceuticals Ltd.,XTLB,hCDR1,,Autoimmune/immunology,Arthritis,Sjogren's Syndrome,Immune System,"Ligand Pharmaceuticals, Inc., Yeda R&D Company","edratide, TV-4710, TV4710, TV 4710",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Israel,Asia,,601,45587,662,670,N/A,$16.97M ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),"Kineta, Inc.",,Dalazatide,dalazatide,Autoimmune/immunology,Other,Sporadic Inclusion Body Myositis (sIBM),Potassium channels,"Kv1.3 Therapeutics, Inc.","ShK186, ShK 186, ShK-186",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Washington,United States,North America,,20882,52910,3909,3379,N/A, ,,
II,,,10/01/2005,10/01/2005,,Peptide,Subcutaneous (SQ),XTL Biopharmaceuticals Ltd.,XTLB,hCDR1,,Autoimmune/immunology,Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus (SLE),Immune System,"Ligand Pharmaceuticals, Inc., Yeda R&D Company","edratide, TV-4710, TV4710, TV 4710",Y,II,20% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Israel,Asia,,601,1215,662,282,N/A,$16.97M ,,
III,03/02/2011,03/02/2011,07/05/2006,07/05/2006,,Peptide,Subcutaneous (SQ),"Avion Pharmaceuticals, LLC",,Lupuzor,rigerimod,Autoimmune/immunology,Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus (SLE),T lymphocytes,"ImmuPharma PLC, SymBio Pharmaceuticals Limited","P-140, P 140, P140, rigerimod, Forigerimod, CEP33457, CEP-33457, CEP 33457, IPP201101, IPP-201101, IPP 201101, SyB1001, SyB 1001, SyB-1001",Y,III,51% (8% Below Avg.), - , - , - ,,,,,,,05/10/2006,,New Molecular Entity (NME),"Fast Track,SPA",,No,,Georgia,United States,North America,,10863,13628,8117,282,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Kineta, Inc.",,Dalazatide,dalazatide,Autoimmune/immunology,Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus (SLE),Potassium channels,"Kv1.3 Therapeutics, Inc.","ShK186, ShK 186, ShK-186",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,05/10/2016,,New Molecular Entity (NME),,,No,,Washington,United States,North America,,20882,34020,3909,282,N/A, ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),Promore Pharma AB,PROMO,PXL-01,,Autoimmune/immunology,General,Wound Healing,Lactoferrin Receptor,"Cellastra Inc., PharmaResearch Products Ltd.","PXL01, PXL 01",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Sweden,Europe,,20613,54439,3854,1578,N/A,$13.68M ,,
II,,,,12/15/2020,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Tirzepatide,tirzepatide,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,"GIP Receptor (GIPR)/Glucose-Dependent Insulinotropic Polypeptide Receptor,GLP-1 Receptor",,"LY3298176, LY-3298176, LY 3298176",N,II,13% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Indiana,United States,North America,,29260,61997,136,264,N/A,$158.63B ,,
II,,,,09/22/2008,10/31/2007,Peptide,Subcutaneous (SQ),"Palatin Technologies, Inc.",PTN,PL-3994,,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,Natriuretic Peptide Receptors,,PL3994,Y,II,13% (Same As Avg.), - , - , - ,,,,,,,10/31/2007,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,8649,10752,504,264,N/A,$162.89M ,,
Investigator Initiated,,,10/16/2013,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Victoza,liraglutide recombinant,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,GLP-1 Receptor,Johnson & Johnson,"liraglutide, NN2211 (diabetes), NN9211 (adjunct), NN9223 (depot)",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,18MG/3ML (6MG/ML) (SOLUTION;SUBCUTANEOUS),,Denmark,Europe,95%,1712,37782,292,264,N/A,$108.42B ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),"Antlia Bioscience, Inc.",,LANA-CF,,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,Unknown,,LANA CF,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,43529,61378,25965,264,N/A, ,,
Suspended,,,,12/27/2002,,Peptide,Subcutaneous (SQ),Bristol Myers Squibb Company,BMY,AC2592,,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,GLP-1 Receptor,Restoragen Inc.,"rGLP-1, Glucagon-Like Peptide-1 (7-36) Amide, Betatropin",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,New York,United States,North America,90%,248,372,73,264,N/A,$140.92B ,,
Suspended,,,,09/30/2010,,Peptide,Subcutaneous (SQ),GlaxoSmithKline plc,GSK,Tanzeum,albiglutide,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,GLP-1 Receptor,,"Albugon, GSK716155, Syncria, Eperzan (EU)",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,United Kingdom,Europe,100%,128,23599,180,264,N/A,$94.89B ,,
Suspended,12/02/2013,12/02/2013,,,,Peptide,Subcutaneous (SQ),Takeda Pharmaceutical Co. Ltd.,TAK,Firazyr,icatibant,Cardiovascular,Other,Drug-induced Angioedema,Bradykinin B2 Receptor,Sanofi,"icatibant, SHP667, SHP 667, SHP-667, HOE 140, HOE140, HOE-140",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,02/17/2003,,New Molecular Entity (NME),,,No,EQ 30MG BASE/3ML (EQ 10MG BASE (INJECTABLE;SUBCUTANEOUS),,Japan,Asia,88%,2419,10440,826,3232,N/A,$46.05B ,,
I,,,,,11/01/2019,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,NN6434,,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9),,"NN 6434, NN-6434, NNC0385-0434, NNC0385 0434, NNC03850434, PCSK9i Program, NN6434",N,I,8% (Same As Avg.), - , - , - ,,,,,,,08/20/2019,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,41165,57785,292,506,N/A,$108.42B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Pegilodecakin,pegilodecakin,Cardiovascular,Other,Dyslipidemia / Hypercholesterolemia,IL-10 (Interleukin-10) and IL-10 Receptor (IL-10R),,"AM-0010, AM 0010, PEGylated interleukin-10, LY3500518, LY 3500518, LY-3500518, AM0010",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Indiana,United States,North America,,23876,32912,136,506,N/A,$158.63B ,,
Program Hold,,,05/20/2008,05/20/2008,,Peptide,Subcutaneous (SQ),"Palatin Technologies, Inc.",PTN,PL-3994,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Natriuretic Peptide Receptors,,PL3994,N,II,13% (Same As Avg.), - , - , - ,,,,,,,02/11/2008,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,8649,13258,504,244,N/A,$162.89M ,,
NDA,12/12/2016,12/12/2016,01/13/2014,01/13/2014,,Peptide,Subcutaneous (SQ),BioMarin Pharmaceutical Inc.,BMRN,Vosoritide,vosoritide,Endocrine,Short Stature,Achondroplasia,Natriuretic Peptide Receptors,"Chugai Pharmaceutical Co., Ltd.","BMN-111, BMN 111, BMN111",Y,NDA/BLA,99% (10% Above Avg.),08/20/2021 - 08/20/2021,06/01/2021 - 12/31/2021, - ,,,,08/20/2021,,08/20/2020,01/03/2012,11/29/2011,New Molecular Entity (NME),Orphan,,No,,California,United States,North America,,18967,24960,65,3084,N/A,$16.46B ,,
I,,,,,,Peptide,Subcutaneous (SQ),Enesi Pharma Limited,,Glide Octreotide,octreotide acetate,Endocrine,Other,Acromegaly,Somatostatin Receptors,,octreotide acetate,N,I,14% (Same As Avg.), - , - , - ,,,,,,,05/19/2016,,Non-NME,Rare Disease,,No,,,United Kingdom,Europe,,24425,33881,4510,680,N/A, ,,
III,07/18/2019,07/18/2019,,,,Peptide,Subcutaneous (SQ),Novartis AG,NVS,CAM2029,octreotide,Endocrine,Other,Acromegaly,Somatostatin Receptors,Camurus AB,"octreotide chloride Fluid, Crystal injection depot, CAM 2029, CAM-2029",Y,III,60% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,Rare Disease,,No,,,Switzerland,Europe,,18116,23674,289,680,N/A,$183.31B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Italfarmaco S.p.A.,,ITF-2984,,Endocrine,Other,Acromegaly,Somatostatin Receptors,,"ITF2984, ITF 2984",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,Rare Disease,,No,,,Italy,Europe,,40556,56835,2603,680,N/A, ,,
Suspended,,,,,05/21/2018,Peptide,Subcutaneous (SQ),Midatech Pharma PLC,MTPH,Q-Octreotide,octreotide acetate,Endocrine,Other,Acromegaly,Somatostatin Receptors,China Medical System Holdings Limited,"MTD201, MTD 201, MTD-201, Q Chip",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,05/21/2018,,Non-NME,Rare Disease,,No,,,United Kingdom,Europe,,29117,40450,3464,680,N/A,$23.58M ,,
I,,,,,03/20/2019,Peptide,Subcutaneous (SQ),Arecor Ltd.,,AT247,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"AT 247, AT-247, prandial insulin, Rapid-acting Insulin",N,I,16% (2% Above Avg.), - , - , - ,,,,,,,03/20/2019,,Non-NME,,,No,,,United Kingdom,Europe,,41540,58264,9897,157,N/A, ,,
I,,,,,02/25/2016,Peptide,Subcutaneous (SQ),Gan & Lee Pharmaceuticals,,Basalin,insulin glargine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,Biosimilar Insulin Glargine (Gan & Lee),N,I,15% (1% Above Avg.), - , - , - ,,,,,,,02/25/2016,,Biosimilar,,,No,,,China,Asia,,35223,48884,7536,157,N/A, ,,
I,,,,,06/05/2019,Peptide,Subcutaneous (SQ),"Lannett Company, Inc.",LCI,Biosimilar Insulin Glargine (Lannett/HEC),insulin glargine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,HEC Pharm ,"Biosimilar Insulin Glargine, Insulin Glargine (Lannett/HEC)",N,I,14% (Same As Avg.), - , - , - ,,,,,,,04/22/2016,,Biosimilar,,,No,,Pennsylvania,United States,North America,,40536,56792,8015,157,N/A,$288.98M ,,
I,,,,,10/01/2012,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Insulin icodec,insulin icodec,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"Insulin 287, NNC0148-0000-0287, ultra-long-acting basal insulin analog, LAI 287, LAI287, LAI-287, NN 1436, NN-1436, NN1436, Icodeg, weekly insulin",N,I,14% (Same As Avg.), - , - , - ,,,,,,,11/20/2012,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,21803,29448,292,157,N/A,$108.42B ,,
I,,,,,06/30/2019,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Insulin965,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"NNC0268-0965, NN 1965, NN-1965, NN1965, Insulin 965, Insulin-965, FSI 965, FSI965, FS-I965",N,I,14% (Same As Avg.), - , - , - ,,,,,,,06/30/2019,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,40772,57181,292,157,N/A,$108.42B ,,
I/II,,,,11/13/2013,,Peptide,Subcutaneous (SQ),Adocia,ADOC:FP,BioChaperone Combo,insulin glargine/lispro,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,Tonghua Dongbao Pharmaceutical Co Ltd,"BC Combo, Glargine and Lispro FDC",N,II,22% (2% Below Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,France,Europe,,24315,33681,4106,157,N/A,$73.14M ,,
I/II,,,,11/30/2019,06/01/2017,Peptide,Subcutaneous (SQ),Adocia,ADOC:FP,BioChaperone Glucagon,human glucagon,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,BioChaperone Glucagon,N,II,24% (Same As Avg.), - , - , - ,,,,,,,06/01/2017,,New Molecular Entity (NME),,,No,,,France,Europe,,29671,41148,4106,157,N/A,$73.14M ,,
I/II,,,,11/30/2019,08/24/2015,Peptide,Subcutaneous (SQ),Adocia,ADOC:FP,BioChaperone Lispro U200,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,Tonghua Dongbao Pharmaceutical Co Ltd,BioChaperone Lispro U200,Y,II,24% (Same As Avg.), - , - , - ,,,,,,,08/24/2015,,Non-NME,,,No,,,France,Europe,,25602,35659,4106,157,N/A,$73.14M ,,
II,,,07/07/2016,06/07/2016,,Peptide,Subcutaneous (SQ),Diasome Pharmaceuticals,,HDV-L,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"HDV Insulin Lispro, HDV-Insulin Lispro",N,II,17% (7% Below Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,Ohio,United States,North America,,40649,56988,2113,157,N/A, ,,
II,,,,01/06/2014,,Peptide,Subcutaneous (SQ),Adocia,ADOC:FP,BioChaperone Lispro U100,insulin lispro,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,Tonghua Dongbao Pharmaceutical Co Ltd,"BioChaperone Lispro U100, BC222 Insulin Lispro",Y,II,22% (2% Below Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,France,Europe,,23514,32304,4106,157,N/A,$73.14M ,,
II,,,07/06/2020,07/06/2020,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,LY3209590,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"LY 3209590, LY-3209590, Basal Insulin-Fc, weekly insulin",N,II,24% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Indiana,United States,North America,,31981,60641,136,157,N/A,$158.63B ,,
III,08/02/2017,08/02/2017,,,,Peptide,Subcutaneous (SQ),Sanofi,SNY,SAR341402,insulin aspart,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"SAR-341402, SAR 341402",Y,III,63% (3% Above Avg.), - , - , - ,,06/25/2020,,,,,02/08/2017,,Biosimilar,,,No,,,France,Europe,,33717,46570,51,157,N/A,$107.55B ,,
III,,11/01/2018,,,,Peptide,Subcutaneous (SQ),Viatris Inc.,VTRS,Biosimilar Insulin Aspart (Mylan/Biocon),insulin aspart,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,"Biocon, Ltd.","MYL-1601D, Kixelle (EU)",N,III,60% (Same As Avg.), - , - , - ,,,,,,,04/11/2018,,Biosimilar,,,No,,Pennsylvania,United States,North America,,37836,52783,266,157,N/A, ,,
Investigator Initiated,,,,,,Peptide,Subcutaneous (SQ),Zealand Pharma A/S,ZEAL,Dasiglucagon,dasiglucagon,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Glucagon Receptor,,"ZP-4207, ZP-GA-1, ZP 4207, ZP4207",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,25057,53592,748,157,N/A,$1.48B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Kineta, Inc.",,Dalazatide,dalazatide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Potassium channels,"Kv1.3 Therapeutics, Inc.","ShK186, ShK 186, ShK-186",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,05/10/2016,,New Molecular Entity (NME),,,No,,Washington,United States,North America,,20882,40684,3909,157,N/A, ,,
Suspended,,,,06/10/2008,,Peptide,Subcutaneous (SQ),Diasome Pharmaceuticals,,HDV-B,insulin,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,Injectable basal long acting insulin,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,Ohio,United States,North America,,18041,23562,2113,157,N/A, ,,
Suspended,,,07/07/2016,05/20/2008,,Peptide,Subcutaneous (SQ),Diasome Pharmaceuticals,,HDV-I,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"Injectable Short-acting Insulin, Hepatic-directed vesicles insulin",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,Ohio,United States,North America,,11368,14281,2113,157,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Adocia,ADOC:FP,Biochaperone Lispro Exenatide,insulin lispro recombinant and exenatide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,France,Europe,,33059,45633,4106,157,N/A,$73.14M ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Adocia,ADOC:FP,BioChaperone Lispro U300,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,Tonghua Dongbao Pharmaceutical Co Ltd,BioChaperone Lispro U300,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,France,Europe,,24219,33520,4106,157,N/A,$73.14M ,,
Suspended,,,,06/24/2011,,Peptide,Subcutaneous (SQ),Adocia,ADOC:FP,HinsBet,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"BioChaperone Human Insulin, HinsBet U100, HinsBet U500, Human Insulin is Better",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/15/2011,,Non-NME,,,No,,,France,Europe,,21861,29532,4106,157,N/A,$73.14M ,,
Suspended,,,,01/13/2004,,Peptide,Subcutaneous (SQ),AstraZeneca PLC,AZN,Byetta,exenatide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",GLP-1 Receptor,"3SBio Inc., Bristol Myers Squibb Company, Eli Lilly and Company","Exenatide, Synthetic exendin-4, AC2993, LY2148568",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,"300MCG/1.2ML (250MCG/ML) (INJECTABLE;SUBCUTANEOUS), 600MCG/2.4ML (250MCG/ML) (INJECTABLE;SUBCUTANEOUS)",,United Kingdom,Europe,70%,201,3244,45,157,N/A,$133.38B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Boston Therapeutics, Inc.",BTHE,HIP2B,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Human proIslet Peptide (HIP) Receptor,,HIP2B,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/11/2012,,Biologic,,,No,,New Hampshire,United States,North America,,20644,27575,3656,157,N/A,$2.48M ,,
Suspended,,,10/31/2014,10/31/2014,,Peptide,Subcutaneous (SQ),GlaxoSmithKline plc,GSK,Tanzeum,albiglutide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",GLP-1 Receptor,,"Albugon, GSK716155, Syncria, Eperzan (EU)",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,United Kingdom,Europe,100%,128,40336,180,157,N/A,$94.89B ,,
Suspended,,,,11/03/2008,,Peptide,Subcutaneous (SQ),"Halozyme Therapeutics, Inc.",HALO,Analog Insulin-PH20,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"Aspart-PH20, Ultrafast Insulin, recombinant human insulin with rHuPH20",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,06/09/2008,,Non-NME,,,No,,California,United States,North America,,14196,17975,789,157,N/A,$6.06B ,,
Suspended,10/05/2005,10/05/2005,,11/26/2001,,Peptide,Subcutaneous (SQ),Horizon Therapeutics plc,HZNP,DiaPep277,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Toll-Like Receptor 2 (TLR2),Evotec SE,DiaPep-277,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Orphan,,No,,,Ireland,Europe,,14497,18355,2878,157,N/A,$17.57B ,,
Suspended,,10/17/2011,01/21/2010,01/21/2010,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,LY2605541,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"Basal insulin analog, basal insulin peglispro",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Indiana,United States,North America,100%,16676,21552,136,157,N/A,$158.63B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,NN1438,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"Insulin 338, LAI338, NNC0123-0338",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/27/2014,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,24852,34532,292,157,N/A,$108.42B ,,
Suspended,05/31/2012,05/31/2012,,06/04/2011,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Victoza,liraglutide recombinant,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",GLP-1 Receptor,Johnson & Johnson,"liraglutide, NN2211 (diabetes), NN9211 (adjunct), NN9223 (depot)",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,18MG/3ML (6MG/ML) (SOLUTION;SUBCUTANEOUS),,Denmark,Europe,95%,1712,24135,292,157,N/A,$108.42B ,,
Suspended,,,,,07/25/2017,Peptide,Subcutaneous (SQ),"Rezolute, Inc.",RZLT,AB101,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,AB-101,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/25/2017,06/05/2017,New Molecular Entity (NME),,,No,,California,United States,North America,,22661,30821,4346,157,N/A,$108.41M ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Sanofi,SNY,SAR161271,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,SAR161271,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,04/29/2010,,New Molecular Entity (NME),,,No,,,France,Europe,,16808,21763,51,157,N/A,$107.55B ,,
Suspended,,,,,02/13/2015,Peptide,Subcutaneous (SQ),Sanofi,SNY,SAR440067,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,"Hanmi Pharmaceutical Co., Ltd.","LAPS-insulin 115, HM12470, HM 12470, HM-12470, SAR 440067, SAR-440067",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,02/13/2015,,New Molecular Entity (NME),,,No,,,France,Europe,,25245,35116,51,157,N/A,$107.55B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Sanofi,SNY,TransCon Insulin,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,Ascendis Pharma A/S,"ACP-002, TransCon Hydrogel Insulin",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,France,Europe,,31764,43882,51,157,N/A,$107.55B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Xenetic Biosciences, Inc.",XBIO,SuliXen,insulin,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"polysialic insulin, SYN-20090510RU",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,01/28/2008,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,18033,23552,3211,157,N/A,$20.11M ,,
Suspended,,,04/24/2014,04/24/2014,,Peptide,Subcutaneous (SQ),"Xeris Pharmaceuticals, Inc.",XERS,Gvoke RTU Micro,glucagon,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Glucagon Receptor,Clinigen Group plc,"Glucagon drug/device combination, G-Pen, G-Pump, GlucaPen, CSI-Glucagon, Glucagon Rescue Pen, Gvoke HypoPen, XeriSol Glucagon, Gvoke",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,Illinois,United States,North America,,19444,47329,3561,157,N/A,$284.06M ,,
Withdrawn from Market,02/28/2014,02/28/2014,,,,Peptide,Subcutaneous (SQ),"Samsung Bioepis Co., Ltd.",207940.KS,Lusduna Nexvue,insulin glargine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"MK-1293, MK 1293, MK1293, Lusduna (EU), Biosimilar Insulin Glargine (Merck), SB9, SB 9, SB-9, Lantus biosimilar",N,Approved,100% (Same As Avg.), - , - , - ,07/20/2017,01/04/2017,,,,08/05/2016,01/24/2011,,Biosimilar,505b2,,No,,,Korea (South),Asia,,23734,32687,4607,157,N/A, ,,
I,,,,,12/19/2018,Peptide,Subcutaneous (SQ),Carmot Therapeutics Inc.,,CT-868,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GIP Receptor (GIPR)/Glucose-Dependent Insulinotropic Polypeptide Receptor,GLP-1 Receptor",,"GLP-1R/GIPR Dual Agonists, CT868, CT 868",N,I,14% (Same As Avg.), - , - , - ,,,,,,,12/19/2018,,New Molecular Entity (NME),,,No,,California,United States,North America,,36089,50181,7821,137,N/A, ,,
I,,,,,07/10/2015,Peptide,Subcutaneous (SQ),Adocia,ADOC:FP,BioChaperone Combo,insulin glargine/lispro,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,Tonghua Dongbao Pharmaceutical Co Ltd,"BC Combo, Glargine and Lispro FDC",N,I,14% (Same As Avg.), - , - , - ,,,,,,,07/10/2015,,Non-NME,,,No,,,France,Europe,,24315,35658,4106,137,N/A,$73.14M ,,
I,,,,,,Peptide,Subcutaneous (SQ),Adocia,ADOC:FP,BioChaperone Lispro U100,insulin lispro,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,Tonghua Dongbao Pharmaceutical Co Ltd,"BioChaperone Lispro U100, BC222 Insulin Lispro",N,I,12% (2% Below Avg.), - , - , - ,,,,,,,09/30/2015,,Non-NME,,,No,,,France,Europe,,23514,37455,4106,137,N/A,$73.14M ,,
I,,,,,12/12/2016,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,LY3305677,oxyntomodulin,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GLP-1 Receptor,Glucagon Receptor","Innovent Biologics, Inc.","LY 3305677, LY-3305677, Oxyntomodulin (Eli Lilly), OXM3, IBI362, IBI 362, IBI-362",Y,I,14% (Same As Avg.), - , - , - ,,,,,,,12/12/2016,,New Molecular Entity (NME),,,No,,Indiana,United States,North America,,32894,45406,136,137,N/A,$158.63B ,,
I,,,,,03/13/2019,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,LY3437943,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GIP Receptor (GIPR)/Glucose-Dependent Insulinotropic Polypeptide Receptor,GLP-1 Receptor,Glucagon Receptor",,"LY-3437943, LY 3437943",N,I,14% (Same As Avg.), - , - , - ,,,,,,,03/13/2019,,Unknown,,,No,,Indiana,United States,North America,,41090,57679,136,137,N/A,$158.63B ,,
I,,,,,01/17/2019,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Icosema,semaglutide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GLP-1 Receptor,Insulin Receptor",,"NN-1535, NN 1535, NN1535, LAIsema, NNC0148-0287sema",N,I,14% (Same As Avg.), - , - , - ,,,,,,,01/17/2019,,Non-NME,,,No,,,Denmark,Europe,,40406,56570,292,137,N/A,$108.42B ,,
I,,,,,03/04/2020,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Insulin 147,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","Insulin Receptor,Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)",,"NNC0472-0147, NNC0472 0147, NN1147, NN 1147, NN-1147",N,I,14% (Same As Avg.), - , - , - ,,,,,,,03/04/2020,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,42401,59658,292,137,N/A,$108.42B ,,
I,,,,,02/26/2020,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,NN9389,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,"NN-9389, NN 9389, NNC0480-0389, NNC0480 0389",N,I,14% (Same As Avg.), - , - , - ,,,,,,,02/26/2020,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,42402,59659,292,137,N/A,$108.42B ,,
II,,,04/30/2020,04/30/2020,08/22/2017,Peptide,Subcutaneous (SQ),Boehringer Ingelheim GmbH,,BI 456906,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GLP-1 Receptor,Glucagon Receptor",Zealand Pharma A/S,"GLP-1/glucagon dual-acting agonist, BI456906, BI-456906",N,II,24% (Same As Avg.), - , - , - ,,,,,,,08/22/2017,,New Molecular Entity (NME),,,No,,,Germany,Europe,,35855,49832,70,137,N/A, ,,
II,,,07/12/2018,07/12/2018,,Peptide,Subcutaneous (SQ),"Hanmi Pharmaceutical Co., Ltd.",128940,Efinopegdutide,efinopegdutide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GLP-1 Receptor,Glucagon Receptor","Merck & Co., Inc.","HM-12525A, HM 12525A, LAPS-GLP-1/Glucagon dual agonist, LAPS-GLP-1/GCG, oxyntomodulin based therapy, JNJ64565111, JNJ 64565111, JNJ5111, JNJ 5111, JNJ-5111, JNJ-64565111, HM12525A",N,II,14% (10% Below Avg.), - , - , - ,,,,,,,03/31/2014,,New Molecular Entity (NME),,,No,,,Korea (South),Asia,,22699,30880,3379,137,N/A,$4.34B ,,
II,,,04/24/2019,11/15/2018,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,LY3209590,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"LY 3209590, LY-3209590, Basal Insulin-Fc, weekly insulin",N,II,24% (Same As Avg.), - , - , - ,,,,,,,10/21/2016,,New Molecular Entity (NME),,,No,,Indiana,United States,North America,,31981,44178,136,137,N/A,$158.63B ,,
II,,,05/15/2014,05/15/2014,12/12/2011,Peptide,Subcutaneous (SQ),Opko Health,OPK,OPK-88003,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GLP-1 Receptor,Glucagon Receptor",Eli Lilly and Company,"oxyntomodulin analogue, OPK88003, OPK 88003, LY2944876, LY 2944876, LY-2944876, TT401, TT-401, TT 401, pegapamodutide",Y,II,23% (1% Below Avg.), - , - , - ,,,,,,,12/12/2011,,New Molecular Entity (NME),,,No,,Florida,United States,North America,,19178,25260,1327,137,N/A,$3.00B ,,
III,,10/20/2017,,,,Peptide,Subcutaneous (SQ),Gan & Lee Pharmaceuticals,,Basalin,insulin glargine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,Biosimilar Insulin Glargine (Gan & Lee),N,III,60% (Same As Avg.), - , - , - ,,,,,,,,,Biosimilar,,,No,,,China,Asia,,35223,51420,7536,137,N/A, ,,
III,04/08/2019,12/11/2018,06/04/2017,06/04/2017,05/20/2016,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Tirzepatide,tirzepatide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GIP Receptor (GIPR)/Glucose-Dependent Insulinotropic Polypeptide Receptor,GLP-1 Receptor",,"LY3298176, LY-3298176, LY 3298176",Y,III,66% (6% Above Avg.), - , - , - ,,,,,10/01/2021 - 12/31/2021,,04/29/2016,,New Molecular Entity (NME),,,No,,Indiana,United States,North America,,29260,40619,136,137,N/A,$158.63B ,,
III,12/01/2020,12/01/2020,11/29/2018,11/29/2018,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Insulin icodec,insulin icodec,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"Insulin 287, NNC0148-0000-0287, ultra-long-acting basal insulin analog, LAI 287, LAI287, LAI-287, NN 1436, NN-1436, NN1436, Icodeg, weekly insulin",N,III,64% (4% Above Avg.), - , - , - ,,,,,,,01/31/2013,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,21803,29453,292,137,N/A,$108.42B ,,
III,08/02/2017,08/02/2017,,,,Peptide,Subcutaneous (SQ),Sanofi,SNY,SAR341402,insulin aspart,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"SAR-341402, SAR 341402",N,III,63% (3% Above Avg.), - , - , - ,,06/25/2020,,,,,,,Biosimilar,,,No,,,France,Europe,,33717,52015,51,137,N/A,$107.55B ,,
NDA,03/21/2013,03/21/2013,09/17/2009,09/17/2009,,Peptide,Subcutaneous (SQ),"Intarcia Therapeutics, Inc.",ITCA,ITCA 650,exenatide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,"IQVIA Holdings Inc., Johnson & Johnson, Les Laboratoires Servier","ITCA-650, ITCA650, DUROS continuous delivery of exenatide",Y,NDA/BLA,79% (10% Below Avg.), - , - , - ,,,,,,11/21/2016,04/24/2009,,Non-NME,,,No,,Massachusetts,United States,North America,100%,15615,19892,1376,137,N/A, ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),"Delpor, Inc.",,DLP-414,exenatide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,"DLP414, DLP 414, 3-12 month exenatide",Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,California,United States,North America,,35304,48994,3886,137,N/A, ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),Enesi Pharma Limited,,Glide Exenatide,exenatide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,Exenatide SDI,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,United Kingdom,Europe,,27257,38123,4510,137,N/A, ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),"Rezolute, Inc.",RZLT,AB101,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,AB-101,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,22661,30820,4346,137,N/A,$108.41M ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),Sun Pharma Advanced Research Company Ltd.,SPARC,SDE-124,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,"SDE124, SDE 124",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,India,Asia,,38986,54508,6343,137,N/A, ,,
Suspended,,,,05/08/2003,,Peptide,Subcutaneous (SQ),"ConjuChem, LLC",,DAC:GLP-1,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,CJC-1131,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,2215,3716,446,137,N/A, ,,
Suspended,,,,11/30/2010,,Peptide,Subcutaneous (SQ),"ImmunoForge, Co. Ltd.",,Glymera,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,"PhaseBio Pharmaceuticals, Inc.","PB1023, PB 1023, PB-1023",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Korea (South),Asia,,19578,25841,9146,137,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Naia Pharmaceuticals, Inc.",,NM-002,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,"Amunix Pharmaceuticals, Inc.","NB-1001, NB 1001, NB1001, NM002, NM 002",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,01/05/2015,,New Molecular Entity (NME),,,No,,California,United States,North America,,26863,37547,5531,137,N/A, ,,
Suspended,12/14/2017,12/14/2017,,10/04/2011,,Peptide,Subcutaneous (SQ),"Hanmi Pharmaceutical Co., Ltd.",128940,Efpeglenatide,efpeglenatide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,"HM11260C, HM 11260C, HM-11260C, LAPS-Exendin, LAPS-Exd4, langlenatide, SAR 439977, SAR-439977, SAR439977",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Korea (South),Asia,,18638,24472,3379,137,N/A,$4.34B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Adocia,ADOC:FP,BioChaperone Glargine Dulaglutide,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GLP-1 Receptor,Insulin Receptor",,BioChaperone Glargine Dulaglutide,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,France,Europe,,31169,43107,4106,137,N/A,$73.14M ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Adocia,ADOC:FP,BioChaperone Glargine Liraglutide,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GLP-1 Receptor,Insulin Receptor",,"BioChaperone Glargine Liraglutide,",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,France,Europe,,31171,43109,4106,137,N/A,$73.14M ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Adocia,ADOC:FP,BioChaperone Glucagon,human glucagon,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,BioChaperone Glucagon,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,France,Europe,,29671,41149,4106,137,N/A,$73.14M ,,
Suspended,,,,08/11/2014,11/07/2013,Peptide,Subcutaneous (SQ),"Albireo Pharma, Inc.",ALBO,BIOD-531,insulin recombinant human,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"U-400 concentrated insulin recombinant human, BIOD-530",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,11/07/2013,,Biologic,,,No,,Massachusetts,United States,North America,,22498,30550,2944,137,N/A,$717.68M ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Avadel Pharmaceuticals plc,AVDL,FT-105,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,long-acting basal insulin,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,10/18/2007,,Non-NME,,,No,,,Ireland,Europe,,8671,10783,831,137,N/A,$275.40M ,,
Suspended,,,,,08/05/2015,Peptide,Subcutaneous (SQ),Avadel Pharmaceuticals plc,AVDL,FT228,exenatide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,"Long-acting GLP-1 analog, Medusa Exenatide, FT-228, GLP-1 XL",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/05/2015,,Non-NME,,,No,,,Ireland,Europe,,22245,30113,831,137,N/A,$275.40M ,,
Suspended,,,08/02/2017,03/30/2015,03/30/2015,Peptide,Subcutaneous (SQ),AstraZeneca PLC,AZN,Cotadutide,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GLP-1 Receptor,Glucagon Receptor",,"MEDI-0382, MEDI0382, MEDI 0382",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,26110,36392,45,137,N/A,$133.38B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Boston Scientific Corporation,BSX,CM-3,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,"CM3.1-AC100, CM3",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,12/22/2008,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,18335,24002,72,137,N/A,$52.35B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Boston Therapeutics, Inc.",BTHE,HIP2B,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Human proIslet Peptide (HIP) Receptor,,HIP2B,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/11/2012,,Biologic,,,No,,New Hampshire,United States,North America,,20644,27576,3656,137,N/A,$2.48M ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Zydus Cadila,CDH,ZYD1,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,"ZYD 1, ZYD-1",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,04/07/2011,10/27/2009,New Molecular Entity (NME),,,No,,,India,Asia,,18658,24496,3380,137,N/A,$6.74B ,,
Suspended,,,07/14/2009,07/14/2009,,Peptide,Subcutaneous (SQ),"Halozyme Therapeutics, Inc.",HALO,Analog Insulin-PH20,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"Aspart-PH20, Ultrafast Insulin, recombinant human insulin with rHuPH20",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,06/09/2008,,Non-NME,,,No,,California,United States,North America,,14196,18237,789,137,N/A,$6.06B ,,
Suspended,,06/09/2008,,06/10/2006,,Peptide,Subcutaneous (SQ),Ipsen SA,IPSEY,Taspoglutide,taspoglutide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,"Chugai Pharmaceutical Co., Ltd., Teijin Pharma Limited.","R1583, RG1583, BIM 51077, ITM-077, RO5073031",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,France,Europe,90%,2554,4339,220,137,N/A,$4.57B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,DACRA-089,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","Amylin Receptor,Calcitonin Receptor",Nordic Bioscience A/S,"KBP089, KBP 089, KBP-089",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Indiana,United States,North America,,35202,56521,136,137,N/A,$158.63B ,,
Suspended,,,,12/08/2008,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,LY2428757,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,GLP1-PEG,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,Indiana,United States,North America,,14213,17994,136,137,N/A,$158.63B ,,
Suspended,,10/26/2011,01/15/2010,01/15/2010,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,LY2605541,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"Basal insulin analog, basal insulin peglispro",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Indiana,United States,North America,100%,16676,21553,136,137,N/A,$158.63B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Millendo Therapeutics, Inc.",MLND,Livoletide,livoletide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Ghrelin Receptor,,"unacylated ghrelin analog, AZP-531, AZP 531, AZP531",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/15/2013,,New Molecular Entity (NME),,,No,,Michigan,United States,North America,,20934,28064,4712,137,N/A,$30.78M ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,PYY 1562,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Neuropeptide Y (NPY)/Peptide YY (PYY) Receptors,,"NN 9748, NN-9748, NN9748, PYY1562, PYY-1562, NNC0165-1562, NNC0165 1562, NNC01651562, NN9747, NN 9747, NN-9747",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,04/29/2016,,Biologic,,,No,,,Denmark,Europe,,29570,40983,292,137,N/A,$108.42B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Opko Health,OPK,MOD-6030,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GLP-1 Receptor,Glucagon Receptor",,"PEGylated oxyntomodulin, GLP-1/Glucagon agonist",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Florida,United States,North America,,19932,26438,1327,137,N/A,$3.00B ,,
Suspended,,,,,03/16/2016,Peptide,Subcutaneous (SQ),Opko Health,OPK,MOD-6031,oxyntomodulin,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GLP-1 Receptor,Glucagon Receptor",,"MOD 6031, MOD6031, long-acting oxyntomodulin, OXY-RPEG",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/16/2016,,New Molecular Entity (NME),,,No,,Florida,United States,North America,,26161,36474,1327,137,N/A,$3.00B ,,
Suspended,,,10/20/2015,10/20/2015,06/04/2013,Peptide,Subcutaneous (SQ),"PhaseBio Pharmaceuticals, Inc.",PHAS,PE0139,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,basal insulin elastin like polypeptide (ELP)-fusion,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,06/04/2013,,New Molecular Entity (NME),,,No,,Pennsylvania,United States,North America,,22475,30502,3581,137,N/A,$118.93M ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Roche Holding AG,RHHBY,RO5095932,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Neuropeptide Y (NPY)/Peptide YY (PYY) Receptors,,RO5095932,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/18/2009,,Non-NME,,,No,,,Switzerland,Europe,,16126,20699,149,137,N/A,$227.10B ,,
Suspended,,,,,06/13/2012,Peptide,Subcutaneous (SQ),"Rhythm Pharmaceuticals, Inc.",RYTM,Imcivree,setmelanotide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","Insulin Receptor,Melanocortin (MC) receptors","Camurus AB, Ipsen SA","BIM-22493, BIM 22493, BIM22493, RM-493, RM493, RM 493",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,06/13/2012,,Biologic,,,No,,Massachusetts,United States,North America,,19880,26360,3663,137,N/A,$1.53B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Rezolute, Inc.",RZLT,AB301,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GLP-1 Receptor,Insulin Receptor",,"AB 301, AB-301",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,26747,37350,4346,137,N/A,$108.41M ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Sanofi,SNY,AVE0010 Prolonged Release,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,"Perrigo Company PLC, Zealand Pharma A/S","AVE-0010 PR, ZP10 PR, AVE0010 Sustained Release",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,02/12/2008,,Non-NME,,,No,,,France,Europe,,12985,16369,51,137,N/A,$107.55B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Sanofi,SNY,HM14220,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GLP-1 Receptor,Insulin Receptor","Hanmi Pharmaceutical Co., Ltd.","LAPS-Insulin Combo, HM 14220, HM-14220",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,France,Europe,,25260,35133,51,137,N/A,$107.55B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Sanofi,SNY,SAR161271,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,SAR161271,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,04/29/2010,,New Molecular Entity (NME),,,No,,,France,Europe,,16808,21764,51,137,N/A,$107.55B ,,
Suspended,,,12/01/2016,12/01/2016,07/31/2014,Peptide,Subcutaneous (SQ),Sanofi,SNY,SAR425899,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GLP-1 Receptor,Glucagon Receptor",,"SAR-425899, SAR 425899",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/31/2014,,New Molecular Entity (NME),,,No,,,France,Europe,,24502,34022,51,137,N/A,$107.55B ,,
Suspended,,,,,02/13/2015,Peptide,Subcutaneous (SQ),Sanofi,SNY,SAR440067,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,"Hanmi Pharmaceutical Co., Ltd.","LAPS-insulin 115, HM12470, HM 12470, HM-12470, SAR 440067, SAR-440067",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,02/13/2015,,New Molecular Entity (NME),,,No,,,France,Europe,,25245,35117,51,137,N/A,$107.55B ,,
Suspended,,,,,07/29/2019,Peptide,Subcutaneous (SQ),Sanofi,SNY,SAR441255,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GIP Receptor (GIPR)/Glucose-Dependent Insulinotropic Polypeptide Receptor,GLP-1 Receptor,Glucagon Receptor",,,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/29/2019,,New Molecular Entity (NME),,,No,,,France,Europe,,40938,57455,51,137,N/A,$107.55B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Sanofi,SNY,TransCon Insulin,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,Ascendis Pharma A/S,"ACP-002, TransCon Hydrogel Insulin",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,France,Europe,,31764,43884,51,137,N/A,$107.55B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Xenetic Biosciences, Inc.",XBIO,PSA-Oxyntomodulin,oxyntomodulin,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GLP-1 Receptor,Glucagon Receptor",,PSA-Oxyntomodulin,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Massachusetts,United States,North America,,24080,33288,3211,137,N/A,$20.11M ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Xenetic Biosciences, Inc.",XBIO,SuliXen,insulin,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"polysialic insulin, SYN-20090510RU",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,01/28/2008,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,18033,23553,3211,137,N/A,$20.11M ,,
Suspended,,,,,09/13/2012,Peptide,Subcutaneous (SQ),Zealand Pharma A/S,ZEAL,ZP2929,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GLP-1 Receptor,Glucagon Receptor",,ZP2929,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,09/13/2012,08/24/2012,New Molecular Entity (NME),,,No,,,Denmark,Europe,,18452,24185,748,137,N/A,$1.48B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Zealand Pharma A/S,ZEAL,ZP3022,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","Cholecystokinin 2 (CCK2 or CCKB) / Gastrin receptor,GLP-1 Receptor",,exenatide-gastrin,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,20242,26959,748,137,N/A,$1.48B ,,
Withdrawn from Market,02/28/2014,02/28/2014,,,,Peptide,Subcutaneous (SQ),"Samsung Bioepis Co., Ltd.",207940.KS,Lusduna Nexvue,insulin glargine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"MK-1293, MK 1293, MK1293, Lusduna (EU), Biosimilar Insulin Glargine (Merck), SB9, SB 9, SB-9, Lantus biosimilar",N,Approved,100% (Same As Avg.), - , - , - ,07/20/2017,01/04/2017,,,,,01/24/2011,,Biosimilar,505b2,,No,,,Korea (South),Asia,,23734,32688,4607,137,N/A, ,,
Withdrawn from Market,02/17/2009,02/17/2009,,03/02/2007,,Peptide,Subcutaneous (SQ),GlaxoSmithKline plc,GSK,Tanzeum,albiglutide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,"Albugon, GSK716155, Syncria, Eperzan (EU)",Y,Approved,100% (Same As Avg.), - , - , - ,04/15/2014,03/21/2014,,,,01/14/2013,05/10/2006,,Biologic,,,No,,,United Kingdom,Europe,100%,128,4647,180,137,N/A,$94.89B ,,
II,,,,09/25/2020,,Peptide,Subcutaneous (SQ),AstraZeneca PLC,AZN,Cotadutide,,Endocrine,Diabetes Mellitus,Diabetic Nephropathy,"GLP-1 Receptor,Glucagon Receptor",,"MEDI-0382, MEDI0382, MEDI 0382",N,II,24% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,26110,62122,45,492,N/A,$133.38B ,,
III,06/18/2019,06/18/2019,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Ozempic,semaglutide,Endocrine,Diabetes Mellitus,Diabetic Nephropathy,GLP-1 Receptor,,"Once-weekly GLP-1 analogue, NN9536, NN 9536, NN-9536, NN 9535, NN9535, NN-9535, semaglutide injection",N,III,60% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,10488,56640,292,492,N/A,$108.42B ,,
Suspended,06/02/2015,,,,,Peptide,Subcutaneous (SQ),Mundipharma International Limited,,Eligard,leuprolide acetate,Endocrine,General,Endocrine Disorder,Gonadotropin-Releasing Hormone (GnRH) Receptor,"Astellas Pharma, Inc., Medigene AG, Sanofi, Sosei Co., Ltd, Tolmar Pharmaceuticals, Inc.","leuprolide acetate, SOT-375, SOT375, SOT 375",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,"22.5MG/VIAL (INJECTABLE;SUBCUTANEOUS), 30MG/VIAL (INJECTABLE;SUBCUTANEOUS), 45MG/VIAL (INJECTABLE;SUBCUTANEOUS), 7.5MG/VIAL (INJECTABLE;SUBCUTANEOUS)",,United Kingdom,Europe,,1819,52299,667,182,N/A, ,,
NDA,06/28/2017,06/28/2017,01/27/2016,01/27/2016,,Peptide,Subcutaneous (SQ),Zealand Pharma A/S,ZEAL,Dasiglucagon,dasiglucagon,Endocrine,Other,Hyperinsulinemia/Hypoglycemia,Glucagon Receptor,,"ZP-4207, ZP-GA-1, ZP 4207, ZP4207",N,NDA/BLA,96% (7% Above Avg.),03/27/2021 - 03/27/2021, - , - ,,,,03/27/2021,,03/31/2020,11/17/2014,,New Molecular Entity (NME),Orphan,,No,,,Denmark,Europe,,25057,34839,748,3358,N/A,$1.48B ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),Adocia,ADOC:FP,BioChaperone Glucagon,human glucagon,Endocrine,Other,Hyperinsulinemia/Hypoglycemia,Insulin Receptor,,BioChaperone Glucagon,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,France,Europe,,29671,60536,4106,3358,N/A,$73.14M ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Hypopen-1513,,Endocrine,Other,Hyperinsulinemia/Hypoglycemia,Glucagon Receptor,,"NNC9204-1513, NN9513, HypoPen 1513",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,02/22/2018,,Non-NME,,,No,,,Denmark,Europe,,38516,53779,292,3358,N/A,$108.42B ,,
Suspended,,,03/03/2015,03/03/2015,,Peptide,Subcutaneous (SQ),Myovant Sciences Ltd.,MYOV,RVT-602,,Endocrine,Other,Hypogonadism,Gonadotropin-Releasing Hormone (GnRH),"Roivant Sciences, Takeda Pharmaceutical Co. Ltd.","MVT-602, MVT602, MVT 602, TAK-448, TAK448, TAK 448, RVT602, RVT 602",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United Kingdom,Europe,,20846,35505,6241,549,N/A,$2.28B ,,
II,,,09/23/2019,09/23/2019,,Peptide,Subcutaneous (SQ),AstraZeneca PLC,AZN,Cotadutide,,Endocrine,Other,Non-Alcoholic Steatohepatitis (NASH),"GLP-1 Receptor,Glucagon Receptor",,"MEDI-0382, MEDI0382, MEDI 0382",N,II,25% (1% Above Avg.), - , - , - ,,,,,,,06/01/2018,,New Molecular Entity (NME),Fast Track,,No,,,United Kingdom,Europe,,26110,57489,45,683,N/A,$133.38B ,,
II,,,11/18/2019,11/18/2019,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Tirzepatide,tirzepatide,Endocrine,Other,Non-Alcoholic Steatohepatitis (NASH),"GIP Receptor (GIPR)/Glucose-Dependent Insulinotropic Polypeptide Receptor,GLP-1 Receptor",,"LY3298176, LY-3298176, LY 3298176",N,II,25% (1% Above Avg.), - , - , - ,,,,,,,06/08/2019,,New Molecular Entity (NME),Fast Track,,No,,Indiana,United States,North America,,29260,56826,136,683,N/A,$158.63B ,,
II,,,11/30/2016,11/30/2016,11/28/2017,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Ozempic,semaglutide,Endocrine,Other,Non-Alcoholic Steatohepatitis (NASH),GLP-1 Receptor,,"Once-weekly GLP-1 analogue, NN9536, NN 9536, NN-9536, NN 9535, NN9535, NN-9535, semaglutide injection",N,II,27% (3% Above Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,10488,45559,292,683,N/A,$108.42B ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),Boehringer Ingelheim GmbH,,BI 456906,,Endocrine,Other,Non-Alcoholic Steatohepatitis (NASH),"GLP-1 Receptor,Glucagon Receptor",Zealand Pharma A/S,"GLP-1/glucagon dual-acting agonist, BI456906, BI-456906",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Germany,Europe,,35855,59780,70,683,N/A, ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),"Hanmi Pharmaceutical Co., Ltd.",128940,Efinopegdutide,efinopegdutide,Endocrine,Other,Non-Alcoholic Steatohepatitis (NASH),"GLP-1 Receptor,Glucagon Receptor","Merck & Co., Inc.","HM-12525A, HM 12525A, LAPS-GLP-1/Glucagon dual agonist, LAPS-GLP-1/GCG, oxyntomodulin based therapy, JNJ64565111, JNJ 64565111, JNJ5111, JNJ 5111, JNJ-5111, JNJ-64565111, HM12525A",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Korea (South),Asia,,22699,60679,3379,683,N/A,$4.34B ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),Sanofi,SNY,SAR425899,,Endocrine,Other,Non-Alcoholic Steatohepatitis (NASH),"GLP-1 Receptor,Glucagon Receptor",,"SAR-425899, SAR 425899",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,France,Europe,,24502,52779,51,683,N/A,$107.55B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Pegilodecakin,pegilodecakin,Endocrine,Other,Non-Alcoholic Steatohepatitis (NASH),IL-10 (Interleukin-10) and IL-10 Receptor (IL-10R),,"AM-0010, AM 0010, PEGylated interleukin-10, LY3500518, LY 3500518, LY-3500518, AM0010",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Indiana,United States,North America,,23876,32910,136,683,N/A,$158.63B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Victoza,liraglutide recombinant,Endocrine,Other,Non-Alcoholic Steatohepatitis (NASH),GLP-1 Receptor,Johnson & Johnson,"liraglutide, NN2211 (diabetes), NN9211 (adjunct), NN9223 (depot)",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,18MG/3ML (6MG/ML) (SOLUTION;SUBCUTANEOUS),,Denmark,Europe,95%,1712,37880,292,683,N/A,$108.42B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Enesi Pharma Limited,,Glide Teriparatide,teriparatide,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Parathyroid Hormone Receptor (PTHR),,Teriparatide SDI,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,United Kingdom,Europe,,27258,38125,4510,242,N/A, ,,
Suspended,,,,08/21/2009,,Peptide,Subcutaneous (SQ),Nordic Bioscience A/S,,SAN 134,,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,GLP-2 Receptor,,SAN-134,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,21941,29663,2459,242,N/A, ,,
Withdrawn from Market,,,,,,Peptide,Subcutaneous (SQ),Novartis AG,NVS,Cibacalcin,calcitonin-human for injection,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Calcitonin Receptor,"Unigene Laboratories, Inc.",synthetic human calcitonin,Y,Approved,100% (Same As Avg.), - , - , - ,10/31/1986,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,2887,4930,289,242,N/A,$183.31B ,,
Withdrawn from Market,,,,,,Peptide,Subcutaneous (SQ),Novartis AG,NVS,Cibacalcin,calcitonin-human for injection,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Paget Disease of Bone,Calcitonin Receptor,"Unigene Laboratories, Inc.",synthetic human calcitonin,Y,Approved,100% (Same As Avg.), - , - , - ,10/31/1986,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Switzerland,Europe,,2887,4929,289,368,N/A,$183.31B ,,
II,,,06/04/2015,06/04/2015,,Peptide,Subcutaneous (SQ),"Rhythm Pharmaceuticals, Inc.",RYTM,Imcivree,setmelanotide,Endocrine,Other,Prader-Willi Syndrome,"Insulin Receptor,Melanocortin (MC) receptors","Camurus AB, Ipsen SA","BIM-22493, BIM 22493, BIM22493, RM-493, RM493, RM 493",N,II,24% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,"Orphan,Rare Disease",,No,,Massachusetts,United States,North America,,19880,36488,3663,708,N/A,$1.53B ,,
III,,08/17/2015,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Victoza,liraglutide recombinant,Endocrine,Other,Prader-Willi Syndrome,GLP-1 Receptor,Johnson & Johnson,"liraglutide, NN2211 (diabetes), NN9211 (adjunct), NN9223 (depot)",N,III,60% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,18MG/3ML (6MG/ML) (SOLUTION;SUBCUTANEOUS),,Denmark,Europe,95%,1712,37148,292,708,N/A,$108.42B ,,
Suspended,03/14/2019,03/14/2019,,,,Peptide,Subcutaneous (SQ),"Millendo Therapeutics, Inc.",MLND,Livoletide,livoletide,Endocrine,Other,Prader-Willi Syndrome,Ghrelin Receptor,,"unacylated ghrelin analog, AZP-531, AZP 531, AZP531",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Fast Track,Orphan,Rare Disease",,No,,Michigan,United States,North America,,20934,28065,4712,708,N/A,$30.78M ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),"ImmunoForge, Co. Ltd.",,Glymera,,Endocrine,Other,Sarcopenia,GLP-1 Receptor,"PhaseBio Pharmaceuticals, Inc.","PB1023, PB 1023, PB-1023",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Korea (South),Asia,,19578,56515,9146,646,N/A, ,,
Suspended,,,,,01/24/2013,Peptide,Subcutaneous (SQ),"Aileron Therapeutics, Inc",ALRN,ALRN-5281,,Endocrine,Short Stature,Short Stature / Growth Hormone Deficiency,Growth Hormone Releasing Hormone (GHRH) Receptor,,ALRN-5281,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,01/24/2013,,Biologic,,,No,,Massachusetts,United States,North America,,21708,29302,4074,285,N/A,$50.04M ,,
II,,,04/16/2013,04/16/2013,,Peptide,Subcutaneous (SQ),Allergan plc,AGN,Relamorelin,relamorelin,Gastroenterology (Non Inflammatory Bowel Disease),Other,Chronic Idiopathic Constipation,Ghrelin Receptor,"Ipsen SA, Rhythm Pharmaceuticals, Inc.","RM-131, RM131, RM 131, BIM-28131, BIM 28131, BIM28131",N,II,26% (2% Above Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Ireland,Europe,,19879,30222,395,661,N/A,$63.66B ,,
III,10/05/2017,10/05/2017,05/04/2012,05/04/2012,,Peptide,Subcutaneous (SQ),Allergan plc,AGN,Relamorelin,relamorelin,Gastroenterology (Non Inflammatory Bowel Disease),Other,Diabetic Gastroparesis,Ghrelin Receptor,"Ipsen SA, Rhythm Pharmaceuticals, Inc.","RM-131, RM131, RM 131, BIM-28131, BIM 28131, BIM28131",Y,III,63% (1% Above Avg.), - , - , - ,,,,,,,07/15/2011,,Biologic,Fast Track,,No,,,Ireland,Europe,,19879,26356,395,431,N/A,$63.66B ,,
Suspended,,,,04/14/2010,,Peptide,Subcutaneous (SQ),7TM Pharma A/S,,TM30339,,Gastroenterology (Non Inflammatory Bowel Disease),General,Gastroenterologic Disorders,Neuropeptide Y (NPY)/Peptide YY (PYY) Receptors,,TM30339,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,9585,21509,1717,2944,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Kineta, Inc.",,Dalazatide,dalazatide,Gastroenterology (Non Inflammatory Bowel Disease),Other,Irritable Bowel Syndrome (IBS),Potassium channels,"Kv1.3 Therapeutics, Inc.","ShK186, ShK 186, ShK-186",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,05/10/2016,,New Molecular Entity (NME),,,No,,Washington,United States,North America,,20882,40682,3909,435,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Digna Biotech, S.L.",,P17,,Gastroenterology (Non Inflammatory Bowel Disease),Other,Liver Failure / Cirrhosis,Transforming Growth Factor-beta (TGF-beta) and Superfamily,,"P-17, NAFB002",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Spain,Europe,,21876,29571,3227,2866,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"BioVie, Inc.",BIVI,PHT101,,Gastroenterology (Non Inflammatory Bowel Disease),Other,Liver Failure / Cirrhosis,Vasopressin receptors,PharmaIN Corporation,PGC-C12E-Terlipressin,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,California,United States,North America,,21649,29203,4065,2866,N/A,$348.04M ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),Takeda Pharmaceutical Co. Ltd.,TAK,Gattex,teduglutide,Gastroenterology (Non Inflammatory Bowel Disease),Other,Necrotizing Enterocolitis (NEC),GLP-2 Receptor,,"Revestive (EU), ALX-0600, teduglutide, recombinant GLP-2, SHP633, SHP 633, SHP-633",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,5MG/VIAL (POWDER;SUBCUTANEOUS),,Japan,Asia,100%,698,5509,826,737,N/A,$46.05B ,,
I,,,,,,Peptide,Subcutaneous (SQ),Takeda Pharmaceutical Co. Ltd.,TAK,TAK-681,,Gastroenterology (Non Inflammatory Bowel Disease),Other,Short Bowel Syndrome (SBS),GLP-2 Receptor,,SHP681,N,I,16% (Same As Avg.), - , - , - ,,,,,,,03/26/2019,,New Molecular Entity (NME),Rare Disease,,No,,,Japan,Asia,,40836,57293,826,581,N/A,$46.05B ,,
I,,,,,06/26/2019,Peptide,Subcutaneous (SQ),Zealand Pharma A/S,ZEAL,ZP7570,,Gastroenterology (Non Inflammatory Bowel Disease),Other,Short Bowel Syndrome (SBS),"GLP-1 Receptor,GLP-2 Receptor",,"ZP-7570, ZP 7570",Y,I,16% (Same As Avg.), - , - , - ,,,,,,,06/26/2019,,New Molecular Entity (NME),Rare Disease,,No,,,Denmark,Europe,,40606,56912,748,581,N/A,$1.48B ,,
I/II,,,,06/24/2020,,Peptide,Subcutaneous (SQ),"Naia Pharmaceuticals, Inc.",,NM-002,,Gastroenterology (Non Inflammatory Bowel Disease),Other,Short Bowel Syndrome (SBS),GLP-1 Receptor,"Amunix Pharmaceuticals, Inc.","NB-1001, NB 1001, NB1001, NM002, NM 002",N,II,24% (Same As Avg.), - , - , - ,,,,,,,,11/29/2016,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,California,United States,North America,,26863,37543,5531,581,N/A, ,,
III,10/04/2018,10/04/2018,09/17/2015,09/17/2015,,Peptide,Subcutaneous (SQ),Zealand Pharma A/S,ZEAL,Glepaglutide,glepaglutide,Gastroenterology (Non Inflammatory Bowel Disease),Other,Short Bowel Syndrome (SBS),GLP-2 Receptor,,"ZP1848, ZP 1848, ZP-1848",Y,III,64% (2% Above Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Denmark,Europe,,14383,37357,748,581,N/A,$1.48B ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),"Naia Pharmaceuticals, Inc.",,NB1002,,Gastroenterology (Non Inflammatory Bowel Disease),Other,Short Bowel Syndrome (SBS),GLP-2 Receptor,"Amunix Pharmaceuticals, Inc.","NB 1002, NB-1002",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,California,United States,North America,,26864,37544,5531,581,N/A, ,,
I/II,,,,11/23/2015,11/23/2015,Peptide,Subcutaneous (SQ),BioLineRx Ltd.,BLRX,Motixafortide,motixafortide,Hematology,Marrow Or Peripheral Blood Stimulator,Aplastic Anemia,Chemokine (C-X-C motif) Receptor 4 (CXCR4),Biokine Therapeutics Ltd.,"BKT-140, BKT 140, BKT140, BL8040, BL 8040, BL-8040",N,II,30% (Same As Avg.), - , - , - ,,,,,,,,09/10/2015,New Molecular Entity (NME),Rare Disease,,No,,,Israel,Asia,,18717,34838,1248,3247,N/A,$58.92M ,,
I,,,,,01/08/2018,Peptide,Subcutaneous (SQ),"Ra Pharmaceuticals, Inc.",RARX,Zilucoplan,zilucoplan,Hematology,General,Hemolytic Uremic Syndrome (HUS),"C5a Receptor,Complement Pathway",,"RA-101495, RA 101495, RA101495, RA101495 SC, RA101495SC, RA101495-SC",N,I,23% (Same As Avg.), - , - , - ,,,,,,,01/08/2018,,New Molecular Entity (NME),Rare Disease,,No,,Massachusetts,United States,North America,,26745,43721,3732,2893,N/A,$2.27B ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),La Jolla Pharmaceutical Company,LJPC,LJPC-401,hepcidin,Hematology,Other,Sickle Cell Anemia,Hepcidin,,"synthetic human hepcidin, LJPC401, LJPC 401",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,California,United States,North America,,22617,44129,453,576,N/A,$113.63M ,,
II,,,12/04/2017,12/04/2017,10/19/2015,Peptide,Subcutaneous (SQ),La Jolla Pharmaceutical Company,LJPC,LJPC-401,hepcidin,Hematology,Marrow Or Peripheral Blood Stimulator,Thalassemia,Hepcidin,,"synthetic human hepcidin, LJPC401, LJPC 401",Y,II,25% (5% Below Avg.), - , - , - ,,,,,,,10/19/2015,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,California,United States,North America,,22617,30761,453,3638,N/A,$113.63M ,,
Suspended,,,01/09/2019,01/09/2019,05/25/2017,Peptide,Subcutaneous (SQ),"Protagonist Therapeutics, Inc.",PTGX,PTG-300,Hepcidin Mimetic Peptide,Hematology,Marrow Or Peripheral Blood Stimulator,Thalassemia,Hepcidin,,"PTG300, PTG 300",N,Suspended,-5% (5% Below Avg.), - , - , - ,,,,,,,05/25/2017,,New Molecular Entity (NME),"Fast Track,Orphan,Rare Disease",,No,,California,United States,North America,,30855,42664,4983,3638,N/A,$890.35M ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),BioLineRx Ltd.,BLRX,Motixafortide,motixafortide,Hematology,Marrow Or Peripheral Blood Stimulator,Thrombocytopenia,Chemokine (C-X-C motif) Receptor 4 (CXCR4),Biokine Therapeutics Ltd.,"BKT-140, BKT 140, BKT140, BL8040, BL 8040, BL-8040",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Israel,Asia,,18717,30893,1248,188,N/A,$58.92M ,,
II,,,07/07/2020,07/07/2020,,Peptide,Subcutaneous (SQ),"Ra Pharmaceuticals, Inc.",RARX,Zilucoplan,zilucoplan,Infectious Disease,Antiviral,COVID-19 Treatment,"C5a Receptor,Complement Pathway",,"RA-101495, RA 101495, RA101495, RA101495 SC, RA101495SC, RA101495-SC",N,II,27% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,26745,60557,3732,3651,N/A,$2.27B ,,
Investigator Initiated,,,,,,Peptide,Subcutaneous (SQ),Takeda Pharmaceutical Co. Ltd.,TAK,Firazyr,icatibant,Infectious Disease,Antiviral,COVID-19 Treatment,Bradykinin B2 Receptor,Sanofi,"icatibant, SHP667, SHP 667, SHP-667, HOE 140, HOE140, HOE-140",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,EQ 30MG BASE/3ML (EQ 10MG BASE (INJECTABLE;SUBCUTANEOUS),,Japan,Asia,88%,2419,60651,826,3651,N/A,$46.05B ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),"Chrysalis BioTherapeutics, Inc.",,TP508,rusalatide acetate,Infectious Disease,Antiviral,COVID-19 Treatment,Thrombin (Coagulation Factor IIa),,"TP-508, TP 508, TRAP-508, Chrysalin",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Texas,United States,North America,,40796,60065,9284,3651,N/A, ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),BioLineRx Ltd.,BLRX,Motixafortide,motixafortide,Infectious Disease,Antiviral,COVID-19 Treatment,Chemokine (C-X-C motif) Receptor 4 (CXCR4),Biokine Therapeutics Ltd.,"BKT-140, BKT 140, BKT140, BL8040, BL 8040, BL-8040",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Israel,Asia,,18717,61742,1248,3651,N/A,$58.92M ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),ValiRx Plc,VAL,VAL201,,Infectious Disease,Antiviral,COVID-19 Treatment,"Androgen receptors,Src Kinase Family",Cancer Research Technology Ltd.,"VAL 201, VAL-201",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,20954,60341,3920,3651,N/A,$18.30M ,,
Suspended,,,06/27/2007,06/27/2007,,Peptide,Subcutaneous (SQ),"SciClone Pharmaceuticals, Inc.",SCLN,SCV-07,,Infectious Disease,Antiviral,Hepatitis C (HCV) (Antiviral),STAT3 Transcription Factor,Verta Ltd.,gamma-D-glutamyl-L-tryptophan,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,884,8597,491,176,N/A, ,,
III,04/17/2019,04/17/2019,,10/23/2018,,Peptide,Subcutaneous (SQ),MYR GmbH,,Hepcludex,bulevirtide,Infectious Disease,Antiviral,Hepatitis D (HDV) (Antiviral),"Hepatitis B/HBV,Hepatitis D/HDV",Hepatera,"MyrcludexB, Myrcludex-B, Bulevirtide",N,III,63% (2% Above Avg.), - , - , - ,,08/04/2020,,,07/01/2021 - 12/31/2021,,,,New Molecular Entity (NME),"Breakthrough,Orphan",,No,,,Germany,Europe,,24721,34352,4876,3368,N/A, ,,
I,,,,,,Peptide,Subcutaneous (SQ),Navigen Inc,,CPT31,,Infectious Disease,Antiviral,HIV / AIDS,gp41,,"CPT-31, CPT 31",N,I,19% (Same As Avg.), - , - , - ,,,,,,,12/14/2020,12/10/2019,Biologic,,,No,,Utah,United States,North America,,41568,58313,9478,78,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"SciClone Pharmaceuticals, Inc.",SCLN,SCV-07,,Infectious Disease,Antiviral,Influenza (excluding vaccines),STAT3 Transcription Factor,Verta Ltd.,gamma-D-glutamyl-L-tryptophan,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/06/2006,,New Molecular Entity (NME),,,No,,California,United States,North America,,884,4413,491,3302,N/A, ,,
Investigator Initiated,,,,,,Peptide,Subcutaneous (SQ),AstraZeneca PLC,AZN,Byetta,exenatide,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Sepsis and Septic Shock,GLP-1 Receptor,"3SBio Inc., Bristol Myers Squibb Company, Eli Lilly and Company","Exenatide, Synthetic exendin-4, AC2993, LY2148568",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,"300MCG/1.2ML (250MCG/ML) (INJECTABLE;SUBCUTANEOUS), 600MCG/2.4ML (250MCG/ML) (INJECTABLE;SUBCUTANEOUS)",,United Kingdom,Europe,70%,201,26348,45,76,N/A,$133.38B ,,
Suspended,,,,09/28/2002,,Peptide,Subcutaneous (SQ),"SciClone Pharmaceuticals, Inc.",SCLN,SCV-07,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Tuberculosis,STAT3 Transcription Factor,Verta Ltd.,gamma-D-glutamyl-L-tryptophan,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,11/01/2005,,New Molecular Entity (NME),,,No,,California,United States,North America,,884,1039,491,455,N/A, ,,
Suspended,,,,01/31/2008,,Peptide,Subcutaneous (SQ),"Oxeia Biopharmaceuticals, Inc.",,OXE-103,,Metabolic,Other,Cachexia / Weight Loss,Ghrelin Receptor,,"Human Ghrelin, SUN11031, OXE103, OXE 103",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,10647,13330,7671,542,N/A, ,,
Suspended,,,,12/06/2004,,Peptide,Subcutaneous (SQ),AKELA Pharma Inc.,AKLPF,AKL-0707,,Metabolic,Other,Cachexia / Weight Loss,Growth Hormone Releasing Hormone (GHRH) Receptor,,"Akela GHRH, LAB GHRH",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Texas,United States,North America,,9425,11536,1231,542,N/A, ,,
Investigator Initiated,,,,,,Peptide,Subcutaneous (SQ),Shionogi & Co. Ltd.,4507,S-005151,Redasemtide,Metabolic,Single-Gene Disorders (Non-Inborn Errors of Metabolism),Epidermolysis Bullosa,,StemRIM Inc.,"S-005151, S005151",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,,Japan,Asia,,40276,56362,618,657,N/A,$17.14B ,,
I,,,,,02/26/2020,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,NN9389,,Metabolic,Obesity,Obesity,GLP-1 Receptor,,"NN-9389, NN 9389, NNC0480-0389, NNC0480 0389",N,I,16% (Same As Avg.), - , - , - ,,,,,,,02/26/2020,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,42402,59676,292,135,N/A,$108.42B ,,
I,,,,,10/15/2018,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,PYY1875,,Metabolic,Obesity,Obesity,Neuropeptide Y (NPY)/Peptide YY (PYY) Receptors,,"NN 9775, NN-9775, NNC0165-1875, NNC0165 1875, NNC0-165-1875, PYY 1875, NN9775, PYY-1875",Y,I,16% (Same As Avg.), - , - , - ,,,,,,,10/15/2018,,Biologic,,,No,,,Denmark,Europe,,41166,57786,292,135,N/A,$108.42B ,,
II,,,04/30/2020,04/30/2020,08/22/2017,Peptide,Subcutaneous (SQ),Boehringer Ingelheim GmbH,,BI 456906,,Metabolic,Obesity,Obesity,"GLP-1 Receptor,Glucagon Receptor",Zealand Pharma A/S,"GLP-1/glucagon dual-acting agonist, BI456906, BI-456906",N,II,24% (Same As Avg.), - , - , - ,,,,,,,08/22/2017,,New Molecular Entity (NME),,,No,,,Germany,Europe,,35855,49837,70,135,N/A, ,,
II,,,,03/26/2018,,Peptide,Subcutaneous (SQ),"Hanmi Pharmaceutical Co., Ltd.",128940,Efinopegdutide,efinopegdutide,Metabolic,Obesity,Obesity,"GLP-1 Receptor,Glucagon Receptor","Merck & Co., Inc.","HM-12525A, HM 12525A, LAPS-GLP-1/Glucagon dual agonist, LAPS-GLP-1/GCG, oxyntomodulin based therapy, JNJ64565111, JNJ 64565111, JNJ5111, JNJ 5111, JNJ-5111, JNJ-64565111, HM12525A",N,II,21% (3% Below Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Korea (South),Asia,,22699,53587,3379,135,N/A,$4.34B ,,
II,,,,02/27/2014,,Peptide,Subcutaneous (SQ),"Hanmi Pharmaceutical Co., Ltd.",128940,Efpeglenatide,efpeglenatide,Metabolic,Obesity,Obesity,GLP-1 Receptor,,"HM11260C, HM 11260C, HM-11260C, LAPS-Exendin, LAPS-Exd4, langlenatide, SAR 439977, SAR-439977, SAR439977",N,II,25% (1% Above Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Korea (South),Asia,,18638,34014,3379,135,N/A,$4.34B ,,
III,12/04/2019,12/04/2019,,,09/13/2019,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Tirzepatide,tirzepatide,Metabolic,Obesity,Obesity,"GIP Receptor (GIPR)/Glucose-Dependent Insulinotropic Polypeptide Receptor,GLP-1 Receptor",,"LY3298176, LY-3298176, LY 3298176",N,III,62% (Same As Avg.), - , - , - ,,,,,,,09/13/2019,,New Molecular Entity (NME),,,No,,Indiana,United States,North America,,29260,56888,136,135,N/A,$158.63B ,,
Investigator Initiated,,,,,,Peptide,Subcutaneous (SQ),"Arrowhead Pharmaceuticals, Inc.",ARWR,Adipotide,,Metabolic,Obesity,Obesity,"Mitochondria,Prohibitin (PHB)",,Prohibitin-TP01,Y,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,05/25/2012,,New Molecular Entity (NME),,,No,,California,United States,North America,,20566,27419,2853,135,N/A,$8.17B ,,
Investigator Initiated,,,12/08/2014,,,Peptide,Subcutaneous (SQ),AstraZeneca PLC,AZN,Bydureon,exenatide,Metabolic,Obesity,Obesity,GLP-1 Receptor,"3SBio Inc., Alkermes plc, Bristol Myers Squibb Company, Eli Lilly and Company","AC2993/exenatide LAR, long acting synthetic exendin-4, exenatide once weekly (EQW), Exenatide Microsphere",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,"2MG (FOR SUSPENSION, EXTENDED RELEA), 2MG/VIAL (FOR SUSPENSION, EXTENDED RELEA)",,United Kingdom,Europe,63.5%,200,41610,45,135,N/A,$133.38B ,,
Investigator Initiated,,,,03/05/2008,,Peptide,Subcutaneous (SQ),AstraZeneca PLC,AZN,Byetta,exenatide,Metabolic,Obesity,Obesity,GLP-1 Receptor,"3SBio Inc., Bristol Myers Squibb Company, Eli Lilly and Company","Exenatide, Synthetic exendin-4, AC2993, LY2148568",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,"300MCG/1.2ML (250MCG/ML) (INJECTABLE;SUBCUTANEOUS), 600MCG/2.4ML (250MCG/ML) (INJECTABLE;SUBCUTANEOUS)",,United Kingdom,Europe,70%,201,13622,45,135,N/A,$133.38B ,,
NDA,06/04/2018,06/04/2018,,10/01/2015,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Ozempic,semaglutide,Metabolic,Obesity,Obesity,GLP-1 Receptor,,"Once-weekly GLP-1 analogue, NN9536, NN 9536, NN-9536, NN 9535, NN9535, NN-9535, semaglutide injection",N,NDA/BLA,97% (8% Above Avg.),06/04/2021 - 06/04/2021, - , - ,,,,,,12/04/2020,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,10488,37975,292,135,N/A,$108.42B ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),Carmot Therapeutics Inc.,,CT-868,,Metabolic,Obesity,Obesity,"GIP Receptor (GIPR)/Glucose-Dependent Insulinotropic Polypeptide Receptor,GLP-1 Receptor",,"GLP-1R/GIPR Dual Agonists, CT868, CT 868",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,36089,50186,7821,135,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Kineta, Inc.",,Dalazatide,dalazatide,Metabolic,Obesity,Obesity,Potassium channels,"Kv1.3 Therapeutics, Inc.","ShK186, ShK 186, ShK-186",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Washington,United States,North America,,20882,30460,3909,135,N/A, ,,
Suspended,,,,07/07/2005,,Peptide,Subcutaneous (SQ),7TM Pharma A/S,,Obinepitide,,Metabolic,Obesity,Obesity,Neuropeptide Y (NPY)/Peptide YY (PYY) Receptors,,"TM30338, PYY3-36-Pancreatic Polypeptide Analogue",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,9584,11932,1717,135,N/A, ,,
Suspended,,,,03/08/2007,,Peptide,Subcutaneous (SQ),7TM Pharma A/S,,TM30339,,Metabolic,Obesity,Obesity,Neuropeptide Y (NPY)/Peptide YY (PYY) Receptors,,TM30339,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,9585,11935,1717,135,N/A, ,,
Suspended,,,,,08/04/2011,Peptide,Subcutaneous (SQ),AstraZeneca PLC,AZN,AZD2820,,Metabolic,Obesity,Obesity,Melanocortin (MC) receptors,"Palatin Technologies, Inc.",AZD-2820,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/04/2011,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,18630,24463,45,135,N/A,$133.38B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Zydus Cadila,CDH,ZYD1,,Metabolic,Obesity,Obesity,GLP-1 Receptor,,"ZYD 1, ZYD-1",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,02/07/2012,,New Molecular Entity (NME),,,No,,,India,Asia,,18658,25849,3380,135,N/A,$6.74B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,DACRA-089,,Metabolic,Obesity,Obesity,"Amylin Receptor,Calcitonin Receptor",Nordic Bioscience A/S,"KBP089, KBP 089, KBP-089",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/21/2017,,New Molecular Entity (NME),,,No,,Indiana,United States,North America,,35202,48827,136,135,N/A,$158.63B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,NN9030,,Metabolic,Obesity,Obesity,Glucagon Receptor,,"G530L, NNC9204-530, G530S",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,09/09/2014,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,24854,34533,292,135,N/A,$108.42B ,,
Suspended,,,02/02/2010,02/02/2010,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,NN9161,,Metabolic,Obesity,Obesity,Unknown,,NNC 0070-0002-0453,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Denmark,Europe,,16315,21037,292,135,N/A,$108.42B ,,
Suspended,,,,,10/27/2016,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,NN9277,,Metabolic,Obesity,Obesity,"GLP-1 Receptor,Glucagon Receptor",,"NN-9277, NN 9277, NNC9204-1177, NNC-9204-1177, NNC 9204-1177, Glucagon-GLP-1 co-agonist 1177, GG-co-agonist, GG-co-agonist 1177",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,10/27/2016,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,32165,44429,292,135,N/A,$108.42B ,,
Suspended,,,,,06/19/2018,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,PYY 1562,,Metabolic,Obesity,Obesity,Neuropeptide Y (NPY)/Peptide YY (PYY) Receptors,,"NN 9748, NN-9748, NN9748, PYY1562, PYY-1562, NNC0165-1562, NNC0165 1562, NNC01651562, NN9747, NN 9747, NN-9747",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,10/14/2015,,Biologic,,,No,,,Denmark,Europe,,29570,54848,292,135,N/A,$108.42B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Opko Health,OPK,MOD-6030,,Metabolic,Obesity,Obesity,"GLP-1 Receptor,Glucagon Receptor",,"PEGylated oxyntomodulin, GLP-1/Glucagon agonist",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Florida,United States,North America,,19932,26439,1327,135,N/A,$3.00B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Opko Health,OPK,MOD-6031,oxyntomodulin,Metabolic,Obesity,Obesity,"GLP-1 Receptor,Glucagon Receptor",,"MOD 6031, MOD6031, long-acting oxyntomodulin, OXY-RPEG",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/16/2016,,New Molecular Entity (NME),,,No,,Florida,United States,North America,,26161,36475,1327,135,N/A,$3.00B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"PhaseBio Pharmaceuticals, Inc.",PHAS,Oxymera,,Metabolic,Obesity,Obesity,"GLP-1 Receptor,Glucagon Receptor",,oxyntomodulin analogue,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Pennsylvania,United States,North America,,20659,27603,3581,135,N/A,$118.93M ,,
Suspended,,,,,07/29/2019,Peptide,Subcutaneous (SQ),Sanofi,SNY,SAR441255,,Metabolic,Obesity,Obesity,"GIP Receptor (GIPR)/Glucose-Dependent Insulinotropic Polypeptide Receptor,GLP-1 Receptor,Glucagon Receptor",,,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/29/2019,,New Molecular Entity (NME),,,No,,,France,Europe,,40938,57456,51,135,N/A,$107.55B ,,
Suspended,,,,10/21/2008,,Peptide,Subcutaneous (SQ),Takeda Pharmaceutical Co. Ltd.,TAK,Davalintide,davalintide,Metabolic,Obesity,Obesity,Amylin Receptor,Bristol Myers Squibb Company,"AC2307, Second-generation Amylinomimetic",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,01/30/2007,,New Molecular Entity (NME),,,No,,,Japan,Asia,50%,3095,5304,826,135,N/A,$46.05B ,,
Suspended,,,,,09/13/2012,Peptide,Subcutaneous (SQ),Zealand Pharma A/S,ZEAL,ZP2929,,Metabolic,Obesity,Obesity,"GLP-1 Receptor,Glucagon Receptor",,ZP2929,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,09/13/2012,08/24/2012,New Molecular Entity (NME),,,No,,,Denmark,Europe,,18452,24178,748,135,N/A,$1.48B ,,
Investigator Initiated,,,,,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Humulin,human insulin,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Insulin Receptor,3SBio Inc.,"Human Insulin [rDNA origin], Humulin R U-100 (intranasal formulation for Alzheimer's), Humulin R U-500",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,"100 UNITS/ML (INJECTABLE;INJECTION), 10000 UNITS/20ML (500 UNITS/ML (SOLUTION;SUBCUTANEOUS), 1500 UNITS/3ML (500 UNITS/ML) (SOLUTION;SUBCUTANEOUS), 30 UNITS/ML;70 UNITS/ML (INJECTABLE;INJECTION)",Indiana,United States,North America,100%,2146,29972,136,141,N/A,$158.63B ,,
Investigator Initiated,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Levemir,insulin detemir,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Insulin Receptor,,"insulin detemir, NN304, NN 304, NN-304",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,"1000 UNITS/10ML (100 UNITS/ML) (INJECTABLE;SUBCUTANEOUS), 300 UNITS/3ML (100 UNITS/ML) (INJECTABLE;SUBCUTANEOUS)",,Denmark,Europe,100%,1706,30706,292,141,N/A,$108.42B ,,
Investigator Initiated,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Victoza,liraglutide recombinant,Neurology,Neurodegenerative,Alzheimer's Disease (AD),GLP-1 Receptor,Johnson & Johnson,"liraglutide, NN2211 (diabetes), NN9211 (adjunct), NN9223 (depot)",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,18MG/3ML (6MG/ML) (SOLUTION;SUBCUTANEOUS),,Denmark,Europe,95%,1712,58562,292,141,N/A,$108.42B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Kineta, Inc.",,Dalazatide,dalazatide,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Potassium channels,"Kv1.3 Therapeutics, Inc.","ShK186, ShK 186, ShK-186",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,05/10/2016,,New Molecular Entity (NME),,,No,,Washington,United States,North America,,20882,40683,3909,141,N/A, ,,
Suspended,10/14/2005,10/14/2005,,02/16/2005,,Peptide,Subcutaneous (SQ),Voyager Pharmaceutical Corp.,,Memryte,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),Gonadotropin-Releasing Hormone (GnRH) Receptor,DURECT Corporation,"leuprolide acetate, VP 4896",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,North Carolina,United States,North America,,2865,4894,948,141,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Intellect Neurosciences, Inc.",ILNS,RV01,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),"Amyloid Beta/Amyloid Plaques,Immune System",,RVO1,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Vaccine,,,No,,New York,United States,North America,,20171,26841,2081,141,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Intellect Neurosciences, Inc.",ILNS,RV02,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),"Immune System,Tau proteins",,RVO2,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Vaccine,,,No,,New York,United States,North America,,20172,26840,2081,141,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Intellect Neurosciences, Inc.",ILNS,RV03,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),"Amyloid Beta/Amyloid Plaques,Immune System,Tau proteins",,RVO3,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Vaccine,,,No,,New York,United States,North America,,19931,26437,2081,141,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Novolin,"human insulin (regular, NPH, and premixes)",Neurology,Neurodegenerative,Alzheimer's Disease (AD),Insulin Receptor,,"Novolin R, Novolin L, Novolin N, Novolin 70/30, human insulin [rDNA origin], Novolin R U-100 (intranasal formulation for Alzheimer's)",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,"100 UNITS/ML (INJECTABLE;INJECTION), 30 UNITS/ML;70 UNITS/ML (INJECTABLE;INJECTION)",,Denmark,Europe,100%,18154,29971,292,141,N/A,$108.42B ,,
Investigator Initiated,,,,,,Peptide,Subcutaneous (SQ),"Ra Pharmaceuticals, Inc.",RARX,Zilucoplan,zilucoplan,Neurology,Neurodegenerative,Amyotrophic Lateral Sclerosis (ALS),"C5a Receptor,Complement Pathway",,"RA-101495, RA 101495, RA101495, RA101495 SC, RA101495SC, RA101495-SC",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Massachusetts,United States,North America,,26745,57383,3732,193,N/A,$2.27B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Daval International Limited,,Aimspro,,Neurology,Neurodegenerative,Amyotrophic Lateral Sclerosis (ALS),Unknown,,caprine hyperimmune serum against HIV lysate,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/20/2013,,Biologic,Rare Disease,,No,,,United Kingdom,Europe,,18922,30666,3455,193,N/A, ,,
Suspended,,,,09/26/2006,,Peptide,Subcutaneous (SQ),Teva Pharmaceutical Industries Ltd.,TEVA,Copaxone,glatiramer acetate,Neurology,Neurodegenerative,Amyotrophic Lateral Sclerosis (ALS),"Myelin,T lymphocytes","Sanofi, Takeda Pharmaceutical Co. Ltd.","COP-1, copolymer-1, glatiramer acetate",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,"20MG/ML (INJECTABLE;SUBCUTANEOUS), 40MG/ML (INJECTABLE;SUBCUTANEOUS)",,Israel,Asia,100%,595,4821,375,193,N/A,$12.20B ,,
Suspended,,,,02/13/2007,,Peptide,Subcutaneous (SQ),Takeda Pharmaceutical Co. Ltd.,TAK,Firazyr,icatibant,Neurology,Pain,Arthritis Pain,Bradykinin B2 Receptor,Sanofi,"icatibant, SHP667, SHP 667, SHP-667, HOE 140, HOE140, HOE-140",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,EQ 30MG BASE/3ML (EQ 10MG BASE (INJECTABLE;SUBCUTANEOUS),,Japan,Asia,88%,2419,5513,826,1929,N/A,$46.05B ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),"Avion Pharmaceuticals, LLC",,Lupuzor,rigerimod,Neurology,Other,Chronic Inflammatory Demyelinating Polyneuropathy (CIDP),T lymphocytes,"ImmuPharma PLC, SymBio Pharmaceuticals Limited","P-140, P 140, P140, rigerimod, Forigerimod, CEP33457, CEP-33457, CEP 33457, IPP201101, IPP-201101, IPP 201101, SyB1001, SyB 1001, SyB-1001",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Georgia,United States,North America,,10863,53424,8117,3160,N/A, ,,
Suspended,,,,06/16/2011,,Peptide,Subcutaneous (SQ),Cebix Incorporated,,Ersatta,,Neurology,Pain,Diabetic Peripheral Neuropathy (DPN),Unknown,,"CBX129801, long-acting mono-pegylated C-peptide",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Fast Track,,No,,California,United States,North America,,20936,28068,3916,671,N/A, ,,
Suspended,,,09/01/2010,09/26/2010,,Peptide,Subcutaneous (SQ),Daval International Limited,,Aimspro,,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Unknown,,caprine hyperimmune serum against HIV lysate,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,United Kingdom,Europe,,18922,24895,3455,153,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Kineta, Inc.",,Dalazatide,dalazatide,Neurology,Neurodegenerative,Multiple Sclerosis (MS),Potassium channels,"Kv1.3 Therapeutics, Inc.","ShK186, ShK 186, ShK-186",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,05/10/2016,,New Molecular Entity (NME),,,No,,Washington,United States,North America,,20882,40681,3909,153,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),CuroNZ,,NRP2945,,Neurology,Neurodegenerative,Multiple Sclerosis (MS),,,"NRP 2945, NRP-2945",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,New Zealand,Oceania,,37108,51757,8103,153,N/A, ,,
Suspended,,,11/12/2013,11/12/2013,,Peptide,Subcutaneous (SQ),Merck KGaA,MKKGY,PI-2301,plovamer acetate,Neurology,Neurodegenerative,Multiple Sclerosis (MS),T lymphocytes,Novartis AG,"PI2301, PI 2301, plovamer acetate",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,10/03/2007,,New Molecular Entity (NME),,,No,,,Germany,Europe,,10461,13085,255,153,N/A,$12.69B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Xenetic Biosciences, Inc.",XBIO,SuliXen,insulin,Neurology,General,Neurology - Other,Insulin Receptor,,"polysialic insulin, SYN-20090510RU",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,18033,27230,3211,192,N/A,$20.11M ,,
Suspended,,,12/10/2008,03/31/2009,,Peptide,Subcutaneous (SQ),"Amgen, Inc.",AMGN,KAI-1678,,Neurology,Pain,Neuropathic Pain,Protein Kinase C (PKC),,KAI-1678,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,14037,17764,30,362,N/A,$136.24B ,,
Investigator Initiated,,,07/23/2014,,,Peptide,Subcutaneous (SQ),AstraZeneca PLC,AZN,Bydureon,exenatide,Neurology,Neurodegenerative,Parkinson's Disease (PD),GLP-1 Receptor,"3SBio Inc., Alkermes plc, Bristol Myers Squibb Company, Eli Lilly and Company","AC2993/exenatide LAR, long acting synthetic exendin-4, exenatide once weekly (EQW), Exenatide Microsphere",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,"2MG (FOR SUSPENSION, EXTENDED RELEA), 2MG/VIAL (FOR SUSPENSION, EXTENDED RELEA)",,United Kingdom,Europe,63.5%,200,49568,45,194,N/A,$133.38B ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),Peptron inc.,087010,SR-Exenatide,exenatide,Neurology,Neurodegenerative,Parkinson's Disease (PD),GLP-1 Receptor,,"sustained-release (SR) exenatide, Sustained-Release Exendin-4, PT302, PT 302, PT-302",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,Korea (South),Asia,,37882,52864,8353,194,N/A,$319.51M ,,
Suspended,,,12/10/2008,12/10/2008,,Peptide,Subcutaneous (SQ),"Amgen, Inc.",AMGN,KAI-1678,,Neurology,Pain,Postsurgical Pain,Protein Kinase C (PKC),,KAI-1678,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,11/19/2008,,New Molecular Entity (NME),,,No,,California,United States,North America,,14037,26055,30,3130,N/A,$136.24B ,,
II,,,,10/21/2020,,Peptide,Subcutaneous (SQ),"Oxeia Biopharmaceuticals, Inc.",,OXE-103,,Neurology,Other,Traumatic Brain Injury (TBI),Ghrelin Receptor,,"Human Ghrelin, SUN11031, OXE103, OXE 103",N,II,17% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,10647,49547,7671,547,N/A, ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),"Chrysalis BioTherapeutics, Inc.",,TP508,rusalatide acetate,Not Specified,Other,Acute Radiation Syndrome (ARS),Thrombin (Coagulation Factor IIa),,"TP-508, TP 508, TRAP-508, Chrysalin",Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Orphan,,No,,Texas,United States,North America,,40796,57227,9284,666,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),ValiRx Plc,VAL,VAL201,,Obstetrics/Gynecology,Gynecology,Endometriosis,"Androgen receptors,Src Kinase Family",Cancer Research Technology Ltd.,"VAL 201, VAL-201",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,20954,35521,3920,349,N/A,$18.30M ,,
II,,,01/08/2019,05/23/2018,,Peptide,Subcutaneous (SQ),Myovant Sciences Ltd.,MYOV,RVT-602,,Obstetrics/Gynecology,Gynecology,Reproductive Disorder,Gonadotropin-Releasing Hormone (GnRH),"Roivant Sciences, Takeda Pharmaceutical Co. Ltd.","MVT-602, MVT602, MVT 602, TAK-448, TAK448, TAK 448, RVT602, RVT 602",N,II,24% (Same As Avg.), - , - , - ,,,,,,,11/13/2017,,New Molecular Entity (NME),,,No,,California,United Kingdom,Europe,,20846,43718,6241,241,N/A,$2.28B ,,
IIb,,,09/04/2012,09/04/2012,,Peptide,Subcutaneous (SQ),BioLineRx Ltd.,BLRX,Motixafortide,motixafortide,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),Chemokine (C-X-C motif) Receptor 4 (CXCR4),Biokine Therapeutics Ltd.,"BKT-140, BKT 140, BKT140, BL8040, BL 8040, BL-8040",N,II,5% (5% Below Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Israel,Asia,,18717,28080,1248,97, 12%,$58.92M ,Orphan Drug designation,Yes
III,01/08/2020,01/08/2020,12/23/2010,12/23/2010,,Peptide,Subcutaneous (SQ),"SELLAS Life Sciences Group, Inc.",SLS,Zeltherva,galinpepimut-S,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),"Immune System,Wilms' Tumor Protein 1 (WT1)","3D Medicines Co., Ltd., Memorial Sloan Kettering Cancer Center","SLS001, SLS 001, SLS-001, WT1 Cancer Vaccine, WT-1 Vaccine, Galinpepimut-S (GPS)",Y,III,37% (2% Above Avg.), - , - , - ,,,,,,,11/09/2006,,New Molecular Entity (NME),"Fast Track,Orphan,Rare Disease",,No,,New York,United States,North America,,25927,36143,5266,97, 23%,$79.06M ,Drug Modality,Peptide; Vaccine
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Otsuka Holdings Co., Ltd.",4578,OCV-501,,Oncology,Hematologic,Acute Myelogenous Leukemia (AML),"Immune System,Wilms' Tumor Protein 1 (WT1)",,OCV-501,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Japan,Asia,,19776,26194,636,97,N/A,$22.58B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Otsuka Holdings Co., Ltd.",4578,Elpamotide,,Oncology,Solid,Biliary Tract Cancer,VEGF Receptor (VEGFR),FUSO Pharmaceutical Industries Ltd.,"OTS102, OTS-102",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,,Japan,Asia,,25149,34983,636,580,N/A,$22.58B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Shionogi & Co. Ltd.,4507,S-288310,,Oncology,Solid,Bladder Cancer,Immune System,"OncoTherapy Science, Inc.",S-288310,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Japan,Asia,,16125,20698,618,217,N/A,$17.14B ,,
III,12/21/2017,12/21/2017,03/23/2016,03/23/2016,,Peptide,Subcutaneous (SQ),BioLineRx Ltd.,BLRX,Motixafortide,motixafortide,Oncology,"Surgical, Interventional Radiological, and Other Invasive Procedures",Bone Marrow Transplant and Stem Cell Transplant,Chemokine (C-X-C motif) Receptor 4 (CXCR4),Biokine Therapeutics Ltd.,"BKT-140, BKT 140, BKT140, BL8040, BL 8040, BL-8040",Y,III,41% (6% Above Avg.), - , - , - ,,,,,,,08/12/2014,,New Molecular Entity (NME),Orphan,,No,,,Israel,Asia,,18717,32427,1248,300, 51%,$58.92M ,Tumor Type,N/A
II,,,06/01/2015,06/01/2015,11/29/2010,Peptide,Subcutaneous (SQ),"MimiVax, LLC",,SurVaxM,,Oncology,Solid,Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM)),"Immune System,Survivin","Shanghai Fosun Pharmaceutical (Group) Co., Ltd.","SVN53-67/M57-KLH Peptide Vaccine, DRU-2017-5947, SurvVax-M",N,II,10% (Same As Avg.), - , - , - ,,,,,,,09/11/2012,,Biologic,"Orphan,Rare Disease",,No,,New York,United States,North America,,26862,37541,5532,228,  5%, ,Orphan Drug designation,Yes
Suspended,,,,,,Peptide,Subcutaneous (SQ),IMV Inc.,IMV,DPX-Survivac,,Oncology,Solid,Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM)),"Immune System,Survivin",,DPX-Survivac,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Nova Scotia,Canada,North America,,20508,30467,3704,228,N/A,$231.59M ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"SELLAS Life Sciences Group, Inc.",SLS,Zeltherva,galinpepimut-S,Oncology,Solid,Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM)),"Immune System,Wilms' Tumor Protein 1 (WT1)","3D Medicines Co., Ltd., Memorial Sloan Kettering Cancer Center","SLS001, SLS 001, SLS-001, WT1 Cancer Vaccine, WT-1 Vaccine, Galinpepimut-S (GPS)",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,New York,United States,North America,,25927,45703,5266,228,N/A,$79.06M ,,
I,,,,,06/13/2013,Peptide,Subcutaneous (SQ),ValiRx Plc,VAL,VAL201,,Oncology,Solid,Breast Cancer,"Androgen receptors,Src Kinase Family",Cancer Research Technology Ltd.,"VAL 201, VAL-201",N,I,6% (Same As Avg.), - , - , - ,,,,,,,06/13/2013,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,20954,28106,3920,214,N/A,$18.30M ,,
II,,,03/31/2019,03/31/2019,06/26/2012,Peptide,Subcutaneous (SQ),"Marker Therapeutics, Inc.",MRKR,TPIV 110,,Oncology,Solid,Breast Cancer,"HER2/neu or ErbB-2,Immune System,Major Histocompatibility Complex (MHC)",Mayo Clinic,"AdhTAP, multi-epitope HER2 peptide vaccine, TPIV100, TPIV 100/110, TPIV110, TPIV 100",Y,II,10% (Same As Avg.), - , - , - ,,,,,,,08/11/2011,06/13/2011,New Molecular Entity (NME),,,No,,Texas,United States,North America,,19923,26426,3670,214,  8%,$81.64M ,Lead Indication,Yes
Suspended,,,,,,Peptide,Subcutaneous (SQ),IMV Inc.,IMV,DPX-0907,,Oncology,Solid,Breast Cancer,"Abelson Interactor 2 (Abi-2),B-cell receptor-associated protein 31(Bap31),Epithelial Discoidin Domain Receptor 1 (EDDR1),Immune System,Integrin Beta-8 (ITGB8),Junction Plakoblobin (JUP)/Gamma-Catenin,TACE/ADAM 17,Topoisomerase II (DNA gyrase)",,DPX-0907,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Nova Scotia,Canada,North America,,20057,29437,3704,214,N/A,$231.59M ,,
Suspended,,,,,11/25/2013,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Pegilodecakin,pegilodecakin,Oncology,Solid,Breast Cancer,IL-10 (Interleukin-10) and IL-10 Receptor (IL-10R),,"AM-0010, AM 0010, PEGylated interleukin-10, LY3500518, LY 3500518, LY-3500518, AM0010",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,11/25/2013,,Biologic,,,No,,Indiana,United States,North America,,23876,46730,136,214,N/A,$158.63B ,,
Suspended,,,,,07/16/2017,Peptide,Subcutaneous (SQ),Spectrum Pharmaceuticals Inc.,SPPI,Rolontis,eflapegrastim,Oncology,Solid,Breast Cancer,Granulocyte-colony Stimulating Factor (G-CSFR)/CD114,"Hanmi Pharmaceutical Co., Ltd.","conjugated GCSF, LAPS-GCSF, SPI-2012, SPI2012, SPI 2012, HNK460, HNK 460, HNK-460, HM10460A, HM 10460A, HM-10460A",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/16/2017,,New Molecular Entity (NME),,,No,,Nevada,United States,North America,,18641,48198,270,214,N/A,$547.21M ,,
II,,,,10/31/2018,,Peptide,Subcutaneous (SQ),"SELLAS Life Sciences Group, Inc.",SLS,Zeltherva,galinpepimut-S,Oncology,General,Cancer,"Immune System,Wilms' Tumor Protein 1 (WT1)","3D Medicines Co., Ltd., Memorial Sloan Kettering Cancer Center","SLS001, SLS 001, SLS-001, WT1 Cancer Vaccine, WT-1 Vaccine, Galinpepimut-S (GPS)",N,II,11% (1% Above Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New York,United States,North America,,25927,50332,5266,313,N/A,$79.06M ,,
Suspended,,,,,12/21/2017,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Pegilodecakin,pegilodecakin,Oncology,General,Cancer,IL-10 (Interleukin-10) and IL-10 Receptor (IL-10R),,"AM-0010, AM 0010, PEGylated interleukin-10, LY3500518, LY 3500518, LY-3500518, AM0010",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,12/21/2017,,Biologic,,,No,,Indiana,United States,North America,,23876,51530,136,313,N/A,$158.63B ,,
II,,,10/26/2020,10/26/2020,,Peptide,Subcutaneous (SQ),PDS Biotechnology Corporation,PDSB,PDS0101,,Oncology,Solid,Cervical Cancer,"Human Papillomavirus (HPV),Immune System",,"PDS 0101, PDS-0101, Versamune-HPV, R-enantiomer of 1, 2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7",N,II,10% (Same As Avg.), - , - , - ,,,,,,,11/01/2013,,New Molecular Entity (NME),Rare Disease,,No,,New Jersey,United States,North America,,23785,32763,4624,255,  6%,$56.32M ,Drug Modality,Peptide; Vaccine
I,,,,,,Peptide,Subcutaneous (SQ),PDS Biotechnology Corporation,PDSB,PDS0101,,Oncology,Solid,Cervical Dysplasia,"Human Papillomavirus (HPV),Immune System",,"PDS 0101, PDS-0101, Versamune-HPV, R-enantiomer of 1, 2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7",N,I,6% (Same As Avg.), - , - , - ,,,,,,,11/01/2013,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,23785,32762,4624,256,  3%,$56.32M ,Orphan Drug designation,N/A
Suspended,,,03/02/2012,05/06/2009,,Peptide,Subcutaneous (SQ),Zealand Pharma A/S,ZEAL,Elsiglutide,elsiglutide,Oncology,General,Chemotherapy Induced Diarrhea,GLP-2 Receptor,,"ZP1846, ZP1846-TIDE, Z1846",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,11/27/2008,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,13897,17582,748,2952,N/A,$1.48B ,,
Investigator Initiated,,,,,,Peptide,Subcutaneous (SQ),BioLineRx Ltd.,BLRX,Motixafortide,motixafortide,Oncology,Hematologic,Chronic Myelogenous Leukemia (CML),Chemokine (C-X-C motif) Receptor 4 (CXCR4),Biokine Therapeutics Ltd.,"BKT-140, BKT 140, BKT140, BL8040, BL 8040, BL-8040",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Israel,Asia,,18717,31929,1248,198,N/A,$58.92M ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"SELLAS Life Sciences Group, Inc.",SLS,Zeltherva,galinpepimut-S,Oncology,Hematologic,Chronic Myelogenous Leukemia (CML),"Immune System,Wilms' Tumor Protein 1 (WT1)","3D Medicines Co., Ltd., Memorial Sloan Kettering Cancer Center","SLS001, SLS 001, SLS-001, WT1 Cancer Vaccine, WT-1 Vaccine, Galinpepimut-S (GPS)",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,New York,United States,North America,,25927,45702,5266,198,N/A,$79.06M ,,
I/II,,,04/10/2018,04/10/2018,,Peptide,Subcutaneous (SQ),Treos Bio Limited,,PolyPEPI1018,,Oncology,Solid,Colorectal Cancer (CRC),"Immune System,T lymphocytes",,"PolyPEPI 1018, PolyPEPI-1018, PolyPEPI 4",N,II,10% (Same As Avg.), - , - , - ,,,,,,,,12/21/2017,Biologic,,,No,,,United Kingdom,Europe,,37190,51875,8133,213,  3%, ,Drug Modality,Peptide; Vaccine
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Otsuka Holdings Co., Ltd.",4578,OCV-C02,,Oncology,Solid,Colorectal Cancer (CRC),Tumor Cells,"OncoTherapy Science, Inc.","OCV-C02, OCV-103/104, OTS103/104",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Japan,Asia,,25152,34986,636,213,N/A,$22.58B ,,
Suspended,,,,,11/25/2013,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Pegilodecakin,pegilodecakin,Oncology,Solid,Colorectal Cancer (CRC),IL-10 (Interleukin-10) and IL-10 Receptor (IL-10R),,"AM-0010, AM 0010, PEGylated interleukin-10, LY3500518, LY 3500518, LY-3500518, AM0010",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,11/25/2013,,Biologic,,,No,,Indiana,United States,North America,,23876,46731,136,213,N/A,$158.63B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),OSE Immunotherapeutics,OSE,Tedopi,,Oncology,Solid,Colorectal Cancer (CRC),Immune System,"Chong Kun Dang Pharmaceutical Corp., Takeda Pharmaceutical Co. Ltd.","OSE-2101, OSE2101, OSE 2101, EP2101, EP-2101, EP 2101, IDM2101, IDM-2101, IDM 2101",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,France,Europe,,1051,2571,4523,213,N/A,$175.11M ,,
II,,,03/24/2015,10/01/2014,,Peptide,Subcutaneous (SQ),IMV Inc.,IMV,DPX-Survivac,,Oncology,Hematologic,Diffuse Large B-Cell Lymphoma (DLBCL) - NHL,"Immune System,Survivin",,DPX-Survivac,N,II,12% (2% Above Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Nova Scotia,Canada,North America,,20508,34298,3704,3095,N/A,$231.59M ,,
I/II,,,10/18/2017,10/18/2017,,Peptide,Subcutaneous (SQ),BioLineRx Ltd.,BLRX,Motixafortide,motixafortide,Oncology,Solid,Gastric Cancer,Chemokine (C-X-C motif) Receptor 4 (CXCR4),Biokine Therapeutics Ltd.,"BKT-140, BKT 140, BKT140, BL8040, BL 8040, BL-8040",N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Israel,Asia,,18717,50377,1248,223,  5%,$58.92M ,Orphan Drug designation,N/A
II,,,11/09/2020,11/09/2020,,Peptide,Subcutaneous (SQ),PDS Biotechnology Corporation,PDSB,PDS0101,,Oncology,Solid,Head and Neck Cancer,"Human Papillomavirus (HPV),Immune System",,"PDS 0101, PDS-0101, Versamune-HPV, R-enantiomer of 1, 2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7",N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,23785,49204,4624,230,  3%,$56.32M ,Drug Modality,Peptide; Vaccine
Suspended,,,06/23/2005,06/23/2005,,Peptide,Subcutaneous (SQ),AbbVie Inc.,ABBV,ABT-510,,Oncology,Solid,Head and Neck Cancer,"Fas ligand (FasL),Src Kinase Family,VEGF (Vascular endothelial growth factor)",,ABT-510,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Illinois,United States,North America,,14841,18828,5,230,N/A,$188.39B ,,
Suspended,,,,08/14/2007,,Peptide,Subcutaneous (SQ),AbbVie Inc.,ABBV,ABT-510,,Oncology,Hematologic,Hematologic Cancer,"Fas ligand (FasL),Src Kinase Family,VEGF (Vascular endothelial growth factor)",,ABT-510,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Illinois,United States,North America,,14841,18831,5,196,N/A,$188.39B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Ono Pharmaceutical Company, Ltd.",4528:JP,ONO-7268MX1,,Oncology,Solid,Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases),Immune System,"OncoTherapy Science, Inc.","ONO-7268 MX1, peptide cocktail vaccine",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Japan,Asia,,20579,27444,844,297,N/A,$14.88B ,,
Suspended,,,,08/04/2004,,Peptide,Subcutaneous (SQ),"SciClone Pharmaceuticals, Inc.",SCLN,Zadaxin,thymalfasin,Oncology,Solid,Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases),Immune System,"Alfasigma S.p.A., Merck & Co., Inc.","thymosin alpha 1, thymalfasin",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,California,United States,North America,,883,2467,491,297,N/A, ,,
I,,,,,12/06/2018,Peptide,Subcutaneous (SQ),"Neon Therapeutics, Inc.",,NEO-PV-01,,Oncology,Solid,Melanoma,"Immune System,Tumor Cells",BioNTech SE,"NEO-PV01, NEOPV01, NEO PV 01",N,I,6% (Same As Avg.), - , - , - ,,,,,,,12/06/2018,,Biologic,,,No,,Massachusetts,United States,North America,,32954,49450,6931,221,  3%, ,Orphan Drug designation,N/A
I/II,,,,08/31/2017,,Peptide,Subcutaneous (SQ),IO Biotech ApS,,IO101,,Oncology,Solid,Melanoma,"IDO (Indoleamine 2,3-dioxygenase)",,"IO 101, IO-101",N,II,10% (Same As Avg.), - , - , - ,,,,,,,08/31/2017,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,35926,49942,7764,221,N/A, ,,
I/II,,,12/15/2020,12/15/2020,,Peptide,Subcutaneous (SQ),IO Biotech ApS,,IO102,,Oncology,Solid,Melanoma,"IDO (Indoleamine 2,3-dioxygenase)",,"IO 102, IO-102",N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Breakthrough,,No,,,Denmark,Europe,,35927,49943,7764,221,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),AbbVie Inc.,ABBV,ABT-510,,Oncology,Solid,Melanoma,"Fas ligand (FasL),Src Kinase Family,VEGF (Vascular endothelial growth factor)",,ABT-510,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Illinois,United States,North America,,14841,18848,5,221,N/A,$188.39B ,,
Suspended,,09/28/2004,,,,Peptide,Subcutaneous (SQ),Bristol Myers Squibb Company,BMY,MDX-1379,,Oncology,Solid,Melanoma,"HLA-A,Immune System",,MDX-1379,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Fast Track,,No,,New York,United States,North America,,1744,2780,73,221,N/A,$140.92B ,,
Suspended,,,,,11/25/2013,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Pegilodecakin,pegilodecakin,Oncology,Solid,Melanoma,IL-10 (Interleukin-10) and IL-10 Receptor (IL-10R),,"AM-0010, AM 0010, PEGylated interleukin-10, LY3500518, LY 3500518, LY-3500518, AM0010",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,11/25/2013,,Biologic,,,No,,Indiana,United States,North America,,23876,46727,136,221,N/A,$158.63B ,,
Suspended,,11/17/2008,,08/04/2004,,Peptide,Subcutaneous (SQ),"SciClone Pharmaceuticals, Inc.",SCLN,Zadaxin,thymalfasin,Oncology,Solid,Melanoma,Immune System,"Alfasigma S.p.A., Merck & Co., Inc.","thymosin alpha 1, thymalfasin",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,SPA",,No,,California,United States,North America,,883,2465,491,221,N/A, ,,
II,,,,09/04/2014,,Peptide,Subcutaneous (SQ),"SELLAS Life Sciences Group, Inc.",SLS,Zeltherva,galinpepimut-S,Oncology,Solid,Mesothelioma,"Immune System,Wilms' Tumor Protein 1 (WT1)","3D Medicines Co., Ltd., Memorial Sloan Kettering Cancer Center","SLS001, SLS 001, SLS-001, WT1 Cancer Vaccine, WT-1 Vaccine, Galinpepimut-S (GPS)",N,II,15% (5% Above Avg.), - , - , - ,,,,,,,11/09/2006,,New Molecular Entity (NME),"Fast Track,Orphan,Rare Disease",,No,,New York,United States,North America,,25927,36144,5266,652, 16%,$79.06M ,Fast Track,Yes
I/II,,,03/18/2009,07/24/2012,,Peptide,Subcutaneous (SQ),BioLineRx Ltd.,BLRX,Motixafortide,motixafortide,Oncology,Hematologic,Multiple Myeloma (MM),Chemokine (C-X-C motif) Receptor 4 (CXCR4),Biokine Therapeutics Ltd.,"BKT-140, BKT 140, BKT140, BL8040, BL 8040, BL-8040",Y,II,10% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Israel,Asia,,18717,24590,1248,207, 21%,$58.92M ,Orphan Drug designation,Yes
I/II,,,,06/30/2014,,Peptide,Subcutaneous (SQ),"SELLAS Life Sciences Group, Inc.",SLS,Zeltherva,galinpepimut-S,Oncology,Hematologic,Multiple Myeloma (MM),"Immune System,Wilms' Tumor Protein 1 (WT1)","3D Medicines Co., Ltd., Memorial Sloan Kettering Cancer Center","SLS001, SLS 001, SLS-001, WT1 Cancer Vaccine, WT-1 Vaccine, Galinpepimut-S (GPS)",N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Fast Track,Orphan,Rare Disease",,No,,New York,United States,North America,,25927,36145,5266,207, 24%,$79.06M ,Fast Track,Yes
Investigator Initiated,,,,,,Peptide,Subcutaneous (SQ),"MimiVax, LLC",,SurVaxM,,Oncology,Hematologic,Multiple Myeloma (MM),"Immune System,Survivin","Shanghai Fosun Pharmaceutical (Group) Co., Ltd.","SVN53-67/M57-KLH Peptide Vaccine, DRU-2017-5947, SurvVax-M",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,New York,United States,North America,,26862,37542,5532,207,N/A, ,,
I,,,,,05/19/2016,Peptide,Subcutaneous (SQ),Enesi Pharma Limited,,Glide Octreotide,octreotide acetate,Oncology,Solid,Neuroendocrine Tumors (NET),Somatostatin Receptors,,octreotide acetate,Y,I,6% (Same As Avg.), - , - , - ,,,,,,,05/19/2016,,Non-NME,Rare Disease,,No,,,United Kingdom,Europe,,24425,33880,4510,347,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Midatech Pharma PLC,MTPH,Q-Octreotide,octreotide acetate,Oncology,Solid,Neuroendocrine Tumors (NET),Somatostatin Receptors,China Medical System Holdings Limited,"MTD201, MTD 201, MTD-201, Q Chip",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,Rare Disease,,No,,,United Kingdom,Europe,,29117,57403,3464,347,N/A,$23.58M ,,
Suspended,,,07/24/2012,07/24/2012,,Peptide,Subcutaneous (SQ),BioLineRx Ltd.,BLRX,Motixafortide,motixafortide,Oncology,Hematologic,Non-Hodgkin's Lymphoma (NHL),Chemokine (C-X-C motif) Receptor 4 (CXCR4),Biokine Therapeutics Ltd.,"BKT-140, BKT 140, BKT140, BL8040, BL 8040, BL-8040",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Orphan,,No,,,Israel,Asia,,18717,28085,1248,205,N/A,$58.92M ,,
I,,,,,03/07/2018,Peptide,Subcutaneous (SQ),"Neon Therapeutics, Inc.",,NEO-PV-01,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),"Immune System,Tumor Cells",BioNTech SE,"NEO-PV01, NEOPV01, NEO PV 01",N,I,6% (Same As Avg.), - , - , - ,,,,,,,03/07/2018,,Biologic,,,No,,Massachusetts,United States,North America,,32954,51526,6931,211,  2%, ,Orphan Drug designation,N/A
I/II,,,08/22/2018,08/22/2018,,Peptide,Subcutaneous (SQ),IO Biotech ApS,,IO102,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),"IDO (Indoleamine 2,3-dioxygenase)",,"IO 102, IO-102",N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Denmark,Europe,,35927,52380,7764,211,  3%, ,Drug Modality,Peptide; Vaccine
IIb,,,,12/18/2007,,Peptide,Subcutaneous (SQ),Vaxon Biotech,,Vx-001,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),"Immune System,Telomerase",,Vx001,Y,II,10% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Orphan,,No,,,France,Europe,,29121,40455,6138,211,N/A, ,,
III,01/06/2016,01/06/2016,,12/21/2004,,Peptide,Subcutaneous (SQ),OSE Immunotherapeutics,OSE,Tedopi,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),Immune System,"Chong Kun Dang Pharmaceutical Corp., Takeda Pharmaceutical Co. Ltd.","OSE-2101, OSE2101, OSE 2101, EP2101, EP-2101, EP 2101, IDM2101, IDM-2101, IDM 2101",Y,III,32% (3% Below Avg.), - , - , - ,,,,,Now - 03/31/2021,,09/28/2004,,New Molecular Entity (NME),Orphan,,No,,,France,Europe,,1051,1293,4523,211, 15%,$175.11M ,Drug Modality,Vaccine
Investigator Initiated,,,,,,Peptide,Subcutaneous (SQ),IO Biotech ApS,,IO101,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),"IDO (Indoleamine 2,3-dioxygenase)",,"IO 101, IO-101",Y,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,35926,49941,7764,211,N/A, ,,
Suspended,,,03/01/2018,03/01/2018,11/25/2013,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Pegilodecakin,pegilodecakin,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),IL-10 (Interleukin-10) and IL-10 Receptor (IL-10R),,"AM-0010, AM 0010, PEGylated interleukin-10, LY3500518, LY 3500518, LY-3500518, AM0010",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,11/25/2013,,Biologic,,,No,,Indiana,United States,North America,,23876,46728,136,211,N/A,$158.63B ,,
I/II,,,05/02/2016,05/02/2016,,Peptide,Subcutaneous (SQ),"SELLAS Life Sciences Group, Inc.",SLS,Zeltherva,galinpepimut-S,Oncology,Solid,Ovarian Cancer,"Immune System,Wilms' Tumor Protein 1 (WT1)","3D Medicines Co., Ltd., Memorial Sloan Kettering Cancer Center","SLS001, SLS 001, SLS-001, WT1 Cancer Vaccine, WT-1 Vaccine, Galinpepimut-S (GPS)",N,II,11% (1% Above Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,New York,United States,North America,,25927,40577,5266,224,  5%,$79.06M ,Trial Outcome,Positive Result
II,,,,06/20/2011,,Peptide,Subcutaneous (SQ),IMV Inc.,IMV,DPX-Survivac,,Oncology,Solid,Ovarian Cancer,"Immune System,Survivin",,DPX-Survivac,N,II,12% (2% Above Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Fast Track,Orphan,Rare Disease",,No,,Nova Scotia,Canada,North America,,20508,27340,3704,224, 10%,$231.59M ,Fast Track,Yes
Preclinical,,,,,,Peptide,Subcutaneous (SQ),ValiRx Plc,VAL,VAL201,,Oncology,Solid,Ovarian Cancer,"Androgen receptors,Src Kinase Family",Cancer Research Technology Ltd.,"VAL 201, VAL-201",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,United Kingdom,Europe,,20954,28859,3920,224,N/A,$18.30M ,,
Suspended,,,,,03/02/2015,Peptide,Subcutaneous (SQ),Almac Group,,ALM201,,Oncology,Solid,Ovarian Cancer,Microtubules (Tubulin),"Shin Poong Pharm Co., Ltd.",ALM201,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/02/2015,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,United Kingdom,Europe,,22001,29764,2745,224,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),IMV Inc.,IMV,DPX-0907,,Oncology,Solid,Ovarian Cancer,"Abelson Interactor 2 (Abi-2),B-cell receptor-associated protein 31(Bap31),Epithelial Discoidin Domain Receptor 1 (EDDR1),Immune System,Integrin Beta-8 (ITGB8),Junction Plakoblobin (JUP)/Gamma-Catenin,TACE/ADAM 17,Topoisomerase II (DNA gyrase)",,DPX-0907,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Nova Scotia,Canada,North America,,20057,29436,3704,224,N/A,$231.59M ,,
Suspended,,,,,11/25/2013,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Pegilodecakin,pegilodecakin,Oncology,Solid,Ovarian Cancer,IL-10 (Interleukin-10) and IL-10 Receptor (IL-10R),,"AM-0010, AM 0010, PEGylated interleukin-10, LY3500518, LY 3500518, LY-3500518, AM0010",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,11/25/2013,,Biologic,Rare Disease,,No,,Indiana,United States,North America,,23876,54927,136,224,N/A,$158.63B ,,
IIb,,,09/20/2016,09/20/2016,,Peptide,Subcutaneous (SQ),BioLineRx Ltd.,BLRX,Motixafortide,motixafortide,Oncology,Solid,Pancreatic Cancer,Chemokine (C-X-C motif) Receptor 4 (CXCR4),Biokine Therapeutics Ltd.,"BKT-140, BKT 140, BKT140, BL8040, BL 8040, BL-8040",N,II,12% (2% Above Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Israel,Asia,,18717,38216,1248,220, 11%,$58.92M ,Orphan Drug designation,Yes
Suspended,,,,,,Peptide,Subcutaneous (SQ),"OncoTherapy Science, Inc.",4564:JP,OCV-101,,Oncology,Solid,Pancreatic Cancer,Angiogenesis,,OTS11101,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,,Japan,Asia,,26143,36441,3322,220,N/A,$203.86M ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Otsuka Holdings Co., Ltd.",4578,Elpamotide,,Oncology,Solid,Pancreatic Cancer,VEGF Receptor (VEGFR),FUSO Pharmaceutical Industries Ltd.,"OTS102, OTS-102",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,,Japan,Asia,,25149,34979,636,220,N/A,$22.58B ,,
Suspended,01/03/2017,01/03/2017,,,11/25/2013,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Pegilodecakin,pegilodecakin,Oncology,Solid,Pancreatic Cancer,IL-10 (Interleukin-10) and IL-10 Receptor (IL-10R),,"AM-0010, AM 0010, PEGylated interleukin-10, LY3500518, LY 3500518, LY-3500518, AM0010",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,11/25/2013,,Biologic,"Fast Track,Orphan,Rare Disease",,No,,Indiana,United States,North America,,23876,32909,136,220,N/A,$158.63B ,,
II,,,10/30/2019,10/30/2019,,Peptide,Subcutaneous (SQ),"Protagonist Therapeutics, Inc.",PTGX,PTG-300,Hepcidin Mimetic Peptide,Oncology,Hematologic,Polycythemia Vera (PV),Hepcidin,,"PTG300, PTG 300",N,II,12% (2% Above Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Fast Track,Orphan,Rare Disease",,No,,California,United States,North America,,30855,57772,4983,3053, 30%,$890.35M ,Fast Track,Yes
I/II,,,10/14/2014,10/14/2014,06/13/2013,Peptide,Subcutaneous (SQ),ValiRx Plc,VAL,VAL201,,Oncology,Solid,Prostate Cancer,"Androgen receptors,Src Kinase Family",Cancer Research Technology Ltd.,"VAL 201, VAL-201",Y,II,10% (Same As Avg.), - , - , - ,,,,,,,06/13/2013,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,20954,28105,3920,215,N/A,$18.30M ,,
IIb,,,,03/30/2017,,Peptide,Subcutaneous (SQ),RhoVac AB,RHOVAC,RV001,,Oncology,Solid,Prostate Cancer,"Immune System,Rho GTPase/Rho Kinase,Tumor Cells",,"RV 001, RV-001, RV001V",N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Fast Track,,No,,,Sweden,Europe,,35426,49201,7597,215,N/A, ,,
NDA,09/08/2014,09/08/2014,,,,Peptide,Subcutaneous (SQ),"Foresee Pharmaceuticals Co., Ltd.",6576,FP-001,leuprolide mesylate,Oncology,Solid,Prostate Cancer,Gonadotropin-Releasing Hormone (GnRH),"Accord Healthcare Ltd., GeneScience Pharmaceuticals Co., Ltd., MegaPharm Ltd., TRPharm AS","FP 001, FP001, LMIS (Leuprolide Mesylate Injectable Suspension), LMIS, leuprorelin depot, Camcevi (EU)",Y,NDA/BLA,82% (Same As Avg.),05/27/2021 - 05/27/2021,02/01/2021 - 08/31/2021, - ,,,,05/27/2021,,07/27/2020,,,Non-NME,505b2,,No,,,Taiwan,Asia,,33707,46556,7120,215, 94%,$344.15M ,Target has prior approval,Yes
Preclinical,,,,,,Peptide,Subcutaneous (SQ),Veru Inc.,VERU,VERU-100,,Oncology,Solid,Prostate Cancer,Gonadotropin-Releasing Hormone (GnRH) Receptor,,"VERU100, VERU 100",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Florida,United States,North America,,40534,56790,7667,215,N/A,$679.73M ,,
Suspended,05/29/2012,03/10/2011,,,,Peptide,Subcutaneous (SQ),Ipsen SA,IPSEY,Somatuline Autogel,lanreotide acetate,Oncology,Solid,Prostate Cancer,Somatostatin Receptors,Teijin Pharma Limited.,"Somatuline Depot, lanreotide acetate, Somatostatin Analogue",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,"EQ 120MG BASE/0.5ML (EQ 120MG  (SOLUTION;SUBCUTANEOUS), EQ 60MG BASE/0.2ML (EQ 60MG BA (SOLUTION;SUBCUTANEOUS), EQ 90MG BASE/0.3ML (EQ 90MG BA (SOLUTION;SUBCUTANEOUS)",,France,Europe,,3015,23721,220,215,N/A,$4.57B ,,
Suspended,,,11/23/2010,11/23/2010,,Peptide,Subcutaneous (SQ),Myovant Sciences Ltd.,MYOV,RVT-602,,Oncology,Solid,Prostate Cancer,Gonadotropin-Releasing Hormone (GnRH),"Roivant Sciences, Takeda Pharmaceutical Co. Ltd.","MVT-602, MVT602, MVT 602, TAK-448, TAK448, TAK 448, RVT602, RVT 602",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,02/01/2012,,New Molecular Entity (NME),,,No,,California,United Kingdom,Europe,,20846,27907,6241,215,N/A,$2.28B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),FUJIFILM Holdings Corp.,TYO:4901,ITK-1,,Oncology,Solid,Prostate Cancer,"HLA-A,Immune System","BrightPath Biotherapeutics Co., Ltd","ITK1, ITK 1",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Japan,Asia,,27672,38811,4929,215,N/A, ,,
Suspended,,,,08/14/2007,,Peptide,Subcutaneous (SQ),AbbVie Inc.,ABBV,ABT-510,,Oncology,Solid,Renal Cell Cancer (RCC),"Fas ligand (FasL),Src Kinase Family,VEGF (Vascular endothelial growth factor)",,ABT-510,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Illinois,United States,North America,,14841,18827,5,216,N/A,$188.39B ,,
Suspended,,,,07/07/2011,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,LY2510924,,Oncology,Solid,Renal Cell Cancer (RCC),Chemokine (C-X-C motif) Receptor 4 (CXCR4),,"LY2510924, CXCR4 Peptide Antagonist (Eli Lilly), LY 2510924, LY-2510924",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,Indiana,United States,North America,,18573,24379,136,216,N/A,$158.63B ,,
Suspended,,,,,11/25/2013,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Pegilodecakin,pegilodecakin,Oncology,Solid,Renal Cell Cancer (RCC),IL-10 (Interleukin-10) and IL-10 Receptor (IL-10R),,"AM-0010, AM 0010, PEGylated interleukin-10, LY3500518, LY 3500518, LY-3500518, AM0010",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,11/25/2013,,Biologic,Rare Disease,,No,,Indiana,United States,North America,,23876,46729,136,216,N/A,$158.63B ,,
Suspended,,,,11/28/2007,,Peptide,Subcutaneous (SQ),AbbVie Inc.,ABBV,ABT-510,,Oncology,Solid,Sarcoma,"Fas ligand (FasL),Src Kinase Family,VEGF (Vascular endothelial growth factor)",,ABT-510,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Illinois,United States,North America,,14841,18830,5,610,N/A,$188.39B ,,
Suspended,,,10/14/2011,10/14/2011,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,LY2510924,,Oncology,Solid,Small Cell Lung Cancer (SCLC),Chemokine (C-X-C motif) Receptor 4 (CXCR4),,"LY2510924, CXCR4 Peptide Antagonist (Eli Lilly), LY 2510924, LY-2510924",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,Indiana,United States,North America,,18573,25894,136,111,N/A,$158.63B ,,
I,,,,,10/03/2016,Peptide,Subcutaneous (SQ),"Neon Therapeutics, Inc.",,NEO-PV-01,,Oncology,Solid,Solid Tumors,"Immune System,Tumor Cells",BioNTech SE,"NEO-PV01, NEOPV01, NEO PV 01",Y,I,6% (Same As Avg.), - , - , - ,,,,,,,10/03/2016,,Biologic,,,No,,Massachusetts,United States,North America,,32954,45494,6931,197,  3%, ,Indication,"Cancer, solid, unspecified"
I,,,,,10/20/2016,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,LY2510924,,Oncology,Solid,Solid Tumors,Chemokine (C-X-C motif) Receptor 4 (CXCR4),,"LY2510924, CXCR4 Peptide Antagonist (Eli Lilly), LY 2510924, LY-2510924",N,I,6% (Same As Avg.), - , - , - ,,,,,,,10/20/2016,,Biologic,,,No,,Indiana,United States,North America,,18573,44179,136,197,N/A,$158.63B ,,
II,,,02/07/2019,02/07/2019,,Peptide,Subcutaneous (SQ),IMV Inc.,IMV,DPX-Survivac,,Oncology,Solid,Solid Tumors,"Immune System,Survivin",,DPX-Survivac,N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Nova Scotia,Canada,North America,,20508,33018,3704,197,  3%,$231.59M ,Drug Modality,Peptide; Vaccine
IND,,,,,,Peptide,Subcutaneous (SQ),BioLineRx Ltd.,BLRX,Motixafortide,motixafortide,Oncology,Solid,Solid Tumors,Chemokine (C-X-C motif) Receptor 4 (CXCR4),Biokine Therapeutics Ltd.,"BKT-140, BKT 140, BKT140, BL8040, BL 8040, BL-8040",N,IND,0% (Same As Avg.), - , - , - ,,,,,,,,06/01/2017,New Molecular Entity (NME),,,No,,,Israel,Asia,,18717,43085,1248,197,N/A,$58.92M ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),Medicenna Therapeutics Corp.,MDNAF,MDNA11,,Oncology,Solid,Solid Tumors,IL-2 Receptor (IL-2R) ,,"MDNA 11, MDNA-11",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Ontario,Canada,North America,,42372,59613,6304,197,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),AbbVie Inc.,ABBV,ABT-510,,Oncology,Solid,Solid Tumors,"Fas ligand (FasL),Src Kinase Family,VEGF (Vascular endothelial growth factor)",,ABT-510,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/01/2005,,New Molecular Entity (NME),,,No,,Illinois,United States,North America,,14841,18829,5,197,N/A,$188.39B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),IMV Inc.,IMV,DPX-0907,,Oncology,Solid,Solid Tumors,"Abelson Interactor 2 (Abi-2),B-cell receptor-associated protein 31(Bap31),Epithelial Discoidin Domain Receptor 1 (EDDR1),Immune System,Integrin Beta-8 (ITGB8),Junction Plakoblobin (JUP)/Gamma-Catenin,TACE/ADAM 17,Topoisomerase II (DNA gyrase)",,DPX-0907,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/26/2010,,New Molecular Entity (NME),,,No,,Nova Scotia,Canada,North America,,20057,26646,3704,197,N/A,$231.59M ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Medicenna Therapeutics Corp.,MDNAF,MDNA19,,Oncology,Solid,Solid Tumors,"Cluster of Differentiation 122 (CD122),IL-2 Receptor (IL-2R) ",,"MDNA109, MDNA 109, MDNA-109, MDNA-19, MDNA 19, MDNA109-LA1, MDNA109LA1, MDNA109 LA1",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Ontario,Canada,North America,,38698,54026,6304,197,N/A, ,,
III,05/08/2019,05/08/2019,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Ozempic,semaglutide,Ophthalmology,Retinopathy,Diabetic Retinopathy (Ophthalmology),GLP-1 Receptor,,"Once-weekly GLP-1 analogue, NN9536, NN 9536, NN-9536, NN 9535, NN9535, NN-9535, semaglutide injection",N,III,51% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,10488,56641,292,364,N/A,$108.42B ,,
Suspended,,03/05/2009,,,,Peptide,Subcutaneous (SQ),Teva Pharmaceutical Industries Ltd.,TEVA,Copaxone,glatiramer acetate,Ophthalmology,Other,Optic Neuritis (Ophthalmology),"Myelin,T lymphocytes","Sanofi, Takeda Pharmaceutical Co. Ltd.","COP-1, copolymer-1, glatiramer acetate",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,"20MG/ML (INJECTABLE;SUBCUTANEOUS), 40MG/ML (INJECTABLE;SUBCUTANEOUS)",,Israel,Asia,100%,595,21432,375,2486,N/A,$12.20B ,,
Suspended,,,02/07/2006,,,Peptide,Subcutaneous (SQ),Ipsen SA,IPSEY,Somatuline Autogel,lanreotide acetate,Ophthalmology,Other,Thyroid Eye Disease (TED),Somatostatin Receptors,Teijin Pharma Limited.,"Somatuline Depot, lanreotide acetate, Somatostatin Analogue",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,"EQ 120MG BASE/0.5ML (EQ 120MG  (SOLUTION;SUBCUTANEOUS), EQ 60MG BASE/0.2ML (EQ 60MG BA (SOLUTION;SUBCUTANEOUS), EQ 90MG BASE/0.3ML (EQ 90MG BA (SOLUTION;SUBCUTANEOUS)",,France,Europe,,3015,31611,220,3373,N/A,$4.57B ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Kineta, Inc.",,Dalazatide,dalazatide,Ophthalmology,Uveitis,Uveitis (Ophthalmology),Potassium channels,"Kv1.3 Therapeutics, Inc.","ShK186, ShK 186, ShK-186",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/19/2015,,New Molecular Entity (NME),Rare Disease,,No,,Washington,United States,North America,,20882,35421,3909,307,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),Shionogi & Co. Ltd.,4507,S-646240,,Ophthalmology,Macular Degeneration,Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology),Unknown,"OncoTherapy Science, Inc.",S-646240,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Vaccine,,,No,,,Japan,Asia,,20515,27348,618,162,N/A,$17.14B ,,
II,,,07/16/2012,07/16/2012,,Peptide,Subcutaneous (SQ),Allergan plc,AGN,Relamorelin,relamorelin,Psychiatry,Other,Eating Disorders,Ghrelin Receptor,"Ipsen SA, Rhythm Pharmaceuticals, Inc.","RM-131, RM131, RM 131, BIM-28131, BIM 28131, BIM28131",N,II,12% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Ireland,Europe,,19879,27604,395,2951,N/A,$63.66B ,,
Preclinical,,,,,,Peptide,Subcutaneous (SQ),Ferring Pharmaceuticals,,FP-004,,Psychiatry,Other,Substance Use Disorder,Opioid receptors,"Foresee Pharmaceuticals Co., Ltd.","Stabilized Injectable Formulation Peptide, FP 004, FP004",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,Switzerland,Europe,,33713,46564,582,560,N/A, ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Kineta, Inc.",,Dalazatide,dalazatide,Respiratory,Asthma,Asthma,Potassium channels,"Kv1.3 Therapeutics, Inc.","ShK186, ShK 186, ShK-186",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,05/10/2016,,New Molecular Entity (NME),,,No,,Washington,United States,North America,,20882,33180,3909,72,N/A, ,,
Suspended,,,,03/03/2011,,Peptide,Subcutaneous (SQ),"Palatin Technologies, Inc.",PTN,PL-3994,,Respiratory,Asthma,Asthma,Natriuretic Peptide Receptors,,PL3994,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,8649,22586,504,72,N/A,$162.89M ,,
Suspended,,,,,,Peptide,Subcutaneous (SQ),"Digna Biotech, S.L.",,Disitertide (Subcutaneous),,Respiratory,Other,Pulmonary Fibrosis,Transforming Growth Factor-beta (TGF-beta) and Superfamily,,"P-144, NAFB001, P144 SC",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Spain,Europe,,21895,29592,3227,388,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),Shionogi & Co. Ltd.,4507,S-588410,,Oncology,Solid,Bladder Cancer,Immune System,"OncoTherapy Science, Inc.","S588410, S 588410",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Japan,Asia,,23817,32812,618,217,N/A,$17.14B ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),ORYX GmbH & Co. KG,,MicOryx,,Oncology,Solid,Colorectal Cancer (CRC),Immune System,,"Micoryx, FSP peptides",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Germany,Europe,,39011,54545,8694,213,N/A, ,,
Development Outside U.S.,,,,,04/16/2018,Peptide,Subcutaneous (SQ),Adocia,ADOC:FP,Biochaperone Lispro Pramlintide,insulin lispro recombinant and pramlintide acetate,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,BioChaperone LisPram,N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,France,Europe,,33058,45632,4106,157,N/A,$73.14M ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),"Scohia Pharma, Inc.",,TAK-094,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GIP Receptor (GIPR)/Glucose-Dependent Insulinotropic Polypeptide Receptor,GLP-1 Receptor",,TAK 094,N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Japan,Asia,,35012,48508,7495,137,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),Peptron inc.,087010,SR-Exenatide,exenatide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,"sustained-release (SR) exenatide, Sustained-Release Exendin-4, PT302, PT 302, PT-302",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,Korea (South),Asia,,37882,52865,8353,137,N/A,$319.51M ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),"EyeGene, Inc.",185490,EG-Mirotin,,Ophthalmology,Retinopathy,Diabetic Retinopathy (Ophthalmology),Angiopoietins,,"EC-Mirotin, EGMirotin, EC Mirotin, EGT 022, EGT022, EGT-022, Eyegene-1",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Korea (South),Asia,,41562,58304,11071,364,N/A,$139.50M ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),Shionogi & Co. Ltd.,4507,S-588410,,Oncology,Solid,Esophageal Cancer,Immune System,"OncoTherapy Science, Inc.","S588410, S 588410",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Japan,Asia,,23817,37154,618,273,N/A,$17.14B ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),Ergomed plc,ERGO,ReadyFlow,,Hematology,Other,Hemostasis,Fibrinogen (Coagulation Factor I),"Boryung Pharmaceutical Co., Ltd.","HXP 12, HXP12, HXP-12",N,,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,United Kingdom,Europe,,36149,50285,2616,672,N/A,$741.71M ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),MYR GmbH,,Hepcludex,bulevirtide,Infectious Disease,Antiviral,Hepatitis B (HBV) Treatment (Antiviral),"Hepatitis B/HBV,Hepatitis D/HDV",Hepatera,"MyrcludexB, Myrcludex-B, Bulevirtide",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Germany,Europe,,24721,34351,4876,319,N/A, ,,
Development Outside U.S.,,,05/02/2017,,,Peptide,Subcutaneous (SQ),Stealth BioTherapeutics Inc.,MITO,SBT-20,,Neurology,Neurodegenerative,Huntington's Disease,Mitochondria,,"SBT20, SBT 20",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Massachusetts,United States,North America,,34740,48111,3274,296,N/A,$7.02M ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),"Kineta, Inc.",,KCP506,,Neurology,Pain,Inflammatory Pain,Nicotinic Acetylcholine Receptors (nAChR) ,"Kv1.3 Therapeutics, Inc., Roche Holding AG","Conopeptide, RgIA, U2902, CSP-4, KCP-400, KCP 506, KCP-506",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Washington,United States,North America,,24500,34010,3909,3138,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),Shionogi & Co. Ltd.,4507,S-005151,Redasemtide,Neurology,Stroke,Ischemic Stroke,,StemRIM Inc.,"S-005151, S005151",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Japan,Asia,,40276,56360,618,145,N/A,$17.14B ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),CuroNZ,,NRP2945,,Neurology,Seizure Disorders (Epilepsy),Lennox-Gastaut Syndrome (LGS; Epilepsy),,,"NRP 2945, NRP-2945",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,New Zealand,Oceania,,37108,51746,8103,3008,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),Shionogi & Co. Ltd.,4507,S-005151,Redasemtide,Gastroenterology (Non Inflammatory Bowel Disease),Other,Liver Failure / Cirrhosis,,StemRIM Inc.,"S-005151, S005151",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,,Japan,Asia,,40276,60709,618,2866,N/A,$17.14B ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),Novartis AG,NVS,CAM2029,octreotide,Oncology,Solid,Neuroendocrine Tumors (NET),Somatostatin Receptors,Camurus AB,"octreotide chloride Fluid, Crystal injection depot, CAM 2029, CAM-2029",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,Rare Disease,,No,,,Switzerland,Europe,,18116,23675,289,347,N/A,$183.31B ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),"Kineta, Inc.",,KCP506,,Neurology,Pain,Neuropathic Pain,Nicotinic Acetylcholine Receptors (nAChR) ,"Kv1.3 Therapeutics, Inc., Roche Holding AG","Conopeptide, RgIA, U2902, CSP-4, KCP-400, KCP 506, KCP-506",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Washington,United States,North America,,24500,34009,3909,362,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,LY3305677,oxyntomodulin,Metabolic,Obesity,Obesity,"GLP-1 Receptor,Glucagon Receptor","Innovent Biologics, Inc.","LY 3305677, LY-3305677, Oxyntomodulin (Eli Lilly), OXM3, IBI362, IBI 362, IBI-362",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Indiana,United States,North America,,32894,60131,136,135,N/A,$158.63B ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),Shionogi & Co. Ltd.,4507,S-005151,Redasemtide,Rheumatology (Non Autoimmune),Osteoarthritis,Osteoarthritis and Osteoarthritis Pain,,StemRIM Inc.,"S-005151, S005151",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Japan,Asia,,40276,60708,618,249,N/A,$17.14B ,,
Development Outside U.S.,,,02/26/2019,,,Peptide,Subcutaneous (SQ),OSE Immunotherapeutics,OSE,Tedopi,,Oncology,Solid,Pancreatic Cancer,Immune System,"Chong Kun Dang Pharmaceutical Corp., Takeda Pharmaceutical Co. Ltd.","OSE-2101, OSE2101, OSE 2101, EP2101, EP-2101, EP 2101, IDM2101, IDM-2101, IDM 2101",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,France,Europe,,1051,50009,4523,220,N/A,$175.11M ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),Debiopharm S.A.,,Debio 8206,triptorelin pamoate,Oncology,Solid,Prostate Cancer,Gonadotropin-Releasing Hormone (GnRH) Receptor,,"subcutaneous Trelstar (long acting 6 month), triptorelin pamoate, Debio8206, Debio-8206",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,20706,27690,856,215,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),Camurus AB,CAMX,Prosenze,leuprolide acetate,Oncology,Solid,Prostate Cancer,Gonadotropin-Releasing Hormone (GnRH) Receptor,,"CAM2032, CAM 2032",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,,Sweden,Europe,,24567,34121,2067,215,N/A,$1.21B ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),CuroNZ,,NRP2945,,Neurology,Seizure Disorders (Epilepsy),Seizure Disorders (Epilepsy),,,"NRP 2945, NRP-2945",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,New Zealand,Oceania,,37108,51755,8103,272,N/A, ,,
Development Outside U.S.,09/26/2016,,,,,Peptide,Subcutaneous (SQ),"SciClone Pharmaceuticals, Inc.",SCLN,Zadaxin,thymalfasin,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Sepsis and Septic Shock,Immune System,"Alfasigma S.p.A., Merck & Co., Inc.","thymosin alpha 1, thymalfasin",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,883,38421,491,76,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),"Hanmi Pharmaceutical Co., Ltd.",128940,HM10560A,efpegsomatropin,Endocrine,Short Stature,Short Stature / Growth Hormone Deficiency,Growth hormone receptor (GHR),,"LAPS-hGH, LAPSrhGH",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Korea (South),Asia,,18639,24473,3379,285,N/A,$4.34B ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),ORYX GmbH & Co. KG,,VicOryx,,Oncology,Solid,Solid Tumors,"Cyclin Dependent Kinase (CDK),Immune System",,"Vicoryx, P16_37-63, p16INK4a peptide",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Germany,Europe,,39014,54550,8694,197,N/A, ,,
Development Outside U.S.,,,01/31/2018,,,Peptide,Subcutaneous (SQ),"Otsuka Holdings Co., Ltd.",4578,TAS0313,,Oncology,Solid,Solid Tumors,,,"TAS 0313, TAS-0313",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Vaccine,,,No,,,Japan,Asia,,38399,53621,636,197,N/A,$22.58B ,,
Development Outside U.S.,,,,,,Peptide,Subcutaneous (SQ),Promore Pharma AB,PROMO,PXL-01,,Not Specified,Other,Surgical and Procedure Complications,Lactoferrin Receptor,"Cellastra Inc., PharmaResearch Products Ltd.","PXL01, PXL 01",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Sweden,Europe,,20613,27521,3854,2887,N/A,$13.68M ,,
BLA,01/29/2016,01/29/2016,01/09/2013,09/07/2012,12/22/2009,Peptide,Subcutaneous (SQ),Spectrum Pharmaceuticals Inc.,SPPI,Rolontis,eflapegrastim,Hematology,Marrow Or Peripheral Blood Stimulator,Neutropenia / Leukopenia,Granulocyte-colony Stimulating Factor (G-CSFR)/CD114,"Hanmi Pharmaceutical Co., Ltd.","conjugated GCSF, LAPS-GCSF, SPI-2012, SPI2012, SPI 2012, HNK460, HNK 460, HNK-460, HM10460A, HM 10460A, HM-10460A",N,NDA/BLA,90% (6% Above Avg.),10/23/2020 - 02/28/2021, - , - ,,,,Now - 02/28/2021,,12/27/2018,12/22/2009,,New Molecular Entity (NME),,,No,,Nevada,United States,North America,,18641,24475,270,91,N/A,$547.21M ,,
Approved in other than U.S./E.U.,,,,,,Peptide,Subcutaneous (SQ),GC Pharma,006280,Biosimilar Lantus (Green Cross),insulin glargine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,Glia,N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biosimilar,,,No,,,Korea (South),Asia,,37555,52363,3826,157,N/A,$4.44B ,,
Approved in other than U.S./E.U.,,,,,,Peptide,Subcutaneous (SQ),"Jiangsu Hansoh Pharmaceutical Group Co., Ltd",,PEX168,polyethylene glycol loxenatide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,"PEX-168, Polyethylene Glycol Loxenatide, PEX 168",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,China,Asia,,40810,57254,9289,137,N/A, ,,
Approved in other than U.S./E.U.,,,,,,Peptide,Subcutaneous (SQ),GC Pharma,006280,Biosimilar Lantus (Green Cross),insulin glargine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,Glia,N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biosimilar,,,No,,,Korea (South),Asia,,37555,52364,3826,137,N/A,$4.44B ,,
Approved in other than U.S./E.U.,,,,,,Peptide,Subcutaneous (SQ),"SciClone Pharmaceuticals, Inc.",SCLN,Zadaxin,thymalfasin,Infectious Disease,Antiviral,Hepatitis B (HBV) Treatment (Antiviral),Immune System,"Alfasigma S.p.A., Merck & Co., Inc.","thymosin alpha 1, thymalfasin",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,883,2466,491,319,N/A, ,,
Approved in other than U.S./E.U.,09/15/2003,09/15/2003,,,,Peptide,Subcutaneous (SQ),"SciClone Pharmaceuticals, Inc.",SCLN,Zadaxin,thymalfasin,Infectious Disease,Antiviral,Hepatitis C (HCV) (Antiviral),Immune System,"Alfasigma S.p.A., Merck & Co., Inc.","thymosin alpha 1, thymalfasin",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Orphan,,No,,California,United States,North America,,883,1038,491,176,N/A, ,,
Approved in other than U.S./E.U.,,,,01/12/2010,,Peptide,Subcutaneous (SQ),"SciClone Pharmaceuticals, Inc.",SCLN,Zadaxin,thymalfasin,Infectious Disease,Antiviral,Influenza (excluding vaccines),Immune System,"Alfasigma S.p.A., Merck & Co., Inc.","thymosin alpha 1, thymalfasin",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,883,21965,491,3302,N/A, ,,
Approved in other than U.S./E.U.,,,,,,Peptide,Subcutaneous (SQ),Asahi Kasei Corporation,AHKSY,Teribone,teriparatide acetate,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Parathyroid Hormone Receptor (PTHR),,"teriparatide acetate, MN-10-T",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,09/26/2011,,,,,,Non-NME,,,No,,,Japan,Asia,,18908,24875,657,242,N/A, ,,
Approved in other than U.S./E.U.,,,,,,Peptide,Subcutaneous (SQ),AbbVie Inc.,ABBV,Lupron,leuprolide acetate,Metabolic,Single-Gene Disorders (Non-Inborn Errors of Metabolism),"Spinal Bulbar Muscular Atrophy (SBMA, Kennedy's Disease, X-linked spinal muscular atrophy type 1)",Gonadotropin-Releasing Hormone (GnRH) Receptor,"Orion Corporation, Takeda Pharmaceutical Co. Ltd.","Enantone, leuprolide acetate, Leuprolide, Leuprorelin, Leuplin (Japan), Lupron Depot, Lupron Depot-Gyn, Lupron Depot-Ped, Procrin, Lucrin, TAP144SR, TAP-144-SR, TAP 144 SR",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,08/27/2017,,,,,,New Molecular Entity (NME),Rare Disease,,No,"11.25MG/VIAL (INJECTABLE;INJECTION), 15MG/VIAL (INJECTABLE;INJECTION), 22.5MG/VIAL (INJECTABLE;INJECTION), 3.75MG (INJECTABLE;INJECTION), 30MG/VIAL (INJECTABLE;INJECTION), 45MG/VIAL (INJECTABLE;INJECTION), 7.5MG/VIAL (INJECTABLE;INJECTION)",Illinois,United States,North America,,12965,57623,5,3377,N/A,$188.39B ,,
Approved in Europe,,,,,,Peptide,Subcutaneous (SQ),AbbVie Inc.,ABBV,Lupron,leuprolide acetate,Oncology,Solid,Breast Cancer,Gonadotropin-Releasing Hormone (GnRH) Receptor,"Orion Corporation, Takeda Pharmaceutical Co. Ltd.","Enantone, leuprolide acetate, Leuprolide, Leuprorelin, Leuplin (Japan), Lupron Depot, Lupron Depot-Gyn, Lupron Depot-Ped, Procrin, Lucrin, TAP144SR, TAP-144-SR, TAP 144 SR",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,01/31/2004,08/31/2005,,,,,,New Molecular Entity (NME),,,No,"11.25MG/VIAL (INJECTABLE;INJECTION), 15MG/VIAL (INJECTABLE;INJECTION), 22.5MG/VIAL (INJECTABLE;INJECTION), 3.75MG (INJECTABLE;INJECTION), 30MG/VIAL (INJECTABLE;INJECTION), 45MG/VIAL (INJECTABLE;INJECTION), 7.5MG/VIAL (INJECTABLE;INJECTION)",Illinois,United States,North America,,12965,25889,5,214,N/A,$188.39B ,,
Approved in Europe,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Actraphane,human insulin (regular and NPH premix),Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,soluble human insulin (rDNA) and isophane insulin,Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,10/07/2002,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,100%,18125,23688,292,157,N/A,$108.42B ,,
Approved in Europe,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Actrapid,human insulin (regular),Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,human insulin (rDNA),Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,10/07/2002,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,18126,23690,292,157,N/A,$108.42B ,,
Approved in Europe,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Insulatard,human insulin (NPH),Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,insulin human (rDNA),N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,10/07/2002,,,,,,,Non-NME,,,No,,,Denmark,Europe,,18363,24037,292,157,N/A,$108.42B ,,
Approved in Europe,09/16/2009,09/16/2009,,01/31/2008,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Ryzodeg 70/30,insulin degludec and insulin aspart,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"DegludecPlus, IDegAsp, Soluble insulin analogue combination (SIAC), NN5401, insulin degludec and insulin aspart",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,09/25/2015,01/21/2013,12/25/2012,,,09/29/2011,10/27/2006,,New Molecular Entity (NME),,,No,,,Denmark,Europe,100%,2546,4325,292,157,N/A,$108.42B ,,
Approved in Europe,,,,,,Peptide,Subcutaneous (SQ),Sanofi,SNY,Insuman,"human insulin (regular, NPH, and premixes)",Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"Insuman Rapid, Insuman Comb, Insuman Basal, Human Insulin, Insuman Infustat",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,02/21/1997,,,,,,,New Molecular Entity (NME),,,No,,,France,Europe,,27449,47244,51,157,N/A,$107.55B ,,
Approved in Europe,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Actraphane,human insulin (regular and NPH premix),Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,soluble human insulin (rDNA) and isophane insulin,N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,10/07/2002,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,100%,18125,23689,292,137,N/A,$108.42B ,,
Approved in Europe,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Actrapid,human insulin (regular),Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,human insulin (rDNA),N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,10/07/2002,,,,,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,18126,23691,292,137,N/A,$108.42B ,,
Approved in Europe,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Insulatard,human insulin (NPH),Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,insulin human (rDNA),N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,10/07/2002,,,,,,,Non-NME,,,No,,,Denmark,Europe,,18363,24038,292,137,N/A,$108.42B ,,
Approved in Europe,11/05/2009,11/05/2009,01/31/2008,01/31/2008,10/27/2006,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Ryzodeg 70/30,insulin degludec and insulin aspart,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"DegludecPlus, IDegAsp, Soluble insulin analogue combination (SIAC), NN5401, insulin degludec and insulin aspart",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,09/25/2015,01/21/2013,12/25/2012,,,09/29/2011,10/27/2006,,New Molecular Entity (NME),,,No,,,Denmark,Europe,100%,2546,4326,292,137,N/A,$108.42B ,,
Approved in Europe,,,,,,Peptide,Subcutaneous (SQ),Sanofi,SNY,Insuman,"human insulin (regular, NPH, and premixes)",Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"Insuman Rapid, Insuman Comb, Insuman Basal, Human Insulin, Insuman Infustat",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,02/21/1997,,,,,,,New Molecular Entity (NME),,,No,,,France,Europe,,27449,38398,51,137,N/A,$107.55B ,,
Approved (Generic Competition),,02/17/2003,,,,Peptide,Subcutaneous (SQ),Takeda Pharmaceutical Co. Ltd.,TAK,Firazyr,icatibant,Autoimmune/immunology,Other,Hereditary Angioedema (HAE),Bradykinin B2 Receptor,Sanofi,"icatibant, SHP667, SHP 667, SHP-667, HOE 140, HOE140, HOE-140",Y,Approved,100% (Same As Avg.), - , - , - ,08/25/2011,07/11/2008,09/21/2018,,,10/08/2007,,,New Molecular Entity (NME),"Fast Track,Orphan,Rare Disease,SPA",,No,EQ 30MG BASE/3ML (EQ 10MG BASE (INJECTABLE;SUBCUTANEOUS),,Japan,Asia,88%,2419,4096,826,556,N/A,$46.05B ,,
Approved (Generic Competition),,,,,,Peptide,Subcutaneous (SQ),"Momenta Pharmaceuticals, Inc.",MNTA,Glatopa,glatiramer acetate,Neurology,Neurodegenerative,Multiple Sclerosis (MS),T lymphocytes,Novartis AG,"generic Copaxone, glatiramer acetate injection, M356, M-356, M 356",Y,Approved,100% (Same As Avg.), - , - , - ,04/16/2015,,,,,12/27/2007,,,Non-NME,,,No,,Massachusetts,United States,North America,,8661,10767,945,153,N/A,$6.24B ,,
Approved (Generic Competition),,,,08/13/1987,,Peptide,Subcutaneous (SQ),Teva Pharmaceutical Industries Ltd.,TEVA,Copaxone,glatiramer acetate,Neurology,Neurodegenerative,Multiple Sclerosis (MS),"Myelin,T lymphocytes","Sanofi, Takeda Pharmaceutical Co. Ltd.","COP-1, copolymer-1, glatiramer acetate",Y,Approved,100% (Same As Avg.), - , - , - ,12/20/1996,01/01/2001,09/28/2015,,,06/15/1995,,,New Molecular Entity (NME),Orphan,,No,"20MG/ML (INJECTABLE;SUBCUTANEOUS), 40MG/ML (INJECTABLE;SUBCUTANEOUS)",,Israel,Asia,100%,595,1209,375,153,N/A,$12.20B ,,
Approved,,10/16/2006,,,,Peptide,Subcutaneous (SQ),Ipsen SA,IPSEY,Somatuline Autogel,lanreotide acetate,Endocrine,Other,Acromegaly,Somatostatin Receptors,Teijin Pharma Limited.,"Somatuline Depot, lanreotide acetate, Somatostatin Analogue",Y,Approved,100% (Same As Avg.), - , - , - ,08/30/2007,12/31/2005,06/29/2012,,,10/30/2006,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,"EQ 120MG BASE/0.5ML (EQ 120MG  (SOLUTION;SUBCUTANEOUS), EQ 60MG BASE/0.2ML (EQ 60MG BA (SOLUTION;SUBCUTANEOUS), EQ 90MG BASE/0.3ML (EQ 90MG BA (SOLUTION;SUBCUTANEOUS)",,France,Europe,,3015,5145,220,680,N/A,$4.57B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),AbbVie Inc.,ABBV,Lupron,leuprolide acetate,Hematology,Marrow Or Peripheral Blood Stimulator,Anemia,Gonadotropin-Releasing Hormone (GnRH) Receptor,"Orion Corporation, Takeda Pharmaceutical Co. Ltd.","Enantone, leuprolide acetate, Leuprolide, Leuprorelin, Leuplin (Japan), Lupron Depot, Lupron Depot-Gyn, Lupron Depot-Ped, Procrin, Lucrin, TAP144SR, TAP-144-SR, TAP 144 SR",N,Approved,100% (Same As Avg.), - , - , - ,03/30/1995,,,,,,,,New Molecular Entity (NME),,,No,"11.25MG/VIAL (INJECTABLE;INJECTION), 15MG/VIAL (INJECTABLE;INJECTION), 22.5MG/VIAL (INJECTABLE;INJECTION), 3.75MG (INJECTABLE;INJECTION), 30MG/VIAL (INJECTABLE;INJECTION), 45MG/VIAL (INJECTABLE;INJECTION), 7.5MG/VIAL (INJECTABLE;INJECTION)",Illinois,United States,North America,,12965,24989,5,375,N/A,$188.39B ,,
Approved,,07/22/2011,,,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Trulicity,dulaglutide,Cardiovascular,General,Cardiovascular Disease,GLP-1 Receptor,"Lupin Limited, Sumitomo Dainippon Pharma Co., Ltd.","GLP-Fc Analog, Torurishiti (JP), LY 2189265, LY2189265, LY-2189265",N,Approved,100% (Same As Avg.),02/21/2020 - 02/21/2020, - , - ,,10/21/2019,,,,04/19/2019,,,New Molecular Entity (NME),,,No,,Indiana,United States,North America,100%,9921,55231,136,181,N/A,$158.63B ,,
Approved,02/21/2013,02/21/2013,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Ozempic,semaglutide,Cardiovascular,General,Cardiovascular Disease,GLP-1 Receptor,,"Once-weekly GLP-1 analogue, NN9536, NN 9536, NN-9536, NN 9535, NN9535, NN-9535, semaglutide injection",N,Approved,100% (Same As Avg.), - , - , - ,01/16/2020,,,,,03/20/2019,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,10488,58663,292,181,N/A,$108.42B ,,
Approved,05/06/2010,05/06/2010,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Victoza,liraglutide recombinant,Cardiovascular,General,Cardiovascular Disease,GLP-1 Receptor,Johnson & Johnson,"liraglutide, NN2211 (diabetes), NN9211 (adjunct), NN9223 (depot)",N,Approved,100% (Same As Avg.), - , - , - ,08/25/2017,07/27/2017,,,,10/25/2016,,,New Molecular Entity (NME),,,No,18MG/3ML (6MG/ML) (SOLUTION;SUBCUTANEOUS),,Denmark,Europe,95%,1712,49477,292,181,N/A,$108.42B ,,
Approved,08/19/2011,08/19/2011,,01/11/2011,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Basaglar,insulin glargine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,"Boehringer Ingelheim GmbH, Cipla Limited","Biosimilar Insulin Glargine, Abasria, LY2963016, Abasaglar (EU)",N,Approved,100% (Same As Avg.), - , - , - ,12/16/2015,09/09/2014,01/02/2015,,,,,,Biologic,505b2,,No,,Indiana,United States,North America,50%,17839,23762,136,157,N/A,$158.63B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Humalog,insulin lispro,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,Lupin Limited,"Insulin lispro injection, HumaPen MEMOIR, HumaPen LUXURA HD, LY275585, Humalog U-200, Eglucent (India)",N,Approved,100% (Same As Avg.), - , - , - ,06/14/1996,05/01/1996,,,,,,,New Molecular Entity (NME),,,No,100 UNITS/ML (INJECTABLE;INJECTION),Indiana,United States,North America,100%,1924,3097,136,157,N/A,$158.63B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Humalog Mix,insulin lispro and insulin lispro protamine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"insulin lispro protamine suspension and insulin lispro [rDNA] injection, Liprolog (EU)",Y,Approved,100% (Same As Avg.), - , - , - ,12/22/1999,08/01/2001,,,,,,,New Molecular Entity (NME),,,No,"50 UNITS/ML;50 UNITS/ML (INJECTABLE;INJECTION), 75 UNITS/ML;25 UNITS/ML (INJECTABLE;INJECTION)",Indiana,United States,North America,100%,18128,23695,136,157,N/A,$158.63B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Humulin,human insulin,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,3SBio Inc.,"Human Insulin [rDNA origin], Humulin R U-100 (intranasal formulation for Alzheimer's), Humulin R U-500",Y,Approved,100% (Same As Avg.), - , - , - ,10/28/1982,,,,,,,,New Molecular Entity (NME),,,No,"100 UNITS/ML (INJECTABLE;INJECTION), 10000 UNITS/20ML (500 UNITS/ML (SOLUTION;SUBCUTANEOUS), 1500 UNITS/3ML (500 UNITS/ML) (SOLUTION;SUBCUTANEOUS), 30 UNITS/ML;70 UNITS/ML (INJECTABLE;INJECTION)",Indiana,United States,North America,100%,2146,3554,136,157,N/A,$158.63B ,,
Approved,07/19/2017,07/19/2017,,,03/04/2016,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Lyumjev,insulin lispro-aabc,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"LY 900014, LY-900014, LY900014, Lispro with excipients citrate and treprostinil, Ultra-Rapid Insulin, Ultra Rapid Insulin, Ultra Rapid Lispro, URLi, Liumjev (EU), Lumjeb (Japan), Insulin lispro-aabc Injection",Y,Approved,100% (Same As Avg.), - , - , - ,06/15/2020,03/24/2020,03/25/2020,,,08/15/2019,03/04/2016,,New Molecular Entity (NME),,,No,,Indiana,United States,North America,,27788,38962,136,157,N/A,$158.63B ,,
Approved,,08/26/2013,,,05/11/2010,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,FIAsp,insulin aspart,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"NN1218, ultra fast-acting insulin aspart",N,Approved,100% (Same As Avg.), - , - , - ,09/29/2017,01/10/2017,09/30/2019,,,12/09/2015,05/11/2010,,Non-NME,,,No,,,Denmark,Europe,100%,17163,22269,292,157,N/A,$108.42B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Levemir,insulin detemir,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"insulin detemir, NN304, NN 304, NN-304",Y,Approved,100% (Same As Avg.), - ,06/25/2015 - 08/31/2015, - ,06/17/2005,06/01/2004,10/22/2007,,,12/06/2002,,,New Molecular Entity (NME),,,No,"1000 UNITS/10ML (100 UNITS/ML) (INJECTABLE;SUBCUTANEOUS), 300 UNITS/3ML (100 UNITS/ML) (INJECTABLE;SUBCUTANEOUS)",,Denmark,Europe,100%,1706,3256,292,157,N/A,$108.42B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Mixtard,human insulin (regular and NPH premix),Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,insulin human (rDNA),N,Approved,100% (Same As Avg.), - , - , - ,03/11/1988,10/07/2002,,,,,,,Non-NME,,,No,,,Denmark,Europe,,18360,24031,292,157,N/A,$108.42B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Novolin,"human insulin (regular, NPH, and premixes)",Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"Novolin R, Novolin L, Novolin N, Novolin 70/30, human insulin [rDNA origin], Novolin R U-100 (intranasal formulation for Alzheimer's)",N,Approved,100% (Same As Avg.), - , - , - ,06/25/1991,,,,,,,,New Molecular Entity (NME),,,No,"100 UNITS/ML (INJECTABLE;INJECTION), 30 UNITS/ML;70 UNITS/ML (INJECTABLE;INJECTION)",,Denmark,Europe,100%,18154,23748,292,157,N/A,$108.42B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,NovoLog,insulin aspart,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"NovoRapid, insulin aspart",N,Approved,100% (Same As Avg.), - , - , - ,06/08/2000,09/07/1999,10/29/2009,,,,,,New Molecular Entity (NME),,,No,"1000 UNITS/10ML (100 UNITS/ML) (INJECTABLE;SUBCUTANEOUS), 300 UNITS/3ML (100 UNITS/ML) (INJECTABLE;SUBCUTANEOUS)",,Denmark,Europe,100%,1707,3257,292,157,N/A,$108.42B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,NovoLog Mix,insulin aspart and insulin aspart protamine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"NovoMix, NovoRapid Mix, insulin aspart [rDNA origin] protamine suspension & insulin aspart [rDNA origin] injection, biphasic insulin aspart (BIAsp)",N,Approved,100% (Same As Avg.), - , - , - ,11/01/2001,08/01/2000,08/28/2003,,,,,,New Molecular Entity (NME),,,No,"210 UNITS/3ML; 90 UNITS/3ML (7 (INJECTABLE;SUBCUTANEOUS), 700 UNITS/10ML; 300 UNITS/10ML (INJECTABLE;SUBCUTANEOUS)",,Denmark,Europe,100%,18073,23605,292,157,N/A,$108.42B ,,
Approved,09/22/2009,09/22/2009,,01/31/2008,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Tresiba,insulin degludec,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"Degludec, Soluble insulin basal analogue (SIBA), NN1250, IDeg",Y,Approved,100% (Same As Avg.), - , - , - ,09/25/2015,01/21/2013,09/28/2012,,,09/29/2011,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,100%,10482,13112,292,157,N/A,$108.42B ,,
Approved,,10/26/2014,,,,Peptide,Subcutaneous (SQ),Sanofi,SNY,Admelog,insulin lispro,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"Biosimilar Humalog (Insulin Lispro), Insulin lispro Sanofi (100 Units/mL), SAR342434, SAR 342434, SAR-342434",N,Approved,100% (Same As Avg.), - , - , - ,09/01/2017,07/19/2017,,,,11/01/2016,07/31/2013,,Biosimilar,505b2,,No,,,France,Europe,,24504,34025,51,157,N/A,$107.55B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Sanofi,SNY,Lantus,insulin glargine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"insulin glargine [rDNA origin] injection, Optisulin, HOE901",Y,Approved,100% (Same As Avg.), - , - , - ,04/20/2000,06/09/2000,,,,,,,New Molecular Entity (NME),,,No,"100 UNITS/ML (INJECTABLE;INJECTION), 300 UNITS/3ML (100 UNITS/ML) (INJECTABLE;INJECTION)",,France,Europe,100%,2291,3841,51,157,N/A,$107.55B ,,
Approved,,09/12/2012,,08/06/2012,09/06/2011,Peptide,Subcutaneous (SQ),Sanofi,SNY,Toujeo,insulin glargine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"GLA-300, GlarU300, HOE901-U300, HOE 901-U300, insulin glargine, Lantus (new formulation), U300, Lantus XR (Japan)",N,Approved,100% (Same As Avg.), - , - , - ,02/26/2015,04/28/2015,07/03/2015,,,06/14/2014,05/31/2011,,Non-NME,,,No,,,France,Europe,100%,19040,25065,51,157,N/A,$107.55B ,,
Approved,08/26/2014,08/26/2014,,,,Peptide,Subcutaneous (SQ),Viatris Inc.,VTRS,Semglee,insulin glargine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,"Biocon, Ltd., PiSA","Glarvia, biosimilar insulin glargine (rDNA), Basalog, Galactus, MYL-1501D, Semglee, Biosimilar Insulin Glargine (Mylan/Biocon)",N,Approved,100% (Same As Avg.), - , - , - ,06/11/2020,03/27/2018,03/28/2016,,,04/27/2017,04/27/2012,,Biosimilar,505b2,,No,,Pennsylvania,United States,North America,,19066,25100,266,157,N/A, ,,
Approved,03/24/2006,03/24/2006,03/30/2004,06/25/2002,03/26/2001,Peptide,Subcutaneous (SQ),AstraZeneca PLC,AZN,Bydureon,exenatide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,"3SBio Inc., Alkermes plc, Bristol Myers Squibb Company, Eli Lilly and Company","AC2993/exenatide LAR, long acting synthetic exendin-4, exenatide once weekly (EQW), Exenatide Microsphere",Y,Approved,100% (Same As Avg.), - , - ,01/01/2015 - 07/31/2015,01/27/2012,06/17/2011,03/30/2012,,,05/05/2009,03/26/2001,,Non-NME,,,No,"2MG (FOR SUSPENSION, EXTENDED RELEA), 2MG/VIAL (FOR SUSPENSION, EXTENDED RELEA)",,United Kingdom,Europe,63.5%,200,227,45,137,N/A,$133.38B ,,
Approved,12/10/2001,12/10/2001,06/30/1999,06/30/1999,08/18/1998,Peptide,Subcutaneous (SQ),AstraZeneca PLC,AZN,Byetta,exenatide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,"3SBio Inc., Bristol Myers Squibb Company, Eli Lilly and Company","Exenatide, Synthetic exendin-4, AC2993, LY2148568",Y,Approved,100% (Same As Avg.), - , - , - ,04/28/2005,11/20/2006,10/27/2010,,,06/29/2004,08/18/1998,01/13/1999,New Molecular Entity (NME),,,No,"300MCG/1.2ML (250MCG/ML) (INJECTABLE;SUBCUTANEOUS), 600MCG/2.4ML (250MCG/ML) (INJECTABLE;SUBCUTANEOUS)",,United Kingdom,Europe,70%,201,228,45,137,N/A,$133.38B ,,
Approved,08/19/2011,08/19/2011,,01/11/2011,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Basaglar,insulin glargine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,"Boehringer Ingelheim GmbH, Cipla Limited","Biosimilar Insulin Glargine, Abasria, LY2963016, Abasaglar (EU)",Y,Approved,100% (Same As Avg.), - , - , - ,12/16/2015,09/09/2014,01/02/2015,,,,,,Biologic,505b2,,No,,Indiana,United States,North America,50%,17839,23292,136,137,N/A,$158.63B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Humalog,insulin lispro,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,Lupin Limited,"Insulin lispro injection, HumaPen MEMOIR, HumaPen LUXURA HD, LY275585, Humalog U-200, Eglucent (India)",N,Approved,100% (Same As Avg.), - , - , - ,06/17/1996,05/01/1996,,,,,,,New Molecular Entity (NME),,,No,100 UNITS/ML (INJECTABLE;INJECTION),Indiana,United States,North America,100%,1924,23694,136,137,N/A,$158.63B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Humalog Mix,insulin lispro and insulin lispro protamine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"insulin lispro protamine suspension and insulin lispro [rDNA] injection, Liprolog (EU)",N,Approved,100% (Same As Avg.), - , - , - ,12/22/1999,08/01/2001,,,,,,,New Molecular Entity (NME),,,No,"50 UNITS/ML;50 UNITS/ML (INJECTABLE;INJECTION), 75 UNITS/ML;25 UNITS/ML (INJECTABLE;INJECTION)",Indiana,United States,North America,100%,18128,23696,136,137,N/A,$158.63B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Humulin,human insulin,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,3SBio Inc.,"Human Insulin [rDNA origin], Humulin R U-100 (intranasal formulation for Alzheimer's), Humulin R U-500",Y,Approved,100% (Same As Avg.), - , - , - ,10/28/1982,,,,,,,,New Molecular Entity (NME),,,No,"100 UNITS/ML (INJECTABLE;INJECTION), 10000 UNITS/20ML (500 UNITS/ML (SOLUTION;SUBCUTANEOUS), 1500 UNITS/3ML (500 UNITS/ML) (SOLUTION;SUBCUTANEOUS), 30 UNITS/ML;70 UNITS/ML (INJECTABLE;INJECTION)",Indiana,United States,North America,100%,2146,3555,136,137,N/A,$158.63B ,,
Approved,07/26/2017,07/26/2017,,,03/04/2016,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Lyumjev,insulin lispro-aabc,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"LY 900014, LY-900014, LY900014, Lispro with excipients citrate and treprostinil, Ultra-Rapid Insulin, Ultra Rapid Insulin, Ultra Rapid Lispro, URLi, Liumjev (EU), Lumjeb (Japan), Insulin lispro-aabc Injection",Y,Approved,100% (Same As Avg.), - , - , - ,06/15/2020,03/24/2020,03/25/2020,,,08/15/2019,03/04/2016,,New Molecular Entity (NME),,,No,,Indiana,United States,North America,,27788,38963,136,137,N/A,$158.63B ,,
Approved,08/28/2008,08/28/2008,,07/11/2008,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Trulicity,dulaglutide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,"Lupin Limited, Sumitomo Dainippon Pharma Co., Ltd.","GLP-Fc Analog, Torurishiti (JP), LY 2189265, LY2189265, LY-2189265",Y,Approved,100% (Same As Avg.), - , - , - ,09/18/2014,11/21/2014,07/03/2015,,,10/03/2013,12/07/2006,,New Molecular Entity (NME),,,No,,Indiana,United States,North America,100%,9921,12378,136,137,N/A,$158.63B ,,
Approved,09/16/2013,09/16/2013,,,05/11/2010,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,FIAsp,insulin aspart,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"NN1218, ultra fast-acting insulin aspart",Y,Approved,100% (Same As Avg.), - , - , - ,09/29/2017,01/09/2017,09/30/2019,,,12/09/2015,05/11/2010,,Non-NME,,,No,,,Denmark,Europe,100%,17163,22267,292,137,N/A,$108.42B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Levemir,insulin detemir,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"insulin detemir, NN304, NN 304, NN-304",Y,Approved,100% (Same As Avg.), - , - , - ,06/16/2005,06/04/2004,10/22/2007,,,12/06/2002,,,New Molecular Entity (NME),,,No,"1000 UNITS/10ML (100 UNITS/ML) (INJECTABLE;SUBCUTANEOUS), 300 UNITS/3ML (100 UNITS/ML) (INJECTABLE;SUBCUTANEOUS)",,Denmark,Europe,100%,1706,2735,292,137,N/A,$108.42B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Mixtard,human insulin (regular and NPH premix),Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,insulin human (rDNA),N,Approved,100% (Same As Avg.), - , - , - ,03/11/1988,10/07/2002,,,,,,,Non-NME,,,No,,,Denmark,Europe,,18360,24032,292,137,N/A,$108.42B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Novolin,"human insulin (regular, NPH, and premixes)",Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"Novolin R, Novolin L, Novolin N, Novolin 70/30, human insulin [rDNA origin], Novolin R U-100 (intranasal formulation for Alzheimer's)",N,Approved,100% (Same As Avg.), - , - , - ,06/25/1991,,,,,,,,New Molecular Entity (NME),,,No,"100 UNITS/ML (INJECTABLE;INJECTION), 30 UNITS/ML;70 UNITS/ML (INJECTABLE;INJECTION)",,Denmark,Europe,100%,18154,23749,292,137,N/A,$108.42B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,NovoLog,insulin aspart,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"NovoRapid, insulin aspart",N,Approved,100% (Same As Avg.), - , - , - ,06/07/2000,09/07/1999,10/29/2009,,,,,,New Molecular Entity (NME),,,No,"1000 UNITS/10ML (100 UNITS/ML) (INJECTABLE;SUBCUTANEOUS), 300 UNITS/3ML (100 UNITS/ML) (INJECTABLE;SUBCUTANEOUS)",,Denmark,Europe,100%,1707,2910,292,137,N/A,$108.42B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,NovoLog Mix,insulin aspart and insulin aspart protamine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"NovoMix, NovoRapid Mix, insulin aspart [rDNA origin] protamine suspension & insulin aspart [rDNA origin] injection, biphasic insulin aspart (BIAsp)",N,Approved,100% (Same As Avg.), - , - , - ,11/01/2001,08/01/2000,08/28/2003,,,,,,New Molecular Entity (NME),,,No,"210 UNITS/3ML; 90 UNITS/3ML (7 (INJECTABLE;SUBCUTANEOUS), 700 UNITS/10ML; 300 UNITS/10ML (INJECTABLE;SUBCUTANEOUS)",,Denmark,Europe,100%,18073,23606,292,137,N/A,$108.42B ,,
Approved,,06/21/2012,,06/12/2008,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Ozempic,semaglutide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,"Once-weekly GLP-1 analogue, NN9536, NN 9536, NN-9536, NN 9535, NN9535, NN-9535, semaglutide injection",Y,Approved,100% (Same As Avg.), - , - , - ,12/05/2017,02/09/2018,03/23/2018,,,12/05/2016,01/31/2008,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,10488,13119,292,137,N/A,$108.42B ,,
Approved,09/03/2009,09/03/2009,,01/31/2008,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Tresiba,insulin degludec,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"Degludec, Soluble insulin basal analogue (SIBA), NN1250, IDeg",Y,Approved,100% (Same As Avg.), - , - , - ,09/25/2015,01/21/2013,09/28/2012,,,09/29/2011,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,100%,10482,13113,292,137,N/A,$108.42B ,,
Approved,01/27/2006,01/27/2006,,02/10/2003,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Victoza,liraglutide recombinant,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,Johnson & Johnson,"liraglutide, NN2211 (diabetes), NN9211 (adjunct), NN9223 (depot)",Y,Approved,100% (Same As Avg.), - , - , - ,01/25/2010,06/30/2009,01/20/2010,,,03/23/2008,,,New Molecular Entity (NME),,,No,18MG/3ML (6MG/ML) (SOLUTION;SUBCUTANEOUS),,Denmark,Europe,95%,1712,2740,292,137,N/A,$108.42B ,,
Approved,05/29/2008,06/02/2008,,06/25/2003,,Peptide,Subcutaneous (SQ),Sanofi,SNY,Adlyxin,lixisenatide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,"Alkermes plc, Royalty Pharma plc, Zealand Pharma A/S","lixisenatide, Lyxumia, AVE 0010, AVE-0010, AVE0010, ZP 10, ZP10, ZP-10",Y,Approved,100% (Same As Avg.), - , - , - ,07/27/2016,02/01/2013,06/28/2013,,,07/30/2015,,,New Molecular Entity (NME),,,No,,,France,Europe,82%,1700,2727,51,137,N/A,$107.55B ,,
Approved,01/20/2015,11/18/2014,,,,Peptide,Subcutaneous (SQ),Sanofi,SNY,Admelog,insulin lispro,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"Biosimilar Humalog (Insulin Lispro), Insulin lispro Sanofi (100 Units/mL), SAR342434, SAR 342434, SAR-342434",Y,Approved,100% (Same As Avg.), - , - , - ,09/01/2017,07/19/2017,,,,11/01/2016,06/16/2014,,Biosimilar,505b2,,No,,,France,Europe,,24504,34026,51,137,N/A,$107.55B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Sanofi,SNY,Lantus,insulin glargine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"insulin glargine [rDNA origin] injection, Optisulin, HOE901",Y,Approved,100% (Same As Avg.), - , - , - ,04/20/2000,06/09/2000,,,,,,,New Molecular Entity (NME),,,No,"100 UNITS/ML (INJECTABLE;INJECTION), 300 UNITS/3ML (100 UNITS/ML) (INJECTABLE;INJECTION)",,France,Europe,100%,2291,3842,51,137,N/A,$107.55B ,,
Approved,,01/15/2014,11/21/2011,11/21/2011,,Peptide,Subcutaneous (SQ),Sanofi,SNY,Soliqua 100/33,insulin glargine/lixisenatide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GLP-1 Receptor,Insulin Receptor","Alkermes plc, Royalty Pharma plc, Zealand Pharma A/S","Lantus (insulin glargine/HOE901)/Lixisenatide (AVE0010/ZP10) Combination, Fix-Flex (Device), Fixed-Ratio combination, Lantus/Lyxumia, iGlarLixi, Suliqua [EU], LixiLan",Y,Approved,100% (Same As Avg.), - , - ,01/01/2019 - 01/01/2019,11/21/2016,01/11/2017,,,,12/23/2015,02/10/2010,,Non-NME,,,No,,,France,Europe,82%,17888,23368,51,137,N/A,$107.55B ,,
Approved,02/08/2012,02/08/2012,,,09/06/2011,Peptide,Subcutaneous (SQ),Sanofi,SNY,Toujeo,insulin glargine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"GLA-300, GlarU300, HOE901-U300, HOE 901-U300, insulin glargine, Lantus (new formulation), U300, Lantus XR (Japan)",Y,Approved,100% (Same As Avg.), - , - , - ,02/26/2015,04/28/2015,07/03/2015,,,06/14/2014,09/06/2011,,Non-NME,,,No,,,France,Europe,100%,19040,25066,51,137,N/A,$107.55B ,,
Approved,08/26/2014,08/26/2014,,,,Peptide,Subcutaneous (SQ),Viatris Inc.,VTRS,Semglee,insulin glargine,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,"Biocon, Ltd., PiSA","Glarvia, biosimilar insulin glargine (rDNA), Basalog, Galactus, MYL-1501D, Semglee, Biosimilar Insulin Glargine (Mylan/Biocon)",Y,Approved,100% (Same As Avg.), - , - , - ,06/11/2020,03/27/2018,03/28/2016,,,04/27/2017,04/27/2012,,Biosimilar,505b2,,No,,Pennsylvania,United States,North America,,19066,25101,266,137,N/A, ,,
Approved,06/02/2015,06/02/2015,,,,Peptide,Subcutaneous (SQ),"Tolmar Pharmaceuticals, Inc.",,Fensolvi,leuprolide acetate,Endocrine,General,Endocrine Disorder,Gonadotropin-Releasing Hormone (GnRH) Receptor,,Leuprolide Acetate Injectable Suspension,N,Approved,100% (Same As Avg.), - , - , - ,05/04/2020,,,,,07/02/2019,,,Non-NME,505b2,,No,,Illinois,United States,North America,,42361,59602,2701,182,N/A, ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),AbbVie Inc.,ABBV,Lupron,leuprolide acetate,Endocrine,General,Endocrine Disorder,Gonadotropin-Releasing Hormone (GnRH) Receptor,"Orion Corporation, Takeda Pharmaceutical Co. Ltd.","Enantone, leuprolide acetate, Leuprolide, Leuprorelin, Leuplin (Japan), Lupron Depot, Lupron Depot-Gyn, Lupron Depot-Ped, Procrin, Lucrin, TAP144SR, TAP-144-SR, TAP 144 SR",N,Approved,100% (Same As Avg.), - , - , - ,04/16/1993,,08/01/1994,,,,,,New Molecular Entity (NME),,,No,"11.25MG/VIAL (INJECTABLE;INJECTION), 15MG/VIAL (INJECTABLE;INJECTION), 22.5MG/VIAL (INJECTABLE;INJECTION), 3.75MG (INJECTABLE;INJECTION), 30MG/VIAL (INJECTABLE;INJECTION), 45MG/VIAL (INJECTABLE;INJECTION), 7.5MG/VIAL (INJECTABLE;INJECTION)",Illinois,United States,North America,,12965,24535,5,182,N/A,$188.39B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),AbbVie Inc.,ABBV,Lupron,leuprolide acetate,Obstetrics/Gynecology,Gynecology,Endometriosis,Gonadotropin-Releasing Hormone (GnRH) Receptor,"Orion Corporation, Takeda Pharmaceutical Co. Ltd.","Enantone, leuprolide acetate, Leuprolide, Leuprorelin, Leuplin (Japan), Lupron Depot, Lupron Depot-Gyn, Lupron Depot-Ped, Procrin, Lucrin, TAP144SR, TAP-144-SR, TAP 144 SR",N,Approved,100% (Same As Avg.), - , - , - ,10/22/1990,,08/01/1994,,,,,,New Molecular Entity (NME),,,No,"11.25MG/VIAL (INJECTABLE;INJECTION), 15MG/VIAL (INJECTABLE;INJECTION), 22.5MG/VIAL (INJECTABLE;INJECTION), 3.75MG (INJECTABLE;INJECTION), 30MG/VIAL (INJECTABLE;INJECTION), 45MG/VIAL (INJECTABLE;INJECTION), 7.5MG/VIAL (INJECTABLE;INJECTION)",Illinois,United States,North America,,12965,24990,5,349,N/A,$188.39B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Alexion Pharmaceuticals Inc.,ALXN,Fuzeon,enfuvirtide,Infectious Disease,Antiviral,HIV / AIDS,gp41,"Novartis AG, Roche Holding AG","T-20, T20-206, T20-208",Y,Approved,100% (Same As Avg.), - , - , - ,10/15/2004,05/27/2003,,,,09/13/2002,,,New Molecular Entity (NME),,,No,90MG/VIAL (INJECTABLE;SUBCUTANEOUS),Massachusetts,United States,North America,49.25%,575,1222,21,78,N/A,$34.07B ,,
Approved,02/13/2017,02/13/2017,10/17/2013,10/17/2013,,Peptide,Subcutaneous (SQ),"Xeris Pharmaceuticals, Inc.",XERS,Gvoke RTU Micro,glucagon,Endocrine,Other,Hyperinsulinemia/Hypoglycemia,Glucagon Receptor,Clinigen Group plc,"Glucagon drug/device combination, G-Pen, G-Pump, GlucaPen, CSI-Glucagon, Glucagon Rescue Pen, Gvoke HypoPen, XeriSol Glucagon, Gvoke",N,Approved,100% (Same As Avg.), - ,02/15/2021 - 02/15/2021, - ,09/10/2019,,,,,08/10/2018,,,Non-NME,"505b2,Orphan",,No,,Illinois,United States,North America,,19444,25636,3561,3358,N/A,$284.06M ,,
Approved,02/28/2017,02/28/2017,01/04/2013,01/04/2013,06/13/2012,Peptide,Subcutaneous (SQ),"Rhythm Pharmaceuticals, Inc.",RYTM,Imcivree,setmelanotide,Metabolic,General,Metabolic - General,"Insulin Receptor,Melanocortin (MC) receptors","Camurus AB, Ipsen SA","BIM-22493, BIM 22493, BIM22493, RM-493, RM493, RM 493",N,Approved,100% (Same As Avg.), - ,03/01/2021 - 05/31/2021, - ,11/25/2020,,,,,03/30/2020,06/13/2012,,Biologic,"Breakthrough,Orphan",,No,,Massachusetts,United States,North America,,19880,26359,3663,3163,N/A,$1.53B ,,
Approved,03/20/2009,06/01/2006,,,,Peptide,Subcutaneous (SQ),Ipsen SA,IPSEY,Somatuline Autogel,lanreotide acetate,Oncology,Solid,Neuroendocrine Tumors (NET),Somatostatin Receptors,Teijin Pharma Limited.,"Somatuline Depot, lanreotide acetate, Somatostatin Analogue",N,Approved,100% (Same As Avg.), - , - , - ,12/16/2014,02/27/2015,07/03/2017,,,06/30/2014,,,New Molecular Entity (NME),Rare Disease,,No,"EQ 120MG BASE/0.5ML (EQ 120MG  (SOLUTION;SUBCUTANEOUS), EQ 60MG BASE/0.2ML (EQ 60MG BA (SOLUTION;SUBCUTANEOUS), EQ 90MG BASE/0.3ML (EQ 90MG BA (SOLUTION;SUBCUTANEOUS)",,France,Europe,,3015,5146,220,347,100%,$4.57B ,,
Approved,08/23/2018,08/23/2018,,,,Peptide,Subcutaneous (SQ),"RadioMedix, Inc.",,Detectnet,,Oncology,Diagnostics,Neuroendocrine Tumors (NET) - Imaging,Somatostatin Receptors,Curium Pharma,"Copper 64-DOTA-TATE, 64Cu-Dotatate, 64Cu Dotatate, copper Cu 64 dotatate injection, Netmedix",Y,Approved,100% (Same As Avg.), - , - , - ,09/03/2020,,,,,12/31/2019,,,New Molecular Entity (NME),"Fast Track,Orphan",,Yes,,Texas,United States,North America,,40025,55965,8094,3418,100%, ,,
Approved,10/01/2008,10/01/2008,10/06/2006,10/27/2006,,Peptide,Subcutaneous (SQ),Novo Nordisk A/S,NVO,Saxenda,liraglutide recombinant,Metabolic,Obesity,Obesity,GLP-1 Receptor,Johnson & Johnson,"liraglutide, NN8022",N,Approved,100% (Same As Avg.), - , - , - ,12/23/2014,03/23/2015,,,,12/20/2013,,,New Molecular Entity (NME),,,No,,,Denmark,Europe,,43015,60633,292,135,N/A,$108.42B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Eli Lilly and Company,LLY,Forteo,teriparatide recombinant human,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Parathyroid Hormone Receptor (PTHR),Johnson & Johnson,"PTH 1-34, teriparatide [rDNA origin] injection, Forsteo (EU), LY333334",Y,Approved,100% (Same As Avg.), - , - , - ,12/01/2002,06/01/2003,,,,,,,Non-NME,,,No,0.6MG/2.4ML (0.25MG/ML) (INJECTABLE;SUBCUTANEOUS),Indiana,United States,North America,100%,271,433,136,242,N/A,$158.63B ,,
Approved,12/22/2016,12/22/2016,,,01/14/2016,Peptide,Subcutaneous (SQ),Pfenex Inc.,PFNX,Bonsity,teriparatide recombinant human,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Parathyroid Hormone Receptor (PTHR),"Alvogen, Inc., China NT Pharma Group Company Limited, JAMP Pharma Corporation, Kamada Ltd., Pharmbio Korea Inc.","Biosimilar Forteo, Biosimilar Teriparatide (Pfenex), PF708, PF-708, PF 708, Livogiva (EU)",Y,Approved,100% (Same As Avg.), - , - , - ,10/04/2019,08/27/2020,,,,12/07/2018,01/14/2016,,Non-NME,505b2,,No,,California,United States,North America,,26379,36804,4727,242,N/A,$437.28M ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Mundipharma International Limited,,Eligard,leuprolide acetate,Oncology,Solid,Prostate Cancer,Gonadotropin-Releasing Hormone (GnRH) Receptor,"Astellas Pharma, Inc., Medigene AG, Sanofi, Sosei Co., Ltd, Tolmar Pharmaceuticals, Inc.","leuprolide acetate, SOT-375, SOT375, SOT 375",Y,Approved,100% (Same As Avg.), - , - , - ,01/23/2002,12/21/2004,,,,03/23/2001,,,Non-NME,,,No,"22.5MG/VIAL (INJECTABLE;SUBCUTANEOUS), 30MG/VIAL (INJECTABLE;SUBCUTANEOUS), 45MG/VIAL (INJECTABLE;SUBCUTANEOUS), 7.5MG/VIAL (INJECTABLE;SUBCUTANEOUS)",,United Kingdom,Europe,,1819,2903,667,215,100%, ,,
Approved,04/07/2006,04/07/2006,,10/05/2004,,Peptide,Subcutaneous (SQ),Ferring Pharmaceuticals,,Firmagon,degarelix acetate,Oncology,Solid,Prostate Cancer,Gonadotropin-Releasing Hormone (GnRH) Receptor,"Astellas Pharma, Inc.","ASP3550, ASP 3550, ASP-3550, FE200486, degarelix, Gonax (Japan)",Y,Approved,100% (Same As Avg.), - , - , - ,12/24/2008,02/17/2009,06/29/2012,,,02/14/2008,,,New Molecular Entity (NME),,,No,"EQ 120MG BASE/VIAL (POWDER;SUBCUTANEOUS), EQ 80MG BASE/VIAL (POWDER;SUBCUTANEOUS)",,Switzerland,Europe,,10595,13273,582,215,100%, ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),AbbVie Inc.,ABBV,Lupron,leuprolide acetate,Oncology,Solid,Prostate Cancer,Gonadotropin-Releasing Hormone (GnRH) Receptor,"Orion Corporation, Takeda Pharmaceutical Co. Ltd.","Enantone, leuprolide acetate, Leuprolide, Leuprorelin, Leuplin (Japan), Lupron Depot, Lupron Depot-Gyn, Lupron Depot-Ped, Procrin, Lucrin, TAP144SR, TAP-144-SR, TAP 144 SR",Y,Approved,100% (Same As Avg.), - , - , - ,04/09/1985,04/09/1985,07/31/2002,,,,,,New Molecular Entity (NME),,,No,"11.25MG/VIAL (INJECTABLE;INJECTION), 15MG/VIAL (INJECTABLE;INJECTION), 22.5MG/VIAL (INJECTABLE;INJECTION), 3.75MG (INJECTABLE;INJECTION), 30MG/VIAL (INJECTABLE;INJECTION), 45MG/VIAL (INJECTABLE;INJECTION), 7.5MG/VIAL (INJECTABLE;INJECTION)",Illinois,United States,North America,,12965,16341,5,215,100%,$188.39B ,,
Approved,04/06/2004,04/06/2004,,,,Peptide,Subcutaneous (SQ),Takeda Pharmaceutical Co. Ltd.,TAK,Gattex,teduglutide,Gastroenterology (Non Inflammatory Bowel Disease),Other,Short Bowel Syndrome (SBS),GLP-2 Receptor,,"Revestive (EU), ALX-0600, teduglutide, recombinant GLP-2, SHP633, SHP 633, SHP-633",Y,Approved,100% (Same As Avg.), - , - ,01/01/2015 - 01/01/2015,12/21/2012,08/30/2012,,,,11/30/2011,06/29/2000,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,5MG/VIAL (POWDER;SUBCUTANEOUS),,Japan,Asia,100%,698,2331,826,581,N/A,$46.05B ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),Ferring Pharmaceuticals,,Zomacton,human growth hormone,Endocrine,Short Stature,Short Stature / Growth Hormone Deficiency,Growth hormone receptor (GHR),Teva Pharmaceutical Industries Ltd.,"Bio-tropin, human growth hormone, hGH, TevTropin, Tev-tropin, Tjet, ZOMA-Jet",Y,Approved,100% (Same As Avg.), - , - , - ,05/25/1995,,,,,,,,Non-NME,505b2,,No,"10MG/VIAL (INJECTABLE;INJECTION), 5MG/VIAL (INJECTABLE;INJECTION)",,Switzerland,Europe,,862,1035,582,285,N/A, ,,
Approved,,,,,,Peptide,Subcutaneous (SQ),AbbVie Inc.,ABBV,Lupron,leuprolide acetate,Obstetrics/Gynecology,Gynecology,Uterine Fibroids,Gonadotropin-Releasing Hormone (GnRH) Receptor,"Orion Corporation, Takeda Pharmaceutical Co. Ltd.","Enantone, leuprolide acetate, Leuprolide, Leuprorelin, Leuplin (Japan), Lupron Depot, Lupron Depot-Gyn, Lupron Depot-Ped, Procrin, Lucrin, TAP144SR, TAP-144-SR, TAP 144 SR",N,Approved,100% (Same As Avg.), - , - , - ,10/22/1990,,,,,,,,New Molecular Entity (NME),,,No,"11.25MG/VIAL (INJECTABLE;INJECTION), 15MG/VIAL (INJECTABLE;INJECTION), 22.5MG/VIAL (INJECTABLE;INJECTION), 3.75MG (INJECTABLE;INJECTION), 30MG/VIAL (INJECTABLE;INJECTION), 45MG/VIAL (INJECTABLE;INJECTION), 7.5MG/VIAL (INJECTABLE;INJECTION)",Illinois,United States,North America,,12965,51893,5,592,N/A,$188.39B ,,
Preclinical,,,,,,Peptide,"Subcutaneous (SQ), Intradermal",Anergis SA,,AllerDM,,Allergy,General,Allergic Rhinitis,Immune System,,AllerDM,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,25479,35476,3236,236,N/A, ,,
Suspended,,,,,,Peptide,"Subcutaneous (SQ), Intradermal",Anergis SA,,AllerR,,Allergy,General,Allergic Rhinitis,Immune System,,AllerR,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,20459,27277,3236,236,N/A, ,,
Suspended,,,,,,Peptide,"Subcutaneous (SQ), Intradermal",Anergis SA,,AllerT,,Allergy,General,Allergic Rhinitis,Immune System,,AllerT,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Switzerland,Europe,,18147,23738,3236,236,N/A, ,,
Preclinical,,,,,,Peptide,"Subcutaneous (SQ), Intradermal",KAEL Co. Ltd.,082270,GV1001,,Infectious Disease,Antiviral,"Hepatitis B Prevention (Vaccines, Antiviral)","Immune System,Telomerase",,"GV-1001, GV 1001",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Korea (South),Asia,,8307,60099,2546,1328,N/A, ,,
I/II,,,,10/21/2013,,Peptide,"Subcutaneous (SQ), Intradermal",Vaxil Bio Ltd.,,ImMucin,,Oncology,Solid,Breast Cancer,"Immune System,Mucin 1 (MUC-1)",,"MUC1-SP-L, VXL100",N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Israel,Asia,,20718,31714,24750,214,N/A, ,,
Suspended,,,,11/06/2007,,Peptide,"Subcutaneous (SQ), Intradermal",KAEL Co. Ltd.,082270,GV1001,,Oncology,Solid,Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases),"Immune System,Telomerase",,"GV-1001, GV 1001",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Korea (South),Asia,,8307,11796,2546,297,N/A, ,,
Suspended,,,,06/03/2003,,Peptide,"Subcutaneous (SQ), Intradermal",KAEL Co. Ltd.,082270,GV1001,,Oncology,Solid,Melanoma,"Immune System,Telomerase",,"GV-1001, GV 1001",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Korea (South),Asia,,8307,22839,2546,221,N/A, ,,
I/II,,,,10/31/2013,,Peptide,"Subcutaneous (SQ), Intradermal",Vaxil Bio Ltd.,,ImMucin,,Oncology,Hematologic,Multiple Myeloma (MM),"Immune System,Mucin 1 (MUC-1)",,"MUC1-SP-L, VXL100",Y,II,10% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Israel,Asia,,20718,27710,24750,207,N/A, ,,
Suspended,,04/13/2012,,06/03/2003,,Peptide,"Subcutaneous (SQ), Intradermal",KAEL Co. Ltd.,082270,GV1001,,Oncology,Solid,Non-Small Cell Lung Cancer (NSCLC),"Immune System,Telomerase",,"GV-1001, GV 1001",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Korea (South),Asia,,8307,11795,2546,211,N/A, ,,
Suspended,03/15/2007,03/15/2007,,06/03/2003,,Peptide,"Subcutaneous (SQ), Intradermal",KAEL Co. Ltd.,082270,GV1001,,Oncology,Solid,Pancreatic Cancer,"Immune System,Telomerase",,"GV-1001, GV 1001",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Korea (South),Asia,,8307,10296,2546,220,N/A, ,,
Development Outside U.S.,,,,,,Peptide,"Subcutaneous (SQ), Intradermal",KAEL Co. Ltd.,082270,GV1001,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),"Immune System,Telomerase",,"GV-1001, GV 1001",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Korea (South),Asia,,8307,58280,2546,141,N/A, ,,
Suspended,,,,,,Peptide,"Subcutaneous (SQ), Intradermal, Intranasal",Theratechnologies Inc.,THTX,TH1173,,Endocrine,Short Stature,Short Stature / Growth Hormone Deficiency,Growth Hormone Releasing Hormone (GHRH) Receptor,,Second-Generation Growth-Hormone Releasing Factor (GRF) Peptide,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Quebec,Canada,North America,,20141,26796,459,285,N/A, ,,
Suspended,,,,02/24/2013,,Peptide,"Subcutaneous (SQ), Intramuscular (IM)",Recordati SpA,REC:IM,Signifor,pasireotide diaspartate,Gastroenterology (Non Inflammatory Bowel Disease),Other,Dumping Syndrome,Somatostatin Receptors,Novartis AG,"Signifor LAR, SOM230 long-acting release (LAR), SOM 230, SOM-230, Pasireotide, somatostatin analog",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,"EQ 0.3MG BASE/ML (EQ 0.3MG BAS (SOLUTION;SUBCUTANEOUS), EQ 0.6MG BASE/ML (EQ 0.6MG BAS (SOLUTION;SUBCUTANEOUS), EQ 0.9MG BASE/ML (EQ 0.9MG BAS (SOLUTION;SUBCUTANEOUS)",,Italy,Europe,,1888,30603,1008,3347,N/A,$10.59B ,,
I/II,,,12/09/2009,12/09/2009,,Peptide,"Subcutaneous (SQ), Intramuscular (IM)",AC Immune SA,ACIU,ACI-24,,Neurology,Neurodegenerative,Alzheimer's Disease (AD),"Amyloid Beta/Amyloid Plaques,Immune System",,"ACI24, ACI 24",Y,II,17% (Same As Avg.), - , - , - ,,,,,,,,,Vaccine,,,No,,,Switzerland,Europe,,20260,26982,2541,141,N/A,$408.16M ,,
I,,,,,04/05/2016,Peptide,"Subcutaneous (SQ), Intramuscular (IM)",AC Immune SA,ACIU,ACI-24,,Neurology,Neurodevelopmental Disorders,Down Syndrome,"Amyloid Beta/Amyloid Plaques,Immune System",,"ACI24, ACI 24",N,I,10% (Same As Avg.), - , - , - ,,,,,,,04/05/2016,,Vaccine,,,No,,,Switzerland,Europe,,20260,31731,2541,2671,N/A,$408.16M ,,
Suspended,,,,,,Peptide,"Subcutaneous (SQ), Intramuscular (IM)",Recordati SpA,REC:IM,Signifor,pasireotide diaspartate,Not Specified,Other,Surgical and Procedure Complications,Somatostatin Receptors,Novartis AG,"Signifor LAR, SOM230 long-acting release (LAR), SOM 230, SOM-230, Pasireotide, somatostatin analog",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,"EQ 0.3MG BASE/ML (EQ 0.3MG BAS (SOLUTION;SUBCUTANEOUS), EQ 0.6MG BASE/ML (EQ 0.6MG BAS (SOLUTION;SUBCUTANEOUS), EQ 0.9MG BASE/ML (EQ 0.9MG BAS (SOLUTION;SUBCUTANEOUS)",,Italy,Europe,,1888,20538,1008,2887,N/A,$10.59B ,,
III,,09/07/2006,,,,Peptide,"Subcutaneous (SQ), Intramuscular (IM)","Verity Pharmaceuticals, Inc.",,Trelstar,triptorelin pamoate,Oncology,Solid,Breast Cancer,Gonadotropin-Releasing Hormone (GnRH) Receptor,"Debiopharm S.A., Ipsen SA, Knight Therapeutics, Inc., Orient EuroPharma Co., Ltd., Vifor Pharma Group ","Decapeptyl (EU), Trelstar Depot, Trelstar Long-Acting (LA), triptorelin embonate, Pamorelin, Salvacyl, Debio 8206 (IM), Debio8206, Debio-8206",N,III,35% (Same As Avg.), - , - , - ,,03/13/2017,,,,,,,New Molecular Entity (NME),,,No,"EQ 11.25MG BASE/VIAL (INJECTABLE;INTRAMUSCULAR), EQ 22.5MG BASE/VIAL (INJECTABLE;INTRAMUSCULAR), EQ 3.75MG BASE/VIAL (INJECTABLE;INTRAMUSCULAR)",Ontario,Canada,North America,,10858,13615,10000,214, 48%, ,Drug has prior approval,Yes
Investigator Initiated,,,07/16/2015,,,Peptide,"Subcutaneous (SQ), Intramuscular (IM)","Verity Pharmaceuticals, Inc.",,Trelstar,triptorelin pamoate,Oncology,Solid,Head and Neck Cancer,Gonadotropin-Releasing Hormone (GnRH) Receptor,"Debiopharm S.A., Ipsen SA, Knight Therapeutics, Inc., Orient EuroPharma Co., Ltd., Vifor Pharma Group ","Decapeptyl (EU), Trelstar Depot, Trelstar Long-Acting (LA), triptorelin embonate, Pamorelin, Salvacyl, Debio 8206 (IM), Debio8206, Debio-8206",N,Investigator Initiated,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,"EQ 11.25MG BASE/VIAL (INJECTABLE;INTRAMUSCULAR), EQ 22.5MG BASE/VIAL (INJECTABLE;INTRAMUSCULAR), EQ 3.75MG BASE/VIAL (INJECTABLE;INTRAMUSCULAR)",Ontario,Canada,North America,,10858,38260,10000,230,N/A, ,,
Suspended,,,,,,Peptide,"Subcutaneous (SQ), Intramuscular (IM)",Recordati SpA,REC:IM,Signifor,pasireotide diaspartate,Oncology,Solid,Merkel Cell Carcinoma,Somatostatin Receptors,Novartis AG,"Signifor LAR, SOM230 long-acting release (LAR), SOM 230, SOM-230, Pasireotide, somatostatin analog",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/03/2012,,Non-NME,Rare Disease,,No,"EQ 0.3MG BASE/ML (EQ 0.3MG BAS (SOLUTION;SUBCUTANEOUS), EQ 0.6MG BASE/ML (EQ 0.6MG BAS (SOLUTION;SUBCUTANEOUS), EQ 0.9MG BASE/ML (EQ 0.9MG BAS (SOLUTION;SUBCUTANEOUS)",,Italy,Europe,,1888,35633,1008,3585,N/A,$10.59B ,,
Suspended,04/07/2008,04/07/2008,,06/06/2006,,Peptide,"Subcutaneous (SQ), Intramuscular (IM)",Recordati SpA,REC:IM,Signifor,pasireotide diaspartate,Oncology,Solid,Neuroendocrine Tumors (NET),Somatostatin Receptors,Novartis AG,"Signifor LAR, SOM230 long-acting release (LAR), SOM 230, SOM-230, Pasireotide, somatostatin analog",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,"Orphan,Rare Disease",,No,"EQ 0.3MG BASE/ML (EQ 0.3MG BAS (SOLUTION;SUBCUTANEOUS), EQ 0.6MG BASE/ML (EQ 0.6MG BAS (SOLUTION;SUBCUTANEOUS), EQ 0.9MG BASE/ML (EQ 0.9MG BAS (SOLUTION;SUBCUTANEOUS)",,Italy,Europe,,1888,5060,1008,347,N/A,$10.59B ,,
Suspended,,,,,04/15/2013,Peptide,"Subcutaneous (SQ), Intramuscular (IM)",Recordati SpA,REC:IM,Signifor,pasireotide diaspartate,Oncology,Solid,Prostate Cancer,Somatostatin Receptors,Novartis AG,"Signifor LAR, SOM230 long-acting release (LAR), SOM 230, SOM-230, Pasireotide, somatostatin analog",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/18/2012,,Non-NME,,,No,"EQ 0.3MG BASE/ML (EQ 0.3MG BAS (SOLUTION;SUBCUTANEOUS), EQ 0.6MG BASE/ML (EQ 0.6MG BAS (SOLUTION;SUBCUTANEOUS), EQ 0.9MG BASE/ML (EQ 0.9MG BAS (SOLUTION;SUBCUTANEOUS)",,Italy,Europe,,1888,27673,1008,215,N/A,$10.59B ,,
Suspended,,,,,,Peptide,"Subcutaneous (SQ), Intramuscular (IM)",Recordati SpA,REC:IM,Signifor,pasireotide diaspartate,Renal,Polycystic Kidney Disease,Polycystic Kidney Disease,Somatostatin Receptors,Novartis AG,"Signifor LAR, SOM230 long-acting release (LAR), SOM 230, SOM-230, Pasireotide, somatostatin analog",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,"EQ 0.3MG BASE/ML (EQ 0.3MG BAS (SOLUTION;SUBCUTANEOUS), EQ 0.6MG BASE/ML (EQ 0.6MG BAS (SOLUTION;SUBCUTANEOUS), EQ 0.9MG BASE/ML (EQ 0.9MG BAS (SOLUTION;SUBCUTANEOUS)",,Italy,Europe,,1888,31123,1008,334,N/A,$10.59B ,,
Development Outside U.S.,,,,,,Peptide,"Subcutaneous (SQ), Intramuscular (IM)",Antev Limited,,Teverelix,,Urology,General,Benign Prostatic Hyperplasia (BPH),Gonadotropin-Releasing Hormone (GnRH),,"Teverelix (Antev), ANT101, ANT-101, ANT 101",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,40048,55993,9038,569,N/A, ,,
Development Outside U.S.,,,,,,Peptide,"Subcutaneous (SQ), Intramuscular (IM)",Antev Limited,,Teverelix,,Obstetrics/Gynecology,Gynecology,Endometriosis,Gonadotropin-Releasing Hormone (GnRH),,"Teverelix (Antev), ANT101, ANT-101, ANT 101",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,40048,55998,9038,349,N/A, ,,
Development Outside U.S.,,,,,,Peptide,"Subcutaneous (SQ), Intramuscular (IM)",Antev Limited,,Teverelix,,Oncology,Solid,Prostate Cancer,Gonadotropin-Releasing Hormone (GnRH),,"Teverelix (Antev), ANT101, ANT-101, ANT 101",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,40048,55997,9038,215,N/A, ,,
Approved in other than U.S./E.U.,,,,,,Peptide,"Subcutaneous (SQ), Intramuscular (IM)","Verity Pharmaceuticals, Inc.",,Trelstar,triptorelin pamoate,Obstetrics/Gynecology,Gynecology,Endometriosis,Gonadotropin-Releasing Hormone (GnRH) Receptor,"Debiopharm S.A., Ipsen SA, Knight Therapeutics, Inc., Orient EuroPharma Co., Ltd., Vifor Pharma Group ","Decapeptyl (EU), Trelstar Depot, Trelstar Long-Acting (LA), triptorelin embonate, Pamorelin, Salvacyl, Debio 8206 (IM), Debio8206, Debio-8206",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,"EQ 11.25MG BASE/VIAL (INJECTABLE;INTRAMUSCULAR), EQ 22.5MG BASE/VIAL (INJECTABLE;INTRAMUSCULAR), EQ 3.75MG BASE/VIAL (INJECTABLE;INTRAMUSCULAR)",Ontario,Canada,North America,,10858,26863,10000,349,N/A, ,,
Approved,01/14/2008,01/14/2008,,01/31/2007,,Peptide,"Subcutaneous (SQ), Intramuscular (IM)",Recordati SpA,REC:IM,Signifor,pasireotide diaspartate,Endocrine,Other,Acromegaly,Somatostatin Receptors,Novartis AG,"Signifor LAR, SOM230 long-acting release (LAR), SOM 230, SOM-230, Pasireotide, somatostatin analog",N,Approved,100% (Same As Avg.), - , - ,01/01/2014 - 01/01/2015,12/16/2014,11/24/2014,,,,11/15/2013,,,Non-NME,"Orphan,Rare Disease",,No,"EQ 0.3MG BASE/ML (EQ 0.3MG BAS (SOLUTION;SUBCUTANEOUS), EQ 0.6MG BASE/ML (EQ 0.6MG BAS (SOLUTION;SUBCUTANEOUS), EQ 0.9MG BASE/ML (EQ 0.9MG BAS (SOLUTION;SUBCUTANEOUS)",,Italy,Europe,,1888,5059,1008,680,N/A,$10.59B ,,
Approved,01/31/2007,01/31/2007,,04/01/2004,,Peptide,"Subcutaneous (SQ), Intramuscular (IM)",Recordati SpA,REC:IM,Signifor,pasireotide diaspartate,Endocrine,Other,Cushing's Syndrome,Somatostatin Receptors,Novartis AG,"Signifor LAR, SOM230 long-acting release (LAR), SOM 230, SOM-230, Pasireotide, somatostatin analog",Y,Approved,100% (Same As Avg.), - , - ,01/01/2014 - 01/01/2014,12/14/2012,04/24/2012,,,,03/31/2012,,,Non-NME,Rare Disease,,No,"EQ 0.3MG BASE/ML (EQ 0.3MG BAS (SOLUTION;SUBCUTANEOUS), EQ 0.6MG BASE/ML (EQ 0.6MG BAS (SOLUTION;SUBCUTANEOUS), EQ 0.9MG BASE/ML (EQ 0.9MG BAS (SOLUTION;SUBCUTANEOUS)",,Italy,Europe,,1888,3044,1008,637,N/A,$10.59B ,,
Approved,,,,,,Peptide,"Subcutaneous (SQ), Intramuscular (IM)","Verity Pharmaceuticals, Inc.",,Trelstar,triptorelin pamoate,Oncology,Solid,Prostate Cancer,Gonadotropin-Releasing Hormone (GnRH) Receptor,"Debiopharm S.A., Ipsen SA, Knight Therapeutics, Inc., Orient EuroPharma Co., Ltd., Vifor Pharma Group ","Decapeptyl (EU), Trelstar Depot, Trelstar Long-Acting (LA), triptorelin embonate, Pamorelin, Salvacyl, Debio 8206 (IM), Debio8206, Debio-8206",Y,Approved,100% (Same As Avg.), - , - , - ,06/15/2000,10/13/2009,,,,,,,New Molecular Entity (NME),,,No,"EQ 11.25MG BASE/VIAL (INJECTABLE;INTRAMUSCULAR), EQ 22.5MG BASE/VIAL (INJECTABLE;INTRAMUSCULAR), EQ 3.75MG BASE/VIAL (INJECTABLE;INTRAMUSCULAR)",Ontario,Canada,North America,,10858,13616,10000,215,100%, ,,
Suspended,,,,04/27/2012,10/07/2009,Peptide,"Subcutaneous (SQ), Intranasal",Azelon Pharmaceuticals,,ZT-034,teriparatide,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Parathyroid Hormone Receptor (PTHR),,"hPTH (1-34), teriparatide",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,10/07/2009,,Non-NME,,,No,,Pennsylvania,United States,North America,,15889,20341,552,242,N/A, ,,
II,,,,11/05/2009,,Peptide,"Subcutaneous (SQ), Intranasal",ISA Pharmaceuticals B.V.,,ISA101,HPV16,Infectious Disease,Antiviral,Human Papillomavirus (HPV) Treatment (Antiviral),Immune System,"Shin Nippon Biomedical Laboratories, Ltd.","SLP-HPV-01, ISA-HPV-SLP, HPV-SLP, ISA 101, ISA-101, ISA101b",Y,II,27% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Orphan,,No,,,Netherlands,Europe,,17802,23231,3000,238,N/A, ,,
I/II,,,,10/29/2013,,Peptide,"Subcutaneous (SQ), Intranasal",ISA Pharmaceuticals B.V.,,ISA101,HPV16,Oncology,Solid,Cervical Cancer,Immune System,"Shin Nippon Biomedical Laboratories, Ltd.","SLP-HPV-01, ISA-HPV-SLP, HPV-SLP, ISA 101, ISA-101, ISA101b",N,II,10% (Same As Avg.), - , - , - ,,,,,,,06/02/2010,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Netherlands,Europe,,17802,23229,3000,255,  4%, ,Drug Modality,Peptide; Small Molecule; Vaccine
II,,,12/07/2015,12/07/2015,,Peptide,"Subcutaneous (SQ), Intranasal",ISA Pharmaceuticals B.V.,,ISA101,HPV16,Oncology,Solid,Head and Neck Cancer,Immune System,"Shin Nippon Biomedical Laboratories, Ltd.","SLP-HPV-01, ISA-HPV-SLP, HPV-SLP, ISA 101, ISA-101, ISA101b",N,II,10% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Netherlands,Europe,,17802,37971,3000,230,  3%, ,Drug Modality,Peptide; Small Molecule; Vaccine
Suspended,,,03/06/2006,03/06/2006,11/29/2002,Peptide,"Subcutaneous (SQ), Intravenous (IV)",Serodus ASA,,SER100,,Cardiovascular,Congestive Heart Failure,Acute Decompensated Heart Failure,Opioid receptors,,"SER 100, SER-100, SER 200, SER200, SER-200, ZP 120, ZP120, ZP-120",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,11/29/2002,,New Molecular Entity (NME),,,No,,,Norway,Europe,,17754,23153,2987,575,N/A, ,,
Suspended,,,08/08/2016,08/08/2016,,Peptide,"Subcutaneous (SQ), Intravenous (IV)","PhaseBio Pharmaceuticals, Inc.",PHAS,Vasomera,,Cardiovascular,Congestive Heart Failure,Congestive Heart Failure (CHF) and Cardiomyopathies,Vasoactive Intestinal Peptide (VIP) Receptor,,"PB1046, PB-1046, PB 1046, VIP-ELP-120, VIPELP120, VIP ELP 120",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Orphan,,No,,Pennsylvania,United States,North America,,19579,42489,3581,264,N/A,$118.93M ,,
Suspended,,,11/05/2013,11/05/2013,,Peptide,"Subcutaneous (SQ), Intravenous (IV)",Serodus ASA,,SER100,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Opioid receptors,,"SER 100, SER-100, SER 200, SER200, SER-200, ZP 120, ZP120, ZP-120",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,09/02/2010,,New Molecular Entity (NME),Orphan,,No,,,Norway,Europe,,17754,23154,2987,244,N/A, ,,
Suspended,,,,,02/22/2012,Peptide,"Subcutaneous (SQ), Intravenous (IV)","PhaseBio Pharmaceuticals, Inc.",PHAS,Vasomera,,Cardiovascular,Hypertension (Systemic),Hypertension (Systemic),Vasoactive Intestinal Peptide (VIP) Receptor,,"PB1046, PB-1046, PB 1046, VIP-ELP-120, VIPELP120, VIP ELP 120",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,02/22/2012,,New Molecular Entity (NME),,,No,,Pennsylvania,United States,North America,,19579,25842,3581,244,N/A,$118.93M ,,
Suspended,,01/10/2001,,,,Peptide,"Subcutaneous (SQ), Intravenous (IV)",Debiopharm S.A.,,Sanvar IR,vapreotide acetate,Cardiovascular,Other,Portal Hypertension,Somatostatin Receptors,,"vapreotide acetate, RC-160, Octastatin, BMY 41606, Debio 8609",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,03/02/2004,,,Biologic,Orphan,,No,,,Switzerland,Europe,,7497,9207,856,699,N/A, ,,
IIb,,,08/07/2018,08/07/2018,10/20/2017,Peptide,"Subcutaneous (SQ), Intravenous (IV)","PhaseBio Pharmaceuticals, Inc.",PHAS,Vasomera,,Cardiovascular,Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH),Vasoactive Intestinal Peptide (VIP) Receptor,,"PB1046, PB-1046, PB 1046, VIP-ELP-120, VIPELP120, VIP ELP 120",Y,II,13% (Same As Avg.), - , - , - ,,,,,,,10/20/2017,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,Pennsylvania,United States,North America,,19579,34268,3581,245,N/A,$118.93M ,,
Suspended,,,,,,Peptide,"Subcutaneous (SQ), Intravenous (IV)",Serodus ASA,,SER100,,Cardiovascular,Pulmonary Arterial Hypertension,Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH),Opioid receptors,,"SER 100, SER-100, SER 200, SER200, SER-200, ZP 120, ZP120, ZP-120",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,,Norway,Europe,,17754,36014,2987,245,N/A, ,,
I,,,,,01/10/2020,Peptide,"Subcutaneous (SQ), Intravenous (IV)",Eli Lilly and Company,LLY,LY3493269,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II","GIP Receptor (GIPR)/Glucose-Dependent Insulinotropic Polypeptide Receptor,GLP-1 Receptor",,"LY-3493269, LY 3493269",N,I,14% (Same As Avg.), - , - , - ,,,,,,,01/10/2020,,Unknown,,,No,,Indiana,United States,North America,,41810,58711,136,137,N/A,$158.63B ,,
I/II,,,,10/09/2018,,Peptide,"Subcutaneous (SQ), Intravenous (IV)",TherAchon AG,,Apraglutide,apraglutide,Gastroenterology (Non Inflammatory Bowel Disease),Other,Short Bowel Syndrome (SBS),GLP-2 Receptor,"CTI BioPharma Corp., Ferring Pharmaceuticals","FE 203799, FE-203799, FE203799",Y,II,24% (Same As Avg.), - , - , - ,,,,,,,01/17/2018,,Biologic,"Orphan,Rare Disease",,No,,,Switzerland,Europe,,35189,48800,7317,581,N/A, ,,
Suspended,,,07/16/2020,07/16/2020,,Peptide,"Subcutaneous (SQ), Intravenous (IV)","PhaseBio Pharmaceuticals, Inc.",PHAS,Vasomera,,Infectious Disease,Antiviral,COVID-19 Treatment,Vasoactive Intestinal Peptide (VIP) Receptor,,"PB1046, PB-1046, PB 1046, VIP-ELP-120, VIPELP120, VIP ELP 120",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,05/27/2020,New Molecular Entity (NME),,,No,,Pennsylvania,United States,North America,,19579,59872,3581,3651,N/A,$118.93M ,,
Suspended,,,08/08/2016,08/08/2016,,Peptide,"Subcutaneous (SQ), Intravenous (IV)","PhaseBio Pharmaceuticals, Inc.",PHAS,Vasomera,,Metabolic,Single-Gene Disorders (Non-Inborn Errors of Metabolism),Muscular Dystrophy,Vasoactive Intestinal Peptide (VIP) Receptor,,"PB1046, PB-1046, PB 1046, VIP-ELP-120, VIPELP120, VIP ELP 120",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Orphan,,No,,Pennsylvania,United States,North America,,19579,36050,3581,674,N/A,$118.93M ,,
Suspended,,,,01/30/2018,,Peptide,"Subcutaneous (SQ), Intravenous (IV)",TherAchon AG,,Apraglutide,apraglutide,Oncology,Hematologic,Hodgkin's Lymphoma,GLP-2 Receptor,"CTI BioPharma Corp., Ferring Pharmaceuticals","FE 203799, FE-203799, FE203799",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,,Switzerland,Europe,,35189,52698,7317,204,N/A, ,,
Suspended,,,,01/30/2018,,Peptide,"Subcutaneous (SQ), Intravenous (IV)",TherAchon AG,,Apraglutide,apraglutide,Oncology,Hematologic,Non-Hodgkin's Lymphoma (NHL),GLP-2 Receptor,"CTI BioPharma Corp., Ferring Pharmaceuticals","FE 203799, FE-203799, FE203799",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Switzerland,Europe,,35189,52697,7317,205,N/A, ,,
Suspended,,,,,,Peptide,"Subcutaneous (SQ), Intravenous (IV)","PhaseBio Pharmaceuticals, Inc.",PHAS,Vasomera,,Respiratory,Cystic Fibrosis,Cystic Fibrosis (CF),Vasoactive Intestinal Peptide (VIP) Receptor,,"PB1046, PB-1046, PB 1046, VIP-ELP-120, VIPELP120, VIP ELP 120",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Pennsylvania,United States,North America,,19579,50024,3581,74,N/A,$118.93M ,,
Approved in other than U.S./E.U.,,,,,,Peptide,"Subcutaneous (SQ), Intravenous (IV)","Biocon, Ltd.",,Insugen,"human insulin (regular, NPH, and premixes)",Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type I",Insulin Receptor,,"Biosimilar Recombinant Human Insulin (Biocon), recombinant human insulin (rDNA)",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biosimilar,,,No,,,India,Asia,,18198,23803,2652,157,N/A, ,,
Approved in other than U.S./E.U.,,,,,,Peptide,"Subcutaneous (SQ), Intravenous (IV)","Biocon, Ltd.",,Insugen,"human insulin (regular, NPH, and premixes)",Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",Insulin Receptor,,"Biosimilar Recombinant Human Insulin (Biocon), recombinant human insulin (rDNA)",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biosimilar,,,No,,,India,Asia,,18198,23804,2652,137,N/A, ,,
II,,,,03/03/2014,,Peptide,"Subcutaneous (SQ), Intravenous (IV), Intradermal",Apitope Technology (Bristol) Ltd,,ATX-MS-1467,,Neurology,Neurodegenerative,Multiple Sclerosis (MS),"Immune System,Myelin Basic Protein (MBP)",,"ATX-MS-1467, M2736",Y,II,18% (1% Above Avg.), - , - , - ,,,,,,,02/06/2007,,Biologic,,,No,,,Belgium,Europe,,8687,10801,1403,153,N/A, ,,
Preclinical,,,,,,Peptide,"Subcutaneous (SQ), Oral (PO)","Bioniz Therapeutics, Inc.",,BNZ-2,,Autoimmune/immunology,Inflammatory Bowel Disease,Celiac Disease,"IL-15 (Interleukin-15)/IL-15 Receptor,IL-21 (Interleukin-21)",,"BNZ2, BNZ 2, BNZ-132-2",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,36020,50089,7115,2304,N/A, ,,
Preclinical,,,,,,Peptide,"Subcutaneous (SQ), Oral (PO)","Bioniz Therapeutics, Inc.",,BNZ-2,,Autoimmune/immunology,Inflammatory Bowel Disease,Inflammatory Bowel Disease (IBD),"IL-15 (Interleukin-15)/IL-15 Receptor,IL-21 (Interleukin-21)",,"BNZ2, BNZ 2, BNZ-132-2",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,36020,50090,7115,464,N/A, ,,
I,,,,,02/05/2018,Peptide,"Subcutaneous (SQ), Oral (PO)","Palatin Technologies, Inc.",PTN,PL-8177,,Autoimmune/immunology,Inflammatory Bowel Disease,Ulcerative Colitis (UC),Melanocortin (MC) receptors,,"PL8177, PL 8177",N,I,14% (Same As Avg.), - , - , - ,,,,,,,02/05/2018,01/03/2018,New Molecular Entity (NME),Orphan,,No,,New Jersey,United States,North America,,23796,32779,504,321,N/A,$162.89M ,,
Preclinical,,,,,,Peptide,"Subcutaneous (SQ), Oral (PO)","Palatin Technologies, Inc.",PTN,PL-8177,,Infectious Disease,Antiviral,COVID-19 Treatment,Melanocortin (MC) receptors,,"PL8177, PL 8177",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,23796,60182,504,3651,N/A,$162.89M ,,
Preclinical,,,,,,Peptide,"Subcutaneous (SQ), Oral (PO)","Palatin Technologies, Inc.",PTN,PL-8177,,Ophthalmology,Retinopathy,Diabetic Retinopathy (Ophthalmology),Melanocortin (MC) receptors,,"PL8177, PL 8177",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,New Jersey,United States,North America,,23796,59600,504,364,N/A,$162.89M ,,
Preclinical,,,,,,Peptide,"Subcutaneous (SQ), Oral (PO)","Palatin Technologies, Inc.",PTN,PL-8177,,Ophthalmology,Uveitis,Uveitis (Ophthalmology),Melanocortin (MC) receptors,,"PL8177, PL 8177",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Orphan,Rare Disease",,No,,New Jersey,United States,North America,,23796,56798,504,307,N/A,$162.89M ,,
II,,,09/12/2019,09/12/2019,05/08/2018,Peptide,"Subcutaneous (SQ), Percutaneous Catheter/Injection",Ascendis Pharma A/S,ASND,TransCon CNP,,Endocrine,Short Stature,Achondroplasia,Natriuretic Peptide Receptors,Visen Pharmaceuticals,"extended-release C-type natriuretic peptide (CNP), long-acting prodrug of C-type natriuretic peptide (CNP)",Y,II,24% (Same As Avg.), - , - , - ,,,,,,,05/08/2018,,Non-NME,Orphan,,No,,,Denmark,Europe,,33055,45627,3938,3084,N/A,$5.37B ,,
Preclinical,,,,,,Peptide,Sublingual (SL)/Oral Transmucosal,"Aquestive Therapeutics, Inc.",AQST,AQST-305,octreotide,Endocrine,Other,Acromegaly,Somatostatin Receptors,,"AQST305 , AQST 305",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,Rare Disease,,No,,New Jersey,United States,North America,,39817,55685,3465,680,N/A,$192.31M ,,
Suspended,,,,,,Peptide,Sublingual (SL)/Oral Transmucosal,"NHTherapeutics, Inc.",,NH901,leuprolide acetate,Endocrine,Other,Hypogonadism,Gonadotropin-Releasing Hormone (GnRH) Receptor,,Leuprolide,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,Ontario,Canada,North America,,26124,36413,5312,549,N/A, ,,
Suspended,,,,,,Peptide,Sublingual (SL)/Oral Transmucosal,"Albireo Pharma, Inc.",ALBO,VIAcal,,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Calcitonin Receptor,,Calcitonin,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,Massachusetts,United States,North America,,8106,10001,2944,242,N/A,$717.68M ,,
Suspended,,,,,,Peptide,Surgical Implantation,"Aevi Genomic Medicine, Inc.",GNMX,MDGN-205,,Gastroenterology (Non Inflammatory Bowel Disease),Other,Short Bowel Syndrome (SBS),,,"MDGN205, TARGT-GLP-2",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,Pennsylvania,United States,North America,,24398,33825,3685,581,N/A, ,,
I/II,,,03/10/2020,03/10/2020,03/10/2020,Peptide,Topical,"Amytrx Therapeutics, Inc.",,AMTX-100,,Allergy,General,Atopic Dermatitis (Eczema),Unknown,,"AMTX100, AMTX 100",N,II,24% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,Tennessee,United States,North America,,43303,61063,25607,385,N/A, ,,
II,,,01/16/2019,01/16/2019,03/23/2017,Peptide,Topical,"Brickell Biotech, Inc.",BBI,BBI-2000,,Allergy,General,Atopic Dermatitis (Eczema),,,"BBI 2000, BBI2000",N,II,24% (Same As Avg.), - , - , - ,,,,,,,03/23/2017,,New Molecular Entity (NME),,,No,,Colorado,United States,North America,,34381,47506,390,385,N/A,$57.26M ,,
Suspended,,,,,,Peptide,Topical,"Kv1.3 Therapeutics, Inc.",,KPI-150,,Allergy,General,Atopic Dermatitis (Eczema),Potassium channels,,"dalazatide analogue, ShK-186, ShK186, ShK 186, KPI150, KPI 150",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Washington,United States,North America,,29366,40737,6172,385,N/A, ,,
Suspended,,,,,,Peptide,Topical,"Kv1.3 Therapeutics, Inc.",,KPI-150,,Autoimmune/immunology,Psoriasis,Psoriasis,Potassium channels,,"dalazatide analogue, ShK-186, ShK186, ShK 186, KPI150, KPI 150",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Washington,United States,North America,,29366,40739,6172,155,N/A, ,,
Suspended,,,12/28/2005,08/01/2003,,Peptide,Topical,"TG Therapeutics, Inc.",TGTX,Topical PTH (1-34),parathyroid hormone,Autoimmune/immunology,Psoriasis,Psoriasis,Parathyroid Hormone Receptor (PTHR),,Topical parathyroid hormone,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,New York,United States,North America,,2488,4219,763,155,N/A,$7.40B ,,
Suspended,,,,06/27/2011,,Peptide,Topical,"Digna Biotech, S.L.",,Disitertide (Topical),,Autoimmune/immunology,Other,Scleroderma,Transforming Growth Factor-beta (TGF-beta) and Superfamily,,"P-144, P144 Topical Cream, NAFB001",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,,Spain,Europe,,21871,29548,3227,457,N/A, ,,
Suspended,,,,,,Peptide,Topical,"Kv1.3 Therapeutics, Inc.",,KPI-150,,Autoimmune/immunology,Systemic Lupus Erythematosus (SLE),Systemic Lupus Erythematosus (SLE),Potassium channels,,"dalazatide analogue, ShK-186, ShK186, ShK 186, KPI150, KPI 150",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Washington,United States,North America,,29366,40738,6172,282,N/A, ,,
II,,,,10/08/2011,,Peptide,Topical,"FirstString Research, Inc.",,Granexin Gel,,Autoimmune/immunology,General,Wound Healing,Unknown,,Granexin Gel,N,II,20% (Same As Avg.), - , - , - ,,,,,,,09/08/2010,,New Molecular Entity (NME),,,No,,South Carolina,United States,North America,,23014,31412,4438,1578,N/A, ,,
Suspended,,,,,,Peptide,Topical,Integra LifeSciences Holdings Corporation,IART,Aclerastide,,Autoimmune/immunology,General,Wound Healing,Unknown,,"DSC127, Angiotensin, DSC-127, NorLeu3-A(1-7), USB-001, USB001",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,New Jersey,United States,North America,,17951,31518,1122,1578,N/A,$5.55B ,,
II,,,04/15/2014,12/08/2005,,Peptide,Topical,"Maruho Co., Ltd.",,CLS001,omiganan,Dermatology,General,Acne,Unknown,"BioWest Therapeutics, Inc.","MBI 594AN, MX-594AN, omiganan 2.5% ",N,II,24% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Japan,Asia,,2456,4657,2983,603,N/A, ,,
Preclinical,,,,,,Peptide,Topical,CLINUVEL PHARMACEUTICALS LIMITED,CLVLY,CUV9900,,Dermatology,General,Dermatology,Melanocortin (MC) receptors,,CUV-9900,N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Australia,Oceania,,24637,34232,2880,151,N/A,$609.58M ,,
Suspended,,,11/25/2015,,,Peptide,Topical,"Maruho Co., Ltd.",,CLS001,omiganan,Dermatology,General,Dermatology,Unknown,"BioWest Therapeutics, Inc.","MBI 594AN, MX-594AN, omiganan 2.5% ",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Japan,Asia,,2456,41897,2983,151,N/A, ,,
Suspended,10/14/2015,10/14/2015,01/22/2007,01/22/2007,,Peptide,Topical,"Maruho Co., Ltd.",,CLS001,omiganan,Dermatology,General,Rosacea,Unknown,"BioWest Therapeutics, Inc.","MBI 594AN, MX-594AN, omiganan 2.5% ",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,12/08/2005,,New Molecular Entity (NME),,,No,,,Japan,Asia,,2456,4166,2983,584,N/A, ,,
III,07/31/2015,07/31/2015,,10/07/2011,,Peptide,Topical,"FirstString Research, Inc.",,Granexin Gel,,Endocrine,Diabetes Mellitus,Diabetic Foot and Other Ulcers,Unknown,,Granexin Gel,N,III,60% (Same As Avg.), - , - , - ,,,,,,,09/08/2010,,New Molecular Entity (NME),,,No,,South Carolina,United States,North America,,23014,31413,4438,694,N/A, ,,
Suspended,02/06/2013,02/06/2013,11/20/2008,11/20/2008,,Peptide,Topical,Integra LifeSciences Holdings Corporation,IART,Aclerastide,,Endocrine,Diabetes Mellitus,Diabetic Foot and Other Ulcers,Unknown,,"DSC127, Angiotensin, DSC-127, NorLeu3-A(1-7), USB-001, USB001",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,New Jersey,United States,North America,,17951,23445,1122,694,N/A,$5.55B ,,
Suspended,,07/26/1999,,,,Peptide,Topical,PLx Pharma Inc.,PLXP,Locilex,pexiganan acetate,Endocrine,Diabetes Mellitus,Diabetic Foot and Other Ulcers,"Bacteria-miscellaneous,Cell Membrane",,"Cytolex, magainin peptide, MSI-78, pexiganan acetate cream 8%",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),SPA,,No,,Texas,United States,North America,,20106,26728,3708,694,N/A,$81.80M ,,
Suspended,,,,,,Peptide,Topical,Promore Pharma AB,PROMO,LL-37,ropocamptide,Endocrine,Diabetes Mellitus,Diabetic Foot and Other Ulcers,,,"LL37, LL 37",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Sweden,Europe,,20615,27525,3854,694,N/A,$13.68M ,,
Suspended,,,,,,Peptide,Topical,"Acologix, Inc.",,AC-100,,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteopetrosis,,,"AC 100, Dentonin",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,Rare Disease,,No,,California,United States,North America,,21940,30123,4132,540,N/A, ,,
Suspended,,,,07/24/2006,,Peptide,Topical,"Acologix, Inc.",,AC-100,,ENT/Dental,General,Periodontitis,,,"AC 100, Dentonin",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,10/04/2004,,Biologic,,,No,,California,United States,North America,,21940,29662,4132,621,N/A, ,,
Suspended,,,09/26/2006,11/02/2004,,Peptide,Topical,"G-treeBNT Co., Ltd",,RGN-137,timbetasin,Hematology,Other,Chronic Pressure Ulcers,"Actin Filaments,ATP Synthase,Integrin-linked kinase (ILK)","Lee's Pharmaceutical Holdings Limited, RegeneRx Biopharmaceuticals, Inc.","thymosin beta 4 (TB4) peptide, RGN137, RGN 137",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Korea (South),Asia,,10785,15672,4636,617,N/A, ,,
II,,,,10/11/2011,,Peptide,Topical,"FirstString Research, Inc.",,Granexin Gel,,Hematology,Other,Chronic Venous Ulcers,Unknown,,Granexin Gel,N,II,30% (Same As Avg.), - , - , - ,,,,,,,09/08/2010,,New Molecular Entity (NME),,,No,,South Carolina,United States,North America,,23014,31414,4438,425,N/A, ,,
Suspended,,,,12/20/2004,,Peptide,Topical,"G-treeBNT Co., Ltd",,RGN-137,timbetasin,Hematology,Other,Chronic Venous Ulcers,"Actin Filaments,ATP Synthase,Integrin-linked kinase (ILK)","Lee's Pharmaceutical Holdings Limited, RegeneRx Biopharmaceuticals, Inc.","thymosin beta 4 (TB4) peptide, RGN137, RGN 137",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Korea (South),Asia,,10785,16116,4636,425,N/A, ,,
Program Hold,,,03/20/2017,03/20/2017,07/30/2014,Peptide,Topical,Ergomed plc,ERGO,PeproStat,,Hematology,Other,Hemostasis,Fibrinogen (Coagulation Factor I),"Boryung Pharmaceutical Co., Ltd.","HXSA902, HXSA 902",N,II,30% (Same As Avg.), - , - , - ,,,,,,,07/30/2014,,Biologic,,,No,,,United Kingdom,Europe,,34142,47145,2616,672,N/A,$741.71M ,,
Suspended,06/27/2005,06/27/2005,,02/09/2005,,Peptide,Topical,"BioWest Therapeutics, Inc.",BWE:CN,Omigard,omiganan,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Antibacterial - General,Cell Membrane,,"CPI-226, omiganan 1% aqueous gel, MX-226, MBI-226",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Fast Track,SPA",,No,,,Canada,North America,,1995,3220,624,3121,N/A, ,,
Suspended,,,,03/07/2006,,Peptide,Topical,Dr. Reddy's Laboratories Ltd.,RDY,OP-145,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Ear Infections (Antibacterial),Biofilms,GC Pharma,OP-145,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,01/15/2004,,New Molecular Entity (NME),,,No,,,India,Asia,,20773,27796,766,3124,N/A,$6.57B ,,
Suspended,,,,05/18/2010,,Peptide,Topical,NovaBiotics Ltd,,Novexatin,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Fungal Infections - Non-Systemic,Cell Membrane,,NP213,Y,II,27% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,26882,37574,5540,3117,N/A, ,,
Preclinical,,,,,,Peptide,Topical,NovaBiotics Ltd,,Novamycin,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Fungal Infections - Systemic,Cell Membrane,,NP339/NP525,Y,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,26885,37577,5540,3116,N/A, ,,
Suspended,,,,,,Peptide,Topical,Promore Pharma AB,PROMO,LL-37,ropocamptide,Infectious Disease,Antiviral,Hepatitis C (HCV) (Antiviral),,,"LL37, LL 37",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Sweden,Europe,,20615,31165,3854,176,N/A,$13.68M ,,
Suspended,,,07/27/2016,07/27/2016,,Peptide,Topical,"Maruho Co., Ltd.",,CLS001,omiganan,Infectious Disease,Antiviral,Human Papillomavirus (HPV) Treatment (Antiviral),Unknown,"BioWest Therapeutics, Inc.","MBI 594AN, MX-594AN, omiganan 2.5% ",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/20/2016,,New Molecular Entity (NME),,,No,,,Japan,Asia,,2456,41898,2983,238,N/A, ,,
Suspended,,,,07/01/2005,,Peptide,Topical,Takeda Pharmaceutical Co. Ltd.,TAK,R-851,epetirimod esylate,Infectious Disease,Antiviral,Human Papillomavirus (HPV) Treatment (Antiviral),"Human Papillomavirus (HPV),Immune System",Bausch Health Companies Inc.,"Topical anti-HPV Gel, 851B, TAK-851, epetirimod esylate",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,03/01/2005,,Non-NME,,,No,,,Japan,Asia,,3001,5116,826,238,N/A,$46.05B ,,
Suspended,,,09/01/2010,09/01/2010,,Peptide,Topical,Lytix Biopharma AS,,Lytixar,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),Cell Membrane,,"LTX-109, LTX109, LTX 109, AMC-109, AMC109, AMC 109",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/19/2009,,New Molecular Entity (NME),,,No,,,Norway,Europe,,17791,23209,2958,440,N/A, ,,
Suspended,,,,,,Peptide,Topical,PLx Pharma Inc.,PLXP,Locilex,pexiganan acetate,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Skin and Skin-Structure Infections (Antibacterial),"Bacteria-miscellaneous,Cell Membrane",,"Cytolex, magainin peptide, MSI-78, pexiganan acetate cream 8%",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/17/2014,,New Molecular Entity (NME),,,No,,Texas,United States,North America,,20106,33794,3708,440,N/A,$81.80M ,,
Suspended,,,,05/20/2010,,Peptide,Topical,Lytix Biopharma AS,,Lytixar,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Staphylococcal Vaccines and Other Staphylococcus-Specific Agents (Antibacterial),Cell Membrane,,"LTX-109, LTX109, LTX 109, AMC-109, AMC109, AMC 109",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Norway,Europe,,17791,23210,2958,3109,N/A, ,,
II,,,,06/04/2004,,Peptide,Topical,"G-treeBNT Co., Ltd",,RGN-137,timbetasin,Metabolic,Single-Gene Disorders (Non-Inborn Errors of Metabolism),Epidermolysis Bullosa,"Actin Filaments,ATP Synthase,Integrin-linked kinase (ILK)","Lee's Pharmaceutical Holdings Limited, RegeneRx Biopharmaceuticals, Inc.","thymosin beta 4 (TB4) peptide, RGN137, RGN 137",Y,II,17% (7% Below Avg.), - , - , - ,,,,,,,,,Biologic,"Orphan,Rare Disease",,No,,,Korea (South),Asia,,10785,13511,4636,657,N/A, ,,
III,,12/18/2017,,,,Peptide,Topical,"FirstString Research, Inc.",,Granexin Gel,,Not Specified,Other,Acute Radiation Syndrome (ARS),Unknown,,Granexin Gel,N,III,62% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,South Carolina,United States,North America,,23014,51445,4438,666,N/A, ,,
I/II,,,,12/10/2014,,Peptide,Topical,Stealth BioTherapeutics Inc.,MITO,Elamipretide (Ophthalmic Delivery),elamipretide,Ophthalmology,Retinopathy,Diabetic Macular Edema (Ophthalmology),Reactive Oxygen Species/Free Radicals,Alexion Pharmaceuticals Inc.,"elamipretide (ophthalmology), Ocuvia, SS-31",Y,II,24% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,25164,35005,3274,476,N/A,$7.02M ,,
I/II,,,,12/10/2014,,Peptide,Topical,Stealth BioTherapeutics Inc.,MITO,Elamipretide (Ophthalmic Delivery),elamipretide,Ophthalmology,Macular Degeneration,Dry Age-Related Macular Degeneration (Dry AMD)/Geographic Atrophy (Ophthalmology),Reactive Oxygen Species/Free Radicals,Alexion Pharmaceuticals Inc.,"elamipretide (ophthalmology), Ocuvia, SS-31",N,II,24% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,25164,35010,3274,2870,N/A,$7.02M ,,
I/II,,,,07/20/2017,,Peptide,Topical,"TearSolutions, Inc.",,Lacripep,,Ophthalmology,Other,Dry Eye (Ophthalmology),Cluster of Differentiation 138 (CD138)/ Syndecan 1 (SDC1),,,N,II,24% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Virginia,United States,North America,,35800,49762,7720,548,N/A, ,,
III,09/16/2015,09/16/2015,09/14/2010,05/14/2010,,Peptide,Topical,"RegeneRx Biopharmaceuticals, Inc.",RGRX,RGN-259,timbetasin,Ophthalmology,Other,Dry Eye (Ophthalmology),"Actin Filaments,ATP Synthase,Integrin-linked kinase (ILK)","Alfasigma S.p.A., Lee's Pharmaceutical Holdings Limited","thymosin beta 4 (TB4) peptide, RGN259, RGN 259, GBT-201, GBT201, GBT 201",N,III,45% (6% Below Avg.), - , - , - ,,,,,Now - 03/31/2021,,,,Biologic,,,No,,Maryland,United States,North America,,10783,21706,460,548,N/A,$62.06M ,,
Preclinical,,,,,,Peptide,Topical,OKYO Pharma Limited,OKYO,OKYO-0101,,Ophthalmology,Other,Dry Eye (Ophthalmology),"ChemR23,GPR1",,"OKYO0101, OKYO 0101, OK-113, OK113, OK 113",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,40788,57209,9283,548,N/A,$75.42M ,,
Suspended,,,,,,Peptide,Topical,"Kv1.3 Therapeutics, Inc.",,KPI-190,,Ophthalmology,Other,Dry Eye (Ophthalmology),Potassium channels,,"Kv1.3 inhibitor, KPI190, KPI 190",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Washington,United States,North America,,29369,40743,6172,548,N/A, ,,
II,,,04/14/2016,04/14/2016,,Peptide,Topical,Stealth BioTherapeutics Inc.,MITO,Elamipretide (Ophthalmic Delivery),elamipretide,Ophthalmology,Congenital Blindness,Leber's Hereditary Optic Neuropathy (LHON) (Ophthalmology),Reactive Oxygen Species/Free Radicals,Alexion Pharmaceuticals Inc.,"elamipretide (ophthalmology), Ocuvia, SS-31",N,II,20% (4% Below Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),"Fast Track,Orphan,Rare Disease",,No,,Massachusetts,United States,North America,,25164,35008,3274,2962,N/A,$7.02M ,,
III,09/21/2015,09/21/2015,,04/30/2007,,Peptide,Topical,"RegeneRx Biopharmaceuticals, Inc.",RGRX,RGN-259,timbetasin,Ophthalmology,Other,Ophthalmic Wound Healing (Ophthalmology),"Actin Filaments,ATP Synthase,Integrin-linked kinase (ILK)","Alfasigma S.p.A., Lee's Pharmaceutical Holdings Limited","thymosin beta 4 (TB4) peptide, RGN259, RGN 259, GBT-201, GBT201, GBT 201",Y,III,49% (2% Below Avg.), - , - , - ,,,,,,,,,Biologic,Orphan,,No,,Maryland,United States,North America,,10783,13509,460,265,N/A,$62.06M ,,
II,,,03/08/2016,03/08/2016,,Peptide,Topical,Stealth BioTherapeutics Inc.,MITO,Elamipretide (Ophthalmic Delivery),elamipretide,Ophthalmology,Other,Other Ophthalmological Indications (Ophthalmology),Reactive Oxygen Species/Free Radicals,Alexion Pharmaceuticals Inc.,"elamipretide (ophthalmology), Ocuvia, SS-31",N,II,24% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,25164,38937,3274,2569,N/A,$7.02M ,,
Suspended,,,,,,Peptide,Topical,Mallinckrodt plc,MNK,DE-105,,Ophthalmology,Corneal Conditions,Persistent Corneal Epithelial Defects (Ophthalmology),Unknown,,DE-105,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/03/2010,,New Molecular Entity (NME),,,No,,,United Kingdom,Europe,,17530,22834,556,3026,N/A,$63.44M ,,
Preclinical,,,,,,Peptide,Topical,"Kv1.3 Therapeutics, Inc.",,KPI-190,,Ophthalmology,Uveitis,Uveitis (Ophthalmology),Potassium channels,,"Kv1.3 inhibitor, KPI190, KPI 190",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),Rare Disease,,No,,Washington,United States,North America,,29369,40742,6172,307,N/A, ,,
Development Outside U.S.,,,05/28/2015,,,Peptide,Topical,"Maruho Co., Ltd.",,CLS001,omiganan,Allergy,General,Atopic Dermatitis (Eczema),Unknown,"BioWest Therapeutics, Inc.","MBI 594AN, MX-594AN, omiganan 2.5% ",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Japan,Asia,,2456,41896,2983,385,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Topical,Transdermal Therapeutic Technologies LLC,,DPK-060,,Allergy,General,Atopic Dermatitis (Eczema),"Bacteria-miscellaneous,Candida,Staphylococcus",Promore Pharma AB,DPK060,Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,New York,United States,North America,,20614,27523,7984,385,N/A, ,,
Development Outside U.S.,,,09/11/2012,,,Peptide,Topical,Promore Pharma AB,PROMO,LL-37,ropocamptide,Hematology,Other,Chronic Venous Ulcers,,,"LL37, LL 37",N,Development Outside U.S.,1% (1% Above Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,,Sweden,Europe,,20615,27524,3854,425,N/A,$13.68M ,,
Development Outside U.S.,,,,,03/18/2019,Peptide,Topical,Cytovation AS,,CyPep-1 (Topical),,Dermatology,General,Dermatology,Tumor Cells,,"CyPep 1, CyPep1",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Norway,Europe,,40259,56337,9115,151,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Topical,Shionogi & Co. Ltd.,4507,SR-0379,,Endocrine,Diabetes Mellitus,Diabetic Foot and Other Ulcers,PI3K/AKT pathway,FunPep Co. Ltd.,"SR0379, SR 0379, FPP001",Y,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Japan,Asia,,26974,37707,618,694,N/A,$17.14B ,,
Development Outside U.S.,,,,,,Peptide,Topical,"Allegro Ophthalmics, LLC.",,ALG-1007,,Ophthalmology,Other,Dry Eye (Ophthalmology),Integrins,,"ALG 1007, ALG1007",N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,California,United States,North America,,40414,56584,3683,548,N/A, ,,
Development Outside U.S.,,,01/16/2012,,,Peptide,Topical,Transdermal Therapeutic Technologies LLC,,DPK-060,,Infectious Disease,"Antibacterial, Mycobacterial, or Fungal",Ear Infections (Antibacterial),"Bacteria-miscellaneous,Candida,Staphylococcus",Promore Pharma AB,DPK060,N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,New York,United States,North America,,20614,27522,7984,3124,N/A, ,,
Preclinical,,,,,,Peptide,Transdermal,CLINUVEL PHARMACEUTICALS LIMITED,CLVLY,VLRX001,,Dermatology,General,Vitiligo,Melanocortin (MC) receptors,,"VLRX001, VLRX-001",N,Preclinical,0% (Same As Avg.), - , - , - ,,,,,,,,,New Molecular Entity (NME),,,No,,,Australia,Oceania,,25989,36227,2880,3103,N/A,$609.58M ,,
Suspended,,,,,,Peptide,Transdermal,Syneron Medical Ltd.,,ViaDor-GLP1,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,transdermal ViaDerm-GLP1,Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,09/14/2010,,New Molecular Entity (NME),,,No,,Massachusetts,United States,North America,,17308,22467,1343,137,N/A, ,,
Suspended,,,,,,Peptide,Transdermal,AstraZeneca PLC,AZN,Exenatide Patch,,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,"Bristol Myers Squibb Company, Eli Lilly and Company, Nitto Denko Corporation","transdermal exenatide, PassPort Basal Insulin",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,04/01/2009,,Non-NME,,,No,,,United Kingdom,Europe,,14870,18861,45,137,N/A,$133.38B ,,
Suspended,,,,,,Peptide,Transdermal,Zosano Pharma Corporation,ZSAN,Semaglutide Transdermal Patch,semaglutide,Endocrine,Diabetes Mellitus,"Diabetes Mellitus, Type II",GLP-1 Receptor,,semaglutide,N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,California,United States,North America,,23710,32649,2946,137,N/A,$53.49M ,,
Program Hold,,,,01/31/2015,,Peptide,Transdermal,Zosano Pharma Corporation,ZSAN,ZP-Glucagon Transdermal Patch,,Endocrine,Other,Hyperinsulinemia/Hypoglycemia,Glucagon Receptor,,Glucagon,Y,II,24% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,,,No,,California,United States,North America,,26274,36652,2946,3358,N/A,$53.49M ,,
Program Hold,,,,10/10/2011,,Peptide,Transdermal,Zosano Pharma Corporation,ZSAN,ZP PTH (Weekly),teriparatide,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Parathyroid Hormone Receptor (PTHR),,"AK-159, teriparatide, Teribone transdermal patch",Y,I,14% (Same As Avg.), - , - , - ,,,,,,,04/30/2014,,Non-NME,,,No,,California,United States,North America,,17478,22743,2946,242,N/A,$53.49M ,,
Suspended,,,,06/12/2008,,Peptide,Transdermal,Syneron Medical Ltd.,,ViaDor-hPTH (1-34),teriparatide,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Parathyroid Hormone Receptor (PTHR),,"ViaDerm-hPTH (1-34), transdermal teriparatide transdermal, ViaDor-PTH1-34",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,07/09/2007,,Non-NME,,,No,,Massachusetts,United States,North America,,19199,25286,1343,242,N/A, ,,
Suspended,,,,06/19/2007,,Peptide,Transdermal,Zosano Pharma Corporation,ZSAN,ZP PTH (Daily),teriparatide,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Parathyroid Hormone Receptor (PTHR),,"ZP-PTH, Macroflux PTH, PTH 1-34 patch, Teribone patch",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,,,Non-NME,505b2,,No,,California,United States,North America,,22235,30092,2946,242,N/A,$53.49M ,,
Suspended,,,03/10/2009,03/10/2009,,Peptide,Transdermal,"Vyteris, Inc.",VYTRQ,Lutrepatch,,Obstetrics/Gynecology,Gynecology,Reproductive Disorder,Unknown,,"Fertility Enhancement Peptide, Ferring/Vyteris Fertility Peptide Patch, transdermal fertility patch",Y,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,08/10/2006,,Non-NME,,,No,,New Jersey,United States,North America,,11128,13976,1219,241,N/A, ,,
Suspended,,,,,,Peptide,Transdermal,Syneron Medical Ltd.,,ViaDor-Calcitonin,,Rheumatology (Non Autoimmune),Osteoarthritis,Musculoskeletal Conditions,Calcitonin Receptor,,"ViaDerm-Calcitonin, transdermal ViaDor-Calcitonin",N,Suspended,0% (Same As Avg.), - , - , - ,,,,,,,01/11/2011,,Non-NME,,,No,,Massachusetts,United States,North America,,17844,23297,1343,715,N/A, ,,
Development Outside U.S.,,,,,,Peptide,Transdermal,Corium Inc.,,MicroCor PTH,teriparatide,Endocrine,Osteoporosis And Related Disorders Of Bone Breakdown ,Osteoporosis / Osteopenia,Parathyroid Hormone Receptor (PTHR),,MicroCor hPTH(1-34) Therapy,N,Development Outside U.S.,0% (Same As Avg.), - , - , - ,,,,,,,,,Biologic,,,No,,California,United States,North America,,26489,36952,5268,242,N/A, ,,
